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  Executive summary 
EXECUTIVE SUMMARY 
 
We use the term ‘extra-medical opioid use’ to include the use of any illegal opioids and the use of 
pharmaceutical opioids not as prescribed. 
 
Introduction 
In recent decades the range and patterns of opioids used for extra-medical purposes have changed. The 
use of pharmaceutical opioids exceeds the use of heroin. In 2017, 63 percent of opioid deaths were 
attributed exclusively to pharmaceutical opioids, 28 percent to illicit opioids and 8 percent to both illicit 
and pharmaceutical opioids (aged 15-64 years) (Chrzanowska et al., 2019). The extra-medical use of 
opioids is also likely to result in other adverse outcomes including those that: require the use of health 
services; reduce work productivity; or, result in contact with the criminal justice system. 
 
The objective of this report was to estimate the social costs arising from extra-medical opioid use in 
Australia for the financial year 2015/16. Due to data limitations in most cases we only estimated the costs 
occurring in this 12 month period. For example, on-going care of chronic conditions was not included. 
The exceptions to this were for certain harms which occurred in 2015/16 but which had longer-term 
ramifications, for example premature deaths, where discounted streams of future costs (lost economic 
activity and lost contributions to household chores) and partially offsetting savings (future health 
expenditure ’avoided’ by premature deaths) were estimated. We also included the long-term costs of road 
traffic accidents, as were the expected future costs of opioid attributable imprisonment for those 
sentenced in 2015/16. 
 
Using the Global Burden of Disease Study, we estimated that there were 104,026 people who met the 
criteria for dependence on opioids (Global Burden of Disease Collaborative Network, 2018). We focused 
on those who were dependent as research shows that costs associated with dependent use are much 
greater than for other people who use opioids not categorised as dependent (Moore, 2007). Further, 
there are economic arguments that those who are not ‘dependent’ may be making rational and informed 
decisions regarding their consumption of opioids and this type of cost should not be included with social 
costs (Cawley and Ruhm, 2011). Nevertheless, in some areas, such as deaths and criminal justice, the 
cost accruing from any level of opioid use was eligible for inclusion. We estimated that the total tangible 
cost was $5.63 billion. There was a further $10.13 billion from intangible costs, giving a total of $15.76 
billion 1(Summary Table 1 and Summary Figure 1).  
 
We identified 2,203 deaths with over 70,000 years of life lost. These deaths had a (gross) tangible cost 
of $2.62 billion: the largest tangible cost domain. However, there was an offset of $138.6 million in 
‘avoided’ health care costs from these deaths, leaving a net cost of $2.49 billion.  
 
The cost of in-patient care, which involved nearly 32,000 hospital separations, was over $249.3 million. 
In addition, there was expenditure on other (out-of-hospital) health care. This included GP services, opioid 
agonist therapy and treatment of opioid attributable diseases and contributed a further $829.5 million. 
The costs of crime, including police, courts, prisons and victims of crime was substantial and constituted 
                                                     
1 Due to the rounding up and down of each figure to one decimal place, the rounded totals may not add up exactly.. See 
Summary Table 1 for detailed estimates. 
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the second largest tangible cost domain, totalling $936.1 million. Opioid use also had impacts on business 
through workplace injuries and absenteeism totalling over $458.7 million. Workplace costs due to 
premature mortality and road traffic accidents were counted elsewhere. 
 
In addition to the tangible costs of extra-medical opioid use, there are very significant intangible costs 
(e.g. the value of life lost). These costs are due to premature mortality and in 2015/16 we estimated that 
these costs amounted to over $10.13 billion. This was based on the valuation of a statistical life year 
being $286,553.  
 
Summary Table 1: Summary of opioid-related costs (with ranges) in 2015/16 





Tangible costs    
Tangible costs of premature mortality (gross) (Chapter 3) 2,623,976,267 2,334,000,842 3,133,336,196 
Avoided healthcare costs (Chapter 3) -138,572,724 -131,958,751 -148,291,545 
Hospital inpatient care (Chapter 4) 249,336,383 180,093,533 366,781,646 
Other health care (chapter 5) 829,458,043 512,389,905 1,215,407,757 
Other workplace costs (Chapter 6) 458,666,743 173,689,506 743,643,980 
Criminal justice (Chapter 7) 936,070,281 565,013,385 1,755,302,874 
Traffic accidents (Chapter 8) 480,624,725 270,294,018 691,951,715 
Other costs (Chapter 11) 193,964,241 183,282,646 204,645,837 
Total tangible costs 5,633,523,959 4,086,805,084 7,962,778,460 
Intangible costs    
Intangible cost of premature mortality (Chapter 3) 10,127,150,276 5,668,284,222 36,200,205,774 
TOTAL COSTS 15,760,674,235 9,755,089,306 44,162,984,234 
 
There were also some cost domains where we produced tentative estimates that were not included in 
our overall figures. There is increasing interest in the harms that people experience from the substance 
use of others. To date, most of the focus has been on alcohol and tobacco (Laslett et al., 2015; Nayak et 
al., 2019; US Department of Health and Human Services, 2006). We estimated that about 70,000 children 
live with a person with extra-medical opioid dependence. In addition, we estimated that about 41,000 
adults are the partner of a person with extra-medical opioid dependence. This results in lost quality of life 
for these co-residents that we valued at $11.98 billion. This was not included in our main estimates due 
to uncertainty as to the extent to which the assessed loss of quality of life for resident family members is 
captured in other elements of the costing such as victim of crime costs. Similarly, being dependent on 
drugs results in reduced quality of life for the drug consumer. With respect to extra-medical opioids we 
estimated this cost at $14.93 billion (Summary Table 2).  
 
Summary Table 2: Summary of costs for tentative estimates and ‘internalities’ (with ranges) in 
2015/16 but not included in the overall total 





Harms to others – partners & children (Chapter 9) 11,977,778,228 1,880,978,459 35,169,824,629 
Value of DALY lost by ‘dependent’ use (Chapter 10) 14,934,290,151 2,345,266,170 43,850,900,857 
Extra-medical opioid purchases (Chapter 10) 1,443,408,941 244,936,850 2,641,881,032 
TOTAL COSTS 28,355,477,320 4,471,181,479 81,662,606,518 
DALY = disability adjusted life years 
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Limitations 
There are technical challenges associated with any social cost study, for example in estimating costs 
from administrative data. Investigations of illicit drug use raise other challenges such as in estimating the 
size of the population in question, especially those with more significant problems who could be classified 
with drug dependence. We believe that the Global Burden of Disease (GBD) compare tool (2018) 
provides the best estimate of the number of Australians dependent on opioids in Australia (n = 104,026). 
However, this does not differentiate between those dependent on illegal drugs, such as heroin and those 
misusing pharmaceutical drugs. Our estimation assumes that any harms or costs are equivalent 
regardless of the specific opioid used. In addition, injecting drug use confers additional risks and potential 
harms but the GBD tool does not provide a separate estimate of these cases. Therefore, a further layer 
of uncertainly is introduced in estimating the proportion of people who consume opioids via injection. 
 
As with the recent analysis of costs due to methamphetamine use (Whetton et al., 2016), there were 
major domains where there were clearly costs, but we were unable to identify a method of attributing a 
fraction of these cost to opioids. For example, the budgets for the Australian Federal Police and Border 
Protection. There are also allied health services such as dental care and (out-of-hospital) physical 
rehabilitation where we could not attribute costs. 
 
The costs across the criminal justice system constitute one of the major cost domains. We used an 
established method with attributable fractions (AF) generated from self-reported attribution of the relevant 
most serious offence by police detainees to drug use. However, the potential for error in this method 
needs to be acknowledged. The level of confidence is greatest with respect to the attribution of police 
costs (as the AF derive from a survey of persons in police custody), however the potential for error 
increases as these AF are generalised to more distal areas (courts, prisons, victims of crime).  
 
Conclusions 
The extra-medical use of opioids places considerable social and economic costs on Australia. In 
particular, the number of premature deaths result in substantial tangible and intangible costs in addition 
to the impact on family and friends. Against this backdrop we note the importance of providing 
comprehensive treatment programs including opioid agonist treatment in improving multiple health and 
social outcomes (Degenhardt et al., 2019). In addition, improved treatment for blood borne viruses 
combined with Australia’s harm reduction interventions, such as needle and syringe programs, have 
prevented many deaths. Further, strategies to prevent and respond to overdoses including the recent 
provision of intra-nasal naloxone to enable laypeople to reverse opioid overdoses provides hope of further 
reductions in these deaths. While each of these individual programs provide benefits, a comprehensive 
‘overdose’ prevention strategy is required to coordinate activities to maximise their effectiveness.  
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CHAPTER 1: INTRODUCTION 
Steve Whetton, Robert J. Tait, Agata Chrzanowska, Neil Donnelly, Alice McEntee, Aqif Mukhtar, Emma 
Zahra, Gabrielle Campbell, Louisa Degenhardt, Tania Dey, Suraya Abdul Halim, Wayne Hall, Marshall 
Makate, Richard Norman, Amy Peacock, Ann Roche & Steve Allsop 
 
This report draws extensively on the previous analysis of the social cost of methamphetamine 
(Whetton et al., 2016) and the recent social costs of tobacco report (Whetton et al., 2019) with 
considerable duplication of the underlying rationale and methods. 
 
1.1 Rationale 
The National Drug Research Institute at Curtin University was engaged by the Australian Government 
Commonwealth Department of Health to undertake research into the costs of extra-medical opioid use and 
heroin use to Australia in collaboration with a multi-disciplinary team of Australian researchers from the South 
Australian Centre for Economic Studies, University of Adelaide, the National Drug and Alcohol Research 
Centre, University of New South Wales, the NSW Bureau of Crime Statistics and Research, the National 
Centre for Education and Training on Addiction, Flinders University, the Centre for Youth Substance Abuse 
Research, University of Queensland, and the School of Public Health, Curtin University.  
 
The overarching objective was to produce as comprehensive as possible an estimate of the costs of the 
misuse of pharmaceutical opioids and the use of illegal opioids. Costs arising for the side-effects of 
pharmaceutical opioids used as prescribed are excluded from these estimates. Henceforth, we use the term 
“extra-medical opioid use” to include the use of illicit opioids and the use of pharmaceutical opioids that 
have not been used as directed or have been used without a prescription. We address these separately in 
estimating specific cost items where possible.  
 
The remainder of this chapter sets out the background for the project. Chapter 2 provides a rationale and 
description of the methods used and the epidemiology underpinning the analyses. The starting point in 
determining the methods for the study was the approach used in the recent analysis of tobacco social costs 
(Whetton et al., 2019). However, we also drew on the 2016 analysis of methamphetamine social costs 
(Whetton et al., 2016). For example, the methamphetamine study used direct attribution on the cause of 
premature mortality based on coronial finding that were reported in the National Coronial Information System 
(NCIS). In the analysis of premature mortality due to tobacco, we used indirect attribution from the Australian 
Institute of Health and Welfare (AIHW) mortality data. In the current study a combination of the two 
approaches was used, with deaths directly caused by extra-medical use of opioids (such as acute toxicity) 
identified through the NCIS data, and types of death partially caused by opioids calculated using the indirect 
approach. 
 
In addition, Chapter 2 reports on the conditions wholly or partially caused by opioids and the attributable 
fractions (AF) calculated for each condition. Premature mortality and the methods used in determining eligible 
cases are detailed in Chapter 3. The costs of hospital inpatient morbidity and the extraction of information 
from the National Hospital Morbidity Database (NHMD) held by AIHW are described in Chapter 4. Chapter 5 
addresses other health care costs such as general practitioners, specialist drug treatment agencies and 
ambulance.  
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The costs of determining workplace absenteeism and injuries associated with extra-medical opioid use are 
evaluated in Chapter 6. Chapter 7 examines the costs of the criminal justice system (police, courts and 
prisons) and the costs to victims of crime. The chapter drew on “Drug Use Monitoring in Australia” (DUMA) 
data to derive AF for each offence category. In Chapter 8, the role and associated costs of extra-medical 
opioid use in road traffic accidents are presented. Other resident, in particular parents, partners and children 
living with a person dependent on extra-medical opioids are likely to have a reduced quality of life: Chapter 
9 provides a tentative estimate of these costs. Chapter 10 assesses the internalities for people who use extra-
medical opioids including the intangible costs of the lost quality of life arising from associated ill health. In 
Chapter 11 some of the smaller cost items such as child protection, child death reviews and harm reduction 
measures are addressed. Chapter 12 provides concluding remarks and highlights areas for future research 
and additional data requirements. 
 
1.2 Background 
Globally, in 2017, there were 53.4 million past-year users of extra-medical opioids. This equates to 1.1 
percent of the global population aged 15-64 years (United Nations Office of Drugs and Crime, 2019b). Extra-
medical opioids account for 73 percent of drug-related deaths and 73 percent of drug-related disability 
adjusted life years (DALY) (Degenhardt et al., 2018). Of particular concern, about 26.8 million people have 
problems of sufficient severity to be classified as dependent on opioids (Degenhardt et al., 2018). There are 
also 11.0 million people who inject drugs (PWID) (Degenhardt et al., 2017) of whom the majority primarily 
inject opioids, with the concomitant risk of blood borne infections (Degenhardt et al., 2017). 
 
Between 2010 and 2016, in the USA, there was a more than six-fold increase in the rate of deaths caused 
by synthetic opioid overdoses (e.g., fentanyl). Most notably, the percentage of opioid-related deaths due to 
synthetic opioids rose from 14 percent in 2010 to 46 percent in 2016 (Jones et al., 2018; Seth et al., 2018). 
By 2017, opioids accounted for 67.8 percent of the more than 70,000 drug overdose fatalities with fentanyl 
and its analogues accounting for over 28,000 or 58.8 percent of deaths involving opioid drugs (Scholl et al., 
2019). A major problem in relation to fatal and non-fatal overdoses with the synthetic opioids is their extreme 
potency, with fentanyl being 100 times and carfentanil 10,000 times more potent than morphine (Comer and 
Cahill, 2019). 
 
Although the types of opioids used in Australia also changed in the twenty-first century, this was less dramatic 
than in the USA. Using NCIS data, Roxburgh et al. (2017) reported that 559 opioid overdose deaths occurred 
in 2001. Over half (55%) of these deaths were attributable to pharmaceutical opioids (Roxburgh et al., 2017). 
The number of opioid-induced deaths increased to 1,153 (all ages) in 2017, according to Chrzanowska et al. 
(2019) who used ABS data. Approximately two thirds of these deaths (671, 63%) were attributed exclusively 
to pharmaceutical opioids, one quarter (301, 28%) to illicit opioids, and 8 percent (88) to both illicit and 
pharmaceutical opioids (aged 15-64) (Chrzanowska et al., 2019).  
 
The prevalence of recent (last year) heroin use among Australian adults has remained stable at about 0.2 
percent since 2001 (Australian Institute of Health and Welfare, 2017a). However, the stigma associated with 
illicit drug use and the sample frame (“households”) means that this figure is likely to be an under-estimate. 
The questions in the National Drug Strategy Household Survey (NDSHS) on the misuse of pharmaceuticals 
changed for the 2016 survey, so long-term comparisons are not possible. In 2013, 2.3 percent of those aged 
14 and older reported recent misuse of pharmaceutical analgesics / opioids (excluding over-the-counter 
products) and in 2016 the figure was 3.6 percent (Australian Institute of Health and Welfare, 2017a).  
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In 2016, in Australia, it was estimated that about 39,700 people had used illegal opioids (heroin or opium), 
about 715,000 had used pharmaceutical opioids for non-medical purposes and 3.1 million had used 
prescription opioids2 as prescribed (Australian Institute of Health and Welfare, 2017a, 2018d). In the USA, 
although most people who use heroin report the misuse of prescription opioids prior to initiating heroin use, 
few who misuse prescription opioids use heroin and the rate of transition to heroin is low (Compton et al., 
2016). A similar pattern can be observed in Australia, with 61.6 percent of those who used heroin in the past 
year also reporting misuse of prescription opioids, whereas only 2.9 percent of those reporting last year extra-
medical use of prescription opioids reported heroin use in the last year (Australian Institute of Health and 
Welfare, 2017i). 
 
1.3 Previous cost estimates  
We identified four studies, published since 2000, on the costs of illicit opioids in Australia (Table 1.1). The 
economic costs in Victoria of heroin dependence were estimated at $845 million in 2002. The analysis 
included the costs of drug treatment, health care, criminal activity, prisons, reduced taxes and social security 
payments, but which excluded premature mortality (Clark et al., 2003). An analysis covering Victoria and 
New South Wales focused on the health care and treatment costs of heroin dependence. In 2002, for 596 
clients, the total cost was $3.9 million (Shanahan et al., 2006). A national estimate of health care, crime and 
road accident costs for people who use heroin was $4.6 billion (Moore, 2007). Importantly, this latter study 
illustrated the difference in per annum costs between a dependent ($105,342) and a non-dependent ($1,965) 
person who uses heroin. An estimate of hospital costs for illicit opioid treatment found that in 2004/2005 the 
total was about $16 million (Riddell et al., 2007). We note that the availability of data and the methods used 
may also impact on the comparability of social cost estimates.  
 
Table 1.1: Previous Australian estimates of the social costs of illicit opioids  
Report Target year 
Conditions included Total  
($) 
2015/16 values  
($) 1  
Riddell (2007) 2004/05 National hospital separations  16,386,976 21,795,683 
Moore (2007) 2004 Deaths, national hospital costs; other health care; cost of crime; and road accidents 4,574,000,000 6,151,632,754 
Shanahan 
(2006) 2002 
Health service use: substance use treatment 
NSW & Vic cohort (n=596) 3,901,416 5,521,064 
Clark (2003) 2002 
Hospital & other healthcare costs; excess social 
welfare; excess government administration; 
reduced tax revenue; costs of crime 
844,751,000 1,195,443,974 
ꝉ Adjusted using the RBA consumer price index inflation calculator to December 2015 values (Reserve Bank of Australia, 2019) 
 
1.4 Conclusions 
We were unable to identify any recent Australian data on the social costs of either the misuse of 
pharmaceutical opioids or use of illegal opioids. However, data from the USA suggest that the costs of both 
the misuse of pharmaceutical opioids and of illicit opioids are significant, with costs per person who uses 
drugs in the order of USD 41,000 for misuse of pharmaceutical opioids in 2013 (Florence et al., 2016) and 
USD 50,799 per person who uses heroin in 2015 (Jiang et al., 2017). When the intangible costs of premature 
mortality are included, the estimated social cost increase significantly, with the US President’s Council of 
Economic Advisers (2017) estimating the total cost of all illicit opioid use in the USA at USD 210,000 per 
case in 2015. 
                                                     
2 Excludes private prescriptions and over-the-counter codeine products available at that time (Australian Institute of Health 
and Welfare, 2018d) 
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Box 1.1 Key opioid definitions:  
Naturally derived opioids 
These are products that can be derived either directly from opium poppies (e.g. opium, morphine) or 
synthesised from them (e.g. heroin, codeine, buprenorphine, hydrocodone, oxycodone). 
 
Synthetic opioids 
These products can be manufactured without materials from opium poppies and include tramadol, 
methadone and fentanyl. 
 
Weak versus strong opioids 
Products within either of the above classes can also be classified in terms of their potency relative to oral 
morphine. Codeine, tramadol and opium are considered to be “weak” or less potent than oral morphine 
whereas heroin, methadone, buprenorphine and fentanyl are considered to be ‘strong”, with the latter being 
100 times more potent than oral morphine (Australian Institute of Health and Welfare, 2018d; United Nations 
Office of Drugs and Crime, 2019b). 
 
Hazardous use 
A pattern of consumption that increases the risk of subsequent harmful outcomes for the consumer – these 
include social, physical and mental health outcomes. This term is used by the World Health Organisation but 
is not a diagnostic category within the International Classification of Diseases (ICD) (World Health 
Organization, 1993, 2009). 
 
Harmful use  
A pattern of consumption that is causing damage to physical or mental health or adverse outcomes for 
interpersonal relationships (with respect to opioids, ICD code F11.1) (World Health Organization, 1993). 
 
Dependent use 
A cluster of cognitive, behavioural and physiological phenomena such as impaired control, craving, tolerance 
/ withdrawal, continued use despite clear evidence of harm and pre-occupation with use (with respect to 
opioids, ICD code F11.2). Both dependence and harmful diagnostic criteria require these to have persisted 
for at least one month or repeatedly over 12 months. 
 
Adapted from Larance et al. (2011) and AIHW (2018d)  
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CHAPTER 2: METHODS 
Steve Whetton, Agata Chrzanowska, Neil Donnelly, Alice McEntee, Aqif Mukhtar, Emma Zahra, Gabrielle 
Campbell, Louisa Degenhardt, Tania Dey, Suraya Abdul Halim, Wayne Hall, Marshall Makate, Richard 
Norman, Amy Peacock, Ann Roche, Robert J. Tait & Steve Allsop 
 
2.1 Background 
As noted above (Section 1.1), as a starting point, the methods sought to replicate those used in the Social 
Costs of Tobacco report (Whetton et al., 2019) or the Social Costs of Methamphetamine study (Whetton et 
al., 2016) where possible. For example, premature mortality directly caused by extra-medical use of opioids 
was calculated using the same direct attribution method as in the methamphetamine report with data from 
the National Coronial Information System (NCIS), whereas causes of death partially caused by opioids such 
as deaths from blood borne viruses or accidental injuries, were calculated using the indirect approach as was 
the case in the tobacco analysis. This decision was driven by the limited AF available for opioid and 
methamphetamine use (see Section 11.2 and Table 11.1 for further details of the differences in the methods 
used between reports). 
 
Typically, the objective of “social cost studies” is to provide an estimate in monetary terms of the overall costs 
of a condition, disease or behaviour. For illicit substance use, in particular for those with a substance use 
disorder, these costs are likely to include: medical costs arising from conditions caused (wholly or partly) by 
the substance; substance use treatment; costs of crime caused by use of the substance (including victims of 
crime costs); lost workplace productivity and injury; other tangible costs such as road traffic accidents; and, 
intangible costs (e.g. the intangible costs of premature death and reduced quality of life from ill-health 
attributable to substance use). Costs especially difficult to quantify are the tangible and intangible costs of 
substance use on other people, such as resident partners and children. Social costs studies are most 
frequently used for advocacy in public health and in the identification of high-cost areas. 
 
In conducting social cost studies decisions need to be made regarding:  
● What costs are eligible for inclusion in the analysis, in particular whether or not costs to the 
person who uses the substance are included with broader social costs?  
● The timeframe for the analysis – that is, do the costs in the target period include use during that 
period and include the cost of previous use or is the analysis focused on use in the target period 
and future costs? 
 
Having determined the overall scope of the study, it is necessary to: 
● Estimate the prevalence of use, by level of potential harm for different types of use where 
possible; 
● Quantify the types of harm that are either wholly or partially caused by the drug (e.g. via AF 
calculated from RR); and, 
● Identify sources of cost data for each outcome and the proportion of the total cost that can be 
attributed to the target substance. 
 
2.2 Approach to economic analysis 
2.2.1 Private and social costs 
In conducting social cost studies, the typical approach is to exclude any (net) private costs, i.e. costs that 
accrue to the individual who is purchasing the substance in question. This is on the assumption that in 
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purchasing any particular good or service an individual will only do so where the benefits are expected to be 
the same or greater than the cost of consumption, including an evaluation of potential non-financial costs 
such as increased risk of ill-health or other adverse outcomes. Where this is the case there is no need for 
public policy intervention. 
 
While this approach is generally accepted for standard products, there is debate about its applicability for 
substances with ‘addictive’ potential, especially where costs are incurred by those classified with a substance 
use dependence. In these cases, consumption decisions may not necessarily be rational and informed. 
Cawley and Ruhm (2011) provided an excellent review on this topic, which underpins this section (See 
Appendix 2.1). 
 
The ‘rational addiction’ hypothesis (Becker and Murphy, 1988) has been widely used in modelling the 
consumption of addictive substances. By definition it assumes people make rational evaluations of the current 
and future costs of their drug use and it contends that people who use addictive substances consider the risk 
of dependence when they start using a substance. Therefore, based on this theory any harms arising to that 
individual should not be a factor in policy decisions and costs to a person who uses drugs are excluded from 
social cost analyses. 
 
The validity of the ‘rational addiction’ hypothesis for those with a drug dependence has been called into 
question by research findings that undermine its fundamental assumptions, namely that people:  
● Typically underestimate the risk of becoming dependent on a drug (Gruber and Köszegi, 2001; 
Kenkel, 1991); 
● Underestimate the potential harms to themselves and have incomplete information on the future 
adverse effects of using the particular drug (Gruber and Köszegi, 2001; Kenkel, 1991); 
● Have inconsistent preferences for the drug in question over time with the likelihood of a present-
bias, such as a desire to consume now versus quitting in the future (Angeletos et al., 2001; 
Gruber and Köszegi, 2001; Laibson, 2001); and,  
● Make decisions based on heuristics using incomplete evidence, and do not consider the full 
future consequences (Akerlof, 1991; Suranovic et al., 1999).  
 
Overall, if the key assumptions of the ‘rational addiction’ hypothesis are incorrect, then at a minimum, some 
of the costs of drug dependence can be considered within a social cost framework and can be used to justify 
public policy interventions that aim to reduce consumption to the point where all costs are factored into 
consumption decisions (US National Cancer Institute and World Health Organization, 2016). The form that 
policy interventions take could include actions that decrease availability, increase price, or provide more 
comprehensive information to existing and potential persons who use drugs.  
 
Those costs borne by the person who is dependent that are not factored into the consumption decision are 
termed ‘internalities’. Internality Theory allows for time inconsistent decisions by consumers and states that 
government policy decisions should factor in both internal and external costs. Therefore, changes in taxation 
levels or other interventions can be justified even when there are no external costs to ensure that people who 
use substances take all costs into account in their decision making (US National Cancer Institute and World 
Health Organization, 2016). Thus, social cost studies need to decide if these costs are eligible, and if so, how 
they should be included.  
 
There are three approaches typically used in addressing ‘internalities’ in social cost studies: 
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● Exclude all costs accruing to the person who uses the substance based either on, a) the belief 
that the framework provided by the ‘rational addiction’ hypothesis still confers some utility or, b) 
the inherent difficulty of quantifying internalities; 
● Exclude costs incurred by non-dependent persons who use but include those costs incurred by 
those with a drug dependence (i.e. drug-purchases). For instance, where it is reasonable to 
assume that the person held incomplete information (such as the costs related to premature 
mortality), include the intangible costs of premature mortality of all persons who use the 
substance, and the cost of drug purchases by persons who are dependents (Collins and 
Lapsley, 2008); and, 
● Consider any indirect costs arising from consumption of a substance as a social cost as well as 
costs directly arising from dependence. The rationale for this approach is that few of the key 
assumptions underpinning the ‘rational addiction’ hypothesis are likely to be fulfilled in this 
situation, with continued consumption amongst those who are dependent likely to be mainly 
driven by the dependence rather than fully informed and rational decisions. Expenditure on the 
drug incurred by those who are not dependent is still considered as ineligible. 
 
Consistent with the approach used in our previous analyses of the costs of tobacco and methamphetamine 
use (Whetton et al., 2015; Whetton et al., 2019), and the evidence that persons who are dependent do not 
necessarily fully integrate these costs into their decision making, some internal costs were included in our 
analysis. We included those internal costs that appear to arise from dependence and those costs where it 
was not possible to separate those who were dependent and not dependent (such as premature mortality). 
Internal costs for those who were not dependent, such as illicit opioid purchase costs by those who were not 
dependent, were excluded. 
 
2.2.2 Timeframe 
The period selected for the study was the financial year 2015/16. This was the most recent year with 
reasonably comprehensive data. In the current analysis the availably of information on deaths from the NCIS 
was the critical component in selecting the target year. Coronial findings may be subject to delay, in particular 
in cases where there are criminal or other proceedings. We selected 2015/16 as the year that provided the 
best compromise between contemporaneous and comprehensive data. This also coincided with the triannual 
National Drug Strategy Household Survey (NDSHS) which was conducted in 2016 (Australian Institute of 
Health and Welfare, 2017g). As detailed below, substance use leading to some of the adverse health 
conditions could have occurred many years earlier. For example, the burden of liver cancer secondary to 
hepatitis C and B infection arising from opioid injecting drug use (IDU) occurs a number of years after the 
hepatitis infection. Therefore, where necessary we used (and report) the prevalence of IDU from an earlier 
period.  
 
2.2.3 Approaches to estimating cost 
Consistent with earlier analyses undertaken for the Australian Government, that quantified the social costs 
of substance use, including illicit drugs, methamphetamine, alcohol and tobacco (Collins and Lapsley, 1996, 
2002, 2008; Whetton et al., 2016; Whetton et al., 2019), this study estimated the costs of illicit opioids for one 
recent year, namely the financial year 2015/16.  
 
Two broad approaches 3 can be taken to assessing the costs related to a particular study year for a social 
cost study: 
                                                     
3 Unique to their studies, Collins and Lapsley (1996, 2002, 2008) adopted an alternative method to costing premature mortality 
which they called the demographic approach. This involved estimating the number of premature substance use attributable 
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(a) The “incidence approach” involves valuing the marginal impact of drug use in the target year for 
all subsequent harms of that drug use. The identified future costs are then converted back to 
their present value equivalent by applying an appropriate discount rate e.g. seven percent. To 
calculate future harms in the incidence approach, ‘damage functions’ are required for each 
attributable form of illness and premature mortality, in order that the increased probability of 
illness and death for all future years that arose from drug use in the target year can be 
calculated; or, 
(b) The “prevalence approach” involves valuing the costs incurred in the target year from the harms 
that occur in that year, whenever the drug use began that produced that harm. The prevalence 
approach estimates the monetary value of all forms of harm attributable to the drug identified in 
the target year. In the case of harms which occur in the target year but incur costs into the future, 
such as the lost economic output due to premature mortality, these costs are estimated and 
then discounted back to their present values by applying an appropriate discount rate. 
 
These two approaches have their own strengths and weaknesses. Where the aim of the study is to assess 
the future cost of a policy or treatment change, then the incidence approach is preferred. The incidence 
approach assesses the ‘flow’ of new harms into the future from consumption in the study year. In contrast, 
the prevalence approach includes some acute harms (‘flow’) and some harms that have arisen from prior 
exposure (‘stock’ measures). If the aim of the analysis is to evaluate the resources required to address the 
harms in the target year, then the prevalence approach is preferred. This is especially the case when the 
stream of future costs is uncertain, if the ‘damage functions’ applicable to the drug are not known for all types 
of harm, or when there is uncertainty about the lag between exposure and the harm.  
 
In the case of the social cost of extra-medical opioids, there are limited epidemiological data to calculate 
damage functions, and inform assumptions about the lags between exposures and harms, especially extra-
medical opioid attributable ill-health for ‘chronic’ conditions. Therefore, we have adopted a prevalence 
approach focussing on the costs of harm that occurred in the study year. Where possible we have adopted 
‘stock’ measures of cost, for example the extra-medical opioids attributable costs of formal and informal care 
are included for the stock of those receiving care for impairments arising from liver cancer, regardless of 
when the cancer was first diagnosed. However, in those cases where harms that occurred in the study year 
produce long-lived impacts (for example premature deaths, or imprisonment for opioid attributable crime) we 
have included the present value of all future costs of those harms. Overall, we anticipate that the incidence 
and prevalence approach would produce similar results in the analysis of extra-medical opioid costs given 
the preponderance of acute harms compared with chronic harms. This is in contrast to tobacco-related social 
costs where chronic conditions predominate. 
 
2.2.4 Summary of approach to identification of social costs of extra-medical opioids use in Australia 
in 2015/16 
The objective of this study was to determine the (net) social costs arising from the extra-medical use of 
opioids in the financial year 2015/16. To achieve this, we estimated the number of people whose death was 
attributable to extra-medical use of opioids (via the NCIS, the GBD study and AIHW data4), the number of 
hospital separations attributable to opioids (extracted from NHMD), and other health care costs. We also 
                                                     
deaths that occurred over the 40 years preceding the study year, and then estimating how many of these prematurely 
deceased individuals would have still been alive in the study year (and how many would have been in workforce in the study 
year). This approach was not used for the current study as, in our opinion, the epidemiological data on historical substance 
use attributable deaths was not of sufficient quality. 
4 See Chapters 3 and 4 methods for details on the identification and attribution of deaths and separations 
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estimated the long-term future costs of lost productivity and the avoided health care costs associated with 
extra-medical opioid attributable deaths that occurred in 2015/16. We also estimated the intangible value of 
those deaths. Hospital separations attributable to extra-medical opioids were costed based on acuity adjusted 
average cost of hospital separations, weighted for the cost of the treatments used. From the DUMA data we 
estimated the scale of opioid attributable crime, with costs to police, courts and corrections systems identified 
from administrative data and the costs to victims of crime from estimates produced by the Australian Institute 
of Criminology. Costs of absenteeism and workplace injury were estimated from NDSHS (Australian Institute 
of Health and Welfare, 2017g) and Safe Work Australia (2015) reports. While the specific details in the 
remainder of this chapter relate most closely to Chapters 3 and 4, the issues of identification of relevant cases 
and their attribution to opioids is applicable throughout. 
 
2.3 Attribution of causality 
The use of opioids is the causal factor for a number of conditions and one of several potential causal factors 
for other conditions. In estimating the costs of extra-medical opioid use, we needed to correctly apportion the 
premature deaths and morbidity for conditions that are partially caused by their use. Social cost studies have 
developed three approaches to estimating these costs. 
 
2.3.1 Indirect attribution 
Indirect attribution involves using AF calculated from relative risks (RR) or odds ratios (OR) for the role of 
opioids use in the condition and population specific exposure to opioids. This method is considered to be the 
most robust as it draws on estimates of relative risk identified from large populations together with time and 
location specific exposure data to identify the share of harms attributable to the risk factor in question. In 
order to calculate the AF, we require the RR from case-control or cohort studies, showing the risk of dying or 
developing the condition for those who use opioids extra-medically compared with those who do not. Further, 
we need the population prevalence of extra-medical use of opioids use by age and gender, typically from 
self-reported surveys. This was our preferred method for calculating the proportion of hospital separations in 
this study (see Section 4.3) and for partially attributable causes of death (see Section 3.1.7). 
 
English et al. (1995) developed the method used in calculating AF from RR. The formula below is used to 
determine the AF for a specific condition where the extent of risk varies by the level of consumption of the 






















Where -  
i = the consumption levels (in most cases for this study this will be dependent use from the GBD 
(Global Burden of Disease Collaborative Network, 2018));  
Pi = the proportion of the target population who are using at level of consumption i; and, 
RRi = the relative risk of a person at consumption level i of having the condition. 
 
For conditions such as blood borne viruses (BBV) and consequences of those infections (liver cancer and 
cirrhosis), AF were initially calculated for injecting drug use as a whole using the relevant age group and 
gender specific RR for persons who inject drugs for each condition, and the prevalence of injecting drug use. 
The AF were then adjusted by the prevalence of injecting opioids among people who regularly inject drugs 
to apportion a fraction of each of the AF of the condition due to extra-medical opioid use by injecting. 
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Table 2.1 shows for each condition (by specified ICD-10-AM code) the method of attribution used together 
with the AF or RR used in the analyses. We note that extra-medical opioid use is associated with mental 
health disorders such as depression and anxiety, but currently there is no suitable quality review estimating 
the effect sizes for these conditions (Degenhardt et al., 2019. 
11  Chapter 2: Methods 
 
Table 2.1: Opioid attributable conditions 
Condition/Risk/Injury ICD-10-AM code Level of attribution Approach 
Relative risk (RR) (95 % CI) 
Attributable Fraction (AF) Source 
Unintentional opioid toxicity/poisoning/overdose T40.0 - T40.4, T40.6 Wholly Direct AF = 1 NCIS / ICD-10-AM  
Mental and behavioural disorders due to use of 
opioids F11* Wholly Direct AF = 1 ICD-10-AM 
Injecting-related skin and vascular infections** 
L02*, L03*, I80*, L97*, L98.8, M79.3, A48.0, G06*, G09, K63.0, 
K65.0, K75.0, M54.02, M72.6*, N10, R02, A40*, A41*, I26.9, 
I40.0, R57.2, R65.1, R65.9, M86*, M89.9 
Wholly 
Partially Direct 
AF = 1 of fraction adjusted for 
polysubstance use (see 
Table 4.4) 
ICD-10-AM 
Non-fatal brain injury due to toxicity** G40*-G47*, G92, G93.1, G93.6, G93.9, G94.2, R40*, R09.0 Wholly Partially Direct 
AF = 1 of a fraction adjusted 
for polysubstance use (see 
Table 4.5) 
ICD-10-AM 
Suicide and self-harm X60-84, Y87.0 Partially Indirect RR = 9.01 (6.28-12.92) Larney (2019)  
Road crash injuries 
V12-V14 (.3 -.9), V19.4-V19.6, V19.9, V20-V28 (.3 -.9),  
V29-V79 (.4 -.9), V80.3-V80.5,V81.1, V82.1, V82.9, V83-V86 
(.0 -.3), V87.0-V87.9, V89.2, V89.3, V89.9, V02-V04 (.1, .9), 
V06.1, V09.2, V09.3 
Partially Indirect RR = 7.35 (4.69, 11.51) a 
Larney (2019) Data on the age 
profile of drivers culpable for road 
crashes resulting in serious injury 
Drummer (2003) 
Other accidental injuries 
V01-V99 not included in road crash accidents, W00–W19; 
W20–W64; W65–W74; W75–W84; W85–W99; X00–X19; X58–
X59; Y85- Y86 
Partially Indirect RR = 7.35 (4.69-11.51) Larney (2019) 
Acute hepatitis C virus B17.1, B18.2 Partially Indirect AF in Table 4.5 GBD (2018) 
Acute hepatitis B virus B16*, B17.0, B18.0, B18.1 Partially Indirect AF in Table 4.5 GBD (2018) 
Human immunodeficiency virus  B20*-B24* Partially Indirect AF in Table 4.5 GBD (2018) 
Liver cirrhosis secondary to hepatitis B or C K70.2, K70.3, K70.4, K72.1, K74.0, K74.3, K74.4, K74.5, K74.6, I85.0, I85.9, I86.4, I98.2, I98.3 Partially Indirect AF in Table 4.5 GBD (2018) 
Liver cancer secondary to hepatitis B or C C22* Partially Indirect AF in Table 4.5 GBD (2018) 
Low birthweight P07.0, P07.1 Partially Indirect RR = 3.28 (2.47‐4.39) Hulse (1997) 
Interpersonal violence X85–Y09, Y87.1 Partially Excess attribution AF = 0.0214 DUMA data, analysis by AIC 
Neonatal abstinence syndrome P96.1 Partially Excess attribution AF = 0.965 Abdel-Latif (2013) 
Infective endocarditis I33.0 Partially Excess attribution AF = 0.008 b Larney (2019) 
*Code starting with; **coupled with opioid-related ICD-10-AM code in additional diagnosis (see Sections 4.2.2 and 4.2.3 for more details)  
a Attributable fractions for road crash accidents were calculated for specific age groups using the prevalence of persons dependent on opioids, this was then weighted to give an all ages AF 
using the age profile of culpable drivers: b of the population of PWID  
AIC = Australian Institute of Criminology 
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2.3.2 Excess attribution 
Excess attribution estimates are derived from studies that identified ‘excess’ mortality or morbidity from the 
condition, as well as incidence of crime attributable to the substance, giving an AF or proportion of cases 
attributable to opioids directly.  
 
2.3.3 Direct attribution 
Direct attribution involves the use of expert opinion to attribute additional specific cases. Expert attribution 
has important limitations, in particular in the criteria used to attribute cases, variation between experts and 
the extent to which the cases reflect the exposure patterns in the population. However, in the case of rare 
events, such as illicit drug-related deaths, the level of uncertainly due to random variation between risk and 
outcomes means that ‘correct’ apportionment using the indirect approach is problematic. Therefore, in 
determining deaths directly attributable to illicit opioids, we used direct attribution based on the forensic 
pathologists’ reports in coronial files (see Sections 3.2.1 and 3.2.2 for details). Direct attribution is also 
implicitly used in those cases which are attributable wholly to opioids, by definition in that we are reliant on 
the coding undertaken in the hospital as to the cause being one that is wholly attributable to opioids. 
 
2.4 Epidemiological basis for cost calculations 
2.4.1 Which people who use substances are included? 
The total and component parts of extra-medical opioid use (pharmaceutical opioid misuse and illegal opioid 
use) are critical in many of the calculations of their attributable harms. The attributable harms arising from 
pharmaceutical opioid misuse and illegal opioid use are likely to vary with the type, quantity and frequency 
with which the drugs are used, the context of use, level of drug dependence and, method of use (e.g. 
injected). In some instances, the prevalence of interest may be “any use” over the past year which 
approximates to all persons who currently uses. In other cases, the focus of interest is on persons who are 
dependent in estimating the extent of harm. Finally, there are some types of harm where the drug use per se 
is not the causal factor, but the critical factor is whether or not the drug is injected, such as in the transmission 
of BBV. Notably, treatment data showed that 81 percent of those seeking treatment for heroin use reported 
injecting as the most common route of administration (Australian Institute of Health and Welfare, 2017a).  
 
One key source of data was the NDSHS (Australian Institute of Health and Welfare, 2017g). The NDSHS is 
a triennial national survey of the use of licit (i.e. alcohol, tobacco) and illicit drugs (cannabis, 
methamphetamine, cocaine, heroin etc.). The survey collects demographic information, measures wellbeing, 
and gathers opinions on alcohol and other drug issues. The NDSHS uses a complex multi-stage probabilistic 
sampling framework in order to collect data on a representative sample of people. In 2016, 23,772 individuals 
aged 12 years and over in Australia were surveyed with a response rate of 51.1 percent achieved. Many 
questions however were not asked of 12 and 13 year-olds (Australian Institute of Health and Welfare, 2017g). 
In 2016, 0.2 percent of Australians aged 14 years or older had used heroin in the past 12 months and 3.6 
percent had misused pain-killers/pain-relievers and opioids in the last 12 months (Australian Institute of 
Health and Welfare, 2017i).  
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Table 2.2: Estimated 2015/16 prevalence of heroin use and misuse of pharmaceutical opioids aged 14 years 
or older by frequency of use over the past year 
Heroin Source N (%) 
 Daily + once a week or more (“Dependent use”) 1 14,739 (0.074) 
 Once a month + every few months 1 7,657 (0.033) 
 Once or twice a year 1 7,772 (0.039) 
 Any use – total a 1 30,167 (0.152) 
Pharmaceutical opioid (misuse)   
 Daily + once a week or more (“Dependent use”) 1 184,959 (0.932) 
 Once a month + every few months 1 269,131 (1.356) 
 Once or twice a year 1 181,421 (0.091) 
 Any use – total b 1 635,511 (3.202) 
Extra-medical opioid use    
 Daily + once a week or more (“Dependent use”) c, d 1 190,525 (0.960) 
 Any use a 1 645,260 (3.251) 
 Clinical criteria Dependent use 2 104,026 (0.480) 
Source: 1 = National Drug Strategy Household Survey (Australian Institute of Health and Welfare, 2017i): 2 = Global Burden of 
Disease (Global Burden of Disease Collaborative Network, 2018) 
a Recent use but did not answer frequency of use = 3,000 
b Recent use but did not answer frequency of use = 79,153 
c Heroin and / or pharmaceutical opioid: 
d There were 64 people who reported illicit use of methadone or buprenorphine (unable to cut down or stop) who were not 
classified as “dependent” on either heroin or pharmaceutical pharmaceuticals – these were not included in the count as 
frequency of use was not asked for illicit methadone or buprenorphine. 
  
The prevalence estimates for alcohol and tobacco use, and commonly used illicit drugs, such as cannabis, 
is generally regarded as reliable, especially over time, in the NDSHS. The accuracy of data for other illicit 
drugs, those with a drug use disorder, and those who inject, is likely to be less reliable (Hickman et al., 2002). 
Household surveys rely on self-report and will miss the most disadvantaged persons who use drug, such as 
those who are homeless, living in hostels, institutions or in unstable accommodation. Furthermore, heavy or 
problematic substance use is not uniformly distributed geographically, and thus may not be adequately 
sampled in national household surveys (McKetin et al., 2005). Finally, at least in the case of 
methamphetamine, media attention appears to have increased stigmatisation of methamphetamine use, 
resulting in under-reporting in the NDSHS in comparison to cocaine and ecstasy use. With respect to heroin 
use, the pattern of data did not allow clear conclusions to be drawn about the extent of under-reporting 
(Chalmers et al., 2016). 
 
For some forms of harm the relevant prevalence is not persons who use extra-medical opioids, but persons 
who are dependent on opioids. The NDSHS does not estimate dependence; instead the prevalence of extra-
medical opioid dependence was from the GBD Results Tool. As this tool reports data by calendar year, we 
took the mean for the years 2015 and 2016 (2015 – 101,934 (87,777-117,298): 2016 – 106,118 (91,192-
123,093), to give an average for 2015/16 of 104,026 (Global Burden of Disease Collaborative Network, 2018). 
For males aged 15-49 years, the prevalence was 1.118 percent (range 0.935-1.325 percent): for females it 
was 0.479 percent (range 0.386-0.586). 
 
The GBD systematically reviews the literature on each topic (e.g. opioid dependence) to identify reports on 
the prevalence, incidence, remission and excess mortality, which must include a measure of clinical 
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“caseness” (e.g. based on ICD criteria.) Prevalence by age, sex, year and country is estimated using DisMod-
MR modelling. The GBD study acknowledges the potential for under-reporting of stigmatised behaviours, 
such as illicit drug use, in data collected through direct survey methods. Therefore, preference is given to 
indirect methods including back-projection and capture-recapture and these estimates are used to adjust 
(“crosswalk”) prevalence estimated derived from surveys (Vos et al., 2017). However, the GBD study does 
not provide an estimate of the prevalence of non-dependent extra-medical opioid use. 
 
We used these data on the prevalence of persons dependent on opioids in estimating the intangible costs to 
people who used extra-medical opioids in 2015/16 in terms of suffering disability, pain and other reductions 
to quality of life due to opioid attributable disease. It was also the prevalence used in many of the indirect 
attribution estimates of opioid attributable mortality and morbidity. Spending on extra-medical opioids by 
persons who are dependent was also calculated. For some measures, such as harms to others, where the 
household structure of people who were dependent on opioids were required, a proxy measure of 
dependence had to be derived from the NDSHS data. This estimate was based on the frequency of use (daily 
+ once a week or more often) to approximate ‘dependence’ (See Table 2.2) (Australian Institute of Health 
and Welfare, 2017g). 
 
2.4.2 Polysubstance use 
Polysubstance use is common among people who use drugs of all types. For example, among those seeking 
treatment for heroin use, 52 percent also listed an additional drug of concern (amphetamine 23%, cannabis 
19%, nicotine 17%, alcohol 12%, benzodiazepines 11%) (Australian Institute of Health and Welfare, 2017c). 
This has implications for all aspects of the current analysis in attributing costs (e.g. health care, crime). 
However, polysubstance use is a particular complication in attributions of mortality, with nearly half of opioid-
induced deaths in 2016 involving benzodiazepines, 26 percent antidepressants, 16 percent antipsychotics 
and 15 percent alcohol (Roxburgh et al., 2018). In 2017 this had increased, with over half of opioid-induced 
deaths involving benzodiazepines, 32 percent antidepressants, 19 percent antipsychotics, 16 percent 
paracetamol and 16 percent alcohol (Chrzanowska et al., 2019). For further details on the classification of 
polysubstance use and mortality, see Chapter 4. Therefore, except for instances where the AF is one, such 
as opioid dependence, the attribution of harms to a particular substance carries a measure of uncertainty 
and, in some cases, uses relatively crude estimates of the attributable costs.  
 
2.4.3 Generalising from a sample 
As noted above (Section 2.3.1), even nationally representative data sets may not provide reliable data on the 
extent of extra-medical opioid use, especially for those with more severe substance use problems or in 
specific groups or locations not well represented in the data. However, national data are not available for all 
extra-medical opioid-related harms (e.g. Section 11.2.3 Child protection costs). Therefore, we have had to 
rely on state–based or even single-study estimates of some harms. In these cases, this has been 
acknowledged in the limitations section of the respective Chapters. 
 
2.4.4 Range of costs 
As a result of these uncertainties, in addition to our best estimate of costs, we also estimated a lower and 
upper range where possible, using plausible alternative values or sources of data. Where data are available, 
we present our best estimate of costs together with a high and low range. Where a range was not calculated 
we used the central estimate to replace the missing boundary(s) (e.g. Summary Table 11.3.). Alternatively, 
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where we were only able to estimate the outer boundaries, their mean was used as the central estimate (e.g. 
expenditure on extra-medical opioids Chapter 10). 
 
2.5 Included and Excluded Costs 
The issue of excluded costs, in particular where data were missing, is detailed in Chapter 12. Nevertheless, 
we are aware of areas where costs were incurred but we were unable to quantify them – for example, the 
Australian Federal Police and border control operations. In addition, it seems likely that those living in remote 
and regional areas will have different costs to those in metropolitan areas: we were unable to quantify the 
extent of this difference.  
 
Our analysis has not attempted to estimate the “opportunity costs” in this area. For example, expenditure on 
the treatment of extra-medical opioid related conditions could have been used in other areas of government 
expenditure. 
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CHAPTER 3: PREMATURE MORTALITY  
Emma Zahra, Steve Whetton, Gabrielle Campbell, Louisa Degenhardt, Agata Chrzanowska & Robert J. Tait 
 
3.1 Background  
Of all illicit drugs, opioids make the largest contribution to the global burden of disease (GBD), and their use 
is associated with the highest risk of premature mortality arising from illicit drugs (United Nations Office of 
Drugs and Crime, 2019a). In 2017, globally a total of 585,000 people died due to illicit drug use, with opioids 
responsible for two-thirds of these deaths (United Nations Office of Drugs and Crime, 2019a). Opioid use 
disorders accounted for over half of the 42 million years of healthy life lost due to all illicit drug use disorders 
and related infectious diseases; hepatitis C virus (HCV), human immunodeficiency virus (HIV) and acquired 
immune deficiency syndrome (AIDS) (United Nations Office of Drugs and Crime, 2019a).There are estimated 
to be 26.8 million cases of opioid dependence globally, which equates to 353.0 cases per 100,000 people 




Findings from a meta-analysis of forty-three cohorts, estimated the pooled all-cause standardized mortality 
ratio (SMR) of people that use extra-medical opioids compared to their counterparts, was 10.0 (95% CI 7.6, 
13.2). Extra-medical use of opioids increases the risk of death from overdose, communicable and non-
communicable disease, suicide, and injuries (Larney et al., 2019). 
 
In 2016, a total of 1,119 opioid-induced deaths were reported in Australia, representing 0.7 percent of all 
deaths that occurred that year (Australian Institute of Health and Welfare, 2018). The median age of opioid-
induced deaths was low, 38 years, compared to the median age for all causes of death, at 81 years. The 
number and rate of opioid-induced deaths has continued to increase since 2007, and comparatively the total 
number in 2016 was almost double that of the number recorded in 2007 (Australian Institute of Health and 
Welfare, 2018d). In Australia there has been a shift in the pattern of opioid attributable overdose deaths. 
While rates of heroin overdoses remained relatively stable between the years 2001 and 2012, rates of 
                                                     
5 There is currently debate as to whether the term ‘uncertainly interval’ should replace ‘confidence interval’ (Gelman and 
Greenland, 2019): The Degenhardt paper used ‘uncertainly interval’, so that was reported here. 
Box 3.1: Terminology used to describe cause of death  
An opioid-induced death has an underlying cause of death directly attributed to one or more opioids, e.g. 
poisoning, overdose or toxicity.  
 
An opioid-related death is when opioid use was found to be contributory to the death (indirectly, partially 
attributable), e.g. transport accidents, suicide, interpersonal violence and disease processes like blood-
borne virus infections. 
 
This report will use the term opioid deaths to include both opioid-induced and opioid-related deaths. 
When the separation between these two types of causes of death is to be made, the specific terminology 
will be stipulated.  
 
Our definitions align with the ABS terminology for causes of death, Australia, 2016 (Australian Bureau of 
Statistics, 2017b). 
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pharmaceutical opioid overdose deaths have increased (Roxburgh and Burns, 2017). Figure 3.1 shows the 
changes in the types of opioids cited in opioid-induced deaths between 1997 and 2017. 
 
Figure 3.1: Rate of opioid-induced deaths per 100,000 people aged 15-64 for all opioid types, 
heroin, methadone, natural and semi-synthetic opioids (e.g., morphine, oxycodone), opium, 
synthetic opioids (e.g., fentanyl, tramadol) and other opioids, 1997-2017 
 
Reproduced with permission from (Chrzanowska et al., 2019) 
 
The deaths wholly attributed to opioid use (opioid-induced) arise due to drug toxicity, however opioid use has 
a partially causal role for other conditions and injuries which can be categorised into the following causes; 
diseases (and their subsequent impacts), suicide, interpersonal violence, accidental injury, and low 
birthweight resulting from in-utero exposure to opioids. Deaths in which opioids play a partially causal role, 
will be referred to as opioid-related in this report (Box 3.1).  
 
3.1.1 Drug toxicity  
Opioids have a high lethal potential due to their pharmacological mechanisms of action. As a central nervous 
system (CNS) depressant, they act on the opiate receptors in the brain producing analgesic, sedative and 
euphoric effects. Symptomatology of opioid toxicity is clinically acknowledged as the overdose triad of miosis 
(pupil constriction), respiratory depression and reduced level of consciousness. These effects are further 
intensified with concomitant use of other CNS depressants, such as alcohol, barbiturates and 
benzodiazepines, which are a common occurrence in identified overdoses. Without timely administration of 
the opioid antagonist naloxone, toxicity can result in coma, respiratory and cardiac arrest. Asphyxia, 
pulmonary aspiration, anoxic brain damage, increased intracranial pressure and hypotension are also 
recognized consequences of greater than therapeutic and lethal opioid toxicity (Darke et al., 2019; Leikin and 
Paloucek, 2015). 
 
It is challenging to quantify what opioid levels will result in death, as multiple factors are important. These 
include characteristics of the substance (e.g., adulterants, purity), the individual (e.g., tolerance, concurrent 
injuries or illness) and the environment or context (e.g., polysubstance use and external exposures). Focusing 
on the two key factors of opioid type and tolerance, it should be noted that opioids have varying toxicity levels 
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as their properties differ (Baselt, 2008). Meaning, each drug has individual pharmacokinetic characteristics, 
and therefore different potencies and associated risks. For example, fentanyl is highly potent and has a more 
rapid onset of action, but a shorter duration of effect compared to morphine. As fentanyl is lipophilic 
(dissolving in fats), whilst morphine is hydrophilic (dissolving in water), fentanyl crosses over into the brain at 
a faster rate (Bryant and Knights, 2014). 
 
Tolerance to opioids can occur with long-term use, and conversely tolerance can be lost in times of 
abstinence. As a result of this, people who use opioids are at greater risk of overdose after times of 
abstinence, such as release from prison, or returning to the community from hospital or rehabilitation services 
(Marsden et al., 2017). On the other hand, it has been theorised that long-term use of opioids, even without 
periods of abstinence, can increase the risk of overdose, as tolerance to the euphoric effects builds faster 
than tolerance to the effects on the respiratory system. Essentially, people that use opioids long-term require 
larger doses to achieve previous euphoric experiences, but the respiratory system is overwhelmed by the 
effects causing respiratory depression/arrest (Darke, 2016; White and Irvine, 1999). 
 
3.1.2 Injuries and diseases related to injecting risks 
Opioid-related diseases that lead to premature mortality, are not only linked to the pharmacological properties 
of the substance, but also the different routes of drug administration. The mortality rate for people who inject 
drugs (PWID) (including cohorts that inject opioids, amphetamine and cocaine), is 15 times that of people 
who do not inject (Mathers et al., 2013). The harms associated with injecting drug use (IDU) include the 
transmission of communicable diseases, with the predominant pathogens being hepatitis C virus (HCV), 
hepatitis B virus (HBV) and HIV (Degenhardt et al., 2017). 
 
Other risks of IDU include but are not limited to, cardiovascular disease (heart and blood vessels), skin and 
soft tissue conditions, nerve damage, and the dispersion of foreign material amongst the body causing 
inflammation and/or occlusions (Darke et al., 2019; Larney et al., 2017b). Unsterile injecting practices and 
methods of tampering with pharmaceutical opioids that are designed for alternate administration, such as 
oral tablets or transdermal patches, can lead to disease and fatal outcomes (Peacock et al., 2015). 
Furthermore, intravenous administration is a direct bolus of the substance into the circulatory system, 
therefore concentrations will peak faster and at higher concentrations, as other processors of metabolism 
have been bypassed, increasing the danger of toxicity (Bryant and Knights, 2014). Finally, HBV and HCV 
increase the risk of developing cirrhosis of the liver and liver cancer. 
 
Not all these risks are currently able to be quantified from the available epidemiological data, however RR 
for IDU are available for HBV and HCV, HIV, liver cirrhosis secondary to HBV and HCV, liver cancer 
secondary to HBV and HCV, and infective endocarditis. 
 
3.1.3 Suicide  
The GBD estimated the pooled RR of suicide for opioid dependence was 6.9 (95% CI: 4.5, 10.5) (Degenhardt 
et al., 2013b). In Australia in 2016, the AIHW estimated that 14 percent of all deaths directly caused by 
opioids (opioid-induced) were the result of suicide. Gender and age comparisons of suicides involving opioids 
revealed that the largest disparity was in the age group of 25 years or under, with male suicide rates twice 
as high as female rates (Australian Institute of Health and Welfare, 2018d). 
 
19  Chapter 3: Premature mortality 
 
More specifically, it has been found that people with heroin dependence, as opposed to opioid dependence 
more broadly, are at greater risk of attempted and completed suicide. In comparison to the general 
population, people with heroin dependence are 14 times as likely to complete suicide (Darke, 2011).  
 
3.1.4 Interpersonal violence  
Persons who use drugs extra-medically (particularly with heavier and dependent use) are both more likely to 
commit violent crime, but are also more likely to be victims of violent crime (Darke, 2010; Torok et al., 2008) 
Mechanisms for the increased probability of committing violent crime include economic crime to fund drug 
consumption (economic/compulsive crime), crime aimed at supporting or protecting systems of drug 
distribution and use, such as violence used to recover debts from people who use drugs (systemic crime), 
and violence that results from the altered mental state and/or reduced inhibition caused by consumption of 
many illicit drugs, or withdrawal from them (pharmacological crime) (Darke, 2010; McKetin et al., 2006; 
Nicosia et al., 2009; Stretesky, 2009; Torok et al., 2008). 
 
Torok and colleagues (2008) surveyed a group of people who regularly used methamphetamine and heroin, 
161 of whom primarily used heroin. Of the primarily heroin using group, 62 percent reported having been 
charged with a violent crime at some point in their lives (with 58% reporting having been convicted) and 35 
percent reported having committed at least one violent crime in the past 12 months, with 72 percent of those 
committing violent crime having committed multiple offences. The persons using heroin also reported high 
rates of being victims of interpersonal violence, with 40 percent having been a victim of violent crime in the 
past 12 months, 87 percent of whom had been the victim on more than one occasion. 
 
The specific rates of crimes of violence committed by, and experienced by, the cohort included in the Torok 
study may not be representative of the broader population of persons who use opioids extra-medically, as 
the severity of dependence was high amongst the sample population, with a mean severity of dependence 
scale score of 9.0 for the sub-sample who primarily used heroin. Instead, for this analysis we have used the 
estimated AF for violent crime derived from the Drug Use Monitoring Australia (DUMA) (Australian Institute 
of Criminology, 2019) survey, which for heroin is 0.021 (see Chapter 7 for details). 
 
3.1.5 Accidental injury (trauma)  
As explained above, opioids have sedative effects, causing cognitive impairment and drowsiness (Chihuri 
and Li, 2017). This means that people who use opioids may be more prone to accidental injuries and trauma; 
such as motor vehicle accidents, drownings, falls and workplace incidents. Furthermore, individuals with 
decreased levels of consciousness are vulnerable to other harms. These harms can occur from external 
hazards, such as smoke and fire, or other environmental factors such as low temperatures leading to 
hypothermia (although as the evidence for opioid attribution of the latter form of accidental death is not 
available it has not been included in this analysis). An unconscious state is particularly dangerous as the 
airway can easily become compromised, positional asphyxia or aspiration of gastric contents can be a 
consequence of this situation (Darke et al., 2019). 
 
For premature deaths arising from road crashes, the AF was calculated based on the age share of at fault 
drivers to weight the age specific AF for opioid dependence (Drummer et al., 2003). This weighted AF was 
then applied to all road crash deaths, as it is the opioid attribution of the ‘at fault’ driver that is relevant rather 
than the potential opioid attribution of the decedent. As such, deaths for those aged less than 15 are included 
in the calculation of opioid attributable road crash deaths. 
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For all other included forms of accidental deaths, age and gender specific AF were calculated from the 
appropriate relative risk and the estimated prevalence of opioid dependence for that age group and gender 
category. 
 
3.1.6 Low birthweight 
Low birthweight is acknowledged as a risk factor for premature mortality (World Health Organization, 2019). 
Use of opioids during pregnancy increases the risk of low birthweight by 3.28 (2.47-4.39) (Hulse et al., 1997), 
with an estimated prevalence of opioid dependence amongst patients who were pregnant of 0.66 percent 
(Abdel-Latif et al., 2013), giving an AF of 0.015 (0.010 – 0.022).  
 
3.1.7 Identification of opioid attributable deaths 
There are three approaches that can be adopted in estimating the number of deaths attributable to a specific 
substance. The first being an indirect method, in which AF are deduced from strong epidemiological research, 
and then applied to the gross number of deaths attributable to the cause or risk factor. The second being 
through direct attribution, in which deaths that have been deemed attributable to a substance in the coronial 
record, as determined by the forensic pathologist, are examined. Finally, deaths can be attributed to a 
substance through an ‘excess risk’ approach which identifies the extent to which harms are more prevalent 
amongst the exposed population compared to the non-exposed population. 
 
This study has used a mix of the two approaches. For those deaths where the cause of death was drug 
toxicity, drug toxicity and disease processes, and drug effect and disease processes, we have used the direct 
approach to identify them in the National Coronial Information System (NCIS) database based on the 
assessment made by the forensic pathologist as to whether or not opioids were the causal factor. For those 
conditions where opioids are one of several (or indeed many) potentially causal factors, we have used the 
indirect method where possible to attribute a proportion of those deaths to opioids based on RR identified 
from the literature and data on the prevalence of use (or dependent use) in that age and gender category. 
These causes of death were: 
• Suicide;  
• Road crash and other accidental injuries; 
• Interpersonal violence; and,  
• Low birthweight. 
 
Causes of death resulting from injecting drug use were also estimated using the indirect method, with the 
relevant exposure prevalence being injecting drug use where the most frequently injected drug in the last 
month was opioids. These causes of death were: 
• Acute HCV; 
• Acute HBV; 
• HIV; 
• Liver cirrhosis secondary to HBV; 
• Liver cirrhosis secondary to HCV; 
• Liver cancer secondary to HBV; and, 
• Liver cancer secondary to HCV. 
 
Relative risk estimates were not available for the extent to which interpersonal violence can be attributed to 
extra-medical use of opioids. Instead the excess attribution approach was used, with the source of the AF 
being the DUMA survey of Australian police detainees. 
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Injecting drug use is a causal factor for infective endocarditis and is estimated to be responsible for 6.8 
percent of cases in Europe (Slipczuk et al., 2013). Unfortunately, the deaths data in the GBD compare 
database aggregates for infective endocarditis with other forms of endocarditis, and so it has not been 
possible to estimate the number of deaths attributable to injecting drug use. Similarly data gaps precluded 
the inclusion of neonatal abstinence syndrome in the deaths data. Both of these conditions were included in 
the morbidity calculations, with the AF identified using the excess risk approach. 
 
3.2 Identification of deaths wholly attributable to opioids 
3.2.1 National Coronial Information System  
NCIS is a centralised database of Australian and New Zealand coronial cases. The system was established 
by the Australian Coroners Society to achieve a collection of national information. Contributions from all 
Australian states and territories commenced from the 1st of July 2000, except for Queensland which followed 
on the 1st of January 2001. The database is a valuable retrospective tool utilised by researchers to inform 
public policy and clinical practice through analysis of unnatural death and injury data. 
 
A death is determined to be reportable to a coroner in accordance with the corresponding jurisdictional 
Coroners Act, meaning specific requirements differ for each state and territory. However, as broadly defined, 
a reportable death is: “unexpected or unexplained; the result of an accident or injury; in care or custody; 
healthcare related; or the person’s identity is unknown” (National Coronial Information System, 2019a). As 
reported on 9th January 2019, 12.4 percent of all deaths in 2015 and 2016 were recorded in the NCIS (Table 
3.1) (Australian Bureau of Statistics, 2016b, 2018c; National Coronial Information System, 2019b) 
 
A complete coronial case includes four reports: a findings report completed by the coroner; an autopsy report 
completed by the forensic pathologist; supporting medical investigations (i.e. toxicology report and/or imagery 
reports); and, a police narrative of the circumstances preceding/surrounding the death. Inquests and public 
health recommendations are made by the coroner when required. The structure and comprehensiveness of 
these reports differ depending on the jurisdiction and date of completion. A coronial case is ‘closed’ upon 
completion of the coroner’s investigations. After closure, the case becomes available for review by authorised 
researchers. Therefore, a delay exists between the time of death and the ability for researchers to access 
case files - this can span months to years. 
 
At the time this study was conducted, the share of closed cases for deaths notified in 2015 and 2016 were 
91.1 percent and 87.0 percent respectively (Table 3.1) (National Coronial Information System, 2019b). It is 
likely that there are systematic variations in the types of cases that remain open, in particular cases involving 
criminal proceedings may be delayed. 
 
Table 3.1: Total number of deaths in Australia, 2015 & 2016 as per Australian Bureau of Statistics (ABS), 
compared to number of National Coronial Information System (NCIS) cases 
Category 2015 2016 
Total Deaths in Australia 1 159,052 158,504 
Total NCIS notified cases in Australia 2 19,774 19,678 
NCIS Closed cases in Australia 2, n (%) 18,011 (91.1) 17,112 (87.0) 
1 (Australian Bureau of Statistics, 2019b): 2 Numbers reported at time of case extraction, 9th January 2019 (National Coronial Information System, 
2019b): calculations by the authors. 
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3.2.2 Search strategy in NCIS 
A retrospective file review of closed coronial cases in Australia, with date of death between 1st July 2015 and 
30th June 2016, was conducted between February and May 2019. All cases coded by NCIS with a positive 
detection of an opioid or its metabolite in the toxicology report were retrieved. This was achieved by searching 
the field ‘Object or Substance Producing Injury’, for each opioid parent drug type, as listed in Table 3.2. 
Additionally, text searches for opioid names and related terminology in cause of death fields were conducted, 
see Table 3.2 for the full list. Both illicit and pharmaceutical opioids were evaluated.   
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Table 3.2: Illicit and pharmaceutical opioids, by NCIS coded parent drug type 
NCIS coded parent drug type for  
‘Substance producing injury’ field 
Text searches in  





Dihydrocodeine "dihyro"  
Fentanyl "fentanyl" 
Poppy Capsules "poppy", "opium" 





Morphine and Metabolites "morphine" 
Opioids (not classified)  "opiate", "opioid", "narco" 






Synthetic Opioids  
Other semisynthetic opioid analgesics  
Other synthetic opioids  
NCIS = National Coronial Information System 
 
For the purposes of this analysis, pharmaceutical opioids listed as a cause of death are deemed ‘extra-
medical use’ as it has resulted in grievous harm contributing to death. As further explained in the limitations 
of this chapter, we are unable to determine if the pharmaceutical opioid/s listed were diverted or not used as 
prescribed (i.e. right person, dose, route, indication, time). Therefore, the inclusion of cases reflects the 
determined cause of death listed by the forensic pathologist.  
 
The results were compiled, and duplicate cases were removed. Each case was reviewed to determine if an 
opioid was listed as a cause of death by the forensic pathologist and separated into one of three categories:  
1) Medical Cause of Death (COD): directly attributable when an opioid was listed as the medical 
cause of death; 
2) Unspecified Multiple Drug: cause of death recorded as unspecified multiple drug toxicity or 
drug effect. For example, ‘multidrug toxicity’, ‘mixed drug effect’; or, 
3) Substance Producing Injury (SPI): when the substance was not listed as a cause of death but 
was detected in the toxicology screen. These cases have been separated out, as the role of 
the opioid is not definitively linked to the cause of death by the forensic pathologist. 
 
3.2.3 Case selection in NCIS 
This study analysed COD and Unspecified Multiple Drug cases only, as opioid-related SPI cases are not 
deemed directly attributable to the cause of death by the forensic pathologist. The intention of the individual/s 
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actions in the event resulting in the death is reported as coded by NCIS. The cases of interest were 
categorised by the following codes: 
1) Unintentional; 
2) Intentional-self harm; 
3) Undetermined intent; 
4) Unlikely to be known; and, 
5) Blank (In the instance where the case is classified as ‘death due to natural cause/s’ at case 
closure, includes disease processes) (National Coronial Information System, 2018). 
 
The role of the opioid in the death, as documented in the coronial record, will be presented in the following 
categories: 
1)  Direct cause; 
2)  Antecedent cause; or, 
3)  Other significant conditions contributing to the death but not relating to the disease or 
condition causing it.  
 
3.2.4 Attributing deaths to illicit opioids from NCIS data 
All opioid directly attributable cases, including unspecified multiple-drug cases, were classified as attributable 
to opioids. This approach was consistent with other previous opioid studies conducted in Australia. 
Additionally, the risk is increased when opioids are taken in conjunction with other CNS depressants due to 
the synergistic effect (Darke et al., 2019). 
 
In order to acknowledge common poly-substances use, we have presented case numbers separating out 
solitary drug listings. The number of cases with a solitary opiate/opioid, multiple opioids and multiple drugs 
listed in the cause of death, were n = 230, n = 55 and n = 737 respectively.  
 
3.2.5 Concomitant drugs in cause of death 
COD cases were further examined to determine the type of opioid listed in the cause of death and other 
concomitant drug types. As multiple variations in the number of poly-substance types exist, the total number 
of drug listings (n = 1,140) will not reflect the total number of COD cases (n = 585: Figure 3.3). As the 
terminology for drug listings in the cause of death is not uniform, we have also included the grouping of 
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Table 3.3 Drug categories for count of concomitant drug cases 







Poppy Capsules Benzodiazepines 
Heroin and/or Metabolites Cannabinoids 
Hydrocodone Hallucinogens 
Hydromorphone Nonsteroidal anti-inflammatory drugs 
Loperamide Non-opioid pharmaceuticals (Such as, but not limited to antihistamines, betablockers, paracetamol, pregabalin) 
Methadone Novel Psychoactive Substances 










3.2.5.1 Poly-substance use findings  
The following categories were not listed in COD fields; tobacco, thebaine, tapentadol, pethidine, loperamide, 
hallucinogens, dihydrocodeine and dextropropoxyphene. The following drug categoriesappeared in 5 or 
fewer cases; anaesthetics, antiepileptics, buprenorphine, dextromethorphan, hydrocodone, non-steroidal 
anti-inflammatory drugs, and pholcodine. To conceal small numbers for ethical reasons, these categories 
have been represented as ‘5’ in Figure 3.2. The most commonly listed substance was heroin at n = 169, 
followed by benzodiazepines at n = 139. The broader terms opioid/s were listed 103 times, while methadone 
(n = 103) was listed more often than fentanyl (n = 80). 
 
3.2.6 Results of NCIS analysis 
A total of 1,453 cases were identified in which an opioid was listed in the COD or was detected in the 
toxicology screen and NCIS coded as such. After the review of each case it was determined that in 675 
instances the forensic pathologist listed an opioid as a medical cause of death. There were 545 cases 
classified as unspecified multiple drug contribution in the form of “use”, “abuse” “effect” or “toxicity”. The 
remaining 233 cases were categorised as SPI, i.e. an opioid was detected in the toxicology screen but was 
not deemed a contribution to the death. The categories of cause of death were explored, and suicide (n =178) 
and accidental injury/trauma (n = 20), were excluded from further analysis, as these categories will be 
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Figure 3.2: Count of substances listed in cause of death 
 
 Drug categories with a count ≤5 have been represented as 5, to ensure individuals cannot be identified. 
 
Figure 3.3: Flowchart of case selection 
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Examination of the medical COD cases in combination with the unspecified multiple drugs cases (Table 3.4, 
n = 1022), revealed that males represented 68.9 percent of the group, with the mean age being 43.0 years 
(SD 11.3), median 42.0 years (range 12-98). An opioid was recorded by the forensic pathologist as a direct 
cause of death in 92.0 percent of cases, an antecedent cause of death in 5.3 percent of cases, and a 
significant contributing condition in 2.7percent of cases. Drug toxicity, including both multiple drug (n = 552) 
and solitary drug (n = 183), accounted for almost three quarters of the deaths at 71.9 percent. Drug toxicity 
in conjunction with a disease process was the cause of death in almost a quarter of cases (24.2%).  
 
Table 3.4: Australia opioid deaths identified via coronial (NCIS) data (financial year 2015/2016): n = 1022 
Characteristic  Value 
Age  mean (SD)   43.0 (11.3) 
  median (range)   42.0 12-98 




 68.9 (704) 
 31.1 (318) 
Intent % (n) 
 Unintentional 
 Undetermined/Unlikely to be known 
 Blank (Death due to natural cause/s)* 
  
 86.7 (886)  
 10.1 (103) 
 3.2 (33) 
Role of Drug Class in Death % (n) 
 Direct cause of death 
 Antecedent cause 
 Significant contributing condition 
  
 92.0 (940) 
 5.3 (54) 
 2.7  (28) 
Category of Cause % (n) 







 71.9 (735) 
  (183) 
  (552) 
 Drug toxicity and disease process  
Solitary 
Multiple 
 24.2 (247) 
  (37) 
  (210) 
 Drug effect and disease process  
Solitary 
Multiple 
 3.9 (40) 
  (10) 
  (30) 
NCIS = National Coronial Information System 
N.B: Multiple Opioids (n = 55) are grouped within multiple drugs (n = 792). Solitary Opioid (n = 230). 
* In the instance where the case is classified as ‘death due to natural cause/s’ at case closure, includes causes of death from 
disease processes (National Coronial Information System, 2018). 
 
3.3 Identification of opioid attributable deaths from other sources 
For those conditions for which opioids were one of several potential causal factors, the numbers of opioid 
attributable deaths were estimated using the indirect approach, using the RR set out in Chapter 2. Conditions 
partially caused by opioids included in this analysis are: 
• Suicide/intentional self-harm; 
• Road injuries and other accidental injury; 
• Interpersonal violence; and, 
• Low birthweight. 
 
Causes of death resulting from injecting drug use were also estimated using the indirect method, with the 
relevant exposure prevalence being IDU where the most frequently injected drug over the past month was 
extra-medical opioids: 
• HIV; 
• Acute HBV;  
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• Liver cirrhosis secondary to HBV; 
• Liver cancer secondary to HBV; 
• Acute HCV; 
• Liver cirrhosis secondary to HCV; 
• Liver cancer secondary to HCV; and, 
• Infective endocarditis (not estimated due to data limitations) 
 
Data on deaths by sex and age group for those causes of death partially caused by extra-medical use of 
opioids was sourced from the GBD project’s compare database (Global Burden of Disease Collaborative 
Network, 2018). Data on interpersonal violence came from the ABS National Hospitals Data Collection 
(Australian Bureau of Statistics, 2019b) while data on low birthweight were sourced from data extracted by 
the AIHW from the National Mortality Database (2018). 
 
3.3.1 Suicide/intentional self-harm 
An estimated 158 persons died prematurely in 2015/16 from intentional self-harm attributable to opioid 
dependence (82.6 to 288.1). Males were significantly more likely to die due to opioid attributable suicide (139 
deaths), and almost all of the premature deaths, 130 out of 158, occur in those aged 15 to 49 years. Deaths 
arising from suicide and intentional self-harm amongst those aged less than 15 years were excluded from 
the calculations. 
 
Table 3.5: Opioid attributable deaths due to suicide/intentional self-harm (n = 158) 





Total 15-70+  
years 
Female central 15.2 2.8 0.7 18.7 
 low 7.6 1.3 0.3 9.3 
 high 28.9 5.7 1.5 36.1 
Male central 114.9 20.0 4.3 139.2 
 low 61.4 9.7 2.0 73.2 
 high 203.7 39.6 8.6 252.0 
Persons central 130.1 22.9 5.0 158.0 
 low 69.1 11.1 2.4 82.5 
 high 232.6 45.4 10.1 288.1 
NB Totals may differ due to rounding 
 
3.3.2 Accidental injury 
Persons who are opioid dependent are more likely to experience (or be the cause of) an accidental injury, 
including fatal injuries. An estimated 121.8 (47.2 to 288.7) premature deaths resulted from opioid attributable 
accidental injury in 2015/16, with the majority of the deaths amongst males (Table 3.6). ‘Road crash injuries’ 
(59.6 deaths) and ‘Falls’ (35.5 deaths) were the most common types of opioid attributable accidental injuries 
causing premature death. 
 
For road crash injuries, as the prevalence of interest is that of the culpable driver rather than the injured 
person, these AF were then weighted by the proportion of accidents where a person in that age group was 
culpable, as assessed by Drummer and colleagues (2003), to give a pooled AF that was applied to all road 
crash injuries regardless of the age of the injured person.  
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This means that the estimated opioid attributed deaths for road crash injuries includes all ages of decedents. 
For all other accidental injury deaths, only those aged 15 or older were included in the calculations, as the 
relative risk was based on persons dependent on illicit opioids. This may understate opioid attributable 
accidental injury deaths slightly as there could be deaths resulting from inadequate supervision of children 
where the responsible adult was intoxicated by opioids. We were not able to find robust estimates of this risk 
and so these deaths were not included.  
 
Table 3.6: Opioid attributable deaths due to accidental injury 




















Road crash injuries          
Pedestrian road injuries 3.6 1.3 9.0 7.9 3.0 19.1 11.5 4.3 28.1 
Cyclist road injuries 0.2 0.1 0.6 1.6 0.5 4.3 1.9 0.6 5.0 
Motorcyclist road injuries 0.6 0.2 1.7 7.4 2.7 18.3 8.0 2.9 20.0 
Motor vehicle road 
injuries 13.1 5.3 29.8 24.6 9.9 56.2 37.8 15.2 85.9 
Other road injuries 0.2 0.1 0.5 0.2 0.1 0.6 0.4 0.1 1.2 
Other transport injuries 0.4 0.1 1.2 6.2 2.2 15.8 6.6 2.3 17.1 
Falls 11.3 4.6 26.7 24.2 9.7 55.9 35.5 14.3 82.6 
Drowning 0.6 0.2 1.5 6.5 2.5 15.4 7.1 2.7 17.0 
Fire, heat, and hot 
substances 0.4 0.1 0.9 2.0 0.7 5.0 2.4 0.9 5.8 
Unintentional firearm 
injuries 0.1 0.0 0.2 0.4 0.1 1.2 0.5 0.1 1.5 
Other exposure to 
mechanical forces 0.3 0.1 0.7 4.3 1.7 10.3 4.6 1.8 11.0 
Pulmonary aspiration and 
foreign body in airway 1.0 0.4 2.4 3.1 1.2 7.5 4.1 1.6 9.9 
Other unintentional 
injuries 0.1 0.0 0.2 1.3 0.5 3.4 1.4 0.5 3.6 
Total accidental injury 31.8 12.4 75.5 90.0 34.8 213.1 121.8 47.2 288.7 
 
3.3.3 Interpersonal violence 
Interpersonal violence attributable to opioid use was estimated to result in 5.5 premature deaths in 2015/16. 
Deaths categorised by the ABS (2019e) as ‘murder’ and ‘manslaughter’ were included, deaths by dangerous 
driving were excluded as these are included under accidental injury. Attributable fractions are those for violent 
crime calculated from the DUMA survey (AIC DUMA collection 2015/16 [computer file]; confidence intervals 
calculated by authors using Wilson estimator). Males are almost twice as likely to die as a result of opioid 
attributable interpersonal violence than females: 3.6 premature deaths compared to 1.9 deaths. The lower 
bound estimate for deaths due to opioid attributable interpersonal violence is 3.4 premature deaths, and the 
high bound is 9.0 premature deaths 
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Table 3.7: Premature deaths from opioid attributable interpersonal violence 








Females 0.3 0.5 0.6 0.4 1.9 
Males 0.4 1.1 1.4 0.6 3.6 
Persons 0.7 1.7 2.0 1.1 5.5 
Low bound 
Females 0.2 0.3 0.4 0.3 1.1 
Males 0.3 0.7 0.8 0.4 2.2 
Persons 0.5 1.0 1.2 0.7 3.4 
High Bound 
Females 0.5 0.9 1.0 0.7 3.1 
Males 0.7 1.9 2.3 1.1 6.0 
Persons 1.2 2.8 3.2 1.8 9.0 
Source: Australian Bureau of Statistics, 2019. Recorded Crime – Victims, Australia, 2018, cat no. 4510.0, AIC DUMA collection 
2015/16 [computer file]; confidence intervals calculated by authors using Wilson estimator 
 
3.3.4 Low birthweight 
There were 83 infant deaths attributed to low birthweight in 2015/16 (data extracted by the AIHW from the 
AIHW National Mortality Database, unpublished), with an estimated number of opioid attributable deaths of 
1.2 (0.8-1.8). 
 
3.3.5 Blood-borne viruses and sequelae of infection 
Table 3.8 shows the number of deaths by specific BBV and their sequelae separately for males and females: 
Table 3.9 shows the combined totals. Opioid attributable blood-borne viruses (BBV) and their consequences 
were responsible for an estimated 894.0 premature deaths (765.0 to 1,051.1). Cirrhosis secondary to HCV 
infection was the most significant cause amongst both females and males of BBV-related death, causing an 
estimated 476.9 6 premature deaths. Males were more likely than females to die prematurely due to an opioid 
attributable BBV, with male deaths accounting for 65 percent of the deaths. 
 
  
                                                     
6 Total in table differs due to rounding 
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Table 3.8 Opioid attributable deaths from blood-borne viruses 2015/16, by sex 
  Males Females 



















central 0.7 1.2 0.3 2.5 0.1 0.3 0.2 0.7 
low 0.2 0.4 0.1 0.9 0.0 0.1 0.1 0.2 
high 1.5 2.6 0.8 4.8 0.2 0.6 0.5 1.3 
Acute  
hepatitis C 
central 0.1 0.2 0.3 0.4 0.0 0.1 0.4 0.4 
low 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 
high 0.1 0.4 0.6 0.9 0.1 0.3 0.8 0.8 
HIV/AIDS central 1.0 0.4 0.0 1.4 0.3 0.2 0.0 0.4 
low 0.8 0.3 0.0 1.1 0.2 0.1 0.0 0.4 
high 1.3 0.5 0.0 1.7 0.4 0.2 0.0 0.5 
Liver cirrhosis  
due to 
hepatitis B 
central 2.4 1.0 3.8 7.2 0.6 1.3 1.0 2.8 
low 6.4 2.8 10.7 19.9 0.2 0.6 0.4 1.2 
high 2.7 1.2 4.7 8.5 1.0 2.1 1.8 4.9 
Liver cirrhosis  
due to 
hepatitis C 
central 39.5 172.6 104.2 316.3 19.0 65.9 75.7 160.5 
low 33.8 148.8 89.3 272.0 16.4 55.9 62.2 134.5 
high 46.3 197.2 121.3 364.8 22.1 75.7 91.1 188.9 
Liver cancer  
due to  
hepatitis B 
central 0.9 3.6 1.2 5.6 0.3 0.9 0.6 1.9 
low 0.3 1.3 0.4 2.1 0.1 0.4 0.2 0.7 
high 1.6 6.8 2.5 10.9 0.6 1.9 1.3 3.8 
Liver cancer  
due to 
 hepatitis C 
central 6.5 109.0 130.4 246.0 3.5 42.9 101.5 147.9 
low 4.9 91.0 112.4 208.3 2.7 36.6 84.4 123.6 
high 8.6 128.6 149.4 286.6 4.4 50.3 117.2 171.9 
NB Totals may differ due to rounding. 
 










All opioid attributable BBV central 74.8 399.5 419.6 894.0 
 low 66.2 338.3 360.5 765.0 
 high 90.8 468.2 492.1 1,051.1 
 
3.4 Total opioid attributable deaths 
Drawing together the deaths identified through the analysis of the NCIS data with the estimated derived using 
the indirect method, we estimate that there were 2,203 premature deaths attributable to opioids (range 1,921 
to 2,661) (Table 3.10). Opioid toxicity or effect with/without contributing disease process (unintentional and 
undetermined intent only) accounted for just under half of these deaths (n = 1,022) with BBV and their 
consequences the next most significant cause of opioid attributable deaths (with a central estimate of 894 
opioid attributable deaths). 
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Table 3.10: Total estimated opioid attributable deaths 




















‘Opioid deaths' (NCIS 
data) 318.0 a a 704.0 a a 1,022.0 a a 
Blood-borne viruses & 
their consequences 314.6 260.7 372.5 579.4 504.2 678.6 894.0 765.0 1,051.1 
Suicide/ intentional self-
harm 18.7 9.3 36.1 139.2 73.2 252.0 158.0 82.5 288.1 
Accidental injury 31.8 12.4 75.5 90.0 34.8 213.1 121.8 47.2 288.7 
Interpersonal violence 1.9 1.1 3.1 3.6 2.2 6.0 5.5 3.4 9.0 
Low birthweight 0.5 0.3 0.7 0.8 0.5 1.1 1.2 0.8 1.8 
Total opioid 
attributable deaths 685.5 601.8 805.9 1,517.0 1318.9 1854.8 2,202.5 1920.9 2660.7 
Total years of life lost 
to opioid attributable 
death 
20,932.0 18,720.8 24,362.8 50,029.4 43,446.7 61,732.3 70,961.4 62,167.5 86,095.0 
a low/high bound duplicates the central estimate. 
Totals may not sum due to rounding 
 
3.5 Calculating the social cost of premature mortality 
Two broad forms of social cost arise as a result of premature mortality: tangible and intangible costs. Tangible 
costs are those costs for which a market price exists as they can effectively be traded in the market economy. 
Intangible costs are those costs that cannot be traded, such as reduced quality of life from ill-health or the 
value placed on the lost years of being alive. 
 
The ‘years of life lost’ (YLL) for each premature death were calculated using age and gender specific 
estimates for years of life remaining from the ABS life tables (Australian Bureau of Statistics, 2018d).  
 
YLL were calculated in both undiscounted and discounted forms, with the latter used in the cost calculations. 
This approach was taken as confidentiality restrictions on the NCIS dataset precluded the provision of 
premature death estimates in narrow age bands; instead, for these data, YLL (and discounted YLL) were 
calculated for the specific age at death of each opioid premature death, with only aggregate results by gender 
supplied for the cost calculation. Age and gender specific probabilities of employment were used to calculate 
the expected number of working years lost in the study year and the present value over the analysis period. 
Discounting was undertaken using a real discount rate of 7 percent as recommended in Australian 
Government guidance (Department of Finance and Administration, 2006; Department of the Prime Minister 
and Cabinet, 2016) 
 
3.6 Tangible costs of premature mortality 
Tangible costs of premature mortality include: the present value of lost expected lifetime labour in paid 
employment (excluding where possible the present value of any private income that would have flowed to a 
non-dependent person who uses opioids); costs to employers of workplace disruption; the lifetime value of 
lost labour in the household; and, a net cost saving from the present value of avoided lifetime medical 
expenditure by government. Productivity impacts are calculated per year for some period into the future and 
so require the number of deaths in the reference year to be converted into a YLL estimate, whereas intangible 
costs are calculated directly from the number of deaths that occurred in the reference year. 
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No costs have been included in the analysis for funerals and associated expenses, as it has been assumed 
that the cost of these remain constant in real terms and so there is no net cost (or net saving) from them 
having occurred prematurely. 
 
3.6.1 Reductions in workplace productivity due to premature mortality 
The impacts of a premature death on workplace productivity, where the decedent is in paid employment, are 
the present value of expected future economic output from the deceased individual 7, together with the cost 
to employers of filling a job vacancy.  
 
The impact of a smaller labour force on GDP due to opioid attributable deaths in 2015/16 was calculated as 
a present value over a 30-year timeframe (to align with the Department of Finance and Administration 
guidance (2006)) using a real discount rate of 7 percent. It is assumed that the costs of filling job vacancies 
occurred in 2015/16, the year in which the premature death occurred. 
 
The age- and gender-specific probability that an individual will be in employment in each of the following 30 
years was taken from analysis of 2016 Census of Population and Housing data (Australian Bureau of 
Statistics, 2017a, Data extraction by the authors). In the case of the data extracted from the NCIS dataset 
these age and gender specific averages were applied to each identified death, and discounted back to 
present values using a 5.5 percent real discount rate (a 7 percent real discount rate as per Australian 
Government guidelines, combined with an assumption that over the long-term, real output per worker will 
increase by 1.5 percent per annum). The estimates were then aggregated before being provided for the 
economic analysis to ensure confidentiality. In the case of deaths identified through the indirect method, 
where deaths data were available in age groups rather than single years of age, age group specific 
employment rates were calculated by averaging across the age band, with the analysis being otherwise the 
same.  
 
Over the analysis period, an estimated discounted 14,518 years of working life were lost due to opioid 
attributable premature death (CI 12,883 to 17,417).  
 
Data are not available on the way in which the economic output attributable to labour varies across the 
workforce, or how the economic impact of those who die prematurely from opioid attributable causes differs 
from the average. It has been assumed that the economic output of those in work would have equalled the 
population mean. Gross domestic product per employee was calculated from current price estimates of GDP 
for the year to June 2016 from the ABS national accounts and average employment over 2015/16 (Australian 
Bureau of Statistics, 2019a, d) and is $139,697 in 2015/16.8  
 
                                                     
7 To the extent that the deceased person was not an individual who was dependent on opioids, that proportion of expected 
lifetime economic output that would have flowed to them as wages should be excluded, as a private rather than social cost. 
However in this analysis all of the deaths estimated through the indirect approach are either opioid dependent persons (or in 
the case of road crashes, the estimated number of persons who died in a crash where a person dependent on opioids was 
culpable for the accident), or where the opioid dependence of the deceased individual is unknown – those identified through 
the NCIS data who died due to opioid toxicity. 
8 This GDP per worker is slightly different than that used in the recently released report into the social cost of smoking as the 
ABS has made minor revisions to their estimates of current prices, GDP and employment for 2015/16 since the smoking 
analysis was completed. 
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The total present value cost to GDP of premature opioid attributable mortality which occurred in 2015/16 
assessed over 30 years was $2.0 billion in 2015/16 values (low bound $1.8 billion, high bound $2.4 billion) 
(Table 3.11).  
 
In addition, employers face one-off costs to recruit new employees to replace deceased workers, and to train 
those new workers. The estimated cost of this was $6,422 per prematurely deceased employee in 2006 
values (Bureau of Infrastructure Transport and Regional Economics, 2009). Converting to 2015/16 values 
using the change in the CPI (Australian Bureau of Statistics, 2019c) and applying the estimate of 1,175 
persons who died from opioid attributable causes in 2015/16 and were in employment at the time of their 
death, gives a total cost of $9.5 million (Table 3.11).  
 
3.6.2 Reductions in labour in the household 
Collins and Lapsley based their estimates of the value of lost labour in the household on the ABS publication 
Unpaid Work and the Australian Economy 1997 (Australian Bureau of Statistics, 1997; Collins and Lapsley, 
2008). This remains the best available source of data on unpaid work in the household despite now being 
very dated. Under the definitions used in the report, a household activity is considered unpaid work if an 
economic agent other than the household itself could have supplied an equivalent service. Such services 
include domestic activities, childcare, purchasing of goods and services, and volunteer and community work. 
These are all services that are lost by the community in the event of the death or severe illness of the person 
supplying them, and are therefore counted as a component of social costs (Collins and Lapsley, 2008). 
 
The ABS report details two broad approaches that can be taken to valuing unpaid household labour; 
individual function replacement cost (which can be valued either by the cost of outsourcing each of the 
specific tasks, or by the cost of hiring a full time housekeeper to provide all of the services lost) and the 
opportunity cost of time (typically measured by the market value of the deceased person’s time in work). In 
this analysis we have used individual function replacement costs, as using opportunity cost applies a zero 
value to work undertaken by individuals not in the labour force and therefore tends to systematically 
understate the value of work undertaken by women who have lower employment rates. This was also the 
approach taken by Collins and Lapsley in their study (Collins and Lapsley, 2008). 
 
The total value of male unpaid labour in the household was estimated at $82 billion in 2007 values and female 
unpaid labour was valued at $154 billion. Converting these figures to per adult estimates using the population 
data used in the ABS estimates of the value of unpaid household labour (Australian Bureau of Statistics, 
1997) and to 2015/16 values using the CPI (Australian Bureau of Statistics, 2019c) gives values of unpaid 
household work of $19,613 per adult male and $35,016 per adult female. We assumed that the value of 
unpaid labour in the household for those aged less than 18 and those aged over 75 years old was zero, as 
below-18 individuals are often dependent (at least partially) on service provision from adults in the household, 
and above the age of 75 a substantial proportion of the population are either in receipt of formal or informal 
care, or are providing informal care to another member of their household, which is captured as part of ‘other 
medical costs’, see Chapter 5, creating the risk of double counting.  
 
At the same time as the total discounted years of life lost were estimated, we also estimated the number of 
years of life lost within the age ranges used for the household labour calculation to generate age and gender 
(or age group and gender) specific years of household labour lost.  
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Our central estimate was that there were 24,560 discounted years of household labour lost to opioid 
attributable death over the study period (low bound 21,773 high bound 29,334. This gives an estimated 
present value of $586.3 million ($522.3 million to $694.5 million). 
 
3.6.3 Avoided health care costs 
Opioid attributable diseases cause healthcare costs (see Chapters 4 and 5), however the premature deaths 
of persons who use opioids also produces partially offsetting reductions in lifetime healthcare costs which 
these individuals would have incurred in future years had they lived to their expected age at death.  
 
As with the costs of lost economic output, age and gender (or age group and gender) specific discounted 
YLL for each premature death were calculated.  
 
Annual average recurrent healthcare costs per person by five year age group for 2015/16 (all ages average: 
$6,671) were taken from AIHW data (Australian Institute of Health and Welfare, 2017f) and it was assumed 
that healthcare costs would grow in line with per capita GDP (e.g. YLL were discounted at 7 percent to allow 
for an estimated annual real increase in costs of 1.5 percent per annum).  
 
The estimated total net present value (over 30 years using a 7 percent real discount rate) of healthcare costs 
avoided due to premature opioid attributable mortality was a saving of $138.6 million (low bound $131.9 
million, high bound $148.4 million) (Table 3.11). 
 
3.7 Intangible costs of premature mortality 
Much of the cost to society arising from premature mortality relates to intangible costs, e.g. those costs from 
factors that cannot be traded or transferred. Valuation of the intangible costs of premature mortality is usually 
undertaken using what is known as the value of a statistical life (VoSL). 
 
It is important to note that the concept being assessed is not the value of one or more of the individual lives 
lost prematurely due to the health condition or hazard in question. Rather the concept is based on society’s 
average willingness to pay to reduce the risk of premature death by one case. Estimates of this value are 
generally derived from aggregating across individuals’ direct market behaviour, such as willingness to pay 
for products that result in a small reduction of risk, e.g. additional safety features on cars, or the increase in 
wage demanded to take a job that has a higher risk of premature mortality. 
 
Current guidance for cost benefit analyses undertaken for the Australian Government recommends using a 
VoSL that was developed by Abelson (Abelson, 2008). Abelson recommended using a VoSL of $3 to $4 
million in 2006/07 values. Abelson’s recommended value was not derived from a meta-analysis of valuation 
studies, which produce much higher estimates. Rather, whilst it took note of a range of published meta-
analyses of both wage premium studies, product market, and willingness-to-pay approaches to valuing a 
statistical life, it was most strongly influenced by the values recommended by the UK government and the 
European Union member countries.  
 
The Abelson estimate is in 2007 values and needed to be converted to 2015/16 vales for this analysis. The 
rate at which a value of statistical life should increase over time as national incomes increase is determined 
by the income elasticity of demand for reductions in the risk of premature death, with the elasticity 
representing the proportionate increase in the VoSL for a given increase in per capita incomes. For example, 
an income elasticity of 0.5 implies that for a 1 percent increase in per capita income, the VoSL would increase 
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by 0.5 percent. These income elasticities have been variously estimated at 0.5 to 0.6 (Viscusi and Aldy, 
2003), 1.32 (with a range from 1.16 to 2.06) (Kniesner et al., 2010) and 1.5 to 1.6 (Costa and Kahn, 2004). 
We followed the US Department of Transportation (US Department of Transportation, 2015) in adopting a 
relatively conservative assumption of an income elasticity of 1.09, slightly below the average of the three 
studies which was 1.16. 
 
Therefore, the central estimate was converted from 2007 values to 2015/16 values using the change in the 
average nominal national per capita income over that period, giving a 2015/16 VoSL of $4.6 million. 
 
Internationally, much higher values are often used reflecting the findings of studies into the VoSL 10. The US 
Department of Transportation used a VoSL of USD 9.1 million in 2013 values (US Department of 
Transportation, 2015). This was derived by averaging 15 hedonic wage studies (e.g. studies which estimate 
the wage premium demand by workers for more dangerous occupations and use the difference in annual 
mortality rates between industries to calculate the implicit value placed on a premature death). The US 
Environment Protection Authority also adopts a similar approach, using a similar but slightly different value 
derived from a slightly different set of studies. Converting the US Department of Transportation VoSL 
estimate to Australian dollars using Purchasing Power Parity exchange rates (Organisation for Economic 
Cooperation and Development, 2016a), and then to 2015/16 values using the growth in per capita current 
prices GDP (Australian Bureau of Statistics, 2018b) from 2012/13 to 2015/16 gives a VoSL of $13.6 million. 
This value is used as our high bound estimates. 
 
There is a debate in the literature as to whether studies should use a consistent value of averting a premature 
death, regardless of the expected age of person whose death is averted, or whether it would be more 
appropriate to use a consistent value for each expected year of life lost with the value of averting a premature 
death then varying substantially by age.  
 
In general using a consistent value for an averted death tends to be used in studies of reductions in transport, 
health and environmental risks (see for example, (Abelson, 2008; HM Treasury (UK), 2018; US Department 
of Transportation, 2015)). Values based on life years tend to be used in drug or medical device funding 
approvals (see for example National Institute of Clinical Excellence (2004) for the UK and the processes 
adopted for adding pharmaceuticals for PBS subsidies in Australia (Community Affairs References 
Committee, 2015).  
 
Adopting a value of a life year approach has the effect of giving greater weight to premature deaths amongst 
the young and much lower weight to deaths amongst the old. For example, using the value of a statistical life 
year derived from Abelson (2008) updated to 2015/16 values (see below for the approach to this) would imply 
that society would be willing to spend $5.15 million to avert the premature death of a 1 year-old female and 
$5.13 million to avert the premature death of a 1 year-old male, but the willingness to spend to avert the 
premature death of an 80 year-old would be $2.20 million for a female and $1.95 million for a male. On the 
other hand adopting a single value for a VoSL implies higher values per year of life gained for older persons 
and lower values per year of life gained for younger persons. 
 
                                                     
9 This is likely to be an underestimate, as empirical analysis suggests that on average people are risk averse (and in particular 
loss averse) which would imply a price elasticity of averting loss of >1 (Kniesner et al., 2010) 
10 Viscusi and Aldy undertook a meta-analysis of studies that used wage differentials and of those which looked at price premia 
paid for increased safety features in goods purchased and found the mean of the studies was USD 6.7 million in 2000 prices 
(Viscusi and Aldy, 2003) 
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This study has adopted a VoSL approach for its central estimate, reflecting the preponderance of usage in 
policy studies; the pattern of health spending by society over the life which tends to reflect need and therefore 
grow with age from the middle years of life (Australian Bureau of Statistics, 2017c), rather than see a drop 
off in the last years of life when the care could be expected to produce relatively few additional years of 
healthy life; and evidence on changes in individual willingness to pay for safety improvements which only 
appears to fall modestly with age once adjusted for ability to pay and then only after the age of 70 (Pearce, 
2000).  
 
However, as a low bound for our estimate of the intangible cost of opioid attributable mortality we have 
estimated the cost using a value of a statistical life year (VoSLY) approach.  
 
VoSLY are derived from the value of a statistical life by treating the VoSL as the equivalent to the present 
value of an annuity over the expected years of life remaining, using the following formula: 
 
𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 = 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 ×
(1 − (1 + 𝑔𝑔)/(1 + 𝑟𝑟))




VoSL = the VoSL being used, in this case from Abelson, 2008 converted to 2015/16 values; 
g = the annual escalation factor used for the VoSL, in this case the expected long-term per capita 
growth rate in GDP of 1.5 per cent per annum 
r = the discount rate used, in this case seven per cent real per annum; and  
years = the number of years of healthy life remaining assumed to be implicit in the VoSL calculation, 
in this case following Abelson (2008) we have used 40 years. 
 
This VoSLY is applied to the estimated potential years of life lost calculated from the mortality data. Unlike 
the tangible cost estimates, costs are included for each expected year of life remaining even where that 
occurs more than thirty years in the future. These annual costs are then converted to a present value estimate 
using a real discount rate of seven per cent. Using the Abelson estimate of the VoSL, the VoSLY is $286,553. 
 
In order to ensure consistency with other estimates, we used the Abelson values for our main estimates, 
which gives an expected intangible cost of opioid attributable premature mortality in 2015/16 of $10.1 billion 
(with a low bound and a high bound derived from the range of estimates of opioid attributable deaths of $8.8 
billion to $12.2 billion).  
 
If, instead, the VoSL estimate used by the US Department of Transportation (2015) were to be used, then 
the estimated intangible cost of opioid attributable premature mortality in 2015/16 would be $30.0 billion using 
the central estimate of opioid attributable deaths (with a low bound and a high bound derived from the range 
of estimates of opioid attributable deaths of $26.2 billion to $36.2 billion). 
 
Finally, if intangible costs of premature mortality were valued based on potential years of life lost, then the 
intangible cost of opioid attributable premature mortality in 2015/16 would have an expected present value 
of $6.0 billion based on the central estimate of years of life lost to opioid attributable deaths (with a low bound 
and a high bound derived from the range of estimates of opioid attributable deaths of $5.7 billion to $6.4 
billion. 
 
38  Chapter 3: Premature mortality 
 
3.8 Total costs of premature mortality 
Drawing together the estimated tangible and intangible costs of premature opioid attributable mortality, our 
central estimate of the cost is $12.6 billion ($7.9 billion to $39.2 billion). Tangible costs are $2.5 billion, with 
intangible cost accounting for $10.1 billion (Table 3.11). 
 
Table 3.11: Costs of Opioid Attributable Premature Mortality 
Cost  central estimate: 
opioid attributable 
deaths, &  
Abelson (2007) VoSL 
low bound: 
low bound estimate  
of YLD &  
Abelson (2007) VoSL 
high bound:  
high bound of opioid 
attributable deaths &  
US DoT (2015) VoSL 
Tangible costs    
NPV of lost economic output: non-
employee 2,028,163,487 1,802,400,775 2,428,779,202 
Recruitment/training costs to employers 9,540,983 8,543,130 11,209,849 
NPV of value of lost unpaid household work 586,271,797 523,056,937 693,347,145 
NPV of healthcare costs avoided -138,572,724 -131,958,751 -148,291,545 
Total net tangible costs 2,485,403,542 2,202,042,091 2,985,044,651 
Intangible costs    
Value of a statistical life 10,127,150,276 5,668,284,222 36,200,205,774 
TOTAL COSTS 12,612,553,819 7,870,326,313 39,185,250,425 
 
3.9 Conclusions 
Our estimates show the extent of premature mortality caused by opioids, with an estimated 2,203 deaths 
attributed to opioids in 2015/16. The direct impact of opioid toxicity or effect with/without contributing disease 
process (unintentional and undetermined intent only) account for just under half of the estimated deaths with 
substantial numbers of deaths arising from conditions partially caused by opioids, particularly cirrhosis 
secondary to HCV, and liver cancer secondary to HCV. 
 
Due to differences in the approach taken and the conditions included, these estimates cannot be directly 
compared to the AIHW’s estimates of opioid-induced deaths (Australian Institute of Health and Welfare, 
2018d). In particular, the AIHW estimates focus on those conditions for which opioids were the direct cause 
of death, excluding a number of conditions where opioids cause a proportion of the premature mortality, such 
as BBV and their consequences, and accidental injuries. The AIHW also drew exclusively on cause of 
death/substance inducing death categorisations in the NCIS dataset, whereas our estimates for conditions 
such as suicide and interpersonal violence drew on AF calculated using the indirect method.  
 
3.10 Limitations  
The predominant caveats of this study relate to features of the data system, the nature of antemortem and 
post-mortem drug detection, multiple drug toxicity and the complexity of events leading to injury and 
subsequent death. This study is a conservative estimation of opioid deaths. 
 
As explained above, NCIS is a national database and jurisdictional variances exist. These differences include 
but are not limited to: jurisdictional Coroners Acts; the comprehensiveness of files; disparity between 
documentation methods; the ability to screen for novel substances; mandatory toxicology screening 
processes; and, the number of files available in each case.  
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Owing to the delay between the time of death and the closure of a coronial case, there is the potential that 
not all opioid deaths will be captured in this study. Last reported on 9th January 2019, the proportion of 
Australian closed cases (of all cases notified to the coroner) in 2015 and 2016, were 91.1 percent and 87.0 
percent, respectively (National Coronial Information System, 2019b).  
 
Another caveat of this Chapter is the inability to conclusively distinguish extra-medical use of pharmaceutical 
opioids or the source of where the substance was produced - for example, illicitly manufactured or 
pharmaceutically produced fentanyl. Adequate information to determine level of use, tolerance or access to 
substances, is not consistently reported and for the purpose of this study has not been further examined.  
 
Lastly, not all coronial cases result in a conclusive explanation of the circumstances or the cause of death. 
This can be due to factors such as advanced decomposition of the corpse, lack of evidence or the inability to 
determine the series of events prior to death.  
 
Toxicology results need to be considered and interpreted with caution. This study used a direct approach 
and categorised the attributable cause of death as per the forensic pathologist’s findings. Issues related to 
post-mortem toxicology include: lag time between time of death and sample collection (as post-mortem 
changes occur, especially in the heart and abdominal cavity); and, variances between sample sites and 
sample contents (blood, urine or tissue). The differentiation between low, therapeutic and lethal levels of a 
substance can be problematic, as individuals have varying tolerance, dependent on many variables such as 
weight, metabolism, level of usage, and overall state of health. It is also important to note that drug levels for 
inclusion in the cause of death statement by a forensic pathologist is not standardised (Dinis-Oliveira et al., 
2016). 
 
The level of alcohol detected in post-mortem samples can be elevated due to body decomposition, whilst 
putrefaction affects the result levels of substances, increasing some levels and decreasing others. As with 
many diagnostic tests, drug screens can produce false positives. These factors highlight the complexity and 
specialised interpretation of toxicology results as processes can distort or impede the detection of substances 
(Leikin and Paloucek, 2015). 
 
We included low birthweight as one of the conditions partially caused by opioids. However, we note that it is 
not in the conditions listed by the GBD study (Australian Institute of Health and Welfare, 2016a; Global Burden 
of Disease Collaborative Network, 2018) which does not include conditions caused by the secondary effects 
of drug use in the population aged <5 years, and that the cited meta-analysis is now dated (Hulse et al., 
1997), although more recent studies have also identified similar magnitudes of risk. For example, Azuine and 
colleagues found that opioid exposure was linked to higher rates of foetal growth restriction (OR, 1.87; 95%CI, 
1.41-2.47) and pre-term birth (OR, 1.49; 95% CI, 1.19-1.86) (Azuine et al., 2019). Nevertheless, it is included 
as we were not able to identify any subsequent meta-analyses which found an absence of a relationship 
between in-utero exposure to opioids and low birthweight. 
 
Two conditions partially caused by opioid use were not able to be included in the estimate of premature 
mortality due to data limitations. Infective endocarditis can be caused by injecting drug use, and is therefore 
partially caused by opioid use. However, the GBD data does not allow infective endocarditis to be 
distinguished from other forms of endocarditis (for which opioids do not have a partially causal role) and so 
the number of opioid attributable deaths could not be calculated. Neonatal abstinence syndrome (NAS) is 
caused by exposure in-utero to substances that can cause dependence, with opioids estimated to be the 
cause of almost all hospital separations for NAS (Abdel-Latif et al., 2013), however the published perinatal 
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deaths data does not separately identify NAS and it is instead aggregated within ‘Other conditions originating 
in the perinatal period (ICD-10 code = P96)’. Recent studies suggest that although infants with NAS have a 
significantly higher rate of severe morbidity, it does not result in a statistically significant increase in perinatal 
deaths once other factors such as low birth weight have been taken into account, and so the exclusion of 
NAS is unlikely to have a meaningful impact on our estimates. 
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CHAPTER 4: HOSPITAL INPATIENT MORBIDITY 
Agata Chrzanowska, Steve Whetton, Louisa Degenhardt, Amy Peacock, Emma Zahra & Robert J. Tait 
 
4.1 Introduction 
Opioids (illicit and pharmaceutical) are respiratory depressants which affect the central nervous system, 
leading to a greater risk of overdose (both fatal and non-fatal) than other commonly used illicit drugs. In 2018, 
42 percent of an Australian sample of people who regularly inject drugs (PWID) reported lifetime experience 
of non-fatal heroin overdose, and 14 percent reported past 12-month experience of heroin non-fatal overdose 
(Peacock et al., 2018). Analyses of routinely-collected healthcare data suggest opioid-related harms are 
increasing in Australia. Indeed, rates of opioid-related hospitalisations increased substantially between 
2007/08 and 2016/17. The age-adjusted rate of hospitalisations where opioid poisoning was the principal 
diagnosis increased by 25 percent (from 14.1 to 17.6 per 100,000 population), while the rate of 
hospitalisations that included opioid poisoning as any diagnosis (principal or additional) increased by 38 
percent (from 29.0 to 40.1 per 100,000 population) (Australian Institute of Health and Welfare, 2018d). 
Hospitalisations for opioid poisoning in 2016/17 were more likely to involve pharmaceutical opioids than 
heroin (3,14711 versus 832 hospitalisations, respectively).  
 
Beside overdose, opioid use and dependence are linked with an increased risk of a range of serious illnesses 
and injuries (Degenhardt et al., 2019). Opioid use has been identified as a risk factor for conditions such as 
human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) through injection 
of opioids (Degenhardt et al., 2013c) and low birthweight as an outcome of maternal exposure (Cleary et al., 
2011; Darke et al., 2019; Hulse et al., 1997; Ludlow et al., 2004). Injecting drug use is associated with liver 
cancer and cirrhosis secondary to HBV and HCV (Degenhardt et al., 2016b), skin infections and inflammation, 
and infective endocarditis (Ciccarone et al., 2016; Larney et al., 2017b). Furthermore, opioid toxicity can lead 
to further complications like hypoxic or anoxic brain injury (Andersen and Skullerud, 1999; Morrow et al., 
2019). Using opioids during pregnancy can result in a drug withdrawal syndrome in new-borns exposed 
prenatally, known as neonatal abstinence syndrome (NAS) (Abdel-Latif et al., 2013; Rasul et al., 2019). Extra-
medical opioid use is also associated with increased likelihood of suicide attempt (Ashrafioun et al., 2017; 
Kuramoto et al., 2012; Marchand et al., 2017), interpersonal violence (Darke, 2010; Goldstein, 1985; Torok 
et al., 2008) and accidental injuries, which mostly involve traffic accidents (Drummer et al., 2003; Verstraete 
and Legrand, 2014). 
 
To estimate the cost of inpatient hospitalisations related to extra-medical use of opioids we used available 
medical and scientific information on the risk of opioids in causing specific conditions. Given the limited 
number of valid AF for opioid-related conditions, the current study used a variety of methods described in the 
methods section (Chapter 2): 
 
1. Direct attribution for conditions wholly attributable to opioid extra-medical use and dependence, 
based on opioid diagnoses in the inpatient hospital separation data where the below conditions were 
coded at separation: 
• Principal diagnosis was mental and behavioural disorder due to use of opioids or opioid 
poisoning; 
                                                     
11 This includes naturally derived opioids (such as oxycodone, buprenorphine and morphine), synthetic opioids (pethidine, 
fentanyl) and methadone. 
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• Injecting-related infection (IRI) was the principal diagnosis underlying the hospitalisation and 
mental and behavioural disorder due to use of opioids or opioid poisoning were identified in any 
of the additional diagnoses; and, 
• Brain injury was a principal reason of hospitalisation and mental and behavioural disorder due 
to use of opioids or opioid poisoning were identified in any of the additional diagnoses. 
 
2. Indirect attribution for conditions wholly attributable to extra-medical use of opioids and opioid 
dependence, where the AF was calculated based on the available relative risk (RR) and the exposed 
proportion of the population (or its best available estimate), and applied to the total number of hospital 
separations with a principal diagnosis indicating the specific condition or external diagnosis reflecting 
a particular injury (excluding any separation directly attributable to opioids and already counted for 
another condition using the direct approach): 
• HIV, HBV and HCV; 
• Liver cancer secondary to HBV and HCV; 
• Maternal exposure – low birthweight; 
• Intentional self-harm and suicide attempts; and, 
• Accidental injuries including road crash injuries.  
 
3. Excess attribution for conditions partially attributable to opioid use extra-medically and 
dependence, where a RR was not available, but evidence of a causal effect was present. In these 
circumstances, the prevalence from within a single sample was used to estimate the percent of the 
condition-related hospital separations that were attributable to opioids: 
• Interpersonal violence;  
• Infective endocarditis (noting that this was calculated from the prevalence of the condition 
amongst people who inject drugs rather than the population as a whole); and, 
• NAS. 
 
4.1.1 Data sources 
Hospital separation data are an important source for estimating the incidence of non-fatal injuries as well as 
different conditions. Data from the National Hospital Morbidity Database (NHMD) for the 2015/16 financial 
year were obtained from the AIHW (Australian Institute of Health and Welfare, 2018c). This dataset is a 
collection of all de-identified patient-level separation records from public and private hospitals in Australia. All 
diagnoses for all hospitalisations in each jurisdiction were provided with the exception of Tasmania, where i) 
provision of records was restricted to those that included a drug and alcohol related principal and/or additional 
diagnoses and external causes, and ii) only the drug and alcohol related diagnosis codes were provided for 
those records.  
 
In the NHMD extraction for 2015/16, diagnoses and external causes were coded upon separation using the 
International Classification of Diseases, Australian Modification ICD-10-AM 9th edition (Australian 
Consortium for Classification Development 2014). (The ICD-10-AM codes used in this study to identify the 
conditions of interest are listed in Table 2.1 with further details in Appendix 4.1.) 
 
In this report we adopted the terminology relating to hospital separations used by AIHW (Box 4.1) (Australian 
Institute of Health and Welfare, 2017b). 
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For a patient admitted to a hospital due to injury or poisoning, a principal diagnosis code from the range S00–
T75 or T79 is allocated, and an external cause code describing the nature of the injury should be recorded 
as a first reported cause (Australian Institute of Health and Welfare, 2018a). In this report in the sections 
related to injuries, self-harm and interpersonal violence we were interested in separations caused 
unintentionally (accidental injuries) or intentionally (intentional self-harm, or assault) therefore we have only 
included separations with the first reported external cause code.  
 
For the purpose of the government reimbursing hospitals for the cost related to the hospital separation, 
specific cost categories are assigned to each separation record based on the patient’s diagnoses, primary 
type of treatment or service provided, the difficulty of the case, and the severity of any complications. This 
classification system is called the Australian Refined Diagnosis Related Group (AR-DRG) (Independent 
Hospital Pricing Authority, 2015). The NHMD 2015/16 data were coded using AR-DRG version 7.0. Each 
AR-DRG code is also assigned a costweight which indicates the average cost of administering that form of 
treatment relative to the average cost of an acuity adjusted hospital separation (($5,194 in 2015/16) 
Independent Hospital Pricing Authority, 2018). This allows the cost of specific separations to be estimated 
by multiplying their costweight by the average cost of a separation as per the below formula: 
 
Total Cost = $5,194 x average cost weight x number of attributed separations 
 
  
Box 4.1: Summary of terms relating to hospital separations  
An admitted patient is a patient who undergoes a formal admission process to receive treatment and/or 
care in hospital.  
 
A hospital separation (also called hospitalisation) refers to a completed episode of an admitted patient’s 
care in a hospital ending with a discharge, death, transfer or a portion of a hospital stay beginning or 
ending in a change to another type of care. There can be more than one hospital separation for each 
patient and separations can be either same-day (hospital admission and separation happen on the same 
day) or overnight (hospital admission and separation happen on a different date). Each NHMD separation 
record includes one principal diagnosis and up to 99 additional diagnoses.  
 
The principal diagnosis is defined as the diagnosis established after study to be chiefly responsible for 
occasioning the patient’s episode of admitted patient care. Additional diagnoses are conditions or 
complaints that either coexists with the principal diagnosis or develop during the episode of care and 
affect patient’s management. In this report, we use any diagnosis to refer to the principal and/or 
additional diagnosis.  
 
The environmental events, circumstances or conditions that caused injury, poisoning and other adverse 
effects are recorded in NHMD as external causes. Each NHMD separation record includes up to 100 
external causes. 
 
An opioid-related code refers to an ICD-10-AM code which is opioid specific, i.e. F11.0-F11.9, T40.0-
T40.4, T40.6 (Table 2.1 and Appendix 4.1). 
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4.1.2 Polysubstance use 
In determining which separations should be counted as solely due to opioids or due to multiple drugs, we 
worked to develop a consensus approach in defining, for each condition identified with a causal link to opioid 
use, whether there was at least a plausible causal link for other drugs. Since depressant drugs affect the 
CNS and can cause brain damage, co-use of depressant drugs such as benzodiazepines are likely to 
increase the risk of hypoxic or anoxic brain injury (Darke and Farrell, 2014), but co-use of hallucinogenic 
drugs would be unlikely to increase this risk (Darke et al., 2019). Similarly, PWID (whether they inject heroin 
or cocaine or another injectable drug) have an increased risk of skin and soft tissue infections, mostly due to 
using non-sterile injecting equipment and not cleaning injection sites, although risk may be elevated for 
certain substances where there are high levels of excipients (Grant et al., 2012; Larney et al., 2017b; McLean 
et al., 2017; Murphy et al., 2001).  
 
Table 4.1: Possible causal links between use of drugs other than opioids and specific health conditions to 
inform identification of polysubstance hospitalisations 
Other drug types / classes which could have a causal link with the health 
condition and, if their diagnosis code co-occurs with an opioid-related code, 
warrant partial attribution to opioids:  
Anoxic brain 
injury  
Skin and soft  
tissue infections  
Alcohol (F10, T51) Yes 1 Yes 2 
Cannabis (F12, T40.7)* - - 
Benzodiazepines (F13, T42.4) Yes 1 Yes 3 
Cocaine (F14, T40.5) - Yes 3 
Amphetamines (Psychostimulants with abuse potential) (F15, T43.6) - Yes 3 
Hallucinogen (Including LSD) (F16, T40.8, T40.9) - - 
Multiple drug use (F19) Yes Yes 3 
Non-opioid analgesics (T39.0-T39.9) - - 
4-Aminophenol derivatives (paracetamol) (T39.1) - - 
Depressant (T42.0-T42.9 (excl T42.4)) Yes - 
Barbiturates (barbiturates, pregabalin)  (T42.3) Yes Yes 
Antiepileptic & sedative-hypnotic drugs, unspecified (Pregabalin) (T42.7) Yes 1 Yes 
Antidepressants and Antipsychotics (T43.0-T43.5) - - 
* Excluded from the companion report on cannabis related costs to avoid double counting 
Sources: 1 (Darke and Farrell, 2014): 2 (Rehm et al., 2010): 3 (Australian Institute of Health and Welfare, 2019a; Peacock et al., 
2019, (injecting drug use only)). 
Note: Each row was considered a separate drug class in terms of count of substances in polysubstance case, e.g. opioid + 
benzodiazepines + depressant = opioid plus 2 extra drugs. 
 
4.2 Hospital separations directly attributable to extra-medical use of opioids  
4.2.1 Principal diagnosis – opioid use disorder or opioid poisoning 
All hospital separations with a principal diagnosis indicating a mental or behavioural disorder due to use of 
opioids or poisoning by opioids were wholly attributed to opioids, regardless of other drugs being reported in 
additional diagnoses, and the total cost of these separations was counted for the purpose of this report. 
Hospital separations solely attributable to opioids were identified by principal diagnosis in the following ranges 
of ICD-10-AM: 
• F11.0-F11.9 - Mental and behavioural disorders due to use of opioids, 
• T40.0-T40.4, T40.6 - Poisoning by opioids. 
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There were 8,909 separations with an opioid-related ICD-10-AM code as the principal diagnosis in 2015/16: 
4,754 hospitalisations codes as mental and behaviour disorder due to use of opioids and 4,155 
hospitalisations due to opioid poisoning. These are further classified into AR-DRG such as drug intoxication 
and withdrawal, drug use disorder and dependence, poisoning and toxic effect of drugs. For the full list of 
opioid related principal diagnosis by the assigned AR-DRG with cost weights, frequencies and hospitalisation 
costs see Table 4.2. The total cost for hospital separations for opioid-related principal diagnoses was $39.2 
million ($21.9 million for males and $17.3 million for females) 12. 
 
Table 4.2: Number of hospital separations and costs associated with opioid-related principal diagnosis, 
Australia, 2015/16  
DRG 
code DRG description 
Number of hospital separations* Cost 
weight Male Female 
X62B Poisoning/Toxic Effects of Drugs and Other Substances W/O Cat or Sev CC 1302 1375 0.531 
V66Z Treatment for Drug Disorders, Same day 1191 981 0.109 
V63Z  Opioid Use and Dependence 1081 671 1.122 
X62A  Poisoning/Toxic Effects of Drugs and Other Substances W Cat or Sev CC 698 624 1.171 
V61Z  Drug Intoxication and Withdrawal 440 357 1.917 
X40Z  Injuries, Poisoning and Toxic Effects of Drugs W Ventilator Support 60 39 2.113 
A06C  Tracheostomy W/O Ventilation >=96hrs, or Ventilation >=96hrs W/O OR Proc 19 ≤10 10.754 
B64B  Delirium W/O Catastrophic CC ≤10 ≤10 1.488 
X06A  Other Procedures for Other Injuries W Catastrophic or Severe CC ≤10 ≤10 2.682 
B64A  Delirium W Catastrophic CC ≤10 ≤10 2.866 
B82B  Chronic and Unspec Para/Quadriplegia W or W/O OR Proc W Cat CC ≤10 ≤10 7.774 
A06A  Tracheostomy W Ventilation >=96hrs W Catastrophic CC ≤10 ≤10 32.589 
X04A  Other Procedures for Injuries to Lower Limb W Catastrophic or Severe CC ≤10 0 3.280 
801A  OR Procedures Unrelated to Principal Diagnosis W Catastrophic CC ≤10 0 6.861 
X06B  Other Procedures for Other Injuries W/O Catastrophic or Severe CC ≤10 ≤10 0.905 
B63Z  Dementia and Other Chronic Disturbances of Cerebral Function ≤10 ≤10 3.761 
B82C  Chronic and Unspec Para/Quadriplegia W or W/O OR Proc W/O Cat CC ≤10 ≤10 2.012 
B42A Nervous System Disorders W Ventilator Support W Catastrophic CC 0 ≤10 5.7183 
 Total number of separations 4824 4085  
 Average costweight 0.874 0.816  
 Cost ($) 21,898,818 17,313,472  
 Total cost ($)  39,212,290  
* Note. Cell counts less than 10 but not equal to zero are suppressed to protect confidentiality but included in the total count 
CC = Complication and/or comorbidity: Cat = Catastrophic: Proc = Procedures: Sev = severe: W = with: W/O = without. 
 
                                                     
12 The total cost includes the costs of the separations where there were < 10 cases. 
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4.2.2 Injecting-related skin and vascular infections  
Bacterial and fungal infections of the skin and soft tissue are a common problem among PWID, arising from 
use of non-sterile injecting equipment or poor personal hygiene. Other common consequences of injecting 
drugs are cellulitis, abscesses, bacteremia, sepsis and osteomyelitis (Larney et al., 2017b). Opioids are one 
of the most commonly injected drugs in Australia (Australian Institute of Health and Welfare, 2018d; Peacock 
et al., 2018) and globally (Degenhardt et al., 2017), with the estimated proportions of PWID reporting opioids 
as the main drug injected being 60.0 and 82.9 percent, respectively. Administrative data coding systems 
using ICD-10-AM do not capture injecting drug use. The challenge, given the lack of such information, was 
to ascertain which hospital separations were attributable to injecting opioid use and which to non-injecting 
opioid use.  
 
Following the method previously used in estimating social costs of methamphetamine (Whetton et al., 2016), 
we selected hospital separations where an ICD-10-AM principal diagnosis indicated that the episode was 
related to skin infection, skin inflammation or other injecting-related infection and where one of the additional 
diagnoses was an opioid-related code (see Appendix 4.1 for the list of ICD-10-AM codes). The cost of 
separations where no other substance injected was identified was fully attributed to opioids. Poly-substance 
episodes involving other known substances which are injected (i.e. cocaine, amphetamine), were reported 
separately and only a fraction of the separation cost was assigned for that separation computed from the 
number of other drug types involved (Table 4.3). 
 
There were 1,134 hospitalisations identified with a principal diagnosis of an injecting-related skin and vascular 
infections, coupled with an opioid-related code as an additional diagnosis. This included 858 separations 
involving opioids only and a further 276 separations coded as involving opioids and at least one other drug 
type. The total cost of these separations was $14.2 million ($8.3 million for males and $5.9 million for 
females).  
 
Table 4.3: Number of hospital separations and costs associated with opioid-related skin and vascular 
infections in principal diagnosis, Australia, 2015/16 
Number of drugs involved Cost fraction Number of hospital separations Male Female Persons 
Opioid only  1 487 371 858 
Opioid and polysubstance use     
1 extra drug ½ 
171 105 
 
2 extra drugs 1/3 276 
3 extra drugs ¼  
Average costweight adjusted for the polysubstance cost 
fraction 
Opioid only 2.851 2.730  
Polysubstance 
use 1.265 1.117  
Cost ($)  8,335,082 5,869,817 14,204,899 
 
4.2.3 Brain injury  
People who use opioids extra-medically may display a range of cognitive deficits and have a high rate of 
traumatic brain injury (Darke et al., 2019). Non-fatal overdose can cause a wide range of neuropathologic 
changes, particularly associated with hypoxia (Büttner et al., 2000; Darke et al., 2019). Brain injury can also 
occur as a result of stroke, infections and spongiform leukoencephalopathy (non-specific toxic 
demyelination). However, inspection of the NHMD separation records identified few separations with any 
diagnosis coded to G93.1 (anoxic brain damage, not elsewhere classified) that also included an opioid-
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related code in the principal or additional diagnosis fields. Since the separations with an opioid-related 
principal diagnosis were already counted in Section 4.2.1, our central estimate for brain injury related to extra-
medical use of opioids was based on those records where G93.1 was coded in any diagnosis field and there 
was an opioid-related code in the additional diagnosis field.  
 
We used G93.1 as the most likely code to use in case of brain injury due to drug toxicity. If anoxic brain 
damage was documented as the manifestation in the acute poisoning episode of care, then G93.1 could be 
assigned. This formed our central estimate. However, the manifestation of the poisoning may be documented 
in other diagnostic terms e.g. toxic brain injury, acquired brain injury, brain injury, toxic encephalopathy, 
encephalopathy, depression respiratory centre, hypoxia, anoxia, coma, stupor, somnolence, etc. with 
different diagnosis codes. Discussion with clinical coders did not produce a definitive list of codes that could 
be used in identifying these brain injuries. Therefore, given the diverse and non-specific brain injuries 
associated with opioids toxicity, the following codes in the principal diagnosis field - combined with an opioid-
related code in the additional diagnosis field – were used in addition to the G93.1 diagnosis to compute a 
high bound estimate: 
G40-G47 Episodic and paroxysmal disorders;  
G92  Toxic encephalopathy; 
G93.6  Cerebral oedema; 
G93.9  Disorder of brain, unspecified; 
G94.2  Hydrocephalus in other diseases classified elsewhere;  
R40  Somnolence, stupor, coma; 
R09.0  Asphyxia; and, 
R09.2  Respiratory arrest. 
 
Any separation meeting the definition of polysubstance use (see Table 4.1) would then have a fraction of the 
separation cost assigned for that episode depending on the number of other drug types that were identified 
in additional diagnosis fields.  
 
There were 70 hospitalisations identified with a principal diagnosis of a brain injury, coupled with an opioid-
related code as an additional diagnosis. This included 38 separations involving opioids only and a further 32 
separations that were coded as involving opioids and at least one other drug type. The total cost of these 
separations was $1.5 million ($0.9 million for males and $0.5 million for females: Table 4.4).  
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Table 4.4: Hospital separations and costs associated with opioid-related brain injury, Australia, 2015/16 
Number of drugs involved Cost fraction 
Number of hospital separations 
Central estimate (G93.1) High bound a 
Male Female Male Female 
Opioid only  1 26 12 95 92 
Opioid and polysubstance use       
1 extra drug ½ 
20 12 61 26 
2 extra drugs 1/3 
3 extra drugs ¼ 
4 extra drugs 1/5 
Average costweight adjusted for the 
polysubstance cost fraction 
Opioid only 5.015 6.307 2.046 1.668 
Polysubstance 
use 2.581 1.842 1.360 1.247 
Cost ($)  945,360 507,911 1,440,452 965,450 
Total cost ($)  1,453,271 2,405,902 
Note. a Computed based on a broad group of possible brain injuries (G40-G47, G92, G93.1, G93.6, G93.9, G94.2, R40, R09.0, 
R09.0) + opioid related additional diagnosis. 
 
4.3 Hospital separations indirectly attributable to extra-medical use of opioids 
4.3.1 Blood-borne viruses and their secondary consequences 
PWID are at high risk of blood-borne viruses, including HIV, HBV and HCV, because of sharing injecting 
equipment. Globally, it is estimated that 17.8 percent of PWID are living with HIV, 52.3 percent have HCV 
and 9.1 percent have HBV (Degenhardt et al., 2017).  
 
To estimate the proportion of hospital separations coded to BBV that are attributable to injecting opioids we 
used the following formula: 
 
AF cond,age,gender = EF cond,age,gender x MIO gender 
Where: 
age = age group: 15-49, 50-69 and 70+ years 
gender = male, female 
con = HIV, HBV and HCV, lung cancer due to HBV and HCV 
EF cond,age,gender = age group-gender specific estimated fraction of condition in Australia attributable to 
injecting drug use, average of 2015 and 2016 
MIO gender = gender-specific percentage of PWID in Australia who reported mainly injecting opioids 
 
The GBD 2017 study estimated the burden of BBV at the country and global level for each age-gender group 
for the years 1990-2017. More details on the modelling methods used in the GBD study are published 
elsewhere (Degenhardt et al., 2018). Disability-adjusted life years (DALY) were used as a measure of overall 
disease burden. We obtained age group-gender specific estimated fractions of HIV, HBV and HCV 
attributable to injecting drug use for 2015 and 2016 in Australia from the GBD Results Tool (Global Burden 
of Disease Collaborative Network, 2018). We calculated the average of the 2015 and 2016 GBD estimates 
for males and females by age group (i.e., 15-49, 50-69 and 70+ years). We then applied the estimates of the 
percentage of PWID in Australia who reported mainly injecting opioids in the past month (69.7 percent for 
male PWID and 70.5 percent for female PWID) from the Illicit Drug Reporting System (IDRS) 2000 (Topp et 
al., 2001) to the averaged GBD estimates. We chose to use historical data because the period from 
transmission to chronic infection/experience of harms can be long (Gibson et al., 2011). The low and high 
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bound of the estimated AF was calculated based on the low and high bound estimated fraction of HIV, HBV 
and HCV obtained from the GBD Results Tool. 
 
We identified 630 potentially relevant cases of HIV, HBV and HCV in the NHMD by selecting separations 
with the principal diagnosis coded to HIV/HBV/HCV-specific ICD-10-AM codes (Appendix 4.1) and where 
patients were aged 15 years or older. We excluded all episodes already counted using the direct approach 
in Section 4.2. Finally, we applied the AF to the relevant condition, gender and age group. From this, we 
estimated the total number of HIV/HBV/HCV separations that could be attributable to extra-medical use of 
opioids. The total number of separations was 224 (161 among male and 63 among females). The total cost 
of these separations was $2.4 million ($1.9 million for males and $0.5 million for females, Table 4.5).  
 
HBV and HCV infection can lead to the development of liver cancer, cirrhosis and other chronic liver diseases. 
Globally, 56 percent of liver cancer cases are estimated to be attributable to HBV and 20 percent to HCV 
(Maucort-Boulch et al., 2018). Similarly, 57 percent of cirrhosis was found to be attributable to either HBV or 
HCV (Perz et al., 2006). 
 
To estimate the cost of hospital separations related to liver cancer secondary to HBV and HCV that could be 
attributable to extra-medical use of opioids (specifically, injection of opioids) we used a similar approach to 
that for BBV. We obtained the age group-gender specific estimated fractions of liver cancer due to HBV and 
HCV attributable to injecting drug use in Australia in 2015/16 from GBD, and weighted the estimates by the 
proportion of IDRS participants in 2000 who reported an opioid as the drug most injected in the last month 
(Topp et al., 2001). We chose to use historical data for patterns of injecting drug use because liver cancer is 
usually a long-term complication of HBV or HCV (Ananthakrishnan et al., 2006; Bosch et al., 2004). Due to 
lack of ICD-10-AM codes specific to liver cancer secondary to HBV/HCV we further adjusted the AFs by the 
proportion of liver cancer that could be attributable to HBV (11.4 percent for males 11.6 percent for females) 
and HCV (32.6 percent for males 41.5 percent for females). The estimated proportions were obtained from 
the GBD Results Tool (Global Burden of Disease Collaborative Network, 2018).  
 
Finally, the adjusted AF were applied to the total number of hospital separations where liver cancer was the 
principal diagnosis (C22* - Liver cancer (Malignant neoplasm of liver and intrahepatic bile ducts)) and patients 
were 15 years or older. This excluded all episodes already counted using the direct approach outlined in 
Section 4.2. 
 
A total of 4,944 liver cancer separations were identified in the NHMD. Applying the AF to relevant age and 
gender groups resulted in 1,113 liver cancer separations that could be attributable to extra-medical use of 
opioids (Table 4.5). After applying average costweight for these separations and the average acuity adjusted 
cost of a hospital separation, we estimated the total cost for liver cancer attributable to extra-medical opioid 
use to be $11.7 million ($8.8 million for males and $2.9 million for females). 
 
A similar approach was used to estimate the cost of hospital separations related to cirrhosis and other chronic 
liver diseases due to HBV and HCV that could be attributable to extra-medical use of opioids (specifically, 
injection of opioids). The age group-gender specific estimated fractions of cirrhosis and other chronic liver 
diseases due to HBV and HCV attributable to injecting drug use in Australia in 2015/16 were obtained from 
GBD Results Tool (Global Burden of Disease Collaborative Network, 2018), and weighted by the estimated 
proportion of IDRS participants in 2000 who reported an opioid as the drug most injected in the last month 
(Topp et al., 2001). To apply the AFs to hospital separations related to cirrhosis we further adjusted the AFs 
by the proportion of all cirrhosis and other chronic liver diseases that could be attributable to HBV (26.6 
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percent for males and 17.6 percent for females) and HCV (27.9 percent for males and 26.5 percent for 
females). The estimated proportions were obtained from the GBD Results Tool (Global Burden of Disease 
Collaborative Network, 2018). 
 
A total of 11,685 cirrhosis related hospital separations for patients aged 15 years or older were identified in 
the NHMD. Applying the AF to relevant age and gender groups resulted in 3,308 cirrhosis separations that 
could be attributable to extra-medical use of opioids (Table 4.5). After applying average costweight for these 
separations and the average acuity adjusted cost of a hospital separation, we estimated the total cost for 
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Table 4.5: Hospital separations and costs associated with opioid-related blood borne viruses and liver 
cancer due to HBV or HCV, Australia, 2015/16  
Condition  
Attributable fraction by age group and gender Attributable separations 
Male Female Total 
15-49 50-69 70+ 15-49 50-69 70+  
Blood borne viruses 
HIV Central estimate 0.033 0.017 0.006 0.028 0.017 0.008  
 Low bound 0.027 0.014 0.004 0.023 0.014 0.006  
 High bound 0.040 0.021 0.009 0.033 0.021 0.011  
HBV Central estimate 0.071 0.055 0.030 0.047 0.039 0.022  
 Low bound 0.032 0.025 0.014 0.021 0.018 0.010  
 High bound 0.112 0.087 0.053 0.073 0.063 0.041  
HCV Central estimate 0.635 0.635 0.634 0.626 0.627 0.598  
 Low bound 0.635 0.635 0.633 0.615 0.627 0.543  
 High bound 0.636 0.635 0.635 0.632 0.627 0.625  
Separations  Central estimate 161 63 224 
 Low bound 157 61 218 
 High bound 165 64 229 
Average costweight 2.222 1.597  
Cost ($) Central estimate 1,858,112 522,574 2,380,686 
 Low bound 1,811,948 505,984 2,317,932 
 High bound 1,904,276 530,868 2,435,144 
Liver cancer 
Liver cancer  Central estimate 0.008 0.006 0.004 0.005 0.004 0.003  
due to  Low bound 0.004 0.003 0.002 0.002 0.002 0.001  
HBV High bound 0.012 0.010 0.006 0.008 0.007 0.005  
Liver cancer  Central estimate 0.207 0.207 0.207 0.260 0.260 0.254  
due to  Low bound 0.207 0.207 0.207 0.260 0.260 0.241  
HCV High bound 0.207 0.207 0.207 0.260 0.260 0.260  
Separations Central estimate 765 348 1,113 
 Low bound 754 337 1,091 
 High bound 777 355 1,132 
Average costweight 2.420 2.328  
Cost ($) Central estimate 8,828,917 2,886,597 11,715,514 
 Low bound 8,701,965 2,795,354 11,497,319 
 High bound 8,967,410 2,944,660 11,912,070 
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Condition  
Attributable fraction by age group and gender Attributable 
Male Female separations 
15-49 50-69 70+ 15-49 50-69 70+ Total 
Cirrhosis and other liver disease 
Cirrhosis  Central estimate 0.019 0.014 0.008 0.008 0.007 0.004  
due to  Low bound 0.009 0.006 0.004 0.004 0.003 0.002  
HBV High bound 0.030 0.023 0.014 0.013 0.011 0.007  
Cirrhosis Central estimate 0.177 0.177 0.177 0.166 0.166 0.159  
due to  Low bound 0.177 0.177 0.177 0.166 0.166 0.149  
HCV High bound 0.177 0.177 0.177 0.166 0.166 0.165  
Separations Central estimate 2,644 664 3,308 
 Low bound 2,582 643 3,225 
 High bound 2,711 685 3,396 
Average costweight 1.777 1.738  
Cost ($) Central estimate 24,403,201 5,994,820 30,398,021 
 Low bound 23,830,962 5,805,224 29,636,186 
 High bound 25,021,588 6,184,415 31,206,003 
  
4.3.2 Maternal exposure – low birthweight 
Adverse pregnancy outcomes for both the mother and her baby impact the healthcare costs related to those 
patients. Using opioids 13 during pregnancy increases the risk of low birthweight by 3.28 (2.47-4.39) (Hulse 
et al., 1997). Analyses of all separations from public hospitals in New South Wales and the Australian Capital 
Territory in 2004 identified 879 female patients who reported use of a drug of dependence or its derivatives 
during pregnancy (1.4 percent of all patients who had given birth), of which 46.8 percent reported using 
opioids (including heroin, methadone, buprenorphine, codeine, pethidine and tramadol) (Abdel-Latif et al., 
2013). Another retrospective chart review of infants born between 1998 and 2016 at the Royal Hospital for 
Women in Sydney found 58 percent of mothers who used drugs during pregnancy had used opioids (Rasul 
et al., 2019). 
 
To estimate the cost of hospital separations related to low birthweight as a complication from maternal extra-




𝑝𝑝(𝑅𝑅𝑅𝑅 − 1) + 1
 
Where 
p = the prevalence of the risk factor 
RR = the relative risk of incidence of the disease of the exposed over the non-exposed 
 
We used the Hulse et al. (1997) pooled RR estimate for low birthweight of 3.28 (2.47-4.39) and an estimate 
of opioid dependence among pregnant women was calculated from Abdel-Latif et al. (2013) (0.66 percent). 
Low and high bound estimates were calculated based on the low and high bound of the estimated RR.  
 
We identified 142 hospital separations with a principal diagnosis and 16,214 separations with an additional 
diagnosis indicating low or extremely low birthweight 14 (P07.0, P07.1), of which 241 separations were 
                                                     
13 Any level of use, not just opioid dependent cases 
14 Low birth weight 1000 – 2499 g: extremely low birth weight = 999 g or less 
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considered attributable to opioids. Applying the average costweight for these separations and the average 
acuity adjusted cost per hospital separation provided a total estimated cost of $2.4 million ($1.5 million for 
male infants and $1.0 million for female infants: Table 4.6). 
 
Table 4.6: Hospital separations and costs associated with opioid-related low or extremely low birthweight, 
Australia, 2015/16  
  RR Dependence estimate AF 
Attributable separations 
 Male Female Persons 
Separations Central estimate 3.28 0.0066 0.015 126 115 241 
 Low bound 2.47 0.0066 0.010 82 75 157 
 High bound 4.39 0.0066 0.022 187 170 357 
 Average costweight    7.511 6.995  
Cost ($) Central estimate    1,454,175 953,904 2,408,079 
 Low bound    946,368 622,111 1,568,479 
 High bound    2,158,180 1,410,119 3,568,299 
Note. RR: relative risk; AF: attributable fraction.  
 
4.3.3 Intentional self-harm and suicide 
There is growing evidence that opioid dependence could be associated with suicidal acts and self-harm 
behaviour (Krausz et al., 1996; Maloney et al., 2007).  
 
The GBD Results tools were used to obtain age group-gender specific estimates of opioid dependence for 
2015 and 2016 (Global Burden of Disease Collaborative Network, 2018). Age group-gender specific AF were 
calculated using 2015 and 2016 averages of those estimates and the pooled RR from a meta-analysis 
conducted by Larney et al. (2019). We then identified all separations where the first reported external cause 
was coded as intentional self-harm (ICD-10-AM codes X60-X84, Y87.0) and where the patient was aged 15 
years or older. We excluded all episodes already counted using the direct approach outlined in Section 4.2. 
The AFs were applied to selected separations by age group and gender. Low and high bound estimates were 
calculated based on the low and high bound for the RR. 
 
Using this method, we identified 33,826 separations, of which 1,568 were estimated to be attributable to 
extra-medical use of opioids. The estimated cost of these separations was $15.8 million ($10.0 million for 
males and $5.8 million for females: Table 4.7). 
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Attributable fraction Attributable separations 
Cost ($) 













 Male  
Central estimate 9.01 0.082 0.032 0.015 786 69 8 863 9,959,942 
Low bound 6.28 0.047 0.017 0.008 450 37 4 491 5,666,664 
High bound 12.92 0.136 0.057 0.028 1,305 125 15 1,445 16,676,843 
Average costweight        1.244  
 Female  
Central estimate 9.01 0.037 0.014 0.008 658 43 4 705 5,847,847 
Low bound 6.28 0.020 0.007 0.004 356 22 2 380 3,152,031 
High bound 12.92 0.065 0.025 0.016 1,164 79 8 1,251 10,376,817 
Average costweight        1.022  
 Persons  
Central estimate     1,444 112 12 1,568 15,807,789 
Low bound     806 59 6 871 8,818,695 
High bound     2,469 204 23 2,696 27,053,660 
Note. RR(SMR): relative risk based on standardised mortality rates. 
 
4.3.4 Accidental injuries  
As explained earlier in (Section 3.1.5), opioids can cause cognitive dysfunction and drowsiness. This state 
increases the risk of accidental injury where drowsiness or cognitive dysfunction is likely to be a causal factor 
(e.g., motor vehicle accidents, drownings, falls and workplace incidents). The evidence for the relationship 
between opioid use and increased risk of accident is strongest for persons who are dependent on opioids, 
and our analysis of rates of accidental injury is restricted to this population.  
 
The GBD Results tool was used to obtain age-gender specific estimate of opioid dependence for 2015 and 
2016 (Global Burden of Disease Collaborative Network, 2018). We calculated the average of both years for 
age group-gender specific proportions. The pooled RR based on studies that reported standardised mortality 
rate from Larney (2019) was then used to calculate age group-gender specific AF for persons aged 15 years 
and older. For road crash injuries, as the prevalence of interest is that of the culpable driver rather than the 
injured person, these AF were then weighted by the proportion of accidents where a person in that age group 
was culpable, as assessed by Drummer and colleagues (2003), to give a pooled AF that was applied to all 
road crash injuries regardless of the age of the injured person.  
 
We then selected all separations where the first reported external cause was coded to V01-X19, X50–X59, 
Y85 and where patients were aged 15 or older (or all ages for road crash injuries). We excluded all episodes 
already counted using the direct approach outlined in Section 4.2. The AF were applied to the selected 
accidental injury separations by age group and gender and the total cost was estimated. Low and high bound 
estimates were calculated based on the low and high bound for the RR.  
 
We identified 43,228 hospital separations that matched our selection criteria for road crash injuries and 
461,268 further accidental injuries. Of them, 13,472 separations were estimated to be attributable to extra-
medical use of opioids (1,598 road crash injuries and 11,874 other accidental injuries). We estimated the 
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cost of these separations to be $105.0 million ($78.4 million for males and $26.7 million for females: Table 
4.8).  
 
Table 4.8: Hospital separations and costs associated with opioid-related accidental injuries, Australia, 
2015/16 
 Separations Attributable fraction Attributable separations Cost ($)  Age 15 and over Age 15 and over 
Road crash injuries 
 Male  
Central estimate 26525 0.037 981 8,735,880 
Low bound 26525 0.018 483 4,301,152 
High bound 26525 0.070 1,847 16,447,677 
Average costweight   1.714  
 Female  
Central estimate 16703 0.037 617 4,111,116 
Low bound 16703 0.018 304 2,025,574 
High bound 16703 0.070 1,163 7,749,153 
Average costweight   1.283  










years Total  Cost ($) 
Other accidental injuries 
 Male  
Central estimate 7.35 0.066 0.025 0.012 6,750 1,327 962  9,039   69,660,507  
Low bound 4.69 0.033 0.012 0.006 3,375 637 481  4,493   34,626,027  
High bound 11.51 0.122 0.051 0.025 12,478 2,708 2,004 17,190   132,477,499  
Average costweight        1.484  
 Female  
Central estimate 7.35 0.030 0.011 0.007 1,393 518 924  2,835   22,542,430  
Low bound 4.69 0.014 0.005 0.003 650 235 396  1,281   10,185,839  
High bound 11.51 0.058 0.022 0.014 2,693 1,037 1,849  5,579   44,361,275  
Average costweight        1.531  
 Attributable separations 
 Male Female Persons 
 Number Total cost Number Total cost Number Total cost 
Central estimate 10,020 78,396,387 3,452 26,653,546 13,472  105,049,933  
Low bound 4,976 38,927,179 1,585 12,211,413 6,561  51,138,592  
High bound 19,037 148,925,176 6,742 52,110,428 25,779  201,035,604  
 
4.4 Hospital separations attributed to extra-medical use of opioids based on ‘excess 
attribution’ approach 
4.4.1 Interpersonal violence (heroin only) 
As noted in Section 4.1.4, those who use opioids extra-medically are likely to be at increased risk of both 
perpetrating and being the victim of interpersonal violence (Darke, 2010; McKetin et al., 2006; Nicosia et al., 
2009; Stretesky, 2009; Torok et al., 2008). However, there may be differences in the extent of involvement 
with crime, and by implication some types of interpersonal violence, for people who use heroin compared to 
those who use pharmaceutical opioids (Krebs et al., 2017). To include the hospital cost related to assault 
and interpersonal violence we used the proportion of violent crime attributed to heroin (central estimate = 
0.0214) reported in Chapter 7 which was derived by analysis of the DUMA survey (Australian Institute of 
Criminology, 2019). This will likely understate the extent of opioid attributable interpersonal violence as it 
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does not capture attribution to extra-medical opioid use other than heroin. To identify the assault related 
hospital separations, we identified all separations where the first reported external cause was coded to X85–
Y09. We also included Y87.1 ‘Sequelae of assault’ so as to capture the long-term consequences of 
interpersonal violence. We excluded all episodes already counted using the direct approach outlined in 
Section 4.2.  
 
We identified 23,314 hospital separations coded to assault and interpersonal violence. Our central estimate 
was that 500 separations could be attributable to extra-medical use of opioids at a cost of $2.8 million ($2.0 
million for males and $0.8 million for females: Table 4.9).  
 
Table 4.9: Hospital separations and costs associated with opioid-related interpersonal violence, Australia, 
2015/16 
 Attributable separations Total separation 
Average 
costweight Cost ($) 






years All ages 
  
Male 
Central estimate 9.9 252.8 48.0 7.3 318.1 1.199 1,981,179 
Low bound 6.0 153.7 29.2 4.5 193.4 1.199 1,204,529 
High bound 16.3 413.6 78.6 12.0 520.4 1.199 3,240,809 
Female 
Central estimate 8.8 146.5 20.2 5.9 181.5 0.897 845,412 
Low bound 5.4 89.1 12.3 3.6 110.3 0.897 513,999 
High bound 14.4 239.7 33.1 9.6 296.8 0.897 1,382,923 
 
4.4.2 Infective endocarditis 
Injecting drugs can cause complications such as infective endocarditis, bacterial or fungal infection of the 
endocardial surface of heart, which may lead to serious morbidity and mortality.  
 
It is estimated that the prevalence of infective endocarditis in the past 6-12 months among PWID is 1.3 
percent (Larney et al., 2017b). We weighted this estimate by the percentage of PWID interviewed as part of 
the IDRS in 2016 (Stafford and Breen, 2016) reporting an opioid as the drug most injected in the last month 
(59.6 and 61.3 percent for males and females aged 17 years and older, respectively) and this gave us an 
estimated proportion of 0.008 of infective endocarditis attributable to injecting opioids in PWID, for both males 
and females. It is estimated that in 2014 there were 93,000 (68,000 and 118,000) PWID and the proportion 
of general population reporting injecting drugs was stable between 2013 and 2016 according to the NDSHS 
(Australian Institute of Health and Welfare, 2017g; Larney et al., 2017a). We applied the AF to the population 
of PWID and estimated the number of infective endocarditis cases due to injecting opioids to be 730 people. 
 
Infective endocarditis is a severe disease with high morbidity and mortality rates that requires prompt 
treatment. People with infective endocarditis require frequent follow-ups and more than 50 percent undergo 
cardiac surgery during their initial presentation (Tornos et al., 2005). The clinical presentation of infective 
endocarditis and complications include fever, cardiac (e.g. congestive heart failure, new heart murmur and 
atrioventricular block) and non-cardiac (e.g. splenomegaly, rheumatological symptoms, neurological 
manifestations) manifestations (Habib, 2006).  
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We identified 1,987 hospital separations with a principal diagnosis of acute or subacute infectious 
endocarditis (I33.0) and further 1,266 separations where I33.0 appeared as an additional diagnosis. We 
estimated that 730 separations (491 for males and 239 for female) could be attributable to extra-medical use 
of opioids and the cost of these separations was estimated to be $19.6 million ($13.0 million for males and 
$6.6 million for females: Table 4.10). 
 




Number of PWID Proportion Separations Cost ($) 
central low high  central low high central low high 
Male 
5.104 63,500 46,000 80,500 0.008 491 356 623 13,017,027   9,438,008  16,516,513  
Female 
5.334 30,000 22,000 38,000 0.008 239 175 302  6,620,857   4,847,908   8,366,104  
Persons 
5.219 93,500 68,000 118,500 0.008 730 531 925 19,637,884 14,285,916 4,882,617 
 
An alternative method by Riddell and colleagues (2008) used the AF from English et al. (1995). Given the 
time since the original studies and the estimated AF, we decided not to use this approach. However, for 
comparison, outcomes using this method are reported in Appendix 4.2. 
 
4.4.3 Neonatal abstinence syndrome 
Use of opioids during pregnancy can cause a drug withdrawal syndrome in newborns, called NAS, who then 
require longer hospitalisation to be treated. In the United States, NAS hospital admissions increased more 
than fourfold between 2003 and 2012, costing nearly USD316 million in 2012 (Corr and Hollenbeak, 2017).  
 
We have identified two studies that reported on hospital inpatient treatment for NAS among newborns 
exposed to opioids. Rasul et al. (2019) found that half (54 percent) of 442 opioid‐exposed infants were 
medicated for NAS, while Abdel-Latif et al. (2013) reported 96.5 percent of the infants that required NAS 
pharmacotherapy were prescribed morphine, and by implication, had incurred in utero exposure to opioids. 
The estimate from Abdel-Latif et al. was applied directly to the NAS related hospital separations identified by 
P96.1 code in principal diagnosis, to estimate the costs associated with NAS hospitalisations due to opioids. 
We excluded all episodes counted using the direct approach outlined in Section 4.2.  
 
We identified 457 hospital separations which met the above criteria. We estimated that 440 separations could 
be attributable to extra-medical use of opioids at a cost of $4.2 million ($2.2 million for male infants and $2.0 
million for female infants: Table 4.11).  
 
Table 4.11: Hospital separations and costs associated with opioid-related neonatal abstinence syndrome, 
Australia, 2015/16 
  Average 
costweight Prevalence Weight AF Cases Cost ($) 
Male infants Central estimate 1.825 0.965 1 0.965 237 2,246,535 
Female infants Central estimate 1.892 0.965 1 0.965 203 1,994,891 
Total cost ($) Central estimate  0.965 1 0.965 440 4,241,426 
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4.5 Conclusions 
Illness and injury attributable to extra-medical use of opioids are estimated to have caused 30,708 hospital 
separations in 2015/16, with a total cost of $249.3 million (with the cost estimate ranging from a low bound 
of $180.1 million to a high bound of $365.8 million). Hospital separations are much more frequent among 
males, accounting for around two-thirds of the total number of separations and, in turn, total costs incurred 
(Table 4.12). 
 
Table 4.12: Hospital separations summary 
Condition Sex Separations Cost 
    
Central Low bound 
High 
bound Central $ Low bound $ High bound $ 
Opioid poisoning 
Male 4,824 N/A N/A 21,898,818 N/A N/A 
Female 4,085 N/A N/A 17,313,472 N/A N/A 
Injecting related skin & 
vascular injuries 
Male 658 N/A N/A 8,335,082 N/A N/A 
Female 476 N/A N/A 5,869,817 N/A N/A 
Acquired brain injury 
Male 46 N/A 156 945,360 N/A 1,440,452 
Female 24 N/A 118 507,911 N/A 965,450 
Blood borne viruses 
Male 161 157 165 1,858,112 1,811,948 1,904,276 
Female 63 61 64 522,574 505,984 530,868 
Liver cancer secondary to 
HBV & HCV 
Male 765 754 777 8,828,917 8,701,965 8,967,410 
Female 348 337 355 2,886,597 2,795,354 2,944,660 
Cirrhosis and other liver 
disease 
Male 2,644 2,582 2711 24,403,201 23,830,962 25,021,588 
Female 664 643 685 5,994,820 5,805,224 6,184,415 
Low birthweight * 
Male 126 82 187 1,454,175 946,368 2,158,180 
Female 115 75 170 953,904 622,111 1,410,119 
Intentional self-harm 
Male 863 491 1,445 9,959,942 5,666,664 16,676,843 
Female 705 380 1,251 5,847,847 3,152,031 10,376,817 
Accidental injuries 
Male 10,020 4,976 19,037 78,396,387 38,927,179 148,925,176 
Female 3,452 1,585 6,742 26,653,546 12,211,413 52,110,428 
Interpersonal violence 
Male 318 193 520 1,981,179 1,204,529 3,240,809 
Female 181 110 297 845,412 513,999 1,382,923 
Infective endocarditis 
Male 491 356 623 13,017,027 9,438,008 16,516,513 
Female 239 175 302 6,620,857 4,847,908 8,366,104 
Neonatal abstinence 
syndrome* 
Male 237 N/A N/A 2,246,535 N/A N/A 
Female 203 N/A N/A 1,994,891 N/A N/A 
All opioid attributable 
conditions  
Male 21,153 15,356 31,340 173,324,735 123,953,418 257,331,682 
Female 10,555 8,154 14,748 76,011,648 56,140,115 109,449,964 
Persons 31,708 23,510 46,088 249,336,383 180,093,533 366,781,646 
* Sex of infant. 
N/A - Where low or high bound not available, central estimate was used to calculate the separations and cost totals for all opioid 
attributable conditions.  
 
Accidental injuries are the dominant cause of the hospital separation costs arising from extra-medical use of 
opioids, with an estimated 13,452 separations at a cost of $105.0 million. The other substantial drivers of 
cost were opioid poisoning (8,909 separations at a cost of $39.2 million) and cirrhosis and other liver disease 
secondary to HBV and HCV (3,308 separations at a cost of $30.4 million). However, caution should be 
exercised in comparing different causes, as the identification process meant that any separation that included 
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an opioid use or poisoning principal diagnosis, would be allocated to that category regardless of subsequent 
diagnoses or external cause. 
 
4.6 Limitations 
There are some limitations related to these data and the methods of calculating costs. When interpreting the 
data presented in this report, the following restrictions should be considered.  
 
The ICD-10-AM classification itself has limitations and is dependent on the quality of clinical documentation 
and the quality of the coding process itself. Accuracy of the diagnosis codes depends upon the right code 
being entered and hence conditions may be under- or over-ascertained. Further, there could be variations 
among jurisdictions and between private and public hospitals in the way in which hospital services are defined 
and coded. 
 
While the NHMD is extensive, there are some omissions. For 2015/16, almost all public hospitals and the 
great majority of private hospitals provided data for the NHMD, the exceptions were an early parenting centre 
and the private free-standing day hospital facilities in the Australian Capital Territory. In addition, the NHMD 
2015/16 dataset included 5,913 (0.06 percent) hospital separations with a missing principal diagnosis code 
and most of them (n = 4,722) are for the records where the state of hospitalisation was Tasmania. In those 
cases, we were unable to identify the main reason for hospitalisation, even though we know they were 
potentially drug-related. Also in relation to Tasmania, the Tasmanian records accessed by the team only 
included those where there was a drug and alcohol related principal and/or additional diagnoses and external 
causes which enable the identification of separations with other potentially drug-related conditions. As a 
result, these findings likely represent an underestimate of costs as Tasmanian records could not be used in 
calculation of the indirectly attributed conditions. Finally, the NHMD 2015/16 does not contain cross-border 
separations: only separations where the patient’s usual residence was within the state of hospitalisation were 
included. 
 
Importantly for this study, there were 6.2 percent (n = 44,143) of all hospital separations with a principal 
diagnosis coded to an S-code (6.2 percent; n = 31,550 separation) or a T-code (6.3 percent; n = 12,593 
separations) (injury or poisoning related) which did not have an external cause code specified, meaning we 
could not identify whether the separations arose from an accidental injury, or self-harm or assault. In addition, 
the NHMD does not capture features of opioid exposure, including whether use of pharmaceutical opioids 
was extra-medical in nature (i.e., outside the bounds of a doctor’s prescription) (Larance et al., 2011) or the 
route of administration of the opioid, which is pertinent when computing costs arising from conditions where 
risk is via injecting drug use. 
 
There is a limited literature and few other sources that provide AF for the diseases we considered in this 
report. We used other approaches such as the direct approach (selecting separations where both the ICD-
10-AM condition code and opioids related codes were identified) and an approach based on excess 
attribution, which are likely to produce underestimation of costs. The ICD-10-AM coding system does not 
always have a unique code or combination of codes that would allow identification of the condition of interest 
(e.g. brain injury due to drug toxicity). Furthermore, using a RR based on standardised mortality rates for 
morbidity data (accidental injuries, intentional self-harm) is likely to produce estimates that are 
underestimated. 
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With respect to hospital separations, we only considered costs in the target year, whereas some conditions 
will have on-going costs. For example, it is possible that infants born with NAS who survive and leave hospital 
will have life-long health, social and educational consequences which will add to a social cost; however, we 
do not capture these costs in the report. 
 
Due to the lack of appropriate AF, it is challenging to quantify the attribution of opioids to conditions in 
situations where multiple drugs were identified. The approach we undertook to divide the attribution equally 
between the involved substances may produce inaccurate estimates (over- or underestimates). Also, for 
conditions where AF was not available, we could capture only hospital inpatient costs for patients who turned 
up at the hospital under opioid influence at the time of hospitalisation. People who use opioids may have 
flow-on complications such as skin infection or brain injury, or further complications of other opioid-related 
conditions which will result in a hospital admission; however we were unable to identify those episodes and 
their cost was not included. Finally, hospital separations do not capture all health costs: in Chapter 5 further 
out-of-hospital health costs due to opioids are identified. 
 
The current analysis took a different approach to the calculation of costs arising from IDU compared with the 
methamphetamine report (Whetton et al., 2016). In that instance, we used data on the total medical cost of 
those with HCV, HBV, and HIV and apportion that based on the proportion testing positive to the condition 
who reported having injected drugs and that methamphetamine was their most recent drug injected: 
secondary conditions such as cirrhosis and liver cancer were excluded. In the current report we took a 
condition by condition approach estimating the proportion attributable to IDU from RR and the prevalence of 
injecting drug use, then we gave opioids a share based on the proportion of IDU who inject opioids. Also in 
the methamphetamine study, we excluded infective endocarditis given the environmental changes (e.g. NSP) 
since the English et al. (1995) estimate. In the current study we had access to a recent estimate of the 
prevalence of infective endocarditis amongst dependent opioid users (Larney et al., 2017b) thus we included 
infective endocarditis in our analysis. As noted in Section 3.10, we were still unable to cost deaths from 
infective endocarditis. 
 
For more information on the NHMD, go to the Admitted patient care 2015–16 report (Australian Institute of 
Health and Welfare, 2017b, 2019b). 
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CHAPTER 5: OTHER HEALTH CARE COSTS 
Aqif Mukhtar, Steve Whetton & Robert J. Tait 
 
5.1 Background 
People dependent on extra-medical opioid drugs have a range of health and behavioural issues arising from 
their use. People who use extra-medical opioid drugs access many types of health services, including hospital 
emergency departments and outpatient services, general practice, specialist care, ambulance services, 
nursing homes and other carer services. In addition, they are likely to incur further costs for drug rehabilitation 
and the use of pharmaceuticals for the treatment of opioid drug-related conditions. The adverse health 
conditions incurred are also likely to have financial and other impacts on family members who act as carers. 
The costs arising from inpatient admissions are addressed in Chapter 4. 
 
In 2015/16, $170.4 billion was spent on health care. Of this, $70.2 billion (41.2%) was spent by the Australian 
Government, $44.4 billion (26.1%) by state, territory and local governments and the remainder ($55.8 billion, 
32.7%) by households and businesses (Australian Institute of Health and Welfare, 2017f). Public hospitals 
received 40 percent of government spending, with primary care and community health receiving about 30 
percent of government spending (Australian Institute of Health and Welfare, 2017f). Ambulance services 
received government funding of $3.2 billion (Steering Committee for the Review of Government Service 
Provision, 2018b). Household and business spending predominately went toward primary care and allied 
health services. 
 
Correct apportionment of these costs to extra-medical opioid use and related conditions was the first step 
towards estimating their overall costs. However, for most of these costs, such as general practitioner services, 
there is no unambiguous way of attributing costs to extra-medical opioids as there is no consistent and 
reliable equivalent to the ICD-10 coding used for hospital separations. The same limitation was also 
encountered in recent studies calculating societal costs for smoking tobacco or use of methamphetamine 
(Whetton et al., 2016; Whetton et al., 2019). To address this, in calculating the overall cost of tobacco to 
Australian society, the assumption was made that the proportion of other health costs attributable to smoking 
could be reasonably approximated by the proportion of hospital bed-days attributed to smoking on the basis 
that they had a similar distribution of underlying causes (Collins and Lapsley, 2008; Whetton et al., 2013). 
We have used this approach as the starting point in calculating the healthcare costs attributable to extra-
medical opioid use. 
 
However, there are likely to be potentially significant differences between the forms of injury and ill-health 
driving hospital separations and those driving some of the other healthcare costs. For example, many GP 
visits are for reasons entirely unrelated to those which cause hospital separations, such as renewal of 
prescriptions, general health check-ups and vaccinations.  
 
Some component of allied health expenditure must be attributable to extra-medical opioid use or 
dependence. This could include increased dental problems due to poor dental hygiene and tooth decay 
caused by reduced production of saliva due to opioid use. This cohort is also at increased risk of accidental 
injury and stroke which may require them to use out of hospital rehabilitation services. Other problems include 
sleep disturbance and apnoea, lethargy, constipation, reduced libido and sexual dysfunction, potentially 
increasing the number of GP visits among this cohort. Other than GP costs, none of these forms of allied 
health expenditure potentially attributable to opioid use was able to be quantified using current data, and of 
allied health spending, only GP costs were included here. 
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This left the following areas of other healthcare costs for inclusion in this analysis: 
• Ambulance costs; 
• Non-admitted hospital care costs (ED and outpatient services); 
• Primary healthcare costs, including GP visits and specialist visits;  
• Treatment for opioid addiction including community mental health and specialist drug treatment 
services; 
• Pharmaceuticals for opioid attributable diseases or conditions; and, 
Long-term care costs: 
• Residential and other aged care services; and, 
• Costs to family members of providing care. 
 
In each of these cases, we have initially taken the share of extra-medical opioid attributable hospital costs as 
the base for opioid attribution. We then adjusted that figure where possible, to reflect other evidence about 
the factors driving demand for that form of health service.  
 
In 2015/16, total expenditure on hospital separations was $28.3 billion (Independent Hospital Pricing 
Authority, 2018). Extra-medical opioid attributable hospital separations are estimated to have had a total net 
cost of $249.3 million (see Chapter 4 for calculation), giving a cost share of 0.88 percent. This then 
represents a base cost share for other medical costs, to be adjusted based on other evidence on the source 
of costs. A main cost estimate and a high and low bound are also presented where feasible. It should be 
noted that in addition to opioid poisoning and related medical conditions, the 0.88 percent cost share also 
includes the cost of opioid related conditions such as accidental injury, interpersonal violence and intentional 
self-harm.  
 
5.2 Ambulance costs 
In 2015/16, there were 1.8 million ED presentations where the arrival mode was recorded as ambulance, air 
ambulance or helicopter rescue service (Australian Institute of Health and Welfare, 2016c). In addition, there 
were 289,746 intra-hospital transfers for acute patients (Australian Institute of Health and Welfare, 2017b). 
Assuming that all intra-hospital transfers for acute patients used an ambulance service, the total ambulance 
activity in 2015/16 was estimated to be 2.1 million transfers. The total ‘patient transport’ expenditure in 
2015/16 was $3.7 billion (Australian Institute of Health and Welfare, 2017f). Therefore, the average cost of 
an ambulance transfer was calculated as $1,776.  
 
The overall proportion of patients presenting at ED via ambulance was 24 percent. However, the proportion 
of ambulance transfers vary according to the triage category such as T1: Resuscitation (83%), T2: 
Emergency (45%), T3: Urgent (33%), T4: Semi-Urgent (14%) and T5: Non-Urgent (4%). After applying these 
proportions to the 4,921 opioid-related ED presentations (Section 5.3), the estimated number of opioid-
related ED presentations using an ambulance service was 1,908, with a total cost of $3.4 million. We use 
this as lower estimate for our ambulance costs. 
 
Given the similarity of the population they serve, the proportion of ambulance costs attributable to specific 
causal factors is likely to be broadly similar to that of hospital separations. Thus, the proportion of hospital 
separation costs attributable to extra-medical opioid use should provide a reasonable proxy for the proportion 
of ambulance costs that can be attributed to this cohort of patients. 
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As mentioned above, the total ‘patient transport’ expenditure in 2015/16 was $3.7 billion. Applying the cost 
share from the hospital separations data, this suggests that the opioid attributable cost of ambulance service 
was $32.8 million. This forms the high bound for ambulance costs. We used the mean of low and high bound 
values as our central estimate of $18.1 million. 
 
5.3 Emergency department presentations 
Opioid poisoning often requires presentation to a hospital ED. Poisoning could be due to the combination of 
opioids and other depressant drugs, often also combined with alcohol. In such cases, only one drug is listed 
as the principal diagnosis, resulting in potential undercounting of ED presentations for a particular drug. This 
also makes it difficult to get accurate data and costings for a particular drug. 
 
In 2018, AIHW published a report on opioid harm in Australia based on 2016/17 data (Australian Institute of 
Health and Welfare, 2018d). Since our study year (2015/16) is only a year earlier, we calculated the opioid 
related ED presentations based on 2016/17 estimates by applying the proportion (n=5,112: 0.07%) of all 
cause opioid events out of the total ED presentations in 2016/17 (Australian Institute of Health and Welfare, 
2017e) to the 2015/16 total ED presentations data (Australian Institute of Health and Welfare, 2016c). 
 
Using the above methodology, there were 4,921 estimated opioid-related ED presentations during 2015/16. 
These include presentations related to poisoning, dependence and other mental and behavioural issues. 
Almost half (44%) of the presentations were treated as Triage 1 (Resuscitation) or Triage 2 (Emergency) 
episodes. Therefore, we applied average cost by triage categories, derived from a report published by the 
Independent Hospital Pricing Authority (Independent Hospital Pricing Authority, 2018). The total cost of 
opioid-related ED presentations in 2015/16 was calculated to be $3.9 million. This figure is taken as the low 
bound cost estimate.  
  
Total expenditure in 2015/16 on ED presentations which do not result in an admission to hospital was $4.7 
billion (Independent Hospital Pricing Authority, 2018). Applying the cost share from the hospital separations 
data suggests that the extra-medical opioid attributable cost of ED presentations was $41.4 million, this was 
used as the high bound cost estimate. We used the mean of these two values as our central estimate of 
$22.7 million. 
 
5.4 Non-admitted patient care  
In 2015/16, about 33.4 million non-admitted patient care service events (previously referred to as outpatients) 
were provided in Australia (Australian Institute of Health and Welfare, 2017j). Of these, 860,772 (2.6%) 
service events were provided by alcohol and other drug clinics. The proportion of opioid-related episodes 
(F11 - Mental and behavioural disorders due to use of opioids) out of all hospital separations, under the ICD 
codes category F10-F19 (Mental and behavioural disorders due to psychoactive substance) use was 5.6 
percent (Australian Institute of Health and Welfare, 2017b). Applying this proportion to 860,722 non-admitted 
patient service events for alcohol and other drugs clinics resulted in 47,998 estimated opioid related non-
admitted patient service events. The unit cost of a service event in 2015/16 was $303 (Independent Hospital 
Pricing Authority, 2018), resulting in a low bound cost of $14.5 million for opioid-related non-admitted patient 
care.  
 
The total expenditure on non-admitted patient care in 2015/16 was $5.4 billion (Independent Hospital Pricing 
Authority, 2018). Applying the cost share from the hospital separations data, this suggests that the opioid 
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attributable cost of non-admitted patient care was $47.4 million. This forms the high bound for non-admitted 
costs. We used the mean of the low and high bound values as our central estimate of $31.0 million. 
5.5 Primary health care 
Dependence on opioids is associated with a range of health problems that may require treatment from a GP 
or other primary care physician. These include medical and psychological complications that often require a 
long-term care plan. Reviewing data from the Bettering the Evaluation and Care of Health (BEACH) survey 
(Britt et al., 2016) there appears to be at least 19.4 percent of GP visits that should be excluded from the 
calculation as wholly or largely unrelated to the conditions that result in hospital separations (e.g. visits for 
prescriptions, general check-ups and administrative visits). 
 
In-scope ‘un-referred medical services’ are estimated at $9.5 billion (total un-referred medical services 
spending was $11.8 billion in 2015/16, with 19.4 per cent of this spending excluded as it related to ineligible 
costs identified from the BEACH data (Australian Institute of Health and Welfare, 2017f)). Applying the cost 
share from the hospital separations data (0.88%), this suggests that the extra-medical opioid attributable cost 
of the in-scope ‘un-referred medical services’ was $83.3 million, making the low bound cost estimate. The 
high bound estimate was calculated as $103.4 million, being 0.88 percent of the total un-referred medical 
service expenditure. The average of these two estimates, $93.3 million was taken as our central estimate. 
 
There was additional expenditure of $17.7 billion in 2015/16 for ‘referred medical services’, e.g. specialist 
physicians (Australian Institute of Health and Welfare, 2017f). It is not clear whether this should be factored 
down on a similar basis to costs for GPs. Our high estimate of referred medical services is calculated from 
the unadjusted expenditure, on the basis that the reasons why patients will be referred to specialists are likely 
to be closer to the reasons for hospital separations than they are to the reasons for visits to GPs. For our low 
bound estimate of costs, we have factored referred medical costs down on the same basis as for un-referred 
medical costs, giving in scope costs of $14.3 billion. 
 
Applying the cost share from the hospital separations data to the unadjusted referred medical costs gives a 
high bound estimate of extra-medical opioid attributable costs as $155.7 million, and a low bound, calculated 
from the adjusted spending, as $125.5 million. The mean of these two estimates, $140.6 million was taken 
as the central estimate. 
 
5.6 Specialist health care and drug treatment services 
Data on the number of opioid related treatment episodes were obtained from the AIHW dataset Alcohol and 
other drug treatment services (AODTS) (Australian Institute of Health and Welfare, 2017c). Opioids include 
morphine, buprenorphine, heroin, methadone and all other drugs categorised as ‘other opioids’. Costs by 
treatment type and episode were obtained from a range of sources such as state health department, personal 
contacts and previous research. Costs per episode by treatment type, specifically for extra-medical opioid 
use dependence were not available. Therefore, the average costs were multiplied by the relevant frequency 
of episodes of care. The AODTS data also contain information on individuals who seek treatment or support 
for themselves as a consequence of another person’s drug use.  
 
In 2015/16, about 796 AODTS provided just over 206,600 treatment episodes with 96 percent (n = 198,747) 
of treatment episodes were for ‘own drug use’. Of these, nine percent (n = 18,502) of treatment episodes 
were for extra-medical opioids. Of the opioids, heroin (59%) was the most frequent drug requiring treatment, 
followed by ‘other’ opioids (22%) (Australian Institute of Health and Welfare, 2017c).  
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Average treatment costs for different treatment types were replicated from a previous study where they had 
been sourced from public data (Mental Health Commission, 2015) and a personal communication (Personal 
communication TK, 2015). The 2013/14 figures were adjusted to 2015/16 using a CPI inflation calculator 
from the ABS (Australian Bureau of Statistics, 2016c). To avoid double counting, we only costed the 
pharmacotherapy sessions at counselling level service cost since there were resource implications for these 
type of service events. The actual cost of medications resulting from such events should be covered in the 
cost of pharmaceuticals in Section 5.7.  
 
Table 5.1: Costs of treatment episodes, extra-medical opioids primary drug 2015/16 – for own use 
Treatment type   Number of episodes 




Withdrawal    2,478      
 Non-residential a 1,178  $4,979 $5,865,592 
 Residential a 1,300  $7,539 $9,800,213 
Rehabilitation   1,054    
 Non-residential a,b 165  $2,077 $342,640 
 Residential a 889  $7,539 $6,701,838 
Counselling a  4,381  $2,077 $9,097,617 
Support & case management only c  1,540  $1,802 $2,774,997 
Information & education only c  453  $380 $172,022 
Assessment only c  3,196  $117 $372,408 
Other including pharmacotherapy a  5,400  $2,077 $11,213,680 
Total    18,502    46,341,007  
Sources: a (Mental Health Commission, 2015); b (Personal communication TK, 2015); c (Ngui and Shanahan, 2010);  
Note: * these data do not include visits to general practitioners or other health care provided in community mental health which are 
captured elsewhere in the chapter 
 
  
Overall, the total cost of treatment for own use of extra-medical opioids was $46.3 million (Table 5.1). 
Individual proportions by treatment type from AODTS data were applied to the total of those who were 
seeking assistance due to others’ drug use. The same average costs of treatment were applied to these 
episodes. 
 
Table 5.2: Costs of treatment for those seeking treatment due to others’ extra-medical opioid use 
Treatment type 
Total episodes - 
'Seeking treatment for 
own other drug use' 
(n) 
Episodes - 'Seeking 
treatment for own 
drug use'  
(% of total episodes) 
Episodes - 
'Seeking treatment  




Counselling* 5,580 6.3% 351 $729,336 
Support & case management only 738  5.7% 42 $75,682 
Information & education only 951  2.5% 23 $8,914 
Assessment only  431  9.7%  42 $4,867 
Total 7,700   458 $818,799 
Note: * these data do not include visits to general practitioners or other health care provided in community mental health which are captured 
elsewhere in the chapter. 
 
To calculate treatment episodes for clients who were seeking treatment for ‘other’s drug use’ such as a family 
member, relative or friend, we applied individual proportions out of the total by treatment types. Thus, for 
counselling own extra-medical opioid use accounted for 4,381 (6.3%) out of 69,604 counselling episodes. 
The same proportion was applied to the 5,580 episodes of counselling for other’s drug use (n = 351 episodes). 
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The additional cost of episodes was $0.8 million (Table 5.2). The total costs of other specialist and drug 
treatment services for extra-medical opioid related cases was $47.1 million (Table 5.3). 
 
Table 5.3: Total expenditure on treatment for extra-medical opioid at specialist treatment centres 
Client Type Costs 
Treatment for own use 46,341,007  
Treatment for others’ use  $818,799 
Total  47,159,806  
 
5.7 Opioid agonist therapy 
Opioid dependence is a chronic and relapsing disorder that affects physical and mental health and social 
wellbeing and function (Australian Institute of Health and Welfare, 2017g). From the GBD study in 2015/16 
there were an estimated 104,026 (0.48%) people dependent on opioids in Australia (Global Burden of 
Disease Collaborative Network, 2018). Despite the low prevalence of use, the economic and social cost of 
extra-medical opioid drug use is relatively high due to medical and mental health consequences, loss of life 
due to overdose and social consequences to individuals and their communities (NSW Ministry of Health, 
2018). Opioid agonist therapy (OAT) in the form of either methadone or buprenorphine (Pharmaceutical 
Benefits Scheme, 2018a), is the most commonly used treatment provided for opioid (mainly heroin) 
dependence in Australia and has been shown to be effective (Sordo et al., 2017; Teesson. et al., 2006). 
 
The list of PBS medications to treat opioid dependence were identified via the PBS website for drugs under 
the category of ‘Drugs used in opioid dependence’ (Pharmaceutical Benefits Scheme, 2018a). During 2015, 
the total cost of OST borne by PBS was $70.7 million. There were 1.54 million occasions when OST was 
dispensed, resulting in a total co-payment cost of $9.5 million with an overall cost of $80.3 million (Table 
5.4).  
 
Table 5.4: Cost of extra-medical opioid agonist therapy  
Cost area Central estimate  ($) 
PBS & RPBS pharmacotherapy 70,713,157 
PBS & RPBS co-payments 9,547,059 
Total 80,260,216 
PBS = Pharmaceutical Benefits Scheme: RPBS = Repatriation Pharmaceutical Benefits Scheme 
 
5.8 Cost of pharmaceuticals prescribed for illicit opioid attributable disease 
Pharmaceuticals used in treating extra-medical opioid-related conditions, received during a hospital admitted 
episode, are included within the costs derived from diagnosis-related grouping codes, and form part of the 
costs reported in Chapter 4. Therefore, only the cost for treatment of extra-medical opioid-related conditions 
outside the hospital system needs to be estimated. Previous estimates have determined the net cost by 
adjusting for premature deaths in the target group, for example smokers (Whetton et al., 2019) by subtracting 
saving from premature deaths among smokers. The same approach was used in this instance, with the 
notional future savings reported in Chapter 3 with the mortality estimates. 
 
Our preferred approach to estimate extra-medical opioid attributable pharmaceutical costs was to calculate 
it on a substance specific basis. As noted in Section 2.2, opioid attributable conditions were identified via the 
GBD Study (Degenhardt et al., 2013b; Degenhardt et al., 2013c) and the Australian Burden of Disease Study 
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(ABDS) (Australian Institute of Health and Welfare, 2018b). The conditions identified through this process 
were: BBV including human immunodeficiency virus (HIV), hepatitis B and C viruses (HBV, HCV) and liver 
cancer or cirrhosis secondary to HBV and HCV. Other conditions included skin and soft tissue infections, 
infective endocarditis low birth-weight and neonatal abstinence syndrome. (Costs of drugs used for treating 
opioid dependency are shown in Table 5.4). PBS items were designated to some of the above conditions 
while some conditions were excluded. The process is described below in detail.  
 
The drugs used in treating HIV were identified via the PBS website for drugs under the category of ‘Antivirals 
for treatment of HIV infections’. The list of PBS medications for HCV were also identified via the PBS website 
for drugs under the category of ‘Antivirals for treatment of HCV infections’ (Pharmaceutical Benefits Scheme, 
2018a). The medications for HBV were identified through PBS review to examine the utilisation of medicines 
for the treatment of hepatitis (Pharmaceutical Benefits Scheme, 2015). The drugs used to treat skin and soft 
tissue infections were identified through published clinical guidelines (Ramakrishnan et al., 2015). For the 
treatment of opioid related neonatal abstinence syndrome (NAS), clinical guidelines suggest the use of 
morphine and/or phenobarbitone in addition to supportive care (Commonwealth of Australia, 2006). We did 
not have access to the age of the patient receiving medication, therefore, only PBS prescriptions for oral 
morphine 15 were counted for the cost calculation, as specified in the clinical guidelines. It is also suggested 
in the literature that methadone and buprenorphine, similar to that used in the treatment of opioid-dependent 
pregnant women can also be used to treat NAS (Fábio Martins, 2019). The cost of these latter drugs have 
already been included under treatment for opioid dependence.  
 
In January 2016, the co-payment costs for prescription medications were $6.20 for concessional patients and 
$38.30 for general patients (Pharmaceutical Benefits Scheme, 2016a). When general patients reach their 
safety net threshold, they then pay $6.20 per prescription and when concessional patients reach their 
threshold, they make no co-payment. Co-payments for those covered by the RPBS depend on which 
Department of Veterans’ Affairs concessional card they hold. Gold and Orange card holders receive the 
concessional rate on all listed medications, while those on the White card can receive the concessional rate 
on medications for their service related condition(s) (Department of Veterans' Affairs, 2018). The maximum 
co-payment is $6.20: when safety net thresholds are reached there are no further co-payments. We applied 
these values to the ‘service’ (e.g. number of prescriptions) data from the PBS (Pharmaceutical Benefits 
Scheme, 2016b) to calculate the co-payment costs.  
 
For each medication (PBS item number) listed in Appendix 5.1, government costs in terms of Services (n) 
and Benefits ($) were extracted from the PBS website and co-payments estimated from the associated 
patient benefit categories (Pharmaceutical Benefits Scheme, 2016b) (Table 5.5).  
 
There were other health problems that were too broad or generic to be associated with a specific list of 
medications, especially to narrow it down to only persons who use extra-medical opioids. These include 
suicide and self-harm, low birthweight, sleep problems, constipation and accidental injuries. Also, we were 
not able to find specific prescription medicines for treating liver cancer or cirrhosis secondary to HBV and 
HCV and infective endocarditis. Due to the serious nature of the conditions and high dependence on ‘in-
hospital’ care, we believe that the majority of medicine cost would be covered under the cost of hospital 
separations.  
                                                     
15 Other forms of morphine includes injections, tablets, capsules and granules sachets. 
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Table 5.5: The costs of medications* for key extra-medical opioid-related conditions and opioid 
attributable costs 











HIV / AIDS 210,713,408 0.90 1,898,319 
Hepatitis C 820,134,599 62.14 509,621,210 
Hepatitis B 73,295,743 4.62 3,389,399 
Skin and Soft Tissue Infections 82,596,636 0.71 584,304 
Neonatal Abstinence Syndrome 2,061,365 96.50 1,989,218 
Total 1,188,801,751 - 517,482,450 
 *For individual items number see Appendix 5.1 
 
We did not have access to age-group or sex for the PBS costs and so could not apply the extra-medical 
opioid AF for each condition directly to pharmaceutical costs. Instead we assumed that the proportion of 
pharmaceutical cost for each condition attributable to extra-medical opioids would be equivalent to the 
proportion of total hospital separation costs attributable to extra-medical opioids for that condition, which is 
effectively the age, gender and severity weighted AF for that condition. This gives a total cost of extra-medical 
opioid attributable PBS/RPBS listed medicine costs for the selected conditions of $517.5 million (Table 5.5). 
 
The costs presented in the table above only includes the cost of prescribed medications outside the hospital 
sector. Therefore, the total estimate does not include ‘in-hospital’ pharmaceutical costs (these are included 
in the hospital separation costs reported in Chapter 4) nor does it include pharmaceuticals delivered through 
outpatient hospital clinics (as is the case with a significant proportion of dialysis and chemotherapy). These 
latter costs should be captured in the non-admitted hospital costs calculated above.  
 
As an alternative approach, we also calculated pharmaceutical costs using the same approach as for 
outpatient hospital costs, i.e. allocating a share of total PBS listed pharmaceutical costs equal to the share 
of extra-medical related inpatient separations. In 2015/16 the total cost of PBS and RPBS medications was 
$10.4 billion, with a further $1.5 billion in gap payments (total $11.9 billion) (Pharmaceutical Benefits Scheme, 
2018b). Assuming that the proportion of PBS listed pharmaceutical costs attributable to extra-medical opioids 
matched the share of hospital separation costs in 2015/16, it gives an estimate of pharmaceutical costs of 
$104.7 million.  
 
Since the direct cost of $517.5 million (Table 5.6) is higher than the cost of $104.7 million based on the 
alternative method using share of opioid related hospital separations, direct cost is taken as a high bound 
and hospital separations based cost was taken as a low bound. The mean of the low and high bound values 
was taken as the central estimate of $311.1 million.  
5.9 Community mental health services 
The number of service contacts and the costs of community mental health expenditure data were sourced 
from the AIHW web report providing statistics for mental health services in Australia (Australian Institute of 
Health and Welfare, 2019c). During 2015/16, around 9.4 million community mental health care service 
contacts were provided to approximately 414,000 patients across Australia. Of these, 102,709 (1.1%) service 
contacts were for the principal diagnosis ‘Mental and behavioural disorders due to use of opioids (F11)’. The 
69  Chapter 5: Other health costs 
 
total expenditure on community mental health care services in Australia during the same time period was 
$2,047 million.  
 
We also applied 1.1 percent (for opioid service contacts out of total service contacts) to the total expenditure 
of $49.1 million on the national suicide prevention program (Australian Institute of Health and Welfare, 2019c) 
to estimate the cost of suicide prevention for people who use extra-medical opioids ($0.54 million). Applying 
the proportionate share of opioid related service contacts and adding the cost of suicide prevention gives us 
an approximate cost of $22.9 million. 
 
5.10 Residential and other aged care services 
High-level residential care (previously known as nursing home care) is likely to include a proportion of people 
either dependent on extra-medical opioids or with health conditions attributable to opioids. Notably, many 
older patients remain in hospital while waiting for access to residential age care: in 2015/16 it was estimated 
that this period was 11.3 days per 1,000 patient days (Steering Committee for the Review of Government 
Service Provision, 2018c)16. These days in hospital are included with other hospital costs and are reported 
in Chapter 4. Furthermore, until 2005/06, high-level residential services were classified with health services 
but were subsequently counted with welfare services, so caution is required in assessing changing 
expenditure over time within categories (Australian Institute of Health and Welfare, 2017f).  
 
Residential care data (excluding expenditure on high-level residential care for younger people with disability 
were extracted from the Community Services report on aged care (Steering Committee for the Review of 
Government Service Provision, 2017b)). This item accounted for over two-thirds of the total aged care 
expenditure ($11.5 of $16.8 billion) with other services such as home care and other support services 
accounting for the remainder. As only data on Government expenditure on aged care services is available 
it is likely that these costs will be underestimated. 
 
Data from the AIHW suggest that 53 percent of nursing home residents suffer from some form of dementia 
(Australian Institute of Health and Welfare, 2012). We have assumed that those with dementia would be in 
nursing home care regardless of other conditions and so have excluded them from the calculation of opioid 
attributed costs. Discounting the expenditure on high level residential care to exclude patients who have 
dementia gives potentially in scope government costs of $5.5 billion. 
 
Other aged care services have total government expenditures of $5.1 billion. Assuming that a similar 
proportion of other aged care costs are attributable to dementia, this gives in scope government costs of $2.4 
billion. Applying the cost share from the hospital separations data suggests that the extra-medical opioid use 
attributable cost to government of high level residential care was $48.1 million and the attributable cost to 
government of other aged care services was $20.8 million. However, in recognition of the lack of information 
on the extent of extra-medical opioid dependence and associated health problems within the aged care 
sector, age care costs have only been included in the high bound estimate. 
 
5.11 Informal carers 
The economic contribution of informal carers in reducing government costs by providing health care is an 
area of growing interest (Oliva-Moreno et al., 2017). In a recent analysis of the contribution in caring for those 
with chronic conditions, dementia had the highest cost followed by mental illness (Oliva-Moreno et al., 2017). 
In the UK, the cost of caring for those who had suffered a stroke was estimated at 27 percent of the overall 
                                                     
16 These data on hospital days come from the 2018 report; costs come from the 2017 report. 
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cost of stroke care (Saka et al., 2009). However, other than a recent report on the costs associated with 
tobacco use, where the estimate was $2.0 billion in 2015/16 (Whetton et al., 2019), we have yet to identify 
any studies estimating the value contributed by informal carers to health conditions caused by alcohol or illicit 
drugs. 
 
In estimating the cost of informal care for those with ill-health due to extra-medical opioid use, two methods 
were used to provide the high and low bound, with the mean used as the central estimate. In Australia, the 
total value of informal care was assessed at $60.3 billion in 2015. This involved 825,000 persons who were 
primary carers of someone impaired due to disability or ageing: there were an additional 2,032,000 
Australians who reported that they were a non-primary carer (Deloitte Access Economics, 2015). The 
economic contribution of carers will tend to vary with the severity of the condition of the person being cared 
for. It is likely that those with more severe conditions will require more hours of care per week. In 2015, it was 
estimated that the average cost across level of severity was $70,362 per person per year (Deloitte Access 
Economics, 2015).  
 
From confidentialised unit record file data on Disability, Ageing and Carers, the following primary conditions 
were included in the unit record data in a disaggregated form 17 and were at least partially caused by extra-
medical opioid use (Australian Bureau of Statistics, 2017c): 
• Other neoplasms - liver cancer (not skin / breast / bowel / prostate); 
• Head injury (acquired brain injury); 
• Arm/shoulder/hand damage from accident or injury; 
• Leg/knee/foot/hip damage from accident or injury; and, 
• Other injury / poisoning and consequences. 
 
In each case the number of persons reporting that they received informal assistance for activities was 
adjusted to opioid attributable cases using the proportion of hospital separation costs for that condition 
attributable to opioids. 
 
There were 379 persons reporting that they needed informal assistance at least once per week due to an 
opioid attributable condition, or 0.162 percent of the total persons reporting needing informal assistance at 
this frequency for any condition. We applied the average cost ($70,362 per person per year (Deloitte Access 
Economics, 2015)) to obtain the opioid attributed low bound cost of $26.6 million. 
 
To calculate the high bound cost, we multiplied the share needing at least weekly care for opioid conditions 
(0.162%) by the total value of informal care in Australia ($60.3 billion), which gave a total of $97.9 million. 
The mean of the low and high bound gave the central value for informal care of $62.3 million. 
 
5.12 Conclusions 
This chapter presented health costs in primary care and for other health costs for non-admitted treatment. 
The estimated total healthcare cost attributable to extra-medical opioid use was $829.4 million in 2015/16 
(Table 5.6). If we exclude the cost of $62.3 million attributed to informal care, the healthcare costs are $767.1 
million. These costs are considerably greater than those for inpatient care. The continuing emphasis on 
reducing length of hospital inpatient stays, given the demand for beds and the costs of inpatient care 
(Australian Institute of Health and Welfare, 2017b) means that the relative cost of out-of-hospital care is likely 
to increase in the future. Including an additional valuation for care provided by family members, substantially 
increases the cost of extra-medical opioid use to society. It should be noted that heroin is the drug of choice 
                                                     
17 A number of conditions caused by opioids, such as blood borne viruses from IDU, were not reported separately in the data, 
and therefore could not be included in the calculation.  
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among opioid dependent persons, as evident from the AODTS where almost 60 percent of opioid related 
service events were for heroin. Therefore, the majority of extra-medical opioid related cost could be 
associated with heroin use even though more people report the use of pharmaceutical opioids for extra-
medical purposes (Australian Institute of Health and Welfare, 2017g). 
 
About 2.7 million Australians are informal carers, including 856,000 who are primary carers for a person with 
a health condition or disability (Australian Bureau of Statistics, 2016e). Many of the conditions caused by 
extra-medical opioid use are either chronic or are likely to involve extended treatment and recovery outside 
the hospital system, with assistance likely to include help from a partner/relative or significant other. We 
believe that this is the first attempt to quantify these costs in relation to opioids. From disease-specific 
assessments, it is clear that the contribution of informal carers makes a significant saving to the health 
budget. For example, in 2007/08 in the UK, the informal cost of caring for stoke patients has been estimated 
at 27 percent of the economic cost of stroke or GBP 2.5 billion for 200,000 cases (GBP 125,000 per case18) 
(Saka et al., 2009). 
 
Table 5.6: Summary of other health costs 
Cost area 
Central estimate Low bound High bound 
($) ($) ($) 
Ambulance costs 18,106,724 3,388,694 32,824,755 
Emergency Department costs 22,663,625 3,904,618 41,422,631 
Non-admitted patient care costs 30,986,407 14,543,339 47,429,476 
Primary healthcare - Total 233,983,558 208,852,090 259,115,026 
Primary healthcare  - GP Visits 93,347,208 83,321,067 103,373,350 
Primary healthcare - Referred Medical services 140,636,350 125,531,024 155,741,676 
Specialist healthcare and drug treatment services cost 47,159,806   
Opioid agonist therapy costs 80,260,216   
Pharmaceuticals for opioid related conditions 311,115,913 104,749,376 517,482,450 
Community mental health and suicide prevention 22,882,465   
High-level residential care   48,129,349 
Aged care   20,752,227 
Informal carers 62,299,328 26,649,300 97,949,355 
Total 829,458,043 512,389,905 1,215,407,757 
Notes: Central estimates have been used to calculate totals where low or high bound costs are not available except for aged / high 
level care. See Section 11.5 for an alternative method of calculation. 
*High bound pharmaceutical costs includes costs for medications for opioid agonist therapy as well. 
 
Table 5.7 summarises all the healthcare related costs mentioned in Chapters 4 and 5 and the proportion of 
cost attributable to opioids. Aged care is not included as its costs are considered for the high bound estimate 
only. Overall, the total relevant healthcare expenditure during 2015/16 was $154.1 billion. Out of that, $1.1 
billion was attributable to opioid-related conditions (0.73 percent of the total). This figure does not include 
costs of high residential and aged care facilities as they are only part of the high bound cost estimates. Figure 
5.1 shows the percentage of costs in each part of the health care system attributable to opioid-related illness. 
 
Table 5.7: Extra-medical opioid attributable cost share of total expenditure for healthcare services  
                                                     
18 Approximately AU$251,232 in 2007 (Organisation for Economic Cooperation and Development, 2016b) 












Hospital Separations 249 28,348 0.88 
Ambulance and ED 41 8,442 0.48 
Outpatient care costs 31 5,392 0.57 
Drug treatment services 47 443 10.63 
Primary healthcare 234 29,460 0.79 
Medications 391 11,909 3.29 
Community mental health 23 2,047 1.12 
Informal care 62 60,272 0.10 
Total healthcare related expenditure 1,079 146,314 0.74 
 
Figure 5.1: Source of extra-medical opioid use attributable costs across the health sector including 
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5.13 Limitations 
In addition to the medical conditions listed in Table 5.5, other medical conditions such as low birth weight, 
suicide and self-harm, motor vehicle accidents and interpersonal violence are also associated with extra-
medical opioid use. It was not possible to identify specific medicines used to treat these conditions. Therefore, 
the costs for treating such conditions are not included in our pharmaceutical cost estimates. We note the very 
high cost of treating HCV (Table 5.5). In 2015/16 Ledipasvir + Sofosbuvir was the most costly drug treatment 
to the PBS (Pharmaceutical Benefits Scheme, 2016c). The introduction of universal access to direct acting 
antiviral therapy (Heard et al., 2018) should greatly reduce the prevalence of HCV infection and associated 
costs in the near future. 
 
The PBS lists various formulations of buprenorphine and methadone for use in the treatment of opioid 
dependence. However, other pharmaceutical medications are also used for extra-medical purposes. In 2013 
there were 10,747 kg of oral morphine equivalent opioids sold in Australia, but the extent to which these were 
used for extra-medical purposes is unknown (Degenhardt et al., 2016a). Without a basis for allocating a 
proportion of these to extra-medical use as opposed to being used as prescribed, we have not included other 
PBS prescription opioids in our analysis and acknowledge that this will under-estimate the extra-medical cost. 
 
Our estimate included a cost for high-level residential care and other aged care services in the high bound 
estimate. It is currently unclear to what extent these services will be used by the target population, where 
most will not be in the oldest age groups, even if the average age is increasing (Larney et al., 2015). 
Nevertheless, we note the growing interest about substance use in older populations as the baby-boomer 
generation ages (Han et al., 2009). Also, our base cost excluded younger people with disabilities and 
dementia cases. However, alcohol related dementia and traumatic brain injuries are common causes of 
dementia (Draper and Withall, 2016). Traumatic and other brain injuries may be prevalent in those with extra-
medical opioid dependence, a group that also has high rates of road traffic accidents (Chihuri and Li, 2019) 
hypoxic brain injuries and cognitive impairments (Darke et al., 2000; O'Brien and Todd, 2009) and thus 
potentially disability requiring extensive care. Therefore, we have included a cost for this type of high-level 
care although the exact quantum is uncertain. 
 
Care must be taken in comparing the costs of other health care between recent reports on methamphetamine 
and tobacco, with slight variations in the methods used and in accessible data. For example, in estimating 
the costs of primary care for methamphetamine, costs were derived from a single survey in calculating 
“excess” GP service use (Whetton et al., 2016). In relation to tobacco, a similar approach was taken to the 
method used here, except due to the greater availability of information on tobacco use, we were able to 
produce a narrower cost range (Whetton et al., 2019). Overall, the estimates here, more closely align with 
the methods used in the tobacco report than the methamphetamine report, where there was access to some 
unique research datasets.  
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CHAPTER 6: WORKPLACE COSTS 
Alice McEntee, Ann Roche & Steve Whetton 
 
6.1 Background 
Of the illicit drugs, opioids used for extra-medical purposes are the third most commonly used substance by 
Australians aged 14 years or older over their lifetime (10.4%) (National Centre for Education and Training on 
Addiction, 2019). Among all drugs used for illicit purposes in the past 12 months, the extra-medical use of 
opioids ranks second (3.7%), after cannabis (10.4%). Extra-medical opioid use is higher for men (3.9%) than 
women (3.6%) and among those aged 18-24 years and 40-49 years (4.7% each) (National Centre for 
Education and Training on Addiction, 2019). Most Australians who have used opioids for extra-medical 
purposes in the past 12 months are employed (58.1% vs 9.5% of unemployed, and 32.4% of those not in the 
labour force) (National Centre for Education and Training on Addiction, 2019). Among workers, prevalence 
of extra-medical opioid use was similar for males and females (3.8%) and highest for 18-24 year-olds (5.4% 
vs 2.7%-4.4% for the other age groups) (National Centre for Education and Training on Addiction, 2019).  
 
Extra-medical opioid use can pose a workplace risk. Use can impair psychomotor and cognitive functioning, 
weaken the immune system, impair driving ability, increase risk of fractures, and dysregulate mood (Chihuri 
and Li, 2017; Manchikanti et al., 2012). These effects can negatively affect workplace safety, performance 
and productivity especially if use has occurred shortly before or during work hours. Opioid effects can last 
two to 72 hours, depending on the type of opioid used, method and quantity of use, and characteristics of the 
person (e.g. metabolism, hydration, body mass) (Smith, 2009). Although extra-medical opioid use by workers 
can present a potential risk to the workplace (Australian Safety and Compensation Council, 2007), there is a 
paucity of research concerning associated workplace safety and productivity costs. 
 
A US study (Ramirez et al., 2013) in Iowa examined toxicology test results of occupational fatalities between 
2005-2009 and reported that opiates were detected in five out of 280 (1.8%) deaths (8.2% of all positive 
toxicology tests). Prior to that, an examination by Li et al. (2011a) of more than one million US post-accident 
workplace drug tests performed between 1995-2005 found 1.2 percent of results were positive for illicit drugs, 
with opiates detected in 2.1 percent of positive tests. A social costs study of pharmaceutical opioid misuse in 
the USA found that work-related costs accounted for USD 25.6 billion (45.9% of total social costs), with 
premature mortality the largest single factor (43.8%) in workplace costs. Presenteeism 19 (8.0%) and 
medically related absenteeism (7.8%) also made substantial contributions (Birnbaum et al., 2011). 
 
In Australia, extra-medical opioid use was responsible for 0.9 percent of the total burden of disease and 
injuries in 2011, equivalent to 31,200 disability-adjusted life years (DALY) in males (1.3% of the total burden 
for males) and 10,693 in females (0.5% of the total burden for females). Of the total burden of disease and 
injuries in 2011 attributed to the extra-medical use of opioids, accidental poisoning accounted for 62.8 
percent, opioid dependence accounted for 29.1 percent, suicide and self-inflicted injuries 7.8 percent, and 
road traffic injuries (motor vehicle occupants and motorcyclists) 0.3 percent (Australian Institute of Health 
and Welfare, 2018b). 
 
To-date, estimates of drug-related absenteeism in Australian workplaces have mostly been limited to alcohol 
and illicit drugs (undifferentiated by specific illicit drug type) (Pidd et al., 2006; Roche et al., 2008; Roche et 
al., 2015). The financial impost of workers’ use of illicit drugs on workplaces was estimated by Roche et al. 
                                                     
19 Presenteeism can be defined as attending work while unwell or impaired, resulting in reduced quality or quantity of work 
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(2015) to cost $1,049.6 million in absenteeism specifically attributed to use of illicit drugs, and up to a further 
$228.7 million in excess illness- and injury-related absenteeism (in addition to the absenteeism incurred by 
workers who did not use illicit drugs). An analysis of the impact of methamphetamine use on workplace 
productivity and accidents estimated a cost of $289.4 million in 2013/14 (Whetton et al., 2016). Notably, this 
estimate excluded work-related traffic accidents and deaths that were costed elsewhere.  
 
It is imperative that all costs specifically attributable to employees’ extra-medical opioid use and their 
associated impact on illness, injury and drug-related absences are quantified.  
 
6.2 Methods 
National data were sourced to estimate the cost of occupational injuries (Section 6.2.1) and absenteeism 
(Section 6.2.2) attributed to extra-medical opioid use. Additional workplace costs due to extra-medical opioid 
use, where national data were not available, are discussed in Section 6.4.1. 
 
6.2.1 Occupational injury 
To establish the cost of occupational injuries, data were sourced from Safe Work Australia. The best available 
data 20 come from 2012/13 where injury data were reported for different severity levels and for claims which 
were compensable and non-compensable and that required an absence of at least part of a workday.  
 
Safe Work Australia (2015) reports the overall number and cost of occupational injuries in 2012/13. The 
method used to determine the number of injuries was based on an incidence approach, rather than a 
prevalence approach (see Appendix 6.1 for further detail of the method used in Safe Work Australia’s 
incidence approach). The method used to determine the costs incurred from injuries was based on the 
concept of the ‘human cost’ of occupational injury. Only costs associated with actual injuries 21 were included 
(see Appendix 6.2 for the type of costs included). 
 
Due to an overlap in the reporting of Safe Work occupational injuries with other sections of this report (e.g. 
Section 3.5.1 reports on workplace costs of premature mortality, and Chapter 8 reports on transport 
accidents), the number and costs associated with occupational injuries were adjusted to prevent double 
counting. The adjustments involved 1) removing the cost of fatalities from the total costs and 2) reducing all 
injury severity type costs by 3.9 percent. The latter adjustment was based on traffic accidents having 
accounted for 3.9 percent of serious compensable occupational injuries (≥5 days off work) in 2012/13 (Safe 
Work Australia, 2014). It was assumed that a similar proportion of traffic accidents occurred for injuries 
involving a short absence, long absence, partial incapacity or full incapacity.  
 
The cost of non-fatal and non-transport accident occupational injuries attributed specifically to the extra-
medical use of opioids was then identified. To determine this, the relative risk (RR) of an occupational injury 
being incurred by workers affected by the extra-medical use of opioids and the prevalence of workers affected 
by extra-medical opioid use were estimated. 
 
                                                     
20 National data for serious compensable injuries (≥5 days off work) are collated annually. Published data which also includes 
lower severity level injuries and non-compensable injuries were last collected in 2012/13. Thus 2012/13 data are used in the 
present report. 
21 Only costs associated with workplace incidents that resulted in an injury were included in the human cost framework. Costs 
of workplace incidents which do not result in an injury are excluded. Such costs excluded include replacing or repairing 
damaged machinery and costs associated with damage to corporate image and loss of goodwill. 
76  Chapter 6: Workplace costs 
 
The RR estimate for extra-medical opioids was determined using findings from Li et al. (2011b) and Grant 
(2014). In Li et al.’s (2011b) case control study of more than one million post-accident workplace drug tests, 
an odds ratio (OR) of 3.4 for an occupational injury among employees who tested positive for drug use was 
reported. To calculate the AF for extra-medical opioids, this odds ratio was converted to a RR. Grant (2014) 
provided the formula for the conversion as follows: 
𝑅𝑅𝑅𝑅 =
𝑂𝑂𝑅𝑅
1 − 𝑝𝑝0 + (𝑝𝑝0 ∗ 𝑂𝑂𝑅𝑅)
 
Where: 
RR = relative risk for the risk factor in question 
OR = odds ratio for the risk factor in question 
p0 = the baseline risk. 
 
Applying this formula to the odds ratios from Li and colleagues (2011b) and using a baseline risk of 
0.032480486 (based on 374,500 occupational injuries (Safe Work Australia, 2015) among a total workforce 
11,530,000 in 2012/13) gives a RR of 3.154.  
 
Data collected by Safework Laboratories indicated an Australian workplace drug testing positivity rate of 2.9 
percent for opioids, 1.7 percent for cannabis, 1.6 percent for ATS, and 0.8 percent for benzodiazepines from 
a sample of 98,599 random workplace drug tests conducted in 2015 (A. Leibie, Safework Laboratories, 
personal communication, 17th May 2016) 22.  
 
Applying the RR calculation gives an aetiological fraction (AF) of 0.132654387 for all drugs detected and an 
AF of 0.05879665 for opioids. The AF for opioid use was then used to determine the opioid attributable cost 
of non-fatal and non-transport accident occupational injuries. The resultant cost was considered the high 
bound cost as the opioid testing positivity rate may have included both extra-medical and licit opioid use.  
 
A low bound calculation was then undertaken using a positivity rate of 0.8 percent. This value was determined 
based on the prevalence of weekly extra-medical opioid use among workers from the 2016 NDSHS. It was 
assumed that most persons who use weekly would return a positive drug test. Applying the RR calculation 
to the adjusted opioid positivity rate gives an AF of 0.016941062 for extra-medical opioids. 
 
6.2.2 Workplace absenteeism  
To estimate the extent and cost of extra-medical opioid related workplace absenteeism, secondary analyses 
were conducted on 2016 NDSHS data (Australian Institute of Health and Welfare, 2017g, unit record file). 
Only respondents who were employed and aged ≥ 14 years were included in the analyses.  
 
An illicit drug use status variable comprising four categories was created. The four categories were 1) extra-
medical opioid use at least weekly, 2) extra-medical opioid use less often then weekly, 3) other drug use, and 
4) no drug use. Frequency of extra medical pain-killer and heroin use were used to estimate extra-medical 
opioid use on a weekly (every day or once a week) or less than weekly (monthly, every few months, or once 
or twice a year) basis. The NDSHS does not request frequency of use data from those who used 
methadone/buprenorphine extra-medically. Thus, such respondents were excluded if they did not also use 
heroin or pain-killers extra-medically 23. 
                                                     
22 National data concerning workplace testing are unavailable prior to 2015. 
23 When those who use extra-medical methadone/buprenorphine, pain-killers and heroin were combined into a past year extra-
medical opioid use group, exclusive methadone/buprenorphine respondents comprised 2% of this group.  
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In relation to absenteeism, two variables were used: absence due to injury and/or illness; and, absence due 
to drug use. Annual absenteeism due to injury and illness involved summing the total number of days absent 
from work, school, university or TAFE due to injury or illness in the past three months and then multiplying 
these days by four to obtain a non-seasonally adjusted annual estimate (with a maximum 240 days absent 
possible). Annual absenteeism due to drug use was also determined by multiplying by four the number of 
days absent from work, school, university or TAFE due to their own drug use in the past three months (with 
a maximum of 240 days absent possible). 
 
Analysis of Variances (ANOVAs) were conducted to establish whether weekly extra-medical use of opioids 
resulted in more days absent from work due to: a) illness/injury and b) drug use, compared to those who: 
• used opioids extra-medically less frequently than weekly; 
• used other types of illicit drugs; and, 
• did not use drugs (this comparison group was only included in the analysis examining days off 
due to illness/injury, as it was not applicable for the drug use analysis). 
 
Two Analysis of Covariances (ANCOVAs) were then conducted to determine mean a) illness and injury 
absenteeism and b) drug-related absenteeism by illicit drug use status while controlling for age, gender, 
marital status, socio economic status, and occupation. These variables were controlled for as they are known 
to be associated with workplace absence (Bush and Wooden, 1995; Ekpu and Brown, 2015). 
 
Total absenteeism-related costs for each category of illicit drug use status was then estimated. To accomplish 
this, the difference in mean number of annual days absent according to illicit drug use status was calculated 
by subtracting the mean days absent among the group of people who do not use drugs from each of the 
other three categories. This figure was then multiplied by $373.66 24 (one day’s wage plus 20% employer 
on-costs, based on the average weekly income in 2015 25) (Australian Bureau of Statistics, 2016a) to obtain 
a cost estimate of extra-medical opioid-related absenteeism (i.e. following a replacement labour cost 
approach, rather than an economic output per day worked approach). 
 
6.3 Costs due to occupational injury 
The results presented below first provide an overview of the number and costs of occupational injuries due 
to all causes (Section 6.3.1), followed by the costs of non-fatal and non-transport occupational all-cause 
injuries borne by employers, employees, and the community. The latter results were then used to estimate 
the cost of occupational injuries (non-fatal and non-transport accidents) attributable to opioids using the RR 
and AF calculations (Section 6.3.2). The 2015 Consumer Price Index (CPI) (Australian Bureau of Statistics, 
2016d) calculator was then applied to the 2012/13 estimates of opioid attributable occupational injury costs. 
 
6.3.1 Number and costs of injuries  
In 2012/13 there were 374,500 occupational injuries (Safe Work Australia, 2015). A breakdown by injury 
severity and compensation status is presented in Table 6.1.  
                                                     
24 Whetten et al. (2016) included an identical method to determine absenteeism costs attributed to methamphetamine with the 
exception of the daily wage calculation. The present report determined daily wage using the full-time adult total earnings 
weekly wage (seasonally adjusted data) for November 2015. The daily wage calculation for the cost of methamphetamine 
was based on the person’s total earnings weekly wage (trend data) for November 2013. Both values were divided by five to 
determine daily wage and then 20% employer on-costs were added. Appendix 6.3 provides estimated costs of absenteeism 
attributed to the extra-medical use of opioids using the November 2015 person’s total weekly earnings trend data. 
25 Average weekly income data for 2015 was selected in order to maintain consistency across other chapters of this report. 
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incapacity d Fatality All 
Compensated 
% 59 34 7 <1 <1 100 
N 122,500 71,500 14,200 400 200 208,800 
        
Not compensated 
% 65 29 6 <1 <1 100 
N 107,200 48,400 9,600 300 200 165,700 
        
All 
% 61 32 6 <1 <1 100 
N 229,700 119,900 23,800 700 400 374,500 
Source: Safe Work Australia, 2015. The Cost of Work-related Injury and Illness for Australian Employers, Workers and the 
Community: 2012–13. Canberra, Safe Work Australia. 
a < 5 days off work. 
b ≥5 days off work and return to work on full duties. 
c ≥5 days off work and return to work on reduced duties or lower income. 
d Permanently incapacitated with no return to work. 
 
The compensable and non-compensable occupational injuries for 2012/13 (Safe Work Australia, 2015) 
resulted in a total estimated cost of $28,230 million (Table 6.2). After excluding fatalities and transport 
accidents (costs accounted for in Chapters 3 and 8, respectively), the adjusted cost is $26,284 million (Table 
6.2).  
 
Table 6.2: Cost ($000,000) of occupational injuries by severity 2012/13 






incapacity d Fatality 
Total 
($000,000) 
       Total cost  960 4,340 19,250 2,800 880 28,230 
Adjusted total cost e f 923 4,171 18,499 2,691 - 26,284 
Sources: Safe Work Australia, 2014. Australian Workers’ Compensation Statistics 2012–13. Canberra, Safe Work Australia. Safe 
Work Australia, 2015. The Cost of Work-related Injury and Illness for Australian Employers, Workers and the Community: 2012–
13. Canberra, Safe Work Australia. 
a < 5 days off work. 
b ≥5 days off work and return to work on full duties. 
c ≥5 days off work and return to work on reduced duties or lower income. 
d Permanently incapacitated with no return to work. 
e Fatalities and transport accidents were excluded as they are reported in Chapter 3 and Chapter 8, respectively.  
f Safe Work Australia (2014) reported that traffic accidents accounted for 3.9% of serious compensable occupational injuries (≥5 
days off work) in 2012/13. It was assumed that a similar proportion of traffic accidents occurred for injuries requiring a short 
absence, long absence, partial incapacity and full incapacity and thus such associated costs were reduced by 3.9%. 
 
Safe Work Australia (2015) estimates of the proportions of occupational injury costs borne by employers, 
employees, and the community were then used to calculate apportioned costs for non-fatal and non-transport 
occupational injuries (Table 6.3). 
 
6.3.2 Costs of injuries due to extra-medical opioid use 
The high and low bound attributed costs of opioid use associated with non-fatal and non-transport occupation 
injuries in 2012/13 were calculated by applying the appropriate AF value. The high bound attributable cost of 
opioid use in 2012/13 was $1,545.4 million (Table 6.3), based on the positive detection rate of 2.9 percent 
(AF = 0.059). Of this total cost, $92.7 million is borne by employers, $386.4 million by the community, and 
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$1,066.3 million by injured employees. Updating the 2012/13 costs to 2015 26 by the CPI  (Australian Bureau 
of Statistics, 2016d) gives a total cost of $1,598.5 million with $95.9 million borne by employers, $399.6 
million by the community, and $1,103.0 million by injured employees (Table 6.3).  
 
Applying the AF for extra-medical opioids based on an adjusted positive detection rate of 0.8% (0.017), the 
low bound attributable cost of extra-medical opioid use associated with non-fatal and non-transport 
occupational injuries in 2012/13 was $445.3 million (Table 6.3). Updating the 2012/13 costs of extra-medical 
opioids to 2015 gives a total low bound cost of $460.6 million with $27.6 million borne by employers, $115.1 
million by the community, and $317.8 million by injured employees (Table 6.3).  
 
The mid-point of the high and low bound 2015 costs were used as the central estimate. The resulting total 
costs was therefore $1,029.5 million, with $61.8 million borne by employers, $257.4 million by the community, 
and $710.4 million by injured employees (Table 6.3). Costs borne by employees ($710.4 million) are internal 
costs and thus not included in the total estimate for workplace costs attributable to opioids ($319.1 million, 
see Table 6.8). 
 
Given the nature of the available data, it is not possible to identify the extent to which the workplace injuries 
occurred to the person who used the drug, or to someone else. As such it is very likely that these estimates 
include some private costs to people who used the drug. 
 
Table 6.3: Costs of non-fatal and non-transport occupational injuries borne by employers, employees, and 





   Cost ($000,000)  























2015 d  
Employer  6 1,577 26.7 27.6 59.7 61.8 92.7 95.9 
Employee 69 18,136 307.2 317.8 686.8 710.4 1,066.3 1,103.0 
Community 25 6,571 111.3 115.1 248.8 257.4 386.4 399.6 
Total 100 26,284 445.3 460.6 995.3 1,029.5 1,545.4 1,598.5 
a 2012/13 all cause occupational injury cost data were multiplied by the aetiological fraction (AF) for extra-medical opioid use 
(0.016941062) to determine costs borne by the employer, employee and community. The AF was calculated using an adjusted 
positivity rate of 0.8 percent for extra-medical opioids. 
b The mid-point of the high and low bound estimates. 
c 2012/13 all cause occupational injury cost data were multiplied by the aetiological fraction (AF) for opioid use (0.05879665) to 
determine costs borne by the employer, employee and community. The AF was calculated using a positivity rate of 2.9 percent for 
opioids (illicit and licit use). 
d Adjusted using the ABS Consumer Price Index inflation calculator to December 2015 values (Australian Bureau of Statistics, 
2016d). 
 
6.4 Costs due to workplace absenteeism 
A total of 11,710 (weighted N = 10,368,379) employed Australians aged 14 years or older provided illicit drug 
status information in the 2016 NDSHS (Australian Institute of Health and Welfare, 2017c, unit record file). Of 
these, 0.8 percent used opioids extra-medically on a weekly basis, 2.9 percent used opioids extra-medically 
                                                     
26 The December 2015 quarterly Consumer Price Index calculator was used to adjust the 2012/13 data to align with timeframes 
used in other Sections of the document. 
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less than weekly, 14.0 percent used illicit drugs other than opioids, and 82.3 percent were people who did 
not use drugs. 
 
Results of the ANOVA indicated that there was a statistically significant association between the four drug 
use groups regarding workplace absenteeism due to illness or injury (F [3, 10446] = 10.367, p < .001). On 
closer inspection, workers who used other illicit drugs were significantly more likely to be absent from work 
than people who did not use drugs (p < .001) (Table 6.4) and those who used opioids extra-medically less 
often than weekly (p = .005) (data not shown). Those who used opioids extra-medically at least weekly were 
also more likely to be absent from work than those who used opioids extra-medically less often than weekly 
(p = .019) (data not shown). Although, workers using extra-medical opioids at least weekly and less than 
weekly were absent from work 7.6 days more and 1.9 days less, respectively, than workers who did not use 
drugs, these differences were not statistically significant (Table 6.4). 
 
Table 6.4: Comparison of unadjusted excess workplace absenteeism due to illness/injury among people 
who use opioids, those who use other drugs and those who do not use drugs (2016 NDSHS data a) 
Drug use 
status 
Annual Illness or Injury Absence  






No drug use 7.754 (7.244 – 8.264)   
Extra-medical opioid use at least weekly 15.333 (6.450 – 24.217) 7.579 (-0.795 – 15.953) .055 
Extra-medical opioid use less often than weekly 5.813 (4.389 – 7.238) -1.941 (-2.855 – -1.026) 1.000 
Other drug use 10.993 (9.568 – 12.418) 3.239 (2.324 – 4.154) <.001 
a Australian Institute of Health and Welfare, 2017. National Drug Strategy Household Survey (NDSHS) 2016, Drug Statistics Series. 
Canberra, Government of Australia. 
b Mean days absent due to illness/injury for a) extra-medical use of opioids at least weekly, b) extra-medical use of opioids less 
often than weekly, c) other drug use, minus mean days absent for no drug use. 
c Significance of mean difference in days absent due to illness/injury for a) extra-medical use of opioids at least weekly, b) extra-
medical use of opioids less often than weekly, c) other drug use, compared to no drug use. 
 
Results of the ANCOVA indicated that, after controlling for age, gender, marital status, socio-economic status, 
and occupation (Bush and Wooden, 1995), there was a significant association between the four drug use 
groups regarding absenteeism due to injury or illness (F [3, 6976] = 10.811, p < .001). Marital status was 
found to be a significant covariate (F = 7.444, p = .006). Workers who used opioids extra-medically at least 
weekly were absent due to injury or illness for an additional 972,150 days from work per year compared to 
workers who did not use drugs, equating to a cost of approximately $363.2 million (Table 6.5). 
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Table 6.5: Comparison adjusted excess workplace absenteeism due to illness/injury among people who 
use opioids, those who use other drugs and those who do not use drugs (2016 NDSHS data a) with 
associated costs (2015 ABS data b) c 
Drug use  
status 
 Annual Illness or Injury Absence 
Estimated 
Population 




Excess Days Absent  
(95% CI) e 
Cost $  
(95% CI) f 
No drug use 8,536,278 7.556  (6.909 – 8.203)    
Extra-medical opioid use 
at least weekly 80,106 
19.692  
(12.619 – 26.765) 
12.136  
(5.710 – 18.562) 
972,150  




Extra-medical opioid use 
less often than weekly 302,521 
4.247  
(0.909 – 7.584) 
-3.309  
(-6.000 – -0.619) 0 (0 – 0) 
g 0 (0 – 0) g 
Other drug use 1,449,475 11.074  (9.547 – 12.600) 
3.518  
(2.638 – 4.397) 
5,098,715  




a Australian Institute of Health and Welfare, 2017. National Drug Strategy Household Survey (NDSHS) 2016, Drug Statistics Series. 
Canberra, Government of Australia. 
b Australian Bureau of Statistics (ABS), 2016. Average Weekly Earnings, Australia, Nov 2015. Cat. no. 6302.0. Canberra, ABS. 
c Calculations based on estimated absenteeism means adjusted for age, gender, marital status, socio-economic status, and 
occupation. 
d Mean days absent due to illness/injury for a) extra-medical use of opioids at least weekly, b) extra-medical use of opioids less 
often than weekly, or c) other drug use, minus mean days absent for no drug use. 
e Difference in mean absence multiplied by estimated population. 
f Excess absence multiplied by $373.66 (2015 average daily wage plus 20% employer on-costs). 
g To simplify interpretation of results, negative difference values (including 95% confidence intervals) were rounded to 0. 
 
Of those who used illicit drugs, extra-medical opioid use did not significantly predict workplace drug-related 
absenteeism (F [2, 1820] = 0.101, p = .904) more than those who used other drugs. 
 
As shown in Table 6.6, after controlling for known confounders (Bush and Wooden, 1995) extra-medical use 
of opioids at least weekly and less than weekly resulted in 32,240 and 88,902 excess days off work due to 
drug use per year, respectively. This equated to an annual cost of approximately $45.3 million per year. 
 
Table 6.6: Adjusted excess workplace absenteeism due to illicit drug use by drug use type (2016 NDSHS 
data a) and associated costs (2015 ABS data b) c 
Drug use  
status 
 Annual Absence Due to Drug Use 
Estimated 
Population 
Mean Days Absent 
(95% CI) 
Excess Days Absent  
(95% CI) d 
Cost $  
(95% CI) e 
Extra-medical opioid use at 
least weekly 80,106 
0.402  
(-0.640 – 1.445) 
32,240  
(0 – 115,786) f 
12,046,866  
(0 – 43,264,673) f 
Extra-medical opioid use 
less often than weekly 302,521 
0.262  
(-0.248 – 0.772) 
88,902  
(0 – 233,452) f 
33,219,290  
(0 – 87,231,532) f 
Other drug use 1,449,475 0.208  (-0.015 – 0.430) 
301,024  
(0 – 623,604)f 
112,480,654  
(0 – 233,015,746) f 
a Australian Institute of Health and Welfare, 2017. National Drug Strategy Household Survey (NDSHS) 2016, Drug Statistics Series. 
Canberra, Government of Australia. 
b Australian Bureau of Statistics (ABS), 2016. Average Weekly Earnings, Australia, Nov 2015. Cat. no. 6302.0. Canberra, ABS. 
c Calculations based on estimated absenteeism means adjusted for age, gender, marital status, socio-economic status, and 
occupation. 
d Days in excess of those who do not use drugs. Mean days absent multiplied by estimated population. 
e Excess absence multiplied by $373.66 (2015 average daily wage plus 20% employer on-costs). 
f To simplify interpretation of results, negative difference values (including 95% confidence intervals) were rounded to 0. 
 
Workers who used opioids extra-medically, however, may also use other drugs and it may be the other drugs 
which account for the worker’s absence. Poly-substance use (excluding alcohol and tobacco) occurred in 22 
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percent of workers who used opioids extra-medically (National Centre for Education and Training on 
Addiction, 2019). Table 6.7 details the proportion of workers who used other drugs in the same 12 month 
period that extra-medical opioids were also used. 
 
Table 6.7: Proportion of workers using other drugs in addition to extra-medical opioids in the past 12 
months by drug type used a  
Drug Type % Drug Type % Drug Type % 
Cannabis 17.4 Tranquillisers 3.7 Inhalants 0.7** 
Ecstasy 6.0 Hallucinogens 3.3* Kava 0.0** 
Methamphetamine 5.1 Ketamine  2.7** Steroids 0.2** 
Cocaine  4.7 GBH 0.8** Other 1.8* 
Source: Australian Institute of Health and Welfare, 2017. National Drug Strategy Household Survey. 
a The NDSHS only asks people who extra-medically used “pain-killers/pain-relievers/opioids” about their poly-substance use. Poly-
substance use data is thus missing from 15 persons who use heroin/methadone/buprenorphine (3% of persons who use extra-
medical opioids). 
* Estimate has a relative standard error of 25% to 50% and should be used with caution. 
** Estimate has a relative standard error greater than 50% and is considered too unreliable for general use. 
 
In order to account for drug-related absenteeism (Tables 6.5 and 6.6) due to poly-substance use (Table 6.7), 
the total cost of extra-medical opioid use was divided by 1.464 (i.e. the summed proportion of persons who 
use extra-medical opioids who also used other drugs). This resulted in an annual cost of extra-medical opioid 
attributable absenteeism due to drug use and illness/injury of $30.9 million 27 and $248.1 million 28, 
respectively. The cost attributable to drug use related absenteeism ($30.9 million) is likely to be a 
conservative estimate as it was obtained from a self-report measure of absenteeism that respondents 
attributed to drug use and was used as our low bound estimate for absenteeism (Table 6.8). The cost 
attributed to injury and illness absenteeism ($248.1 million) however is likely to be an overestimate as higher 
proportions of people who use opioids also smoke tobacco and/or drink alcohol at risky levels, compared to 
the general working population (National Centre for Education and Training on Addiction, 2019). Both of 
these licit drugs have substantial negative impacts on physical health and are unaccounted for in the 
estimates presented here. The cost attributed to injury and illness absenteeism was used as the high bound 
estimate, with the mid-point ($139.5 million) used as the central estimate (Table 6.8). 
 
Table 6.8: Summary: Workplace costs due to extra-medical opioid use 





Occupational injury  319,145,000 a 142,770,000 b 495,520,000 c 
Absenteeism  139,521,743 a 30,919,506 248,123,980 
Total   458,666,743 173,689,506 743,643,980 
a The mid point of the low and high bound estimates. 
b Cost to employer ($27,630,000) plus cost to community ($115,140,000). Employee costs are an internal cost and thus not 
included in the total cost estimate for occupational injury (see Table 6.3). 
c Cost to employer ($95,900,000) plus cost to community ($399,620,000). Employee costs are an internal cost and thus not included 
in the total cost estimate for occupational injury (see Table 6.3). 
 
                                                     
27 The summed cost of absenteeism attributed to extra-medical opioid use at least weekly ($12,046,866) and less often than 
weekly ($33,219,290) divided by 1.464. 
28 The summed cost of absenteeism attributed to extra-medical opioid use at least weekly ($363,253,507) and less often than 
weekly ($0) divided by 1.464. 
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The attributed cost of extra-medical opioid use to workplace absenteeism reported in Tables 6.5 and 6.6 only 
reflects likely workplace costs directly associated with paid sick leave. There are also likely to be other indirect 
costs, such as the costs of finding and paying replacement workers to backfill the absent employee’s work 
role and/or the cost of lost productivity if a replacement worker cannot be sourced. 
 
6.5 Conclusions 
The total cost of extra-medical opioid use to Australian workplaces is estimated to be $458.7 million ($319.1 
million for costs associated with occupational injury and $139.5 million for costs attributed to absenteeism) 
(Table 6.8). As data were only available to determine workplace costs associated with occupational injury 
and absenteeism, it is likely that this estimate underestimates the true cost of extra-medical opioids to the 
workplace. There are additional costs that cannot currently be quantified. These are discussed below. 
 
6.5.1 Other workplace costs 
Additional workplace costs associated with the extra-medical use of opioids that cannot be quantified due to 
lack of data include the following areas.  
 
Presenteeism can be defined as attending work while unwell or impaired, resulting in reduced quality or 
quantity of work. As extra-medical opioid use can impair psychomotor and cognitive functioning, weaken the 
immune system, impair driving ability, and dysregulate mood (Chihuri and Li, 2017; Manchikanti et al., 2012), 
it is likely that extra-medical opioid use contributes to presenteeism. However, there are no current available 
data concerning drug-related presenteeism in Australian workplaces. 
 
Turnover costs are incurred when employees who leave (either voluntarily or involuntarily) are replaced. 
Costs are associated with hiring, training, reduced productivity, and lost opportunity. Extra-medical opioid 
use is likely to contribute to these costs if an employee a) is dismissed for failing a workplace drug test, b) 
leaves because their use has escalated to severe dependence and restricted their ability to work effectively, 
or c) is dismissed due to drug-related poor performance. However, there are no current reliable data 
concerning the costs to Australian workplaces due to drug-related turnover. 
 
Workplace drug testing is becoming more common in Australian workplaces. The costs incurred in 
implementing workplace testing includes a) the purchase of testing services, b) lost productivity while 
employees undergo testing, and c) legal and industrial relation costs in the establishment of, and possible 
defence of, workplace testing procedures. Licit and extra-medical opioid use contributes to these costs, with 
opioids being detected in 2.1 percent of positive workplace tests (Li et al., 2011a). Across the Australian 
workforce, the total costs of workplace drug testing are likely to be substantial. Nearly 7 percent of the 
Australian workforce reports that their workplace conducts drug tests (Pidd et al., 2015), with one of the larger 
workplace drug testing service providers undertaking nearly 100,000 tests across Australia in 2015 (A. Leibie, 
Safework Laboratories, personal communication, 17th May 2016). However, precise and accurate data 
concerning the extent and cost of workplace drug testing across the Australian workforce are not currently 
available. 
 
Employee wellbeing costs are incurred when employee’s mental and physical health is affected by the 
behaviour of co-workers and traumatic workplace incidents. People who use extra-medical opioids are more 
likely to have higher levels of psychological distress (21.8%) than those who used other drugs (16.5%) or 
who do not use drugs (8.3%) (National Centre for Education and Training on Addiction, 2019). Thus, extra-
medical opioid use may contribute to employees seeking counselling, other clinical support and/or utilising 
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Employee Assistance Programs. Additional costs may also be incurred through impacts on employee safety 
and productivity due to poor worker wellbeing.  
 
The cost to workplaces attributed to extra-medical opioid use are likely to be unevenly distributed across 
Australian workplaces. Secondary analysis of the 2016 NDSHS indicates that the prevalence of extra-medical 
opioid and other illicit drug use varies substantially across different occupational and industry groups 
(National Centre for Education and Training on Addiction, 2019). For example, the extra-medical use of 
opioids varied from 0.0 percent - 8.6 percent 29 (National Centre for Education and Training on Addiction, 
2019). Workplace costs are likely to be higher in industries with higher prevalence of the extra-medical use 
of opioids. Although prevalence was similar among employed males and females (3.8% each), extra-medical 
opioid use was highest in employees aged 18-24 years (5.4%) (National Centre for Education and Training 
on Addiction, 2019). As participation in vocational training is high in this age group, extra-medical opioid use 




Extra-medical opioid use can impair memory, concentration, reaction times, dexterity and mood which can 
contribute to the risk of accidents (Australian Safety and Compensation Council, 2007; Chihuri and Li, 2017). 
The impacts of this on road crashes and workplace accidents are explored in Chapter 8 and Section 6.3.1, 
respectively, however there is also the potential for excess rates of other forms of accidental injury, namely 
vehicle crashes that do not occur on the road, falls, burns and scalds, drowning, and sharp object injuries. 
Although extra-medical opioid use has been found to increase these risks, no reliable estimates exist 
concerning the extent to which extra-medical opioid use contributes to excess rates of these forms of injury 
in Australian workplaces.  
 
6.6.2 Occupational injuries 
Data concerning occupational injuries is limited. At present, annual data is reported only for serious (resulting 
in ≥5 days off) compensable injuries. Data concerning less serious compensable and non-compensable 
injuries is reported less frequently. Such data are not reported on by drug-type and thus costs attributed to 
the extra-medical use of opioids were estimated by applying formulas considered reliable. One part of the 
formula referred to data on the extent of workplace testing and the prevalence of positive tests by drug type. 
Data of this type are limited and could only be sourced from one large national workplace testing service 
provider (Safework Laboratories). Due to such limitations, the true cost of occupational injuries attributable 
to the extra-medical use of opioids may not be accurately reflected.  
 
6.6.3 Absenteeism 
Estimates of extra-medical opioid related workplace absenteeism were obtained from a self-report measure. 
Self-report data may not accurately reflect true absenteeism attributed to illness or injury, and drug use. 
Furthermore, a proportion of the absenteeism costs calculated may have already been accounted for in the 
occupational injury estimates if the survey respondent is reporting absenteeism due to an occupational injury. 
 
Absenteeism cost estimates were based on the assumption that people annually worked a five-day working 
week over 48 weeks, with four weeks annual leave. This may inadequately reflect the work schedule of 
                                                     
29 Estimates of extra-medical opioid use in some occupation and industry groups had a relative standard error of 25% to 50% 
and should be used with caution. 
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employees who work part time, overtime, or longer rosters, and limits assumptions about annual absenteeism 
rates. 
 
6.6.4 Reduced participation in the workforce 
Evidence suggests that regular extra-medical opioid use, and particularly dependent use, is correlated with 
reduced participation in the workforce (Organisation for Economic Cooperation and Development, 2018). No 
Australian research quantifies the extent of the impact on employment in terms of its scale, or direction of 
causation. Direction of causation may be important, as it is unclear whether extra-medical opioid use impacts 
workforce participation or whether reduced workforce participation impacts extra-medical opioid use. As such 
these costs cannot currently be quantified. 
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CHAPTER 7: COST OF CRIME RELATED TO HEROIN USE 
Neil Donnelly & Steve Whetton 
 
7.1 Heroin attributable crime 
Note: as explained below, the costs estimated in this chapter relate to heroin only, not to opioids in general. 
 
While studies conducted in the United States, United Kingdom, Canada and Australia have shown a strong 
association between illicit drug use and levels of different types of crime, the causal pathway of this 
relationship remains open to debate. In a meta-analysis of 30 studies Bennett et al. (2008) found that while 
offending was higher among those who use drugs compared with those who do not use drugs, the strength 
of the relationship varied by drug type. Offending was higher among people who used crack (cocaine), heroin 
or (powder) cocaine. The causal issue is complex as it appears to not be a simple question of whether 
initiation of drug use then leads to involvement in crime or vice versa. A cohort study conducted by Pierce et 
al. (2017) in England found that those who went on to use opiates already had higher levels of involvement 
in crime. Importantly the use of opiates then further increased their involvement in crime.  
 
In late 2000, when the heroin shortage occurred in Australia, other than an initial spike in incidents of robbery 
there was a sustained decrease in robbery and burglary. Moffatt et al. (2005) found that rather than the 
decline in non-fatal heroin overdoses explaining the crime declines alone, they were also explained by re-
registrations into methadone treatment by people who used opioids, a decline in unemployed young males 
and improved general consumer sentiment. The complex relationship between opioid use and crime was 
examined by Degenhardt et al. (2013a) in a cohort study of entrants into opioid agonist therapy between 
1985 and 2010. While almost three quarters of the cohort had appeared before a court during the study 
period, Degenhardt et al. (2013a) found that only around one-fifth of the cohort accounted for two thirds of 
the charges. 
 
While understanding the causal issue between opioid use and crime requires more research to be conducted, 
the opportunity remains to investigate the cost of crime related to opioid use. Examples of this include studies 
conducted in the United States (Council of Economic Advisers, 2017; Jiang et al., 2017; Mark et al., 2001) 
and Canada (Canadian Substance Use Costs and Harms Scientific Working Group, 2018; Wall et al., 2000). 
In Australia a recent study by Whetton et al. (2016) estimated of the costs of methamphetamine use to the 
criminal justice system in 2013/14. The current investigation applies a similar methodology to examine the 
costs of crime related to opioid use in Australia in 2015/16. 
 
Criminal justice system data are not generally suited to statistical analyses relating to drug use, as information 
such as heroin or other opioid use, and its alleged role in the offence, is not routinely recorded. If recorded 
at all, the information is often located in narrative and is not available for analysis without first going through 
each file individually and coding the relevant data. Instead, analysis of the role of substance use in crime in 
Australia usually employs the Drug Use Monitoring in Australia (DUMA) survey as this is the only regular 
survey of police detainees and substance use in Australia (Patterson et al., 2018). The DUMA survey has 
several shortcomings; most notably that it only surveys offenders from selected police stations, which may 
not be representative of the population of offenders for the country as a whole 30. Given the lack of data on 
the geographic distribution of dependent heroin use, it is not possible to identify whether the rates of heroin 
                                                     
30 For the 2015/16 survey, data were collected in the following police stations: Brisbane (Queensland); Bankstown and Surry 
Hills (New South Wales); Adelaide (South Australia); and Perth (Western Australia) (Patterson et al., 2018). 
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consumption amongst offenders detained by police at the selected DUMA sites is representative of the 
country as a whole, or under- or overestimates it.  
 
Other limitations of the DUMA survey are that: 
• It can only provide data on those police detainees who were in police custody at the time of the 
survey (which may over-represent those alleged to have committed more serious offences) and 
who consent to participate in the research. The long-term participation rate was 87 percent; in 
2015/16 it was 60 percent overall but was 82 percent if restricted to those detainees deemed 
eligible to participate (Patterson et al., 2018);  
• Attribution to substance use is based on self-assessment by the detainee. It is not known 
whether there are any systematic biases in the propensity of offenders to attribute their offending 
to their use of a substance. These biases include: falsely attributing offending to a substance as 
a self-exculpatory strategy; failing to attribute offending to the substance use that caused it either 
through underestimating the extent the substance distorted their reasoning or through a concern 
of being stigmatised for offending under the influence of the substance; 
• Detainees are automatically excluded from the sample frame if they are observed to be 
intoxicated at the time the researcher attends the station. This may lead the survey to understate 
the role of substances in offending as those who were intoxicated at the time of the offence are 
more likely to be excluded than those who were not; 
• It is only appropriate as a source of data on the involvement of substances in the offending 
behaviour of adults, with the sample of juveniles captured in the survey being too small to derive 
usable attributable fractions (AF). This will tend to understate the impact of substances on crime 
as at least some juvenile offending is likely to be attributable to substance use;  
• The AF for substances calculated from it only relate to crime committed by those who have used 
the substance in the last 30 days. This means it will not capture that proportion of “systemic” 
crime where the perpetrators are not, themselves, people who have recently used the substance 
in question; and,  
• It will not necessarily capture the apparent higher rates of crime victimisation of persons who 
are dependent on methamphetamine or heroin (Torok et al., 2008), except to the extent that the 
perpetrators themselves use the same substance.  
Persons who use drugs extra-medically (particularly with heavier and dependent use) are both more likely to 
commit crime (acknowledging the complexity of this relationship), but also more likely to be victims of violent 
crime. Mechanisms for the increased probability of committing crime include economic crime to fund drug 
consumption (economic/compulsive crime), crime aimed at supporting or protecting systems of drug 
distribution and use, such as violence used to recover debts from people who use drugs (systemic crime), 
and criminal behaviour that results from the altered mental state and/or reduced inhibition caused by 
consumption of many illicit drugs, or withdrawal from them (pharmacological crime) (Darke, 2010; Goldstein, 
1985; Torok et al., 2008). 
 
Torok and colleagues (2008) surveyed a group of people who regularly used methamphetamine and heroin, 
161 of whom primarily used heroin. Of the primarily heroin using group, 62 percent reported having been 
charged with a violent crime at some point in their lives (with 58% reporting having been convicted) and 35 
percent reported having committed at least one violent crime in the past 12 months, with 72 percent of those 
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committing violent crime having committed multiple offences. Self-reported rates of other offending were also 
high, with 30 percent of those who primarily used heroin reporting having committed a property crime in the 
past month (with 6% of the heroin cohort reporting having committed property crime daily), 44 percent 
reported having sold drugs in the past month, and 14 percent reported having committed fraud. The persons 
primarily using heroin also reported high rates of being victims of interpersonal violence, with 40 percent 
having been a victim of violent crime in the past 12 months, 87 percent of whom had been the victim on more 
than one occasion. 
 
The specific rates of crimes of violence committed by, and suffered by, the cohort included in the Torok study 
may not be representative of the broader population of persons who use opioids extra-medically. The severity 
of dependence was high amongst the sample population, with a mean severity of dependence scale score 
of 9.0 for the sub-sample who primarily used heroin. Instead, for this analysis we have used the estimated 
AF for violent crime derived from the DUMA survey. 
 
As with concerns over the representativeness of the sites selected for the survey, it is not possible to 
determine whether the known limitations of the survey will lead to it over- or underestimating the role of 
substance use in offending. Notwithstanding these limitations, the DUMA survey remains the best available 
source of data on drug use of offenders in Australia. 
 
For this project, analysis of the DUMA survey data for the 2015/16 financial year was undertaken by the 
Australian Institute of Criminology (AIC) to identify the proportion of police detainees who attributed their 
offending to different illicit substances. This method uses the responses to several survey questions to 
determine the proportion of detainees who attribute their current offending (i.e. offences for which individuals 
were detained at time of interview), either entirely or partly, to drug use during the past 30 days (Payne and 
Gaffney, 2012). The detainees were asked to consider the main reason why they had been detained and to 
indicate via a three-point scale the extent their drug use contributed to their present situation. The questions 
were asked separately for each different drug type so that attributions could be assigned by drug type. 
Attributions by offence type were estimated by assigning detainees to a most serious offence (MSO) category 
on the basis of the charges recorded against them for their current detention. The MSO hierarchy included 
violence, property, illicit drug, traffic or driving under the influence (DUI), breach, public order and other. 
 
In the DUMA 2015/16 interview, attribution was only asked of those detainees who used heroin in last 30 
days and not of those who had used other opioids such as buprenorphine, methadone, oxycodone or 
morphine. There is some evidence that the proportion of those who use pharmaceutical opioids extra-
medically who commit offences, tend to be much lower than for those who use heroin (Krebs et al., 2017). 
As reported in the introduction, despite the fact that pharmaceutical opioids are killing more people than 
heroin, more primary drug treatment episodes are for heroin (11,003 versus 7,499 (Australian Institute of 
Health and Welfare, 2017c), Table SD.1). In the 2015/16 DUMA detainee sample, 58 per cent of those who 
had used heroin in the past 30 days had also used other opioids. Among those who had used other opioids 
in the past 30 days a much lower percentage had also used heroin (36%). As we do not have data which 
would justify extrapolating the heroin crime attributions to other opioids it is better to acknowledge this 
limitation and focus on heroin attributable crime only. 
 
Table 7.1 provides the heroin AF percentages broken down by the most serious offence category of adult 
detainees. Overall the AF percentages for heroin were very low. In total 3.4 percent of adult detainees 
attributed their offending to heroin. The highest AF percentages were found for detainees whose MSO was 
related to property (6.5%), illicit drugs (4.4%) and breach (3.5%) (see Table 7.2 for more information about 
the types of MSO).  
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The subsequent sections of this chapter will focus on costs related to: (i) police; (ii) courts; (iii) correction 
system; and, (iv) victims of crime. In each section national data reported by the ABS will be used and the AF 
percentages shown in Table 7.1 will be applied to the relevant offence categories. This will include the central 
estimate cost and also a low bound cost and a high bound cost based on the 95% confidence intervals shown 
in Table 7.1. 
 
Table 7.1: Self-reported heroin attribution of crime amongst police detainees by most serious offence, 
DUMA survey July 2015 to June 2016, per cent of total offenders 
Attributable fraction Violent Property Illicit drug Traffic or DUI Breach 
Public 
order  Other Total  
Central estimate (%) 2.1 6.5 4.4 1.7 3.5 1.5 0 3.4 
Confidence Interval (95%) (1.3, 3.5) (4.5, 9.4) (2.3, 8.1) (0.5, 5.9) (2.3, 5.3) (0.4, 5.2) (0.0, 10.7) (2.7, 4.3) 
Sample size (n) 700 400 205 119 574 136 32 2166 
Source: AIC DUMA collection 2015/16 [computer file]; confidence intervals calculated by authors using Wilson estimator;  
DUI = driving under the influence  
 
The ABS defines most serious offence based on the 16 divisions of the Australian and New Zealand Standard 
Offence Classification (ANZSOC) (Australian Bureau of Statistics, 2011). Table 7.2 shows how the DUMA 
most serious offence categories shown in Table 7.1 relate to the ANZSOC divisions. As an example the 
number of ‘Theft’ offenders reported by the ABS would be multiplied by the Property AF shown in Table 7.1 
(6.5%) to provide the number of heroin-related theft offenders. These would then be combined with the 
number of heroin-related ‘Unlawful enter with intent’ offenders and heroin-related ‘Fraud/deception’ offenders 
to provide the total number of heroin-related ‘Property’ offenders.  
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Table 7.2: Mapping of principal offence in Australian Bureau of Statistics data to DUMA most serious 
offence by ANZSOC Divisions  
Most serious offence (MSO) in DUMA ANZSOC Principal Offence (Divisions) 
 01 Homicide and related offences 
 02 Acts intended to cause injury 
 03 Sexual assault and related offences 
Violent 04 Dangerous/negligent acts 
 05 Abduction/harassment 
 06 Robbery/extortion 
 11 Prohibited/regulated weapons 
Property 
07 Unlawful entry with intent 
08 Theft 
09 Fraud/deception 
Illicit drug 10 Illicit drug offences 
Traffic or DUI 14 Traffic and vehicle regulatory 
Breach 15 Offences against justice 
Public order 
12 Property damage and environmental pollution 
13 Public order offences 
Other 16 Miscellaneous offences 
Source: AIC DUMA collection 2015/16 [computer file]; Patterson et al., (2018); ABS (2011), 2011; ANZSOC = Australian and New 
Zealand Standard Offence Classification; DUI = driving under the influence. 
 
7.2 Police costs 
The real recurrent expenditure on state and territory police services in Australia was approximately $11.0 
billion in 2015/16 (costs related to AFP activities outside of general policing in the ACT have not been included 
in this section). However, only a subset of policing costs should be included in the analysis of heroin 
attributable crime, as police perform a range of functions unrelated to, or only partially related to, crime, such 
as protective services, emergency management, policing community events, managing compliance with 
liquor licensing regulations and traffic management.  
 
Smith et al. (2014) reported that it is reasonable to allocate 80 percent of police costs to crime, based on 
2011 data from New South Wales Police. An alternative estimate can be derived from a Western Australian 
Police report (Western Australian Police, 2014), which allocated expenditure between activity types (with 
administrative costs allocated based on their share of operational expenditure). For the purposes of this 
calculation, “Intelligence and protective services”; “Response to, and investigation of, offences”; and 
“Services to the Judicial Process” are assumed to be crime related activities, with “Crime Prevention and 
Public Disorder”; “Community Support (non-offence)”; “Emergency Management”; and, “Traffic Law 
Enforcement and Management” classed as non-crime activities, giving an estimate of 64 percent of police 
time being crime related. As this is a more conservative estimate, we have used the proportion of crime 
allocated to crime estimated from Western Australian Police data for this analysis. 
 
Police costs to be used in estimating the costs of heroin attributable crime also need to be adjusted down as 
our AF are derived from data on adult offenders, and may not be applicable to offenders aged less than 18 
years of age. Some 13 percent of offenders processed by police are aged 17 or younger (Australian Bureau 
of Statistics, 2014), and we use this as an approximation of the share of police time spent on juvenile 
offenders, with 87 percent on adult offending. 
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Applying these two proportions (64% and 87%) to overall police costs of $11.0 billion gives an estimate of 
$6.9 billion in police costs that can be attributed to the response to offences committed by adults. This is the 
base from which the cost of heroin-related police time is calculated. 
 
To allocate the costs of police time across different offence categories, we obtained data on the total number 
of offenders processed by police in 2015/16. This was sourced from the ABS publication “Recorded Crime – 
Offenders” (Australian Bureau of Statistics, 2017g). Unfortunately, this publication does not report the number 
of offenders processed for driving related offences, so for these offences the number of adult defendants 
processed in the courts was used as a reasonable proxy in 2015/16 (Australian Bureau of Statistics, 2017e). 
Simply allocating costs based on the number of offenders processed by police is likely to overestimate the 
amount of police time spent on frequent, but relatively straightforward, cases such as driving offences, and 
underestimate the time spent on cases that involve more intensive investigations, such as murder or major 
fraud. An approach that has been used previously (Moore, 2005) to weighting the raw numbers is to use data 
on the total police custody hours by offence category. It should be noted this relies on 2002 data (Taylor and 
Bareja, 2005). However, this also has the potential to be influenced by variations in the time taken to arrange 
bail or to be transferred to remand. Instead, we use court data on the average length of a trial in 2015/16 
(Australian Bureau of Statistics, 2017e) as a reasonable proxy for the average complexity of cases by offence 
category and, therefore, for the cost of the police investigation.  
 
Table 7.3 provides the heroin attributable police costs by most serious offence for adult offenders in 2015/16. 
The highest heroin attributable cost was found for property offences ($73.1 million). The next highest heroin 
attributable costs were for violent offences ($45.0 million) and drug offences ($38.5 million). Allocating police 
costs between offence categories on this basis, and then applying the AF for offences set out in Table 7.1 
gives a central estimate of total heroin attributable police cost of $202.6 million, with a low bound of $113.6 
million and a high bound of $523.0 million.  
  
Table 7.3: Heroin attributable police costs by most serious offence, 2015/16 





Number of offenders 94,253  73,588  77,346  205,817  26,330  71,305  18,924  567,563  
Weighting for relative 
complexity (from court data) 1.81 1.24 0.92 0.70 0.68 0.64 0.81 1.00 
Estimated weighted share 
of police time on crime (%) 30.0 16.1 12.5 25.5 3.2 8.0 2.7 
 
Estimated value of police 
time on adult crime 
($’million) 
2,100.7 1,125.2 876.2 1,783.5 221.5 562.4 188.6 6,858.1 
Central estimate of heroin 
attributable police costs 
($’million) 
45.0 73.1 38.5 30.0 7.7 8.3 0.0 202.6 
Low bound of heroin 
attributable police ($’million) 27.4 50.3 20.4 8.2 5.0 2.3 0.0 113.6 
High bound of heroin 
attributable police ($’million) 92.4 132.0 89.4 132.5 14.8 36.7 25.4 523.0 
Source: ABS (2017e); Steering Committee for the Review of Government Service Provision, (2017a); AIC DUMA collection 
2015/16 [computer file]; calculations by the authors. Costs relating to juvenile offenders are excluded.  
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7.3 Court costs 
Total recurrent expenditure on criminal courts in Australia was $853.5 million in 2015/16 (Steering Committee 
for the Review of Government Service Provision, 2017a). However, that includes Children’s Court costs for 
which we do not have reliable AF for heroin. Deducting Children’s Court costs leaves $821.4 million in court 
costs that are in-scope. These court costs include the cost of operating such specialist courts as drug courts 
but do not include the cost of Federal courts (which process Commonwealth offences such as customs 
offences). Thus, with the exclusion of Children’s Court and the Federal courts, the court costs are likely to 
understate costs attributable to heroin. 
 
Offender based AF calculated by the AIC from the DUMA survey in 2015/16 were used to assess the court 
costs attributable to heroin. As with police costs, these court costs need to be allocated between offence 
categories (based on the alleged perpetrator’s most MSO) so that the relevant AF can be applied to them. 
This allocation was made on the basis of the proportion of total defendant weeks for that level of court. 
 
Table 7.4 displays the findings from both Higher courts (Supreme and District courts) and Magistrates courts. 
Applying the relevant AF gives a central estimate of total court costs attributable to heroin in 2015/16 of $12.4 
million for Higher courts. The low bound of heroin-related costs was $7.4 million and the high bound costs 
was 21.1 million. In Magistrates Courts applying the relevant AF gives a central estimate of total court costs 
attributable to heroin in 2015/16 of $12.1 million. The low bound of heroin-related costs in Magistrates courts 
was $6.6 million and the high bound costs was $25.5 million. 
 
Combining Higher and Magistrates court costs the central estimate of total heroin attributable court costs in 
2015/16 was $24.5 million. The low bound of total heroin-related court costs was $14.0 million and the high 
bound was $46.6 million. 
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Table 7.4: Heroin attributable court costs by most serious offence and level of court, 2015/16 
  Violence Property Drugs Traffic or DUI Breach Disorder 
Not 
allocated Total 
Higher Courts                 
Number of defendants 
finalised 7,506 1,689 3,827 7 259 342 62  13,692 
Total defendant weeks 335,788 71,789 158,821 188 11,215 14,434 3,212  595,445  
Assumed court costs 
($million) 214.0 45.7 101.2 0.1 7.1 9.2 2.0  379.4 
Central estimate of heroin 
attributable court costs 
($million) 
4.6 3.0 4.4 0.0 0.2 0.1 0.0  12.4 
Low bound of heroin 
attributable court costs 
($million) 
2.8 2.0 2.4 0.0 0.2 0.0 0.0  7.4 
High bound of heroin 
attributable court costs 
($million) 
7.5 4.3 8.2 0.0 0.4 0.5 0.2  21.1 
Magistrates Courts         
Number of defendants 
finalised 94,859 53,509 51,898 205,810 39,331 41,628 10,647 497,697 
Total defendant weeks 1,007,171 425,048 212,782 1,049,631 184,856 180,408 59,623 3,119,519 
Assumed court costs 
($million) 142.7 60.2 30.1 148.7 26.2 25.6 8.4 442.0 
Central estimate of heroin 
attributable court costs 
($million) 
3.1 3.9 1.3 2.5 0.9 0.4 0.0 12.1 
Low bound of heroin 
attributable court costs 
($million) 
1.9 2.7 0.7 0.7 0.6 0.1 0.0 6.6 
High bound of heroin 
attributable court costs 
($million) 
5.0 5.6 2.5 8.8 1.4 1.3 0.9 25.5 
Source: ABS (2017e); Steering Committee for the Review of Government Service Provision, (2017a); AIC DUMA collection 
2015/16 [computer file]; calculations by the authors. 
 
In addition to the direct costs of the court system, there are also social costs imposed through the costs of 
public prosecutors (where cases are not prosecuted by police) and legal aid costs, where that is provided to 
defendants. The costs of counsel funded by defendants themselves are out-of-scope of this report as they 
are a purely private cost. 
 
State and territory governments have legal aid commissions that provide legal support in criminal, civil and 
family law matters. Both Moore (2005) and Ritter et al. (2013) used a top-down approach to allocate a 
proportion of these costs to substance use, which we replicated. First, we estimated the average proportion 
of court activity considered attributable to heroin use (e.g. our estimated heroin attributable court costs divided 
by the total Higher Court and Magistrate’s courts estimates, but excluding Children’s Court costs; see Table 
7.4 for the source data). This proportion was estimated to be 3.0 percent.  
 
Expenditure figures were sourced from the annual reports of each of the Legal Aid Commissions across 
Australia for 2015/16 (Justice and Community Safety Directorate, 2016b; Legal Aid Commission New South 
Wales, 2016; Legal Aid Queensland, 2016; Legal Services Commission of South Australia, 2016; Northern 
Territory Legal Aid Commission, 2016; The Treasurer, 2015; Victoria Legal Aid, 2016). It was not possible to 
identify the spending on criminal matters from the ACT and NT data and so these jurisdictions are excluded 
from the calculation. Legal aid organisations for which data are available are estimated to have spent $306.8 
million on criminal matters. Assuming the share of legal aid costs on Children’s court matters matches the 
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share of Children’s court costs in total court costs, we estimate legal aid costs on adult criminal court matters 
at $295.3 million, with a central estimate of heroin attributable costs of $8.8 million, with a low bound of $5.0 
million and a high bound of $16.8 million (see summary Table 7.18). 
 
State and territory government spending on Department of Public Prosecution (DPP) services was $408.4 
million in 2015/16 (Commonwealth Director of Public Prosecutions, 2016; Director of Public Prosecutions, 
2016; Director of Public Prosecutions Northern Territory, 2016; Justice and Community Safety Directorate, 
2016a; Office of the Director of Public Prosecutions, 2016; The Treasurer, 2016, 2017). As was done for 
Legal Aid Commission expenditure, we applied a multiplier to this total expenditure to derive a heroin specific 
public prosecution expenditure. We estimated this multiplier from the average of Higher and Magistrates’ 
court activity figures, weighted by expenditure (as described earlier) as 2.9 percent. 
 
As with legal aid costs, it has been assumed the DPP costs on Children’s court matters matches their share 
of direct court costs (3.8%) giving $392.9 million in DPP costs related to adult criminal court matters, with a 
central estimate of heroin attributable costs of $11.7 million, with a low bound estimate of $6.7 million and 
an high bound of $22.3 million (see summary Table 7.18). 
 
7.4 Correction system costs 
Conceptually there are two ways that the correction costs attributable to heroin could be calculated. The first 
is to calculate the net present value of all future corrections related costs arising from heroin attributable 
crime committed in 2015/16. The second approach is to calculate the corrections system related costs 
attributable to heroin incurred due to imprisonment in 2015/16, regardless of when the offence itself occurred.  
 
The former approach has the advantage of being based on crime committed in the study year (or at least 
criminal proceedings finalised in the study year) reflecting the pattern of heroin use and crime in the study 
year. The latter has the advantage of being based on known costs and known prison populations. 
 
7.4.1 Estimating the unit costs of imprisonment 
The on-going net recurrent costs (including depreciation of capital items) of corrections facilities cost society 
a total of $3.9 billion in 2015/16, $2.9 billion in capital costs and $1.0 billion in operating costs (Steering 
Committee for the Review of Government Service Provision, 2017a). As at 30 June 2016 there were 38,845 
individuals detained in the adult corrections system including prisoners on remand (Australian Bureau of 
Statistics, 2017f). This gives an annual correction system cost per prisoner of $99,769. We have used this 
average in calculating the cost per heroin attributable prisoner although this is likely to underestimate the true 
per prisoner costs, as it excludes some of the costs associated with in-prison drug and alcohol services. We 
do not have data that would allow us to isolate the cost of these services from the overall prison costs.  
 
There are other less direct costs and offsetting benefits associated with imprisonment, with researchers at 
the AIC identifying the following additional forms of cost and offsetting savings (Morgan and Althorpe, 2014): 
Costs 
• Lost productivity of prisoners (paid and unpaid work); 
• Workplace disruption and costs of recruiting replacement employees; 
• Lost potential lifetime economic output as ex-prisoners have a lower employment participation 
rate post release; 
• Increased risk of homelessness post release; 
• Prison assaults (on both staff and prisoners); 
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• Additional government payments as a result of household income falling due to imprisonment 
of a member of the household who was in work; 
• Health impacts of imprisonment such as transmission of BBV; 
• Cost of out of home care for children whose custodial parent is imprisoned and who cannot be 
placed with another member of the immediate family; and, 
• Childcare and parenting support costs. 
Offsetting savings 
• Reduced government payments; 
• Incapacitation effect of imprisonment (e.g. it is more difficult for imprisoned offenders to commit 
additional crime (excluding prison assaults)); 
• Value of work completed in prison; 
• Reduction in illicit drug use by prisoners (although it should be noted that although rates of drug 
use are likely to fall during imprisonment, the harms per person arising from use may actually 
increase, for example through increased sharing of needles); 
• Reduction in alcohol use (and therefore associated harms) by prisoners; and, 
• Reduction in access to welfare services by prisoners. 
 
Unfortunately, many of these costs cannot be accurately quantified from the available data. Our estimate of 
the net costs of imprisonment was therefore restricted to the following areas (with the method used to quantify 
the amount set out in the discussion that follows): 
• Recurrent costs of corrections facilities: $99,769 / prisoner (calculation set out above); 
• Lost productivity of prisoners in paid work: $23,843 / male prisoner and $10,684 / female 
prisoner; 
• Workplace disruption and costs of recruiting replacement employees $3,017 / male prisoner and 
$1,352 / female prisoner; 
• Lost productivity of prisoners in unpaid household work: $19,685 / male prisoner and $35,146 / 
female prisoner; 
• Prison assaults (on both staff and prisoners): $489; and, 
• Reduced government payments (offsetting saving): -$2,848 / male prisoner and -$3,363 / 
female prisoner. 
 
7.4.1.1: Lost productivity of prisoners in paid work 
A proportion of offenders were in paid work at the time that they were arrested. For these individuals there is 
a social cost from the loss of the economic output that would have been produced had they remained in the 
labour force. Gross domestic product per employee was calculated from current price estimates of GDP for 
the year to June 2016 from the ABS national accounts and average employment over 2015/16 (Australian 
Bureau of Statistics, 2019a, d) and is $139,697 in 2015/16 31. 
 
Unlike the mortality data, this calculation excluded the estimated portion of income flowing to the person 
using heroin themselves. This is partially because criminal behaviours are not as directly linked to 
dependence in the way that medical harms are linked, and partially because if they were included, then 
income would need to be offset against any savings in living expenses for the imprisoned persons, for which 
                                                     
31 This GDP per worker is slightly different than that used in the recently released report into the social cost of smoking as the 
ABS has made minor revisions to their estimates of current prices, GDP and employment for 2015/16 since the smoking 
analysis was completed. 
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data is not available. The average labour share of GDP over the past 20 years has been 54 percent, and so 
only 46 percent ($63,933) of the per employee GDP has been included as a cost in this corrections cost 
calculations.  
 
Data from the 2013/14 Victorian crime statistics (Victoria Police, 2014) indicates that 37 percent of male adult 
alleged offenders and 17 percent of female adult alleged offenders were in employment when they were 
arrested (more up to date data on the employment status of alleged offenders does not appear to be 
available). We have assumed that these employment rates are representative of those arrested for heroin 
attributable offences. These parameters give an estimated annual loss to economic output of $23,843 per 
male prisoner and $10,684 per female prisoner. 
 
7.4.1.2: Workplace disruption and costs of recruiting replacement employees 
Employers face one-off costs to recruit new employees to replace imprisoned workers, and to train those 
new workers. We have assumed that these costs match the costs estimated by the Bureau of Infrastructure, 
Transport and Regional Economics for replacing deceased employees, namely $6,422 in 2006 values 
(Bureau of Infrastructure Transport and Regional Economics, 2009). Converting to 2015/16 values using the 
change in the CPI (Australian Bureau of Statistics, 2019c) gives a cost per imprisoned employee of $8,119. 
Applying the employment shares for alleged offenders (37% for males and 17% for females) (Victoria Police, 
2014) gives an estimated average cost to employers of replacing imprisoned workers of $3,017 per male 
prisoner and $1,352 per female prisoner. 
 
7.4.1.3: Lost productivity of prisoners in unpaid household work 
The estimated value of labour in the household lost due to imprisonment is calculated on the same basis as 
that lost due to premature mortality (see Chapter 3). Following Collins and Lapsley, production losses in the 
household sector are valued on an individual function replacement basis using data from the ABS publication 
Unpaid Work and the Australian Economy 1997 (Australian Bureau of Statistics, 1997; Collins and Lapsley, 
2008). The total value of male unpaid labour in the household is estimated at $82 billion in 2007 values and 
female unpaid labour is valued at $154 billion. Converting these figures to per adult estimates using the 
population data used in the ABS estimates of the value of unpaid household labour (Australian Bureau of 
Statistics, 1997) and to 2015/16 values using the CPI (Australian Bureau of Statistics, 2019c) gives values 
of unpaid household work of $19,613 per adult male and $35,016 per adult female. 
 
7.4.1.4: Prison assaults 
Data from the Review of Government Services Provision (Steering Committee for the Review of Government 
Service Provision, 2017a) estimates that in 2015/16, 1.1 percent of prisoners were the victim of a serious 
assault and 13.6 percent were the victim of an assault, with 0.04 percent of prisoners having committed a 
serious assault on a prison guard and 1.4 percent having committed an assault on a prison guard.  
 
The estimated cost per assault was taken from Smith et al.’s (2014) estimates of the costs of crime in Australia 
(see Table 7.10). Serious assaults were assumed to be equivalent to assaults requiring hospitalisation. Other 
assaults were costed at the average cost of the other assault categories reported in Smith et al. (2014) and 
weighted based on their relative frequency amongst assaults. For assaults on prisoners, the productivity 
costs were not included. Medical costs outside of hospital have been excluded for prisoners as it has been 
assumed that they are included in the overall recurrent costs of prisons.  
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It is less obvious whether productivity costs should be included for prison guards; to the extent to which these 
costs are borne directly by the corrections system then they will be included in the overall recurrent operating 
costs and should not be included in this calculation. However, to the extent they are borne by the employee 
through unpaid time off, or by workers compensation funds they will not be included in the recurrent costs 
and should be included in our costing.32 The estimated cost per assault on prisoners was $26,882 for serious 
assaults and $1,054 for other assaults, and the costs per assault on a prison guard were $61,852 and $1,751 
respectively if productivity costs are included. Applying the relative frequencies to these unit costs, the 
estimated annual cost per prisoner from prison assaults (both on other prisoners and on prison guards) is 
$489. 
 
7.4.1.5: Reduced government payments (offsetting saving) 
Prisoners are not eligible for government income support payments whilst in detention so, to the extent that 
detainees were unemployed and on benefits at the time of their offence, there will be a cost saving for the 
Australian Government. We have not been able to identify data on the proportion of offenders who were in 
receipt of income support benefits at the time of their imprisonment, however the 2013/14 Victorian crime 
statistics (Victoria Police, 2014) reports that 21 percent of male alleged offenders and 25 percent of female 
alleged offenders were unemployed at the time of their arrest (with those neither employed nor unemployed 
being not in the labour force). The annual value of Newstart allowance for singles in 2015/16 was $14,606 
(Centrelink, 2015). Assuming that these rates of unemployment are representative of prisoners detained for 
a heroin attributable offence at the time of their arrest, and that all unemployed alleged offenders were in 
receipt of Newstart allowance at the time of their offence this gives average offsetting savings of -$3,082/male 
prisoner and -$3,639/female prisoner. These estimates are likely to overstate the potential cost savings, as 
not all of those who are unemployed are eligible for Newstart allowance (in which case there would be no 
offsetting benefit) and of those eligible some would have a partner who was also in receipt of income support 
benefits (in which case the cost saving would be the difference between two persons in receipt of the couples 
Newstart allowance and one person in receipt of the single Newstart allowance which is $9,771). On the 
other hand at least some unemployed prisoners would have been in receipt of a more generous benefit such 
as the Disability Support Pension, or be in receipt of other payments such as rent assistance or family tax 
benefit, and for those individuals the offsetting saving will be underestimated. 
 
7.4.1.6: Aggregated net costs per prisoner 
Combining the six sources of cost and offsetting benefit from imprisonment that were able to be quantified 
gives a total estimated net average annual cost of imprisonment in 2015/16 of $143,721 for male prisoners 
and $143,801 for female prisoners. It is not known whether the net costs would be higher or lower if all of the 
unquantifiable costs were able to be quantified. 
 
7.4.2 Estimating the total costs of heroin attributable imprisonment 
The estimated total cost of heroin attributable imprisonment in 2015/16 can be estimated from the total 
number of persons sentenced to custody in 2015/16, the expected duration of their sentences, and the 
proportion of imprisoned persons whose offending was attributable to heroin (Table 7.5).  
                                                     
32 The costs of opioid attributable prison assaults on prison guards should be additional to any workplace costs reported in 
chapter 6. This is because the attribution of workplace injuries to opioids in chapter 6 is based on the prevalence of opioid use 
of employees as it is reporting the estimated cost of injuries caused by the opioid use of an employee (whether the injury is to 
the person who had used the opioid or to one of their colleagues) . The estimate in section 7.4.1.4 is calculating the expected 
increase in assaults of prison guards due the higher prison population that results from opioid attributable crime, no assumption 
is made as to whether opioid use has continued in prison. 
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Data on the number of persons sentenced to custody was taken from the ABS publication ‘Criminal Courts, 
2015/16’ (2017e) using the data on number of persons found guilty and sentenced to ‘custody in a 
correctional institution’. The duration that will be served by those sentenced in 2015/16 cannot be known at 
this point in time; as a proxy we used the mean time served by offence category for persons who have 
completed their sentence from the ABS publication ‘Prisoners in Australia’ (2016f) Heroin attributable persons 
imprisoned were calculated using the AF derived from the DUMA survey. 
 
Table 7.5: Adult prisoners sentenced in 2015/16, total and heroin attributable by most serious offence 
category 









Persons sentenced to custody for a 







01 Homicide and related offences 251 15 5.4 3.3 8.8 
02 Acts intended to cause injury 11,816 2.0 253.2 153.9 414.2 
03 Sexual assault and related offences 1,678 5.8 36.0 21.9 58.8 
04 Dangerous or negligent acts endangering 
persons 2,747 1.5 58.9 35.8 96.3 
05 Abduction, harassment and other offences 
against the person 600 3.6 12.9 7.8 21.0 
06 Robbery, extortion and related offences 1,392 3.6 29.8 18.1 48.8 
07 Unlawful entry with intent/burglary, break and 
enter 3,769 2.1 245.0 168.6 352.5 
08 Theft and related offences 3,783 1.1 245.9 169.3 353.8 
09 Fraud, deception and related offences 1,671 1.9 108.6 74.8 156.3 
10 Illicit drug offences 4,451 3.8 195.4 103.6 361.9 
11 Prohibited and regulated weapons and 
explosives offences 1,601 1.9 34.3 20.9 56.1 
12 Property damage and environmental 
pollution 996 2.0 14.6 4.0 51.8 
13 Public order offences 654 1.5 14.4 4.0 51.0 
14 Traffic and vehicle regulatory offences 2,123 0.6 21.4 5.9 75.4 
15 Offences against justice procedures, 
government security and government 
operations 
3,282 1.2 114.4 74.4 174.6 
16 Miscellaneous offences 139 4.5 0.0 0.0 14.9 
Total 40,953  1,390.1 866.1 2,296.5 
Source: ABS, (2016f); AIC DUMA collection 2015/16 [computer file]; calculations by the authors. 
 
The unit cost of imprisonment used was that calculated in Section 7.4.1. This was applied for each year (or 
fractional year) that a person convicted of that offence would be expected to remain in custody. For instance, 
each person convicted of homicide the annual costs are incurred for 15 years, for each person convicted of 
assault the costs are incurred for two years, and so on. Costs arising from lost economic output, and the 
costs of assaults in prison, increase at the expected nominal rate of growth in GDP per capita, other costs 
are expected to grow in line with the CPI. This series of future costs are converted to a present value using 
a real discount rate of 7 percent. 
 
The total estimated cost of heroin attributable imprisonment is $422.2 million, with a low bound of $257.7 
million and a high bound of $710.7 million (Table 7.6). The majority of the costs arise from the costs of 
operating and maintaining prisons. 
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Table 7.6: Expected total cost of imprisonment for persons sentenced in 2015/16 for heroin attributable 
crime, present values 
Cost items 
Present value of cost, 
central estimate  
($) 
Present value of 
cost, low bound  
($) 
Present value of 
cost, high bound  
($) 
Cost of imprisonment 295,706,745  180,492,981  497,799,909  
Value of lost economic output 66,341,635  40,476,448  111,726,086  
Additional recruitment costs 8,066,690  4,923,732  13,579,661  
Value of lost labour in household 58,860,149  35,926,958  99,086,603  
Cost of prison assault 1,414,507  863,021  2,382,174  
Offsetting saving in reduced benefit payments -8,233,492  -5,025,545  -13,860,460  
Total net costs 422,156,234  257,657,595  710,713,973  
 
7.4.3 Community based correction costs 
The cost of community corrections arising from heroin attributable offences, where the sentence was imposed 
in 2015/16, was estimated from ABS data on the number of persons sentenced to community service orders 
(and the average length of the orders) by broad offence type (Australian Bureau of Statistics, 2017e)33 and 
data on the total cost of the community corrections system (Steering Committee for the Review of 
Government Service Provision, 2017a). It was assumed that the cost of a given order was directly 
proportional to the length of the order, with the average cost per order converted to a per hour cost ($80.99) 
using the mean number of hours for all orders. The data on the mean duration of community service orders 
does not include those orders where the most serious offence was ‘homicide’. For the purposes of the 
calculation we have assumed that the mean duration for these orders was the same as for ‘Acts intended to 
cause injury’. This is likely to understate the mean duration of community service orders for persons 
sentenced for homicide. Data on mean duration is also not available for the most serious offence category 
‘Miscellaneous offences’. Absent any comparable offence category we have excluded these offences from 
the cost calculations. 
 
The mean duration data are also based on a smaller sample for orders issued where the most serious offence 
is ‘Acts intended to cause injury’. The ABS records 7,987 persons as having been sentenced to a community 
service order where this was their most serious offence, however in calculating the mean duration data the 
ABS only had duration information for 4,130 persons sentenced for this offence category (Australian Bureau 
of Statistics, 2017e). For the cost calculations we have assumed that community service orders where the 
duration is not known by the ABS have the same median duration as those whose duration is known. All 
other most serious offence categories have the same sample size  
 
Attribution to heroin was based on the AF calculated from the DUMA survey with a central estimate of 128,451 
hours of community supervision attributable to heroin (Table 7.7). This equates to a cost of $10.4 million for 
heroin attributable community supervision orders in 2015/16 under the central estimate of heroin attribution, 
with a low bound of $6.3 million and a high bound of $18.0 million.  
 
  
                                                     
33 Note that not all forms of non-custodial orders are included in the ABS statistics. Home detention, probation, good behaviour 
bonds and suspended sentences are not included. These types of orders generally require minimal administration and 
supervision, however, so the impact of their omission is reduced. 
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Table 7.7: Community supervision orders, total and heroin attributable, 2015/16 




















01 Homicide and related offences 15 114.4 a 36.8 22.4 60.2 
02 Acts intended to cause injury 7,987 114.4 b 19,579.6 11,904.1 32,028.2 
03 Sexual assault and related offences 562 147.1 1,771.5 1,077.0 2,897.8 
04 Dangerous or negligent acts endangering 
persons 2,352 118.7 5,982.5 3,637.3 9,786.1 
05 Abduction, harassment and other offences 
against the person 680 108.9 1,586.8 964.8 2,595.7 
06 Robbery, extortion and related offences 459 178.5 1,755.7 1,067.4 2,871.9 
07 Unlawful entry with intent/burglary, break and 
enter 2,742 110.6 19,712.2 13,568.2 28,366.0 
08 Theft and related offences 3,942 84.3 21,600.2 14,867.7 31,082.7 
09 Fraud, deception and related offences 1,959 122.3 15,573.1 10,719.2 22,409.7 
10 Illicit drug offences 4,023 114.6 20,240.6 10,726.7 37,490.3 
11 Prohibited and regulated weapons and 
explosives offences 1,421 102.6 3,124.2 1,899.5 5,110.5 
12 Property damage and environmental pollution 1,724 73.9 1,873.6 515.0 6,629.0 
13 Public order offences 1,504 75.2 1,663.2 457.2 5,884.8 
14 Traffic and vehicle regulatory offences 3,713 108.3 6,758.3 1,858.3 23,810.5 
15 Offences against justice procedures, government 
security & government operations 2,859 72.2 7,192.3 4,678.9 10,982.4 
16 Miscellaneous offences 169 c- n/a n/a n/a 
Total hours of community supervision orders 3,741,100 103.6 128,451 77,964 222,006 
Total cost of community supervision orders   $10,403,815 $6,314,640 $17,981,308 
Source: RoGS 2017, (ABS 2017b), calculations by the authors. 
a Duration data is not available for community supervision orders where the most serious offence was homicide; mean duration 
for ‘Acts intended to cause injury’ has been used to calculate the cost of this offence category. 
b Mean duration is for the 4,130 orders where the ABS was able to identify the duration of the order. 
c Duration data was not available for the most serious offence category ‘Miscellaneous offences’ and it was excluded from the 
cost calculations. 
 
7.5 Costs to victims of crime 
As well as the costs arising from the investigation of crime, the administration of justice and the corrections 
system, there are also substantial costs incurred by the victims of crime. Administrative data from police and 
courts authorities are generally poor guides as to the extent of crime victimisation, as many victims do not 
report the offence to the police. Nationally, reporting rates in 2015/16 for selected crimes varied widely, 
ranging from 30 percent for sexual assault to 93 percent for motor vehicle theft (Australian Bureau of 
Statistics, 2017d). 
 
The most comprehensive assessment of the prevalence of crime victimisation in Australia is provided by the 
ABS’s survey ‘Crime Victimisation, Australia’ (2017d). The number of persons reporting that they had been 
a victim of crime (or that their household had been a victim of crime for property offences), by offence type, 
is set out in Table 7.8. It should be noted that the totals cannot be summed to provide an overall number of 
persons who have been a victim of crime in the reference year as not all crimes are in scope, and some 
individuals would have been the victim of more than one type of crime. It is also important to note that not all 
crimes are included in the survey of crime victimisation and for those types of crime costs to victims cannot 
be calculated. 
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Table 7.8: Number of victims of selected crimes, 2015/16 
Offence 
Number of victims of 
crime – reported latest 
incident to police 
(‘000) 
Number of victims of 
crime – did not report 
latest incident to police 
 (‘000) 
Total number of 
victims  
of selected crimes 
(‘000) 
Personal Crimes    
Physical assault 253.6 207.8 462.2 
Face-to-face threatened assault 200.9 294.7 492.0 
Non face-to-face threatened assault 67.7 116.8 182.3 
Robbery 36.5 29.7 70.6 
Sexual assault victims aged 18 years or 
older 23.5 53.0 77.4 
Household crimes    
Break and enter 173.3 52.7 225.7 
Attempted break and enter 80.9 105.0 185.9 
Motor vehicle theft 45.2 4.1 48.6 
Theft from a motor vehicle 142.9 120.4 264.4 
Malicious property damage 234.3 199.3 434.0 
Other theft 99.5 140.3 238.9 
Source: ABS, (2017d) 
Note: Number of victims of crime, not the number of offences. As some victims of crime will have had more than one occasion in 
the year in which they were the victim of a particular crime type, these data understate the cost of crime to victims. 
 
Applying the relevant AF to the total number of victims of crime gives the numbers where the crime was 
attributable to heroin, see Table 7.9. Overall, we estimate that there were 38,600 victims of at least one heroin 
attributable violent crime in 2015/16, and 69,100 households that were victims of some form of heroin 
attributable property crime. 
 
Table 7.9: Number of victims of selected heroin attributable crimes, 2015/16 
Offence 
Number of victims of 
heroin attributable 
crime – central 
estimate (‘000) 
Number of victims of 
heroin attributable 
crime – low bound 
(‘000) 
Number of victims of 
heroin attributable 
crime – high bound 
(‘000) 
Personal Crimes    
Physical assault 9.9 6.0 16.2 
Threatened assault 11.6 6.4 17.2 
Robbery 1.5 0.9 2.5 
Sexual assault victims aged 18 years or older 1.7 1.0 2.7 
Household crimes    
Break and enter 14.7 10.1 21.1 
Attempted break and enter 12.1 8.3 17.4 
Motor vehicle theft 3.2 2.2 4.5 
Theft from a motor vehicle 17.2 11.8 24.7 
Malicious property damage 6.4 1.8 22.6 
Other theft 15.5 10.7 22.3 
Source: ABS (2017d)AIC DUMA collection 2015/16 [computer file]; calculations by the authors 
Note: Number of victims of crime, not the number of offences. As some victims of crime will have had more than one occasion in 
the year in which they were the victim of a particular crime type, these data understate the cost of crime to victims 
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The most comprehensive set of estimates of the costs of crime have been compiled by researchers at the 
AIC (Smith et al., 2014). Drawing together information from a range of Australian and international sources 
on the costs of various types of personal and household crime, they distinguish between medical costs, lost 
output, property loss, property damage, and intangible cost (e.g. pain and suffering). Although not all forms 
of crime are in scope, the analysis covers the majority of the crime types included in the ABS victims of crime 
survey.  
 
Costs of the various forms of personal crime are subdivided by the severity of medical impact on the victim, 
and the number of victims of heroin attributable crime estimated. Table 7.10 has been apportioned between 
severity categories based on the proportions reported in Smith et al. (2014) 
 
In almost all cases, the parameter values chosen by Smith et al. are consistent with the ranges adopted in 
comparable international exercises, however the intangible cost estimate adopted for sexual assault is at the 
lower end of comparable studies (Smith et al., 2014). Smith et al. did not derive a specific estimate for the 
intangible cost of sexual assault but rather based it on the intangible cost used for assault where the victim 
was injured, with treatment other than hospitalisation for sexual assault where the victim sustained physical 
injuries, and assault where the victim was injured and no treatment was required for sexual assault where 
the victim did not sustain physical injuries (Smith et al., 2014). In contrast, Dolan and colleagues (2005) derive 
estimates of intangible costs from estimates of the quality of life impact of sexual assault, expressed in terms 
of disability adjusted life years (DALY) using a value of 0.56 lost DALY for rape and 0.16 lost DALY for other 
sexual assault. This compared to a lost DALY of 0.19 for assault resulting in serious injury (roughly equivalent 
to the assault – hospitalised category used by Smith and colleagues (2014)).  
 
As it is more closely aligned to the approach taken to intangible costs in other areas of this report we have 
used the Dolan et al. (2005) estimates of the intangible costs of sexual assault in place of those derived by 
Smith et al.(2014).  
 
Unit costs for each cost category were converted to 2015/16 values using the change in current price Gross 
State Product (GSP) per capita (Australian Bureau of Statistics, 2019a) from June 2011 to June 2016 for 
intangible costs and lost output, and the CPI for medical costs, property loss and property damage (Australian 
Bureau of Statistics, 2019c). Table 7.10 sets out the unit costs to victims of personal crime while Table 7.11 
reports the unit costs for household crime. 
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Table 7.10: Unit costs to victims of personal crime converted to 2015/16 values 





Assault    
Hospitalised 12,699 34,970 14,183 
Injured, treatment other than hospital 755 2,923 3,031 
Injured no treatment - 725 725 
No injury - 43 433 
Sexual assault    
Injury 1,040 6,929 41,658 
No injury 0 57 10,974 
Robbery    
Hospitalised 12,699 34,970 13,988 
Injured, treatment other than hospital 755 2,923 3,069 
Injured no treatment - 731 725 
No injury - 43 433 
Sources: ABS (2019a, c); Smith et al., 2014, Dolan et al. 2005, calculations by the authors 
 
Table 7.11: Unit costs to victims of property crime from Smith et al. converted to 2015/16 values 
Personal crime offence Property loss & property damage ($) 
Lost output  
($) 
Intangible costs  
($) 
Burglary a    
Completed 1,911 87 1,135 
Attempted 234 57 756 
Motor vehicle theft 4,345 174 2,472 
Theft from a vehicle b 1,135 63 822 
Malicious property damage 621 47 1,346 
Other theft 559 10 250 
Sources: ABS, (2019a, c); Smith et al., (2014), calculations by the authors 
a The unit cost used for burglary is that for burglaries of private residences, as we do not have an estimate for the number of victims 
of burglaries of commercial properties. 
b These costs are the average for thefts from private and from commercial vehicles. 
 
Applying the unit costs outlined in Tables 7.10 to the central estimate of the number of victims of heroin 
attributable crime in 2015/16 gives a total estimated cost to victims of personal crime of $115.0 million (Table 
7.12). Assaults account for 55 percent of the victims of crime costs, with sexual assault accounting for a 
further 40 percent. The costs of premature deaths due to heroin attributable homicide are not included in 
these victim of crime cost estimates as they are included in the calculation of heroin attributable mortality 
(see Chapter 3). 
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Table 7.12: Central estimate of total costs to victims of heroin attributable personal crimes by offence 
type and severity, 2015/16 
Offence 















Assault      
Hospitalised 404 5,130,871 14,129,206 5,730,421 24,990,499 
Injured, treatment other than 
hospital 3,493 2,638,382 10,210,204 10,588,359 23,436,944 
Injured no treatment 6,007 0 4,357,802 4,357,802 8,715,604 
No injury 11,646 0 504,374 5,043,744 5,548,118 
Total 21,551 7,769,253 29,201,586 25,720,326 62,691,165 
Sexual assault . . . . . 
Injury 737 766,703 5,108,176 30,710,483 36,585,362 
No injury 921 0 52,870 10,110,961 10,163,831 
Total 1,659 766,703 5,161,046 40,821,444 46,749,193 
Robbery . . . . . 
Hospitalised 53 672,422 1,851,692 740,677 3,264,791 
Injured, treatment other than 
hospital 207 155,990 603,663 633,846 1,393,500 
Injured no treatment 270 0 197,351 195,890 393,241 
No injury 983 0 42,586 425,865 468,451 
Total 1,513 828,413 2,695,293 1,996,277 5,519,983 
All Personal Crime . . . . . 
Total 24,722 9,364,369 37,057,925 68,538,047 114,960,341 
Sources: ABS (2019a, c); Smith et al., (2014), Dolan et al. (2005),, AIC DUMA collection 2015/16 [computer file]; calculations by 
the authors. 
 
The costs of heroin attributable property crime shown in Table 7.13 are of a similar order of magnitude, with 
the central estimate of the total cost $141.0 million. Burglaries (completed and attempted) are the most 
significant driver of the cost accounting for 42 percent of the total. 
 
Table 7.13: Central estimate of total costs to victims of heroin household crimes in Australia by offence 
type and severity, 2015/16 
Offence 
No. of heroin 
attributable 
cases 
Costs of property loss 
& property damage  
($) 









Burglary 26,754 30,872,793 1,964,053 25,777,501 58,614,347 
Completed 14,671 28,041,892 1,270,677 16,645,869 45,958,437 
Attempted 12,084 2,830,901 693,376 9,131,633 12,655,910 
Motor vehicle theft 3,159 13,726,154 550,650 7,808,288 22,085,092 
Theft from a vehicle 17,186 19,510,649 1,079,203 14,122,671 34,712,523 
Malicious property 
damage 6,382 3,960,307 297,132 8,593,336 12,850,775 
Other theft 15,529 8,686,975 151,312 3,883,665 12,721,951 
Total 69,010 76,756,877 4,042,350 60,185,461 140,984,688 
Sources: ABS (2019a, c); Smith et al., (2014), Dolan et al. (2005), AIC DUMA collection 2015/16 [computer file]; calculations by 
the authors 
Note: values may not sum due to rounding 
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Tables 7.14 and 7.15 set out the estimated cost of heroin attributable crime if the low bound estimate of the 
share of crime attributable to heroin is used, and Tables 7.16 and 7.17 show the estimated cost of crime if 
the high bound estimate for the AF is used.  
 
The plausible range of the costs to victims of heroin attributable violent crime ranges from a low bound of 
$69.9 million to a high bound of $188.1 million.  
 
Similarly, the plausible range of the costs of heroin attributable property crime ranges from a low bound of 
$91.7 million to a high bound of $229.9 million. 
 
Table 7.14: Low bound estimate of total costs to victims of heroin attributable personal crimes by offence 
type and severity, 2015/16 
Offence 















Assault      
Hospitalised 246 3,119,498 8,590,359 3,484,016 15,193,873 
Injured, treatment other than 
hospital 2,124 1,604,099 6,207,661 6,437,574 14,249,334 
Injured no treatment 3,652 0 2,649,483 2,649,483 5,298,965 
No injury 7,081 0 306,653 3,066,526 3,373,178 
Total 13,103 4,723,597 17,754,155 15,637,598 38,115,350 
Sexual assault      
Injury 448 466,145 3,105,699 18,671,543 22,243,387 
No injury 560 0 32,144 6,147,323 6,179,467 
Total 1,008 466,145 3,137,844 24,818,866 28,422,854 
Robbery      
Hospitalised 32 408,823 1,125,803 450,321 1,984,947 
Injured, treatment other than 
hospital 126 94,840 367,019 385,370 847,228 
Injured no treatment 164 0 119,987 119,098 239,085 
No injury 598 0 25,892 258,920 284,812 
Total 920 503,663 1,638,700 1,213,709 3,356,072 
All Personal Crimes 15,031 5,693,405 22,530,699 41,670,172 69,894,276 
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Table 7.15: Low bound estimate of total costs to victims of heroin household crimes in Australia by 
offence type and severity, 2015/16 
Offence 
No. of heroin 
attributable  
cases 
Costs of property loss 
& property damage  
($) 









Burglary 18,415 21,250,210 1,351,887 17,743,044 40,345,141 
Completed 10,098 19,301,658 874,626 11,457,603 31,633,887 
Attempted 8,317 1,948,552 477,261 6,285,441 8,711,254 
Motor vehicle theft 2,174 9,447,919 379,021 5,374,562 15,201,503 
Theft from a 
vehicle 11,829 13,429,474 742,832 9,720,848 23,893,154 
Malicious property 
damage 1,754 1,088,566 81,672 2,362,042 3,532,280 
Other theft 10,689 5,979,376 104,150 2,673,185 8,756,711 
Total 44,861.8 51,195,545 2,659,562 37,873,681 91,728,788 
Sources: ABS (2019a, c); Smith et al., (2014), Dolan et al. (2005); AIC DUMA collection 2015/16 [computer file]; calculations by 
the authors 
 
Table 7.16: High bound estimate of total costs to victims of heroin attributable personal crimes by offence 
type and severity, 2015/16 
Offence 















Assault      
Hospitalised 661 8,393,068 23,112,525 9,373,811 40,879,404 
Injured, treatment other than 
hospital 5,713 4,315,859 16,701,829 17,320,415 38,338,103 
Injured no treatment 9,827 0 7,128,483 7,128,483 14,256,966 
No injury 19,051 0 825,055 8,250,545 9,075,600 
Total 35,253 12,708,927 47,767,892 42,073,254 102,550,073 
Sexual assault . . . . . 
Injury 1,206 1,254,172 8,355,943 50,236,141 59,846,256 
No injury 1,507 0 86,485 16,539,488 16,625,973 
Total 2,713 1,254,172 8,442,428 66,775,630 76,472,229 
Robbery     . 
Hospitalised 87 1,099,947 3,028,994 1,211,598 5,340,538 
Injured, treatment other than 
hospital 338 255,169 987,471 1,036,844 2,279,484 
Injured no treatment 442 0 322,827 320,436 643,263 
No injury 1,609 0 69,663 696,628 766,291 
Total 2,475 1,355,116 4,408,954 3,265,506 9,029,576 
All Personal Crimes 40,440 15,318,215 60,619,274 112,114,390 188,051,878 
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Table 7.17: High bound estimate of total costs to victims of heroin household crimes in Australia by 
offence type and severity, 2015/16 
Offence 
No. of heroin 
attributable 
cases 
Costs of property loss 
& property damage  
($) 









Burglary 38,499 44,426,050 2,826,279 37,093,909 84,346,239 
Completed 21,111 40,352,375 1,828,508 23,953,460 66,134,343 
Attempted 17,388 4,073,676 997,771 13,140,450 18,211,896 
Motor vehicle theft 4,546 19,751,981 792,387 11,236,152 31,780,520 
Theft from a vehicle 24,731 28,075,888 1,552,976 20,322,570 49,951,435 
Malicious property 
damage 22,582 14,012,189 1,051,300 30,404,577 45,468,066 
Other theft 22,346 12,500,585 217,738 5,588,607 18,306,930 
Total 112,703 118,766,694 6,440,681 104,645,815 229,853,190 




This investigation has provided estimates of heroin attributable crime costs among adults in Australia during 
the 2015/16 financial year. The cost estimates are summarised in Table 7.18. A feature of this research was 
that it used the DUMA survey conducted in several police commands in Australia to obtain estimates of the 
extent to which inmates arrested for different offence types attributed their arrest to having used heroin 
recently. Overall, the heroin attributable percentages were very low, with only 3.4% of all detainees attributing 
their arrest to heroin. This heroin attribution did vary by the most serious offence, and was higher for those 
with property offences (4.4%) and illicit drug offences (4.4%). These heroin attributions were then applied to 
range of different national crime statistics reported by the Australian Bureau of Statistics for 2015/16 (2017d, 
e, f, g) 
 
Table 7.18: Summary of heroin attributable crime costs, 2015/16 
Cost area Central estimate ($) Low bound  ($) 
High bound  
($) 
Police (Table 7.3) 202,586,394 113,634,904 523,024,002 
Court (Table 7.4) 24,471,841 14,027,982 46,615,535 
Legal Aid 8,796,892 5,042,639 16,756,886 
Public Prosecutors 11,710,075 6,712,561 22,306,103 
Prisoners sentenced 
(Table 7.6) 422,156,234 257,657,595 710,713,973 
Community correction 
(Table 7.7) 10,403,815 6,314,640 17,981,308 
Personal crime victim 
(Tables 7.12, 7.14, 7.16) 114,960,341 69,894,276 188,051,878 
Household crime victim 
(Tables 7.13, 7.15, 7.17) 140,984,688 91,728,788 229,853,190 
Total 936,070,281 565,013,385 1,755,302,874 
 
The heroin attributable cost of police dealing with adult offenders was $202.6 million. This attributable cost 
was particularly high for property offenders ($73.1 million). For adult offender matters finalised in Higher and 
Magistrates courts the total heroin attributable court costs was $24.5 million. The effect of heroin attribution 
was also examined for legal aid costs and the costs of public prosecutors. For legal aid the heroin attributable 
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cost was $8.6 million and for public prosecutors it was $11.7 million. Correction system costs were examined 
by firstly looking at costs of prisoners sentenced during 2015/16 and secondly looking at community based 
correction costs. The heroin attributable costs of prisoners sentenced during 2015/16 was $422.2 million. 
The heroin attributable community correction costs was $10.4 million during the same 12-month period. 
 
Costs related to victims of personal crime and of household crime were also examined for 2015/16. Heroin-
attributable personal crimes were $115.0 million while heroin attributable household crimes were $141.0 
million. Summing across the eight cost areas shown in Table 7.18 the central estimate of heroin attributable 




The findings of this analysis are markedly different from those of Moore (2007) who reported the cost of 
heroin attributable crime as $1.74 billion in 2004 (without adjusting for inflation). The main driver for this 
difference is in the allocation of costs. Moore drew on the analysis by Mayhew (2003) where the cost of 
crimes included the value of property loss from economic crime, which are typically excluded from economic 
studies, as they represent a transfer (these are about 1/3 of the costs of crime in Moore). This different 
approach more than offsets the lower costs of violent crime in Mayhew compared with a combination of 
medical costs increasing at a rate greater than inflation and the wider range (and higher value) of intangible 
costs in our current study. This is amplified by the fact that in 2005, a greater proportion of crime was for 
property offences, representing 22.2 percent of offences (Moore, 2007, Table A2.2), whereas in the current 
analysis it was 18.5 percent (Australian Institute of Criminology, 2019). Almost all of the cost of heroin 
attributable crime was from property crime, which accounted for $1.579 billion out of $1.743 billion (90.6%) 
(Moore, 2007). In the current analysis, property crime accounted for approximately $387.0 million34  out of 
$923.4 million (41.9%). 
 
There have also been changes to attribution in the DUMA data, but these seem likely to only be a minor 
factor. Allocation between drugs was based on a the proportion of drug consumption episodes for each 
substance summed across the sample, but with cannabis weighted at half for economic crime and excluded 
from non-economic crime e.g. if the 3,500 respondents had taken drugs other than cannabis an average of 
10 times each over the sample period (e.g. denominator = 35,000) and there were a total of 3,500 episodes 
of heroin consumption then heroin would be allocated 10 percent of the costs of drug attributable non-
economic crime. 
 
There are important limitations to the current investigation. Firstly, it relied on the DUMA surveys of detainees 
to obtain estimates of the attributable role of heroin across different types of crime. The DUMA survey is 
currently only conducted in five police commands across Australia and as discussed above, the detainees’ 
survey may be quite different in terms of their illicit substance use and involvement in incidents of crime to 
other people in Australia. The second limitation is that the DUMA survey did not obtain attribution information 
from detainees who had used other opioids, such as buprenorphine, methadone, oxycodone or morphine 
extra medically. A third limitation is that costs associated with drug court were not separately investigated, 
but were included in total court costs.   
 
                                                     
34 Not reported in the results: calculated from tables 7.3, 7.4, 7.5, 7.7, 7.12, 7.13 plus Legal aid and DPP fraction 
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It should be noted that the costs associated with the administration of juvenile justice (e.g. police time, the 
Children’s court, juvenile detention) have not been included, as detailed earlier. Similarly, we have not 
included costs arising from prosecutions occurring in the Federal courts. Although, this would likely entail few 
cases, prosecutions involving the international importation of drugs could be complex and time consuming. 
In common with other sections of this report, the issue of poly-substance use is problematic in attempting to 
assign costs specifically to heroin, although the approach used by the AIC attempts to attribute offending to 
individual substances based on the offender’s self-assessment. 
 
As detailed in section 7.4.1, a number of the potential costs of imprisonment arising from heroin attributable 
crime, and a number of the potentially offsetting cost savings of imprisonment, cannot be reliably quantified 
or costed. 
 
Costs that were not able to be included in the cost of imprisonment calculation include: 
• Lost potential lifetime economic output as ex-prisoners have a lower employment participation 
rate post release; 
• Increased risk of homelessness post release; 
• Additional government payments as a result of household income falling due to imprisonment 
of a member of the household who was in work; 
• Health impacts of imprisonment such as transmission of BBV; 
• Cost of out of home care for children whose custodial parent is imprisoned and who cannot be 
placed with another member of the immediate family; and, 
• Childcare and parenting support costs. 
 
Potential offsetting savings arising from imprisonment for heroin attributable offences that were not able to 
quantify in the cost calculation were: 
• Incapacitation effect of imprisonment (e.g. it is more difficult for imprisoned offenders to commit 
additional crime (excluding prison assaults)); 
• Value of work completed in prison; 
• Reduction in illicit drug use by prisoners (this is potentially ambiguous as although the 
prevalence of heroin use would be expected to fall for persons imprisoned for a heroin 
attributable offence, the harm per person using heroin may well be higher, for example through 
increased sharing of needles); 
• Reduction in alcohol use (and therefore associated harms) by prisoners; and, 
• Reduction in access to welfare services by prisoners. 
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CHAPTER 8: ROAD TRAFFIC ACCIDENTS 
Steve Whetton & Tania Dey 
 
8.1 Opioid use and road crashes 
There are numerous licit and illicit substances that can impair driving ability and as such are likely to increase 
the rate at which road traffic accidents occur. The increase in risk arises from: impairment to the cognitive 
and psychomotor skills necessary to drive safely for example reductions in attentiveness; poor judgement 
and increased impulsiveness; reduced lane control, increased reaction times; and, other impairments to fine 
and gross motor skills (Drummer et al., 2004; Verstraete and Legrand, 2014). Evidence from crash studies 
suggests that alcohol and cannabis are the substances that contribute to the greatest number of road crash 
fatalities and hospitalisations, due to their greater population prevalence and also to the nature of their effect 
on cognitive and psychomotor skills (Ch’ng et al., 2007; Drummer et al., 2003; Verstraete and Legrand, 2014).  
 
In the case of opioids, the evidence on road crash risk is somewhat mixed. Controlled task analysis (i.e. 
driving simulations and similar tests) of the acute effects of opioids suggest no, or only small impacts, on 
most of the relevant cognitive and psychomotor skills at the doses administered in the tests (typically between 
2.5 mg and 17.5 mg morphine per 70 kg body weight; (Verstraete and Legrand, 2014). At dosages above 10 
mg morphine per 70 kg of body weight, impairments have been observed and typically follow a dose response 
relationship (Hill and Zacny, 2000).  
 
Epidemiological studies do generally identify an increased risk of fatal and non-fatal crash where opioid 
metabolites are detected in the blood, but these increases in risk are in many cases not statistically significant 
at the conventional level of 95% confidence intervals. Studies identifying a statistically significant increase in 
risk include: Chihuri and Li (2019) (odds ratio (OR) 2.18, 95% CI 1.91 – 2.48) and Martin et al. (2017) (OR 
2.2, 95% CI 1.06 – 4.61). Studies that identified an increase in risk as their central estimate, but where the 
increase in risk was not statistically significant, include: Drummer and colleagues (2003), (OR 1.41, 95% CI 
0.7 – 2.9); Movig and colleagues (2004) (OR 2.35, 95% CI 0.87 – 6.32); and, Palamara and colleagues (2014) 
(OR 1.18, 95% CI 0.70 – 1.98). Drummer and colleagues (2003) note that the wide confidence intervals of 
the OR estimates frequently result in the lack of statistical significance for opioid intoxication as a causal 
factor for road crashes. This is most likely an effect of the small samples of opioid only cases (most of the 
epidemiological studies exclude polysubstance cases from their analysis) rather than an actual lack of an 
increase in risk (Drummer et al., 2003). The risk may also vary depending on the level of physiological 
tolerance that the person has to the drug. 
 
The evidence for persistent impacts from heroin dependence is much stronger. Persons with heroin 
dependence exhibit a range of cognitive and psychomotor deficits that can increase the risk of road crashes 
(e.g., impaired executive function, reaction times, time perception, special working memory, pattern 
recognition memory, and right-left discrimination with some of the impairments persisting up to a year after 
the last use of heroin) (Aleksandrov, 2004; Bryun et al., 2001; Liu et al., 2005; Liu et al., 2006; Lyvers and 
Yakimoff, 2003; Ornstein et al., 2000; Pau et al., 2002; Verdejo et al., 2004). Larney et al. (2019) found that 
the RR for fatal accidents for persons with extra-medical opioid dependence was 7.35 (95% CI 4.69 – 11.51).  
 
As the evidence of a role for opioid dependence in road crash risks is more robust than that for acute use, 
this analysis focuses on road crashes attributable to persons with opioid dependence. This may well 
understate the role of opioids in road crashes, given that acute opioid exposure appears to increase risk, but 
the evidence for the role of acute exposure is not yet sufficiently robust to include in the analysis. 
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In road crashes, it is the substance use status of the culpable road users that is of most interest. There will 
be some occasions when intoxication by pedestrians or others road uses can increase the risk of death or 
injury, but by focusing on the substance use status of the culpable driver, the potential for error in attribution 
is reduced. Age group and gender specific AF were calculated from the RR estimate from Larney et al. (2019). 
The estimated prevalence of persons who are dependent on opioids by age group was obtained from the 
GBD study (Global Burden of Disease Collaborative Network, 2018). These were then weighted by the 
proportion of accidents where a person in that age group was culpable, as assessed by Drummer and 
colleagues (2003). This population AF (Table 8.1) has also been used to calculate the opioid attributable 
premature deaths and hospital separations arising from road crashes, see sections 3.3.2 and 4.3.4. 
 
Table 8.1: Opioid attributable fractions for road crashes 













AF, central estimate 0.048 0.048 0.048 0.048 0.018 0.009 0.037 
AF, low bound 0.024 0.024 0.024 0.024 0.009 0.004 0.018 
AF, high bound 0.089 0.089 0.089 0.089 0.036 0.019 0.070 
Share of accidents where a road used of this 
age group was culpable (%) 3.5 33.6 11.8 18.5 18.7 13.8 99.9 b 
a The attributable fraction is weighted for all ages. 
b The percentage does not tally to 100% due to rounding. 
 
8.2 Road crash frequency, 2015/16 
The frequency of road crashes can be difficult to quantify, as lower severity crashes are underreported 
because they do not have to be reported to police. There are also differences in the way in which transport 
crashes are classified between different jurisdictions, even for serious accidents Australian states and 
territories use varied definitions of what constitutes a serious accident. The two reliable and consistent forms 
of data on road crash frequency (and transport accidents more broadly) are deaths arising from road crashes 
and hospital separations caused by road crashes. 
 
The most recent comprehensive assessment of road crash frequency and costs, including quantification of 
accident frequency by severity, was undertaken by the Bureau of Infrastructure, Transport and Regional 
Economics (BITRE) in 2009 with a reference year of 2006 (Bureau of Infrastructure Transport and Regional 
Economics, 2009). BITRE estimated the total number of crashes in the reference year by applying estimates 
of the proportion of unreported crashes by severity to data provided by state and territory governments on 
the number of reported road crashes.  
 
There were 1,602 deaths as a result of road crashes in 2006, with a further 31,204 persons admitted to 
hospital, 216,500 persons who were injured but did not need to be admitted to hospital, and 438,700 crashes 
in which no persons were injured (Bureau of Infrastructure Transport and Regional Economics, 2009).  
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Table 8.2: Estimated number of road crashes resulting in injury by severity of injury, 2006 
Severity level Number of crashes 
Number of persons  
injured by severity 
Number of  
vehicles involved 
Fatalities 1,455 1,602 1,886 
Hospitalised 25,498 31,204 n/aa 
Not hospitalised injury 188,200 216,500 n/a 
All crashes resulting in injury   428,643a 
Non-injury crash 438,700 - 715,862 
Total 653,853 249,306 1,146,391 
Source: (Bureau of Infrastructure Transport and Regional Economics, 2009), pp. 10, 13, 14. 
a Data on the number of vehicles involved crashes resulting in injuries do not disaggregate crashed resulting in hospitalised injuries 
and those which resulting in injuries that did not require hospitalisation. 
 
Data on the number of fatal road crashes in 2015/16 were taken from the national road fatalities database 
(Bureau of Infrastructure Transport and Regional Economics, 2019). Data on hospital separations attributable 
to road crashes were sourced from an analysis of the AIHW NHMD (Chrzanowska, 2019, personal 
communication) (Table 8.2). More recent estimates are not available for the number of road crash accidents 
whose consequences are less severe than hospitalisation. We have assumed that the number of other 
accidents have increased by 17.5 percent, the same rate as land transport accident hospital separations over 
the period, which increased from 52,286 in 2005/06 (Pointer, 2018) to 61,454 in 2015/16 (Pointer, 2019). 
This rate of increase roughly reflects the increase in population over this period (Table 8.3).35 
  
Table 8.3: Estimated road crash frequency by severity, 2015/16 
Severity level Injuries by severity 
Estimated opioid 
attributable 
Fatalities a 1,269 46.9 
Hospitalised injuries a 44,017 1,628.0 
Not hospitalised injuries a 254,476 9,411.8 
Non-injury crashes b 515,653 19,071.5 
Sources: (Bureau of Infrastructure Transport and Regional Economics, 2009) pp. 10, 13, 14, Chrzanowska, 2019, personal 
communication. a Number of injuries: b Number of crashes 
 
Applying the population opioid AF for road crashes to the severity categories suggests that there were 47 
premature deaths, and 1,628 hospital separations caused by opioid attributable road crashes in 2015/16. 
 
8.3 Costs of road crash accidents 
There is a range of harms and costs that can arise from transport accidents including:  
• Premature mortality; 
• Hospital separations; 
• Permanent disability; 
• Non-hospitalised injuries; 
• Damage to property; and,  
• Costs of insurance administration. 
                                                     
35 Over the same period road crash hospitalisations increased from 31,204 to 44,007; an increase of 44%. It is not clear why 
road crash hospitalisations increased at a much faster rate than overall transport accident hospitalisations; however as we 
cannot rule out changes in coding practices we have used the more conservative change in transport accidents rather than 
the change in road crashes. 
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The tangible and intangible costs of premature mortality due to opioid attributable transport accidents are 
included in the broader estimates of premature mortality costs (see Chapter 3). The impact on hospital 
separations and other medical costs arising from opioid attributable road crashes are included in Chapters 4 
and 5 respectively. Quantification of the costs of other road crash related harms is undertaken in this chapter. 
 
There are two broad approaches that could be taken to estimating the impacts of long-term injuries and 
medical treatment resulting from road crashes: (1) calculating the costs of each specific form of harm 
individually (e.g. outpatient medical care, and where the injury was severe enough to result in long-term 
impairment, lost lifetime output in the workplace, lifetime value of lost household labour, modifications to 
dwellings and vehicles to adjust for impairment, and long-term care costs over the lifetime); or, (2) using 
compensation payments for injuries where long-term costs are ‘capitalised’ into a single lump sum payment 
in the study year. 
 
The former approach will result in estimates that are consistent with the valuation of other forms of cost in 
this study (e.g. consistent valuation of workplace and household labour, of QALY) and as such has much to 
recommend it. However, using the value of compensation payments has the advantages of avoiding any 
uncertainty of the expected years of life remaining after a road crash resulting in a severe impairment and 
giving a cost that is incurred entirely in the study year. This approach may, however, understate the intangible 
costs relative to society’s willingness to pay to avoid them. Therefore, we will use the compensation payments 
approach to calculate the low bound of costs (Section 8.3.2.1), and the specific costs based approach to 
calculate the high bound (Section 8.3.2.2) and use the average of the two approaches as the central estimate.  
 
8.3.1 Property damage caused by opioid attributable road crashes 
The BITRE (2009) estimated that property damage resulting from road crashes cost Australia $3.9 billion in 
2006. Converting this to 2015/16 values using the CPI (Australian Bureau of Statistics, 2019c) and dividing 
by the estimated number of road crashes in 2006, gives an estimated average property damage per road 
crash of $4,269.90 in 2015/16 . 
 
Our central estimate is that there were 28,626 opioid attributable road crashes in 2015/16 (low bound 11,908, 
high bound 45,532), giving an estimated cost of property damage of $122.2 million ($50.8 million to $194.4 
million) (see summary Table 8.6). 
 
The costs of insurance administration for claims related to road accidents were estimated by BITRE to be 
$257.5 million in 2006, with legal actions costing a further $231.3 million (Bureau of Infrastructure Transport 
and Regional Economics, 2009). Combining these two cost items, converting them to 2015/16 values using 
the CPI (Australian Bureau of Statistics, 2019c), and dividing by the estimated number of road crashes in 
2006 gives a per crash estimate of $945. Multiplying by the estimated number of opioid attributable road 
crashes gives a central estimate of insurance administration and legal costs of $27.1 million (low bound 
$11.3 million, high bound $43.0 million). 
 
Finally, BITRE (2009) estimated that road crash injuries created workplace disruption costs (including 
temporary replacement costs for temporarily impaired workers, and the costs of recruitment and training to 
replace those unable to return to their previous employment) to employers of $77.7 million in 2006. 
Converting this to 2015/16 values using the change in the CPI (Australian Bureau of Statistics, 2019c), and 
dividing by the estimated number of road crashes in 2006, gives an estimated average property damage per 
road crash of $88 in 2015/16. Multiplying by the estimated number of opioid attributable road crashes gives 
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a central estimate of the cost of workplace disruption to employers of $2.4 million (low bound $1.0 million, 
high bound $3.9 million). 
 
8.3.2 Long-term costs of road crash injuries 
We used two approaches in estimating the long-term costs of road crash injuries. These formed the low and 
high bounds of our estimate, with the mean of the two approaches being our central estimate of long-term 
costs.  
 
8.3.2.1 Compensation paid approach (low bound estimate) 
The low bound approach to estimating the Long-term costs of road crash injuries makes use of compensation 
payments made by third party insurance providers. 
 
The Transport Accident Commission (the Victorian provider of third party injury insurance) paid out $1.2 
billion in compensation in 2015/16 (Transport Accident Commission, 2016). Victoria on average accounted 
for 22 percent of road crash fatalities in 2015 and 2016 (Bureau of Infrastructure Transport and Regional 
Economics, 2017), which implies national costs of $5.6 billion.  
 
Applying our central estimate of the proportion of road crashes attributable to opioids gives an estimate of 
compensation awarded for long-term injuries arising from opioid attributbale road crash costs of $207.2 
million (low bound $102.0 million, high bound $390.1 million). 
 
8.3.2.2 Long-term care costs approach (high bound estimate) 
The BITRE (2009) estimated that serious injury road crashes will lead to some degree of permanent 
impairment in around 15 percent of cases, with the degree of permanent impairment varying significantly 
from ‘profound limitations’ (2.2% of serious injury accidents) to ‘mild limitations’ (4.9% of serious injury 
accidents). 
 
Applying these frequencies to the estimated 44,017 road crash hospital separations in 2015/16 suggests just 
over 6,500 persons would be expected to have an on-going impairment due to road crashes injuries. 
 
Average unit costs of disability by severity are taken from BITRE (2009) and these, updated to 2015/16 values 
using the CPI (Australian Bureau of Statistics, 2019c) are shown in Table 8.4. 
 
Table 8.4: Estimated unit costs of equipment and care costs due to permanent impairment from road 
crash injuries, 2015/16 
Severity of 
impairment 
Equipment purchase &  











Profound limitations 49,966.1 271,591.2 1,169.4 7,136.8 
Severe limitations 49,966.1 72,185.7 1,169.4 7,136.8 
Moderate limitations 18,129.5 22,795.5 424.3 4,282.1 
Mild limitations 9,064.7 0.0 212.2 2,569.2 
Source: Bureau of Infrastructure Transport and Regional Economics, (2009), Australian Bureau of Statistics, 2019c. 
 
These unit cost estimates were multiplied by the estimated number of impairments of the relevant severity 
from opioid attributable road crashes and, where costs extend into the future, discounted back to 2015/16 
terms using the Australian Government’s recommended discount rate of 7 percent. This gives a present value 
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of equipment and care costs of $239.1 million (low bound $118.5 million, high bound $448.9 million). Table 
8.5 includes the costs for each of these components: equipment, support workers and medical costs. 
 
In addition to these costs relating to dealing specifically with the impairment arising from road crashes, 
disabilities also impact on the probability of employment. The extent of the impact on employment will vary 
depending on the severity of the impairment, and the extent to which the injured individual’s form of 
employment (or skill set and aptitudes) are amenable to modification to adjust for the impairment. Estimates 
presented by BITRE suggest that the reduction in employment probability ranges from 95 percent for those 
with profound limitations to a 30 percent reduction in the probability of employment for those with mild 
limitations (Bureau of Infrastructure Transport and Regional Economics, 2019).  
 
Data on the estimated age at the point of injury, expected years of working life for that age group and gender, 
and the estimated reduction in the probability of employment were used to develop estimates of the 
(discounted) years of working life lost due to impairment resulting from opioid attributable road crashes. The 
central estimate was a (discounted) loss of 1,293 years of expected working life (low bound 451, high bound 
1,726). Using the same approach as in the premature mortality calculations, each discounted year of working 
life lost was valued at $139,697, giving a total impact of years of life lost to impairment of $180.6 million (low 
bound $63.1 million, high bound $241.1 million). 
 
Permanent impairment also reduces the potential for individuals to contribute to unpaid household labour. It 
was assumed that the impact of impairment on the ability to contribute (unadjusted for labour force status) 
was used as the basis for the calculation, giving an estimated (discounted) number of years of household 
labour lost due to opioid attributable impairment of 1,297 (low bound 453, high bound 1,731). This was valued 
following the same approach as was used for the premature mortality calculation, valuing each year of 
household chores at $19,685 for males and $35,146 for females. Applying this to the estimated (discounted) 
number of years of chores lost gives an estimated cost of $30.9 million (low bound $10.8 million, high bound 
$41.2 million). 
 
As shown in Table 8.5, the central estimate for the lifetime care costs approach for estimating the long-term 
costs arising from opioid attributable road crashes is $450.6 million (low bound $192.3 million, high bound 
$731.3 million).  
 
Table 8.5: Estimated total long-term costs, lifetime care approach 





Equipment costs 7.2 4.3 12.3 
On-going support worker costs 217.5 107.1 409.6 
On-going medical costs  14.4 7.1 27.1 
Lost economic output from reduced employment 180.6 63.1 241.1 
Lost value of household labour 30.9 10.8 41.2 
Total  450.6 192.3 731.3 
 
Central estimate of long-term costs 
The compensation paid approach gives a low bound estimate of these costs of $207.2 million (the central 
estimate of that approach). The calculation approach based on the disaggregated lifetime are costs gives an 
upper bound of $450.6 million (the central estimate of that approach). Taking the mean of the two approaches 
gives a central estimate of long-term care costs of $328.9 million. 




Opioid use has a small, but meaningful impact on road crash risk. The evidence is strongest for opioid 
dependence, which is estimated to cause around 3.7 percent of road crashes (low bound 1.8%, high bound 
7.0%). There is evidence that opioid use by persons who are not dependent also increase road crash risks, 
in which case these are underestimated, however at this point in time the evidence is insufficient to justify 
the inclusion of opioid use more broadly. 
 
The costs arising from premature deaths, and hospital separations, from road crashes attributable to opioid 
dependence are set out in Chapters 3 and 4 respectively. The other costs of opioid attributable road crashes 
are estimated to have cost society $480.6 million in 2015/16 (low bound $270.3 million, high bound $692.0 
million). The most significant contribution to these costs comes from the long-term costs of impairment 
resulting from road crashes ($328.9 million) followed by the cost of property damage $122.2 million (Table 
8.6). 
 
Table 8.6: Opioid attributable road crash cost summary 





Premature mortality a a a 
Hospital separations b b b 
Costs of property damage 122,230,669 50,847,847 194,416,161 
Costs of insurance administration and legal costs 27,053,502 11,254,232 43,030,428 
Costs of workplace disruption 2,429,842 1,010,812 3,864,829 
Long-term costs (average of approaches) 328,910,711 207,181,126 450,640,296 
Total road crash costs not included elsewhere 480,624,725 270,294,018 691,951,715 
a Estimated in Chapter 3: b Estimated in Chapter 4. 
Note: In the text we also report the low and high bound estimates associated with the items that contribute to the long-term estimate. 
These are not included in Table 8.5 
 
8.5 Limitations 
Due to data limitations the impact of extra-medical opioid use on road crash risk was calculated based on a 
meta-analysis of the excess rate of road crashes amongst persons dependent on extra-medical opioids 
(Larney et al., 2019). Ideally the analysis would instead make use of RR for road crash accidents (either for 
persons dependent on opioids or persons who had consumed extra-medical opioids prior to driving) and 
population specific data on the prevalence of driving amongst persons depending on opioids or persons who 
had recently used extra-medical opioids. 
 
There is also a significant data limitation with respect to the impact on road crash risk of those who consume 
extra-medical opioids, but who are not dependent on them, as the sample sizes of persons testing positive 
to metabolites of opioids in road crash studies to date have been too small to make statistically significant 
conclusions as to whether road crash risks are higher. For example, Drummer and colleagues (2003b) had 
only 59 cases in their sample of culpable drivers who tested positive to opioids and did not test positive to 
another substance of interest. As such, although they found an odds ratio of 1.41 for drivers who tested 
positive to opioids only, the confidence interval for this estimate was 0.7 to 2.9 and it is not possible to say 
with confidence given the small sample size whether there was a genuine increase in risk or whether it was 
random variation in the sample. 
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CHAPTER 9: TENTATIVE ESTIMATE OF HARMS TO RESIDENT OTHERS 
Robert J. Tait & Steve Whetton 
 
9.1 Background 
Depending on the perspective that they adopt, social cost studies can include costs incurred by anyone 
affected by another person’s actions, such as substance use. While there is growing research on the 
harms to other people from alcohol use (Callinan et al., 2016; Laslett et al., 2011; Nayak et al., 2019), 
there has been less research on the impacts of illicit drugs. Affected family members, especially parents, 
partners and children living with a person with extra-medical opioid dependence may experience 
intangible costs through reduced quality of life and may also incur tangible costs. Many of the issues 
impacting quality of life can be similar across different drug use disorders and may include: violence; 
emotional abuse; impaired mental wellbeing; increased ill-health; diminished family relationships; and, 
alienation from friends and the wider community (Orford, 2015; Orford et al., 2013). There may also be 
costs through lost wages in caring for the person with drug dependence and, in some cases theft from 
the household. Among those with illicit drug use disorders, there are also potential family concerns about 
criminal activity and exposure to criminal networks and legal repercussions.  
 
While drug use disorders per se are not causal or always predictive of child neglect, (influenced, for 
example, by quality of care), drug use disorders and dependence are associated with increased risk of 
neglect and abuse after controlling for other social and demographic characteristics, with the potential for 
long-term consequences (Chaffin et al., 1996; Leijdesdorff et al., 2017). In 2007, the cost of child abuse 
and neglect in Australia was estimated range from $10.7 billion to $30.1 billion, with the incident cost of 
those first abused in 2007 for their lifetime being $13.7 billion to $38.7 billion (Taylor et al., 2008). While 
the experience of children living with a substance using parent has similarities to those of an adult in 
terms of increased risk of distress and mental and physical health consequences, there may be further 
unique harms in terms of hurt, shame and embarrassment, early caring responsibilities, and in more 
severe cases, through family break-down (Arria et al., 2012; Orford, 2015). Child protection system costs 
are explored in chapter 11, with this chapter focussed on intangible costs. 
 
As previously reported, the attempt to quantify the harms and costs to other people from illicit drug use 
are still in their formative stage, and there do not yet appear to be an agreed set of parameters to be used 
in their estimation (Whetton et al., 2016). Further, even determining the number of partners, other adults 
or children living with a person dependent on illicit drugs is subject to considerable uncertainly, without 
considering the broader range of people affected outside the household (Whetton et al., 2016). Finally, 
some of the intangible costs to those resident with a person who is dependent on opioids may be included 
in other cost calculations in this report, such as the estimated intangible cost to victims of crime. This 
creates the potential for a degree of double counting if harms to others are included in the core cost 
calculations. 
 
9.2 Number of people resident with a person dependent on extra medical opioids 
The best estimate of the number of persons dependent on illicit opioids in Australia is provided in the 
GBD study (Global Burden of Disease Collaborative Network, 2018) with a central estimate of 104,026 
and range of 89,484 to 120,196. These latter figures were used in calculating the low and high bound 
costs. However, these data do not include information on the household of the person dependent on 
opioids. The NDSHS (Australian Institute of Health and Welfare, 2017i) does include data on the 
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household situation of its respondents, including resident dependent children, but does not directly 
capture the number of persons dependent on opioids. What it does collect is the frequency of use, which 
we used as a proxy measure for dependence. Whilst using opioids ‘daily’ or ‘at least weekly’ is not the 
same as dependence, the two populations overlap substantially, but notably the estimate of frequent use 
is almost twice as high as the GBD estimate of persons who are dependent on opioids (see Section 
2.4.1). Therefore, in assessing the number of children and other residents living with a person who was 
dependent on opioids, we had to draw on the NDSHS data for estimates of household structure, but the 
estimated population of persons who are dependent on opioids is from the GBD. 
 
We used these two datasets to estimate the number of persons living with an individual who was 
dependent on opioids in a two-stage process. First, ten-year age-group and gender specific estimates of 
the average number of dependent children36, the average number of resident partners, and the average 
total number of persons resident with a person who uses extra-medical opioids ‘at least weekly’ were 
calculated from the NDSHS. These ‘per person who uses extra-medical opioids frequently’ averages 
were then applied to the gender and ten-year age-group estimates of the total number of persons 
dependent on opioids from the GBD. The number of children resident may be underestimated using this 
approach as the NDSHS records the number of children as 0, 1, 2, or 3+; we coded the latter category 
as 3 children. 
 
These estimated numbers of co-residents are shown in Table 9.1. Based on the central estimate of the 
number of persons who are dependent on opioids, we estimate that there are about 70,000 children, 
41,000 partners and 160,000 others who are living with a person dependent on opioids.  
 
Table 9.1: Estimated number of persons co-resident with a person who is dependent on opioids 
Estimate of persons dependent on opioids Dependent children Partners Other co-residents 
Central estimate 69,969 41,274 160,166 
Low bound 53,956 31,742 122,953 
High bound 88,435 52,488 203,182 
 
9.3 Quantifying the impact on household members 
While it is generally agreed that there are potentially substantial impacts from living with a substance 
dependent person, there is less consensus on how to quantify those harms and costs. One method is to 
assess the reduced quality of life in that situation either as Disability Adjusted Life Years (DALY) or Quality 
Adjusted Life Years (QALY). On the surface, these two measures appear to be the inverse of one another, 
with DALY measuring the number of healthy years of life lost due to disability (e.g. with a year of perfect 
health having a DALY of 0, while a year with a condition that reduces the quality of life by 20% having a 
DALY of 0.2). In comparison, QALY is used to measure the quality adjusted life years lived (e.g. one year 
of perfect health has a QALY of 1, while a year lived with a condition that reduces the quality of life by 
20% has a QALY of 0.8). However, even though they are attempting to measure the same concept, the 
assumptions underpinning their calculation means that they are likely to arrive at different estimates of 
the impact on quality of life. In the current study we followed the GBD approach and opted to use DALY 
(e.g. (World Health Organization, 2016)).  
 
                                                     
36 The NDSHS questionnaire defines dependent children as: “children aged 0 – 14, or older children who are still financially 
dependent, such as full-time students” (Australian Institute of Health and Welfare, 2017h, p3) 
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Estimates have been made of the DALY lost due to substance use disorders, but we are not aware of 
any specific estimates of the quality of life impact on partners or dependent children. The best estimate 
of the DALY by a person dependent on extra-medical opioids is 0.641 (0.459-0.803): this is then adjusted 
to account for asymptomatic dependence, to give a value of 0.501 (0.330-0.689) (Degenhardt et al., 
2013b). A review of the benefits gained from the treatment of alcohol disorders suggests that the benefits 
for family members are of a similar magnitude to the gains for the treated individual (Mortimer and Segal, 
2006). However, an alternative estimate reported that the impact on a co-resident adult from the 
successful treatment of another’s alcohol disorder was 0.108 QALY gained (Salize et al., 2013). An 
approximate conversion formula for QALY to DALY (Sassi 2006), gives a value of 0.154 DALY for a 35-
year-old family member, which is approximately half the DALY arising from moderate alcohol dependence 
(0.388 DALY). Therefore, we constructed a low and high range of the quality of life impact for a co-
resident of a person with extra-medical opioid dependence with values of 0.251 – 0.501 DALY. 
 
9.4 Intangible costs to family members 
Having estimated the number of DALY lost by co-residents, these then need to be monetarised: a process 
that is subject to critical debate (Baker et al., 2010; Dolan, 2010; Donaldson et al., 2011; Miller and 
Hendrie, 2011). In some cases, the value of a year lived with disability has just been equated to the value 
of a statistical life year (e.g. Moore (2007), Nicosia et al., (2009)) an approach that has also been 
recommened for use in governmental cost-benefit analyses (Abelson, 2008). In calculating the value of 
a statistical life year (VoSLY), the same approach is used as in calculating the annual payment for an 
annuity of a given value and is based on the expected average years of life for the individual (typically 40 
years). The formula used is, 
𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉t=1 = 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 ×
(1 − (1 + 𝑔𝑔)/(1 + 𝑟𝑟))




VoSL = estimated value of a statistical life 
g = annual escalation factor for VoSLY, typically the long-run real growth rate in per capita GDP 
r = the discount rate being used, in Australian studies this is usually a real annual rate of 7% 
years = assumed average years of life remaining at the time of the study for the sample used to 
derive the VoSL estimate. 
 
However, this simple approach has been criticised in that the value of a life-year varies depending on 
many factors including: age; health state; expected years of life remaining; the ability to pay; and, the 
person’s preference on the distribution of resources over their lifetime (Baker et al., 2010; Dolan, 2010; 
Donaldson et al., 2011). It is also not clear if the prospective expressed willingness to accept less years 
of life to avoid a particular health condition is accurate given the degree of adaption shown by those 
people with the health condition (Dolan, 2010). 
 
An alternative approach to the estimation of DALY is via specific studies on the preferences of the 
population of interest. The disadvantages of this approach is that preference studies are costly and time 
consuming to conduct and they may result in ‘bespoke’ values largely driven by variations in the sample 
selected rather than the ‘true’ value of averting death or ill health. Therefore, we adopted an estimate 
based on the VoSLY. 
 
As detailed in Section 3.7, our preferred value for a statistical life in 2015/16 was $4.6 million (Abelson, 
2008). From this we calculated the value of a single year of life and hence a VoSLY in 2015/16 of 
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$286,553. Plausible bounds were then placed around that value using the implicit threshold value per 
DALY from PBS approvals of $45,000 as the low bound (Community Affairs References Committee, 
2015; Harris et al., 2008). We then calculated the high bound using the VoSLY derived from the value of 
a statistical life used by the US Department of Transport (2015) which equated to $841,393. 
 
As the exact relationship between the other persons co-resident with the person dependent on opioids is 
likely to impact on the extent to which their quality of life is reduced (for example, parents would arguably 
be more affected than house mates), and as the nature of this relationship cannot be identified from the 
NDSHS data, we have excluded the other co-residents from our preferred estimate. These costs, using 
the low DALY value are included in Table 9.2 for completeness but not added to the estimated cost. 
 







Abelson (2008) VoSLY 
($) 
Low bound 
Implicit PBS value of 
VoSLY($) 
High Bound 
US DoT value of VoSLY 
($) 
  286,553 45,000 841,393 
Resident Children Low DALY 5,022,497,842 788,728,099 14,747,340,027 
 High DALY 10,044,995,684 1,577,456,198 29,494,680,054 
 Mean 7,533,746,763 1,183,092,148 22,121,010,040 
Resident partners Low DALY 2,962,687,644 465,257,540 8,699,209,726 
 High DALY 5,925,375,287 930,515,081 17,398,419,452 
 Mean 4,444,031,466 697,886,311 13,048,814,589 
Total cost partners 
and children Sum of means 11,977,778,228 1,880,978,459 35,169,824,629 
Other persons 
resident Low DALY 14,459,636,577  2,270,727,042  42,457,196,396  
Total cost including 
other co-residents  26,437,414,805  4,151,705,501  77,627,021,025  
GBD = Global Burden of Disease: NDSHS = National Drug Strategy Household Survey: VoSLY = value of statistical life year 
 
Our estimate of the lost quality of life for dependent children and partners resident with a person 
dependent on extra-medical opioids, was the sum of the two central values, $12.0 billion with a range of 
$1.9 billion to $35.2 billion. 
 
9.5 Conclusions 
There is growing interest in the impacts of substance use on others, although to date the literature is 
dominated by investigation of the harms arising from involuntary tobacco smoking (US Department of 
Health and Human Services, 2006) and alcohol use by others (Callinan et al., 2016; Laslett et al., 2011; 
Nayak et al., 2019). In relation to methamphetamine, there has been an estimate of one aspect of harms 
to others, with the cost of child maltreatment and foster care being quantified at USD 904.6 million in 
2005 (Nicosia et al., 2009). We are not aware of previous attempts to estimate the cost of these harms 
for extra-medical opioid use. Therefore, although these costs have been estimated, we have not included 
them in the overall total attributed to extra-medical opioid dependence. 
 
Although we were unable to provide separate estimates of the extent of quality of life lost by parents and 
other adults resident with a person dependent on opioids, we provided an estimate for the number of 
children and partners likely to be impacted. In particular, it should be noted that more than one-third of 
the co-resident people were children, a group where the harms would be expected to be the most 
121 Chapter 9: Harms to others 
substantial and persistent. We estimated that between 54,000 and 88,000 dependent 37 children are 
living with a parent or guardian who is dependent on extra-medical opioids: there may be further children 
living with an adult who is dependent on opioids but who are not financially dependent on that adult. A 
further 32,000 to 52,000 people were partners of the person with extra-medical opioid dependence, who 
could be expected to have greater lost quality of life than other adults in the household. 
 
9.6 Limitations 
In estimating the DALY lost, we assumed that children and partners would suffer the same level of lost 
quality of life, and given the formative stage of the field further adjustment for potential differences 
seemed unwarranted. Also given the formative stage of research, we have provided an initial estimate of 
harms to other resident adults, but not included this in the total. We note that we were not able to identify 
any studies that directly estimated the DALY lost as a result of living with a person dependent on a 
substance; instead we drew on studies that estimated the quality of life impact relative to the DALY lost 
for the substance using person themselves. It is also possible that some of the DALY lost through residing 
with a person dependent on a substance is captured in other costs reported in this study, such as the 
intangible costs to victims of crime. 
 
We were unable to quantify the tangible costs of living with someone dependent on extra-medical opioids, 
for example, theft from the household. In addition, from the literature, informal care makes a substantial 
contribution to health care and hence savings to health budgets (Deloitte Access Economics, 2015; Saka 
et al., 2009). The value of informal care is estimated in Section 5.11, however this relates to informal care 
provided for impairment resulting from an illness or disability attributable to extra-medical opioids, rather 
than care provided for the acute and chronic impacts of opioid use itself. 
 
As noted above, as no information on the household structure of persons dependent on opioids was 
available from the GBD study, we used data on the household structure of those persons who used 
opioids frequently (‘at least weekly’) as a proxy. This rests on the assumption that the characteristics of 
the two populations, once controlled for age and gender, are similar. If the household characteristics of 
those who have been classified as dependent in the GDB data differ systematically from those of the 
most frequent users of opioids in the NDSHS then our estimates of affected partners and dependent 
children will be biased. Whether this would lead to a lower or a higher estimate is not known.  
 
Finally, if opioid dependent persons tend to cohabit with other opioid dependent persons, rather than 
individuals who do not use drugs, the estimate of the number of DALY lost may be inaccurate. We were 
unable to determine if this would be likely to increase or decrease the DALY lost. 
 
                                                     
37 Note the survey asks “Are there any dependent children in this household? (Dependent children are defined as children 
aged 0 – 14, or older children who are still financially dependent, such as full-time students)” This refers to financial rather 
than clinical dependence. 
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CHAPTER 10: INTERNALITIES 
Steve Whetton & Robert J. Tait 
 
10.1 Background 
As previously noted in Section 2.2.1, the estimation of the cost of harms in social cost studies does not 
typically include the harms arising to the consumer. This is predicated on the assumption that any harms 
from consumption will be factored into the purchasing decision along with the purchase price, so that the 
overall benefits outweigh the overall costs (and harms) of consumption(Becker and Murphy, 1988).  
 
This model of rational consumption appears to be less well suited to the explanation of the consumption 
of substances with dependence potential, or more specifically in people who are identified as severely 
dependent on a substance (US National Cancer Institute and World Health Organization, 2016). In 
addition, the fact that the ‘benefits’ of consumption are likely to be immediate and the harms potentially 
distant, undermines the plausibility that the consumer with a substance dependence is maximising their 
lifetime utility at their current level of consumption (Angeletos et al., 2001; Gruber and Köszegi, 2001; 
Laibson, 2001; Akerlof, 1991; Suranovic et al., 1999).  
 
On this basis it is justifiable to include the consumption costs from drug dependence within public policy 
responses to reduce consumption to its ‘optimal’ level, whether by decreasing availability, increasing 
price, or providing information to people who use and to those who will potentially use in the future. As 
the costs to a person with substance dependence are not strictly social costs, they are often termed 
“internalities” or “private costs” – these represent the sum of costs that were not factored into the original 
consumption decision. In some analyses, for example the Productivity Commission’s inquiry into the 
social costs of gambling, an attempt is made to assess what level of consumption and associated harms 
would occur if these consumers were not dependent (Productivity Commission, 1991). In other analyses, 
all costs borne by people who are dependent are treated as internalities. The costs of drug use arising to 
those who are classified as non-dependent are excluded from the internalities estimate, as it is less 
certain that these people depart from the assumptions underpinning the rational model.  
 
It is unclear precisely what negative impacts underpin the evaluation of DALY lost by people with drug 
dependence (see, for example, (Degenhardt et al., 2013c; Pyne et al., 2008)) so we cannot be certain 
that any harms that occur to the consumer and captured as internalities are excluded from DALY. 
Therefore, we adopted a conservative approach and recommend the use of either the quality of life 
impact or the estimated internalities, plus the expenditure by people who are dependent on extra-medical 
opioids. However, we acknowledge that the use of a single approach may underestimate the true extent 
of the internalities. 
 
In the current study, we decided that all costs to who are dependent were potentially in-scope as 
internalities and we preferred to assess these via the quality of life impact plus the cost of extra-medical 
opioid purchases. 
 
10.2 Estimated quality of life impact of dependent extra-medical opioid use 
The quality of life lost from dependence on extra-medical opioids can be quantified via the DALY lost. As 
noted earlier, DALY assess the departure from a year in full health, such that a condition with a DALY of 
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0.2 equates to an average person with that condition having a quality of life equal to 80% of a person in 
full health.  
 
The GBD provides the best available estimate of the DALY lost from opioid dependence at 0.641 
(Degenhardt et al., 2013b; Degenhardt et al., 2013c). However, in recognition that the level of severity is 
likely to vary over the course of a year, we adjusted this value down by 16 percent as recommended by 
the GBD to reflect these periods of reduced severity, giving a final adjusted estimate of 0.501 DALY 
(Degenhardt et al., 2013b; Degenhardt et al., 2013c). Given the use of GBD data elsewhere in this 
analysis, the DALY estimate was our selected measure of reduced quality of life.  
 
Applying the adjusted DALY of 0.501 to the estimated 104,026 people dependent on extra-medical 
opioids in 2015/16 (Global Burden of Disease Collaborative Network, 2018), gives an estimate of years 
of life lost to disability (YLD) due to extra-medical opioid dependence of 52,117 (see Table 10.1). 
 
Table 10.1: Estimated total years of life lost to disability due to extra-medical opioid dependence, 
2015/16 
Basis for estimate YLD 
Based on Degenhardt estimate of a lost DALY of 0.501 for dependent extra-medical opioid 
use and dependent cases = 104,026 52,117 
Sources: (Degenhardt et al., 2013b; Degenhardt et al., 2013c; Global Burden of Disease Collaborative Network, 2018) 
 
In monetising the YLD, we repeated the methods and used the same assumptions as described in 
Section 9.4. Our central cost estimate was based on the VoSL (Abelson, 2008) that we converted from 
the 2007 values to 2015/16 values using the change in the average nominal national per capita income 
over that period. The rate at which a value of statistical life should increase over time as national incomes 
increase is determined by the income elasticity of demand for reductions in the risk of premature death, 
with the elasticity representing the proportionate increase in the VoSL for a given increase in per capita 
incomes. For example, an income elasticity of 0.5 implies that for a 1% increase in per capita income, 
the VoSL would increase by 0.5%. These income elasticities have been variously estimated at 0.5 to 0.6 
(Viscusi and Aldy, 2003), 1.32 (with a range from 1.16 to 2.06) (Kniesner et al., 2010)) and 1.5 to 1.6 
(Costa and Kahn, 2004). We followed the US Department of Transportation (US Department of 
Transportation, 2015) in adopting a relatively conservative assumption of an income elasticity of 1 38, 
slightly below the average of the three studies which was 1.16. 
 
This gave a 2015/16 value of a statistical life of $4.6 million. This figure was then annualised to give the 
VoSLY at $286,553 and hence the value for each DALY lost. As before, we estimated plausible low and 
high bounds per DALY lost from the implied threshold value used for PBS approval of $45,000 
(Community Affairs References Committee, 2015; Harris et al., 2008) and the VoSLY derived from the 
annualised value of the VoSL used by the US Department of Transport (2015), which equated to 
$841,393. 
 
These values were then applied to the estimated YLD due to extra-medical opioid dependence (Table 
10.2). Our central estimate based on the value calculated using the Abelson (2008) VoLSY was, $14.9 
billion. 
 
                                                     
38 This is likely to be an underestimate, as empirical analysis suggests that on average people are risk averse (and in particular 
loss averse) which would imply a price elasticity of averting loss of >1 (Kniesner et al., 2010) 
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Table 10.2: Estimated cost of DALY lost due to the quality of life impact of extra-medical opioid 
dependence, 2015/16 
Basis of VoSLY estimate Abelson 2008 ($) 




Based on Degenhardt estimate of a lost DALY for 
extra-medical opioid dependence (0.501) 14,934,290,151 2,345,266,170 43,850,900,857 
Source: (Degenhardt et al., 2013b; Degenhardt et al., 2013c): US DoT = United States Department of Transport 
 
10.3 Cost of heroin and other extra-medical opioids 
As noted in Section 2.2.1, in the current study we are only considering internalities for those who are 
dependent on extra-medical opioids, defined as the 104,026 cases enumerated via the GBD tool (Global 
Burden of Disease Collaborative Network, 2018). The cost of heroin was obtained from the IDRS surveys. 
The estimated average national price for a gram of heroin was $300 in 2015 and $350 in 2016, with the 
median amount used being 0.5 g per day of use (Stafford and Breen, 2016). The median days of use 
was 75 out of the last 180 days, or 41.7 percent of days. Combining this information for the 104,026 
people who were dependent, equates to 0.076 kg per person per year (at a cost of $24,700) or 7,922 kg 
overall for the dependent cohort, with an estimated overall cost of $2.6 billion. We used this as our high 
bound estimate (Table 10.3). 
 
By way of comparison, the National Waste Water Monitoring Program estimated that in 2016/17 about 
765kg of heroin was consumed in Australia (Australian Criminal Intelligence Commission, 2018) 39. At an 
average cost of $325 per gram (Stafford and Breen, 2016) that equates to $248.6 million. It has been 
estimated that those dependent on heroin consume 85% of the total heroin used in Australia (Moore, 
2007), so this total was reduced by 15 percent to account for use by non-dependent persons. We used 
this ($211.3 million) as the low bound estimate with the mean of the two values our central estimate, $1.4 
billion.  
 
In relation to other opioids, although the IDRS reports typical prices for pharmaceutical opioids obtained 
through ‘illicit’ purchases (e.g. methadone $1 per 1 ml; buprenorphine $25 per 8 mg tablet: 
buprenorphine-naloxone $20 per 8 mg ‘film’: generic oxycodone $50 per 80 mg tablet) (Stafford and 
Breen, 2016), typical frequency and quantity consumed are not reported. However, median days of use 
(in the last 180 days) was reported. For illicit methadone liquid, the median was 5.5 days out of 180 days, 
for illicit buprenorphine it was 7 days, for buprenorphine-naloxone, 11 days, and for oxycodone it was 7 
days. Based on a single 8mg dose per occasion, this corresponds to $350 per illicit buprenorphine using 
individual per year and $440 per person using illicit buprenorphine-naloxone per year. Based on a single 
80mg tablet of oxycodone the cost would be $700 per year. The volume of methadone used was not 
reported so no estimate of the cost has been made. 
 
Among those we defined as dependent (e.g. frequency of use reported as ‘daily + once a week or more’) 
on extra-medical opioids in the NDSHS there were 175,787 (92.3%) people who we defined as dependent 
on other opioids (but not on heroin) and 14,739 (7.7%) who we defined as dependent on heroin ± other 
opioid dependence. If the same ratio applied to the GBD (n = 104,026), there would be 96,016 dependent 
on other opioids and 8,010 dependent on heroin ± other opioid dependence. 
 
                                                     
39 Test results for heroin were first included in the November 2017 report: the cited report is the first to include an estimate of 
the total heroin consumed. 
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If all those dependent on other opioids (96,016) used just buprenorphine, the annual cost would be $33.6 
million and if all used oxycodone the cost would be $67.2 million. In addition, we note that if this method 
is applied to the cost of heroin, then if the 8,100 people dependent on heroin ± other opioid dependence 
consumed the average amount of heroin (0.076 kg at $24,700 per person per year), expenditure on 
heroin would equate to $200.1 million, a value that is close to that obtained via the waste water estimate. 
 
Although waste water analysis collects and reports data on oxycodone and fentanyl, no estimate is made 
of the proportion that is used extra-medically compared with as prescribed. Thus, this information cannot 
be used in estimating the amount and cost of this aspect of extra-medical use (Australian Criminal 
Intelligence Commission, 2018). 
 
Table 10.3: Extra-medical opioid purchases by those with dependence 
Opioid class Central estimate ($) 
Low bound estimate 
($) 
High bound estimate 
($) 
Heroin  1,393,000,541   211,331,250  2,574,669,832  
Other opioid  50,408,400  33,605,600  67,211,200  
Total 1,443,408,941  244,936,850  2,641,881,032  
 
10.4 Conclusions 
Internal costs are seldom included in social cost studies, even for those investigating substances with 
potential for problematic use. In reviewing the literature on social cost studies for extra-medical opioids, 
we only identified two studies that included the cost of drug purchases (Jiang et al., 2017; Lin et al., 2013) 
and one that included the intangible costs of premature mortality (Council of Economic Advisers, 2017). 
No study included an estimate of the intangible costs of dependence. However, as discussed previously, 
in the case of people who are dependent on a drug, the notion of fully rational consumption decisions are 
undermined. On this basis we decided to estimate and report these internal costs, but not include them 
in the overall figure attributed to extra-medical opioid dependence. Our estimate of the overall internal 
costs arising from drug purchases and the reduced quality of life for persons dependent on extra-medical 
opioids was $16.4 billion (Table 10.4). 
 
Table 10.4: Summary of internalities 
Component Central estimate ($) 
Low bound estimate 
($) 
High bound estimate 
($) 
Value of DALY lost 14,934,290,151 2,345,266,170 43,850,900,857 
Extra-medical opioid purchases 1,443,408,941 244,936,850 2,641,881,032 
Total 16,377,699,092  2,590,203,020 46,492,781,889 
 
10.5 Limitations 
In estimating the costs of purchasing heroin, the initial estimate was based on all those meeting the 
criteria for opioid dependence being people who primarily used heroin. When the population was divided 
into the components reported in the NDSHS, the large majority used opioids excluding heroin, with only 
7.7 percent defined as dependent on heroin ± other opioid dependence. In this situation, the cost for 
heroin purchases was dramatically reduced and the approximate concordance of this estimate with that 
based on wastewater analysis, suggests that this approach provides a better estimate of the true cost of 
heroin purchases.  
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There were limited data on the cost, amount consumed and the frequency of use of non-heroin opioid 
drugs. Our estimates are also likely to include some ‘double counting’ where purchases are of 
pharmaceuticals included in the PBS. Therefore, the costs assigned here are speculative. We also note 
that the source document (Stafford and Breen, 2016) emphasises the limited sample reporting on the 
price of illicit buprenorphine and combined buprenorphine-naloxone and the need to interpret these 
values with caution. The IDRS also collects data on other opioids. Medium days of use of oxycodone was 
reported as the combined values for licit and illicit oxycodone. The cost of licit oxycodone purchases will 
also be included in the high bound estimate of pharmaceuticals, meaning that any ‘licit purchases’ of this 
drug will be double counted. Costs for illicit fentanyl and other opioids (including at the time available 
over-the–counter codeine products) were not reported (Stafford and Breen, 2016). Therefore, we were 
unable to estimate the cost of purchasing these other forms of opioids. However, any pharmaceutical 
opioids that were obtained by “doctor shopping” and then bought at a pharmacy, will be included in the 
high bound estimate of PBS medications. 
 
The GBD study provides a disability weight for ‘opioid dependence’ (Degenhardt et al., 2013b) and in 
estimating the intangible costs of extra-medical opioid dependence, we have assumed that the DALY lost 
are the same whether this involves heroin or other forms of opioids. In addition, we assumed that the 
ratio of people dependent on heroin compared with other forms of opioids was the same in the NDSHS 
and GBD data. Any deviation from our assumption that the ratios were the same could markedly impact 
on the estimated cost of drug purchases. 
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CHAPTER 11: MISCELLANEOUS COSTS 
Steve Whetton, Robert J. Tait & Steve Allsop 
 
11.1 Child maltreatment and protection 
11.1.1 Background 
In estimating the social cost in the USA of methamphetamine use, methamphetamine-related child 
endangerment emerged as one of the major components, accounting for USD 904.6 million, the third 
largest area (Nicosia et al., 2009). Further, infants and children exposed to a neglectful upbringing have 
ongoing impaired quality of life (Nicosia et al., 2009). Research commissioned by the US Department of 
Health and Human Service suggested that there is a robust correlation between changes in extra-medical 
opioid use at a county level (as measured by opioid-related hospital separations) and changes in child 
protection substantiation; with a 10 percent increase in hospitalisations associated with a 2.1 percent 
increase in substantiations, a similar order of magnitude impact to that found for stimulants such as 
methamphetamine (Ghertner et al., 2018). In Australia, it has been calculated that child maltreatment 
contributes 1.4 percent of all DALY lost by males and 2.4 percent lost for females when just considering 
key mental health conditions (depression, anxiety and self-harm) (Moore et al., 2015). However, there is 
only limited evidence of the specific contribution of extra-medical opioid use to adverse child outcomes 
in Australia. 
 
The costs associated with premature death and hospital episodes are addressed in Chapters 3 and 4 
with reduced quality of life reported in Chapter 9. The cost of child protection represents a discrete 
component of childhood neglect that can be evaluated. Although, there are marked variations in the legal 
definitions and the child protection systems across Australia, there remain similarities in the stages 
between initial notification to child protection and outcomes such as court orders (Bromfield and Higgins, 
2005). However, in estimating these costs, it is important to recognise the multifactorial nature of the 
cases: removal of a single factor, such as drug use, would not necessarily prevent the death or harm of 
an individual child (Field, 2016).  
 
11.1.2 Number of child protection cases 
In Australia, there are limited public data available on the underlying cause(s) for substantiated protection 
cases beyond the broad categories of “physical”, “sexual”, “emotional” and “neglect” categories 
(Australian Institute of Health and Welfare, 2016b). However, an analysis of cases in Victoria over the 
period 2001-2005 reported that, substantiated cases represented 20.5 percent (n=38,511) of the 188,063 
notifications to child protection. Of these, 35.3 percent (n=13,579) had a parental history of “substance 
abuse”, comprising 15.9 percent (n=6,119) drug use only and 19.4 percent (n=7462) with alcohol and 
drug use (Laslett et al., 2013).  
 
Nationally, in 2015/16 there were 45,714 children (aged 0-17 years) with substantiated cases (Steering 
Committee for the Review of Government Service Provision, 2017b). Applying the above proportions 
(15.9% and 19.4%) to the substantiated 2015/16 cases resulted in 7,269 “drug use” cases and 8,869 
“drug and alcohol” cases for the period. To attribute a proportion of these cases to extra-medical opioid 
use, we used the proportion of people receiving treatment for opioid use (Australian Institute of Health 
and Welfare, 2017d). For heroin use, there were 11,003 episodes of care where it was the primary drug 
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of concern, with a further 4,801 episodes where it was an additional drug of concern. For other opioids 40 
the respective figures were 7,499 and 7,462 episodes of care (Australian Institute of Health and Welfare, 
2017d). In total, there were 18,502 extra-medical opioid cases as the primary drug of concern and 12,263 
episodes as an additional drug of concern. Of the total episodes of care for their own drug use (198,747) 
in 2015/16, 9.3 percent were primarily for extra-medical opioid use: of the 153,271 episodes that involved 
additional drugs of concern, 8.0 percent involved opioids. On this basis we allocated 676.7 instances of 
the substantiated “drug use only” cases to extra-medical opioid use and 709.6 instances of the “drugs 
and alcohol” substantiated cases. From the total of 45,714 substantiated cases, extra-medical opioid use 
was projected to account for 1,386 (3.03%) instances.  
 
An alternative estimate of the role of extra-medical opioid use in child protection cases can be derived 
from a detailed review of 467 cases representing children’s first entry into care in South Australia (Jeffreys 
et al., 2009). The study’s findings suggest that about 70.2 percent (n=328) involved parental substance 
use. A detailed case series of 99 randomly selected out of the original sample revealed that 75 (75.8%) 
involved substance use, with 12.0 percent primarily involving heroin and 2.7 percent primarily involving 
methadone (n = 11 cases). There were also 10.7 percent involving pharmaceutical drugs. From national 
treatment data (Australian Institute of Health and Welfare, 2017d), opioid drugs make up 73 percent of 
the episodes where pharmaceutical drugs are the principal drug of concern. On this basis we allocated a 
further 6 cases due to pharmaceutical opioids, with 17 cases overall.  
 
The case review identified all factors mentioned in the case file as having contributed to the decision to 
place the child in care for both those with and without substance use factors (Jeffreys et al., 2009). No 
weighting or precedence of the factors could be identified. If it is assumed that each of the factors 
contributed an equal weight to the decision to take the child into care, and that none of the factors were 
caused by another factor 41, then the share of total factors can be used to identify the role of extra-medical 
opioids in care decisions. 
 
Weighted up to the whole sample, there were an estimated 74 cases in which extra-medical opioid use 
was one of the factors contributing to the removal of a child into care for the first time, out of a total of 
2,285.4 factors identified in the case review. Thus, extra-medical opioid use accounted for 3.2 percent of 
all factors identified in the care decision (see Table 11.1 below). On the assumption that each factor in 
the decision carried an equal weight, this suggests that 3.2 percent of the decisions to take a child into 
care could be attributed to extra-medical opioid use. 
 
11.1.3 Child protection costs 
In 2015/16, the total cost of child protection services in Australia was $4.8 billion (Steering Committee for 
the Review of Government Service Provision, 2017b). Using the substance use treatment data to allocate 
a share of “drug use only” and “drug and alcohol” substantiated cases to extra-medical opioid use (3.03%) 
equates to $144.3 million. The alternative approach of identifying extra-medical opioid’s total share of 
factors identified in the South Australian case review suggested an extra-medical opioid share of 3.2 
percent or $153.7 million. For the purpose of this report, we use the mid-point as our main estimate: 
$149.0 million (see Table 11.4).  
                                                     
40 Codeine, morphine, buprenorphine, methadone, oxycodone, other opioids 
41 Without a basis for weighting the factors, these were the assumptions that underpinned the estimate. We note, that we do 
not know in which direction any difference from the assumptions is likely to skew the estimates.  
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Table 11.1: Factors influencing decision to take a child into care in South Australia for the first time by 
whether substance use was noted in the case file, 2006 
Factor influencing decision to 
take into care 
Substance 








use: No a  
 # of times 
with factor 
 Substance 
use: Yes b 
 # of times 
with factor 
All cases 







Alcohol use - 77.3 - 253.5 253.5 11.1 
Cannabis use - 53.3 - 174.8 174.8 7.6 
Amphetamine use - 50.7 - 166.3 166.3 7.3 
Heroin use - 12.0 - 39.4 39.4 1.7 
Prescription drug use - 10.7 - 35.1 35.1 1.5 
Intravenous substance use  - 4.0 - 13.1 13.1 0.6 
Methadone use - 2.7 - 8.9 8.9 0.4 
Ecstasy use - 1.3 - 4.3 4.3 0.2 
Inhalant use - 1.3 - 4.3 4.3 0.2 
Parental mental health 54.2 65.3 75.3 214.2 289.5 12.7 
Domestic violence 16.7 69.3 23.2 227.3 250.5 11.0 
Homelessness 8.3 28.0 11.5 91.8 103.4 4.5 
Financial difficulties 0.0 29.3 0.0 96.1 96.1 4.2 
Parental incarceration 4.2 25.3 5.8 83.0 88.8 3.9 
Housing instability 8.3 24.0 11.5 78.7 90.3 3.9 
Transience 0.0 22.7 0.0 74.5 74.5 3.3 
Criminal activity 0.0 20.0 0.0 65.6 65.6 2.9 
Abandonment 4.2 17.3 5.8 56.7 62.6 2.7 
Social isolation 20.8 12.0 28.9 39.4 68.3 3.0 
Parent abused as a child 0.0 13.3 0.0 43.6 43.6 1.9 
Family breakdown 12.5 13.3 17.4 43.6 61.0 2.7 
Parental intellectual disability 25.0 2.7 34.8 8.9 43.6 1.9 
Child behaviours 16.7 4.0 23.2 13.1 36.3 1.6 
Parent/child conflict 16.7 4.0 23.2 13.1 36.3 1.6 
Parent hospitalisation 12.5 4.0 17.4 13.1 30.5 1.3 
Other jurisdiction CP 
involvement 4.2 4.0 5.8 13.1 19.0 0.8 
Parent ex-GOM 12.5 1.3 17.4 4.3 21.6 0.9 
Young parents 8.3 2.7 11.5 8.9 20.4 0.9 
Parental death 0.0 4.0 0.0 13.1 13.1 0.6 
Adolescent at risk 4.2 1.3 5.8 4.3 10.1 0.4 
New arrivals  4.2 1.3 5.8 4.3 10.1 0.4 
Support to relative carers 4.2 1.3 5.8 4.3 10.1 0.4 
Unaccompanied minor, refugee 
program 8.0 0.0 11.1 0.0 11.1 0.5 
Child disability 4.2 1.3 5.8 4.3 10.1 0.4 
Child mental health 0.0 1.3 0.0 4.3 4.3 0.2 
Child intellectual disability 0.0 1.0 0.0 3.3 3.3 0.1 
Previous CP history 4.2 0.0 5.8 0.0 5.8 0.3 
Recovery order 4.2 0.0 5.8 0.0 5.8 0.3 
Total number of factors     2,285.4 100.0 
Note: a 139 cases; b 328 cases. CP = child protection: GOM = Guardianship of the Minister 
Source: (Jeffreys et al., 2009), calculations by the authors  
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11.2 Child Death Reviews 
The major costs of child premature mortality are addressed in Chapter 3. However, there are additional 
specific costs associated with assessing some childhood deaths. The Western Australian Ombudsman 
provides an estimate of the cost of conducting an investigation into those deaths that fulfil the criteria 
from the relevant legislation: the Ombudsman does not investigate all child deaths 42. In 2015/16, the 
Ombudsman reviewed 41 deaths at a cost of $18,597 per review. While not asserting causality, the long-
term average is that 33 percent of cases involve drug use as a contributory factor although no specific 
drug categories were identified, and alcohol was listed as a separate factor (Field, 2016). (The 
identification of drug use maybe by the victim, the perpetrator or both). As a proxy for the potential 
involvement of extra-medical opioid use, we used the proportion of episodes where these drugs were the 
principal drug of concern (14.1%) in illicit drug treatment episodes 43 (Australian Institute of Health and 
Welfare, 2017d. Table SD1). Assuming that this figure translates to Western Australia, then 14.1 percent 
of cases equates to 6 deaths where opioids were potentially a contributory factor. 
 
Child death reviews are investigated by relevant state or territory authorities and so there are variations 
in which deaths are subject to detailed examination. While reports from other jurisdictions identify drug 
use as a contributory factor, such as in unintentional overdoses, suicides, vehicle accidents and neglect 
(McMillan, 2017), the proportion of deaths where drug use was a contributory factor were not reported. 
Therefore, we used the estimate from Western Australia (33%) in projecting the number of deaths 
possibly involving drug use and the treatment data in attributing a fraction of these to opioids (14.1%) 
(Australian Institute of Health and Welfare, 2017d. Table SD1).  
 
There were 226 deaths in the target year or the most recent available year that were either explicitly 
subject to detailed review (New South Wales, Western Australia) or known to the child protection system 
and thus likely to be reviewed (Table 11.2). Based on the Western Australia cost, this equates to $4.2 
million in review costs in addition to any coronial or police investigations that were required. Using the 
14.1 percent from the paragraph above as the proportion involving opioids, the cost of conducting these 
child death reviews was $0.6 million. As discussed in the limitations (Section 11.7), we did not add any 
further ‘cases’ to the number of deaths reported in Chapter 3 from this section of the analysis. 
 
Table 11.2: Child protection deaths 
State or Territory Source Reviewable deaths Year(s) 
New South Wales  1 a 47.5  2015 
Queensland 2 b 46.0 2015/16 
South Australia 3 b, c 24.6 2014-16 
Tasmania 4 d 16.0 2015/16 
Victoria 5 b 38.0 2015/16 
Western Australia 6 41.0 2015/16 
Australian Capital Territory 7 e 0.0 2014/15 
Northern Territory 8 b 12.4 2015 
Total  225.5  
                                                     
42 All ‘reportable’ deaths are reviewed (e.g. where the in the last two years the child’s or a child relative’s safety has been 
raised with the Department for Child Protection and Family Support, or the child or child relative is in their care). The 
Ombudsman can review any other notified death (Field, 2016).  
43 Primary drug of concern, excluding alcohol (63,270) and nicotine (4,688) episodes. 
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a 95 deaths in 2014 to 2015: b Known to the child protection system: c mean of 2014 to 2016: d mean paediatric mortality 
2015 to 2016; e None of the deaths was known to ACT Children and Youth Protection Services 
1 = (McMillan, 2017); 2 = (Vardon, 2016); 3 = (Eszenyi, 2017); 4 = (Council of Obstetric and Paediatric Mortality and 
Morbidity, 2017, 2018); 5 = (Victorian Government, 2016); 6 = (Field, 2016); 7 = (Gregory, 2015) 8 = (Gwynne, 2016) 
 
11.3 Needle, syringe and related programs 
Needle and syringe programs (NSP) have been active in Australia since 1986 and stand at the forefront 
of harm prevention and efforts to prevent the spread of BBV (Iversen et al., 2017). In addition, the 
programs provide a range of health and education services and assist clients in accessing treatment 
programs (Australian National Council on Drugs, 2013). In 2015, there were more than 3500 NSP outlets 
including those in pharmacies and vending machines, with nearly 50 million syringes distributed in 
2015/16 (Iversen et al., 2017). 
 
NSP have been extensively evaluated in Australia (Australian Government Department of Health and 
Ageing, 2002, 2009) and elsewhere (Fernandes et al., 2017; National Institute for Health and Clinical 
Excellence, 2009). It is estimated that between 2000 and 2009 NSP prevented 32,050 new HIV infections 
and 96,667 HCV infections (Australian Government Department of Health and Ageing, 2009).  
 
Among people who use heroin, 81 percent report injecting as the most commonly used route of 
administration, while for those who use pharmaceuticals, including opioids, injecting was less common, 
with 31 percent of clients reporting that they had injected in the last three months. (Australian Institute of 
Health and Welfare, 2017c, d). However, among NSP clients on the audit day, opioids where the most 
commonly reported drug last or about to be injected, representing 41 percent of clients (Iversen et al., 
2017). Despite the prevalence of injecting, the prevalence of HIV infection has remained low, at 1.5 to 
1.6 percent in those who inject heroin and 0.2 to 0.0 percent in those who inject other opioids in 2015 
and 2016 (Heard et al., 2018). In contrast, the prevalence of HCV infection was markedly higher, with the 
respective figures being 73-66 percent and 67-59 percent (Heard et al., 2018). The introduction of 
universal access to direct acting antiviral therapy for HCV in March 2016 is likely to make a dramatic 
impact on the prevalence of HCV (Heard et al., 2018) and the reduction in antibody prevalence noted 
above between 2015 and 2016 is potentially an early indication of this change. 
 
Identifying the budget for NSP has become more difficult in the last decade as it has been included in the 
federal budget as part of the Healthcare Specific Purpose Payment (Ritter et al., 2013). The last time the 
NSP budget was reported as a separate item was in 2007/08, when the NSP received $26.4 million. 
Increasing, this by CPI since that time, gives a cost of $32.1 million in 2015/16 (Australian Bureau of 
Statistics, 2016c). Of this, we allocated 41 percent to the cost of supplying services to people who inject 
opioids, $13.2 million. 
 
In 2015/16, Australia had one Medically Supervised Injecting Centre (MSIC), which was based in Sydney. 
As with the NSP, the international evidence suggests that supervised injecting or drug consumption 
facilities are cost-effective in reducing the harms from drug use (Schatz and Nougier, 2012). In 2013/14 
the budget for the Sydney MSIC was $3.5 million (personal communication manager MSIC). Increasing 
this by CPI to 2015/16 values, gives a total of $3.62 million, from which we allocated 41 percent ($1.5 
million) to extra-medical opioid related services (see Table 11.4). 
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11.4 Prevention programs 
11.4.1 Cost of school prevention programs 
Prevention programs can be sub-divided into primary prevention which attempts to prevent the uptake of 
drug use and secondary prevention which attempts to prevent the transition to more serious drug use. 
Generally, primary programs are delivered through schools, while secondary prevention can be delivered 
through schools or the broader community. Earlier estimates suggest that  Australia spent  $156.8 million 
in 2009/10 on preventing illicit drug use, with $79.2 million (50.5%) spent on school based programs 
(Ritter et al., 2013). 
 
It was estimated that hours of illicit drug education represented 25 percent of drug education for year 8 
and below and 50 percent for later years (Ritter et al., 2013). These represent 0.2 percent of school hours 
and thus were extrapolated to be 0.2 percent of the recurrent expenditure or $79.2 million for 
2009/10.Using the fraction identified above (0.2%), this equated to $113.3 million for illicit drug education. 
However, in order to update these estimates we have retained the approach used by Ritter and 
colleagues (Ritter et al., 2013) which calculated the fraction of time that students spent on drug misuse 
prevention education and applied that to total government spending on school education. In 2015/16 
Federal and other government recurrent expenditure on schools was approximately $55.7 billion 
(Steering Committee for the Review of Government Service Provision, 2018a). In primary schools illicit 
drug education focuses mainly on cannabis and steroids with secondary schools covering a broad range 
of illicit drugs (Auditor General Victoria, 2003). Therefore, these estimates only include the costs incurred 
in secondary school prevention. 
 
Table 11.3: Estimated hours of illicit drug education and costs for secondary students in 2015/16 
 Total student time 
spent on drug 
education (hours) 
Share of student 
time on drug 
education (%) 
Implied government 




to opioids ($) 
Central estimate 8,041,121 0.42 $101,615,987 $20,323,197.32 
Low bound 5,680,792 0.30 $71,788,408 $14,357,681.69 
High bound 10,401,450 0.54 $131,443,565 $26,288,712.95 
 
In 2015/16 there were 1.5 million (full time equivalent) secondary students in government and non-
government schools (Australian Bureau of Statistics, 2017h), with total annual government spending of 
$24.3 billion (Steering Committee for the Review of Government Service Provision, 2018a). The total 
school hours based on a 6 hour day and 40 weeks per year was 1.92 million hours. Drug education hours 
per year (mid-point 10.05 hours per student, range 7.1 to 13.0 hours) were obtained from the Auditor 
General’s report (Auditor General Victoria, 2003) and multiplied by the number of students per year 
(Australian Bureau of Statistics, 2017h) and reduced by 50 percent reflecting the time allocated to illicit 
drug education. The 8.0 million hours on illicit drugs equate to 0.42 percent of total hours (low bound 0.30 
percent, high bound 0.54 percent), giving a total cost for secondary illicit drug education of $101.6 million 
($71.79 million to $131.44 million). 
 
If “ecstasy” is regarded as a separate class of drugs to amphetamine, the Auditor General’s report 
identified five classes of drugs usually included in secondary school programs, with the remainder being 
heroin, cocaine and hallucinogens (Auditor General Victoria, 2003). We were unable to locate the time 
allocated to each drug and have thus assumed that these are approximately equal. On this basis, the 
cost of heroin and the extra medical use of opioid prevention activities in schools was estimated at $20.3 
million (range $14.4-$26.3 million). 
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11.4.2 Cost of general population prevention programs 
In 2009/10, an estimated $77.6 million was spent on general illicit drug programs (Ritter et al., 2013), 
including direct costs of prevention programs, staff salaries and overheads. Of this, $53.7 million was 
from state or territory governments and at the federal level, $18.9 million was spent on prevention via the 
National Illicit Drug Strategy with a further $5.0 million spent on specific Indigenous programs under the 
Closing the Gap strategy (Ritter et al., 2013). 
 
In 2015/16, Western Australia spent $4.67 per head of population aged 14 and above on prevention 
programs, (Mental Health Commission, 2016). With a population of 2.08 million people aged 14 or older 
in 2015/16 (Australian Bureau of Statistics, 2018a), this totalled to $9.7 million. There were no data 
available on the split between alcohol and other drugs or on the proportion spent on heroin or other 
opioids. We were unable to find similar costings for other states or territories. Therefore, we extrapolated 
this figure to the Australian population aged 14 or older in 2015/16 (19,749,225) giving a total cost on 
alcohol and other drug prevention activities of $92.2 million. Based on the assumptions of Ritter et al., 
we allocated 50 percent to illicit drug prevention ($46.1 million) and of this we allocated one fifth to heroin 
and other opioid prevention programs: $9.2 million.  
 
11.4.3 Cost of opioid overdose prevention programs 
In February 2016, injectable naloxone became available in Australia for over-the-counter purchase with 
the aim of enabling lay administration to reduce the number of fatal opioid overdoses: subsequently an 
intra-nasal formulation has been released (Jauncey and Nielsen, 2017; Johnson, 2019). The cost of 
prescribed naloxone for 2015/16 was $62,279 (Pharmaceutical Benefits Scheme, 2018b). In addition, 
there were training programs, typically run by specialist treatment services or community groups, for 
potential overdose witnesses and the kits provided (minijets of naloxone, plus intramuscular needles, 
swabs, gloves and instructional materials) (Lenton et al., 2016). In 2014, it was estimated that training, 
including resources, cost $237 per trainee (Olsen et al., 2015) 44. By October 2017, at least 2,858 people 
had been trained (Lenton and Dietze, 2017). On the assumption that 500 people were trained in 2015/16, 
the cost would be $118,500. Therefore, we estimated that the total cost in 2015/16 was $180,799. 
 
11.5 Commonwealth government programs 
The Commonwealth government has provided about 31 percent of all funding for alcohol and other drug 
treatment in Australia, with the states and territory governments providing a further 49 percent with the 
remainder (20%) privately funded by individuals or philanthropy (Ritter et al., 2014). Much of the 
Commonwealth funding is addressed elsewhere in this report (e.g. public hospitals, PBS, Medicare) 
however, the Commonwealth also funds non-government organisations to provide services. In 2012/13 
these totalled $129 million and were funded through the Non-Government Organisation Treatment Grants 
Program (NGOTPP) and the Substance Misuse Service Delivery Grants Fund (SMSDGF) (Ritter et al., 
2014).  
 
The New Horizons review noted the difficulty in identifying the amount spent on treatment services from 
publicly available documents, including from budget statements (Ritter et al., 2014). Therefore, our main 
estimate uses a bottom up approach and is reported in Section 5.6 and Table 5.2. However, we note two 
Commonwealth Government announcements in the target year of funding for the treatment sector. There 
                                                     
44 We note that less intensive (shorter) courses are now provided, so this cost may fall in future estimates. 
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was $87 million allocated in early 2015 for the 2015/16 financial year to non-government treatment 
agencies (Nash, 2015). These funds were allocated under the SMSDGF and the NGOTGP. 
Subsequently, funding allocation through the SMSDGF and NGOTGP has now been amalgamated into 
the Drug and Alcohol Program (personal communication Prevention and Treatment Section, Alcohol, 
Tobacco and Other Drugs Branch, September 2019). In late 2015, $300 million was announced for a 
four-year period (Turnbull et al., 2015). The funding was in response to the National Ice Taskforce’s Final 
Report, with $298.2 million committed for treatment, workforce support, prevention and education and 
community engagement. The funding was allocated through the Primary Health Networks (PHN) in the 
planning and commissioning of drug and alcohol treatment services (personal communication Prevention 
and Treatment Section, Alcohol, Tobacco and Other Drugs Branch, September 2019). However, as this 
commenced from 1 July 2016 it is outside the target year of this report. 
 
Table 11.4: Summary Chapter 11 costs 
Cost area Central estimate  
($) 




Child protection cases 149,000,856 144,284,776 153,716,936 
Child death reviews 591,301 a b 
Needle and syringe programs 13,161,000 a b 
Supervised Injecting Centre 1,484,200 a b 
School prevention programs 20,323,197 14,357,682 26,288,713 
General prevention programs 9,222,888 a b 
Opioid overdose prevention 180,799   
Federal government programs c - - - 
Total 193,964,241 183,282,646 204,645,837 
a Low bound estimate – duplicated central estimate: b High bound estimate – duplicated central estimate: c See Section 5.6 
for bottom-up cost estimate. 
 
11.6 Intangible costs of opioid attributable ill-health 
11.6.1 Background 
In addition to the tangible costs, many of the health problems attributable to opioids, and the long-term 
consequences of opioid attributable injuries also reduce the quality of life of those experiencing them.  
 
The intangible impacts of road crash injuries are included in the cost calculations for opioid attributable 
road crash accidents set out in Chapter 8. The intangible costs to victims of crime, including the intangible 
costs of violent crime, are included in the cost calculations set out in Chapter 7. As such, the intangible 
costs of road crashes and interpersonal violence are excluded from these calculations. Finally, the 
intangible cost of arising from opioid dependence itself is assessed in section 10.2 and, as such, is 
excluded from these calculations. 
 
As discussed in section 9.3, quality of life impacts due to ill-health are typically quantified through one of 
two measures of the number of health adjusted years of life lost to a condition, either a Disability Adjusted 
Life Year (DALY) or a Quality Adjusted Life Year (QALY). Consistent with the other sections of this report, 
the intangible impacts of ill-health have been measured in DALY, and specifically, as we are measuring 
reduced quality of life rather than reduced length of life, the intangible impact is years of life lost due to 
disability (YLD). 
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11.6.2 Method 
There is considerable debate as to the best approach to expressing YLD (and DALY more generally) in 
monetary terms. Some authors recommend a straightforward conversion of a value of statistical life 
(VoSL) to a value of a life year (VoSLY) by annualising it from an assumed average number of years of 
life to live (Abelson, 2008; Moore, 2007; Nicosia et al., 2009). Others recommend either a context specific 
adaption from a VoSL taking into account current health states and expected future health state, or to 
calculate a VoSLY specific to the context of the particular study through a discrete choice survey of the 
relevant population (Baker et al., 2010; Dolan, 2010; Donaldson et al., 2011; Miller and Hendrie, 2011): 
see section 9.2 for a more extensive discussion.  
 
Again, following the approach used elsewhere in this study we have used a value for a DALY based on 
the VoSLY derived from a VoSL. Our central estimate is based on the Abelson estimate of the value of a 
statistical life ($3-4 million in 2007 values, Abelson (2008), converted to 2015/16 values using the change 
in the average nominal national per capita income over that period, and then converted to a value of a 
life year (again see section 9.2 for the approach taken to the annualisation). Our high bound estimate of 
the VoSLY was derived from the value of a statistical life used by the US Department of Transport (US 
Department of Transportation, 2015).  As a lower bound for the value per DALY lost we have used the 
implicit threshold value per DALY used for PBS approval, of $45,000 in 2014/15 values as the low bound: 
this latter value is implied rather than explicitly stated (Community Affairs References Committee, 2015; 
Harris et al., 2008). 
 
The number of years of life lost due to disability for each partially opioid attributable condition was sourced 
from the Global Burden of Disease Study 2017 (Institute for Health Metrics and Evaluation, 2019). Data 
were extracted by condition, gender and broad age groups for persons aged 15 years and older. The 
data is provided by calendar year and an average was taken of the 2015 and 2016 estimates. In contrast 
to the approach taken elsewhere in this report, data on YLD is only available based on the total burden 
experienced in the year in question (e.g. as a stock measure). It is not possible to identify the extent to 
which these harms were first experienced in the study, or whether they represent long-term quality of life 
loss from harms that occurred in previous years. 
 
The source of the relative risk estimates used to identify what proportion of the intangible cost should be 
attributed to opioids is the same as for the mortality and hospital separation calculations, see Table 2.1 
for a summary. 
 
Not all conditions identified as at least partially caused or prevented by opioids were individually 
identifiable in the GBD data, largely due to aggregation issues. The following conditions that are included 
in our hospital separations cost calculation were excluded from the YLD calculation due to data 
unavailability:  
• Mental and behavioural disorders due to use of opioids or opioid poisoning (including 
overdoses, treatment of withdrawal  and treatment of opioid use and dependence); 
• Injecting-related infection attributable to opioids, 
• Brain injury caused by mental and behavioural disorder due to use of opioids or opioid 
poisoning; 
• Infective endocarditis; and  
• Neonatal abstinence syndrome 
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As noted above, intangible costs arising from interpersonal violence and road crash injuries were 
excluded from this calculation as they have already been quantified in their respective sections, as was 
the cost of opioid dependence, which is assessed in Chapter 10. 
 
11.6.3 Results 
Estimates of the impact on quality of life of opioid attributable ill-health and injury where it can be 
quantified are set out in Table 11.5, expressed in total years of life lost to disability attributable to opioids 
by gender and broad age group. 
 
Amongst those conditions that could be quantified, the total impact of opioid attributable ill-health is 
10,131 years of life lost to disability (low bound: 3,682 YLD, high bound: 26,416 YLD). Seventy four 
percent of the intangible cost is borne by males, and 70 percent is borne by those aged 15 to 49. 
 
Amongst the specific causes of ill-health, accidental injuries contribute a clear majority of the intangible 
cost, with a substantial cost also arising from illnesses secondary to injecting drug use. 
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Table 11.5 Quality of life impact of opioid attributable ill-health, 2015/16 














Acute hepatitis B 15-49 years 3.1 0.8 7.6 6.1 1.6 15.5 
 
50-69 years 1.5 0.3 4.2 2.7 0.7 7.3 
 
70+ years 0.4 0.1 1.2 0.5 0.1 1.6 
Acute hepatitis C 15-49 years 1.1 0.4 2.5 1.4 0.5 3.0 
 
50-69 years 0.7 0.2 1.5 0.6 0.2 1.3 
 
70+ years 0.7 0.3 1.4 0.3 0.1 0.7 
HIV/AIDS and its complications 15-49 years 3.2 1.3 6.8 15.4 6.8 30.7 
 
50-69 years 0.9 0.3 2.1 8.0 3.8 15.1 
 
70+ years 0.1 0.0 0.3 0.5 0.2 1.0 
Cirrhosis and other chronic liver 
diseases due to hepatitis B 
15-49 years 4.6 1.0 12.1 14.1 3.8 34.6 
50-69 years 3.8 0.8 10.6 14.5 4.0 35.4 
70+ years 1.4 0.3 4.1 3.8 1.0 9.7 
Cirrhosis and other chronic liver 
diseases due to hepatitis C 
15-49 years 93.9 49.8 151.9 136.8 78.9 213.3 
50-69 years 113.4 65.5 175.2 203.0 126.3 307.9 
70+ years 50.2 27.1 79.6 70.1 43.0 106.7 
Liver cancer due to hepatitis B 15-49 years 0.1 0.0 0.3 0.6 0.4 0.6 
 
50-69 years 0.2 0.1 0.5 1.4 0.9 1.4 
 
70+ years 0.1 0.0 0.3 0.3 0.2 0.3 
Liver cancer due to hepatitis C 15-49 years 0.6 0.3 0.9 3.8 5.5 2.4 
 
50-69 years 4.4 3.0 6.1 39.5 56.9 25.4 
 
70+ years 7.0 4.5 9.8 30.4 43.0 20.1 
Total illnesses secondary to injecting 
drug use 
15-49 years 106.7 53.8 182.2 178.1 97.5 300.1 
50-69 years 124.9 70.3 200.2 269.7 192.7 393.9 
70+ years 59.9 32.4 96.6 105.9 87.5 140.1 
Complications of low birthweight & 
pre-term birth 
15-49 years 145.6 64.4 307.8 132.7 59.0 284.2 
50-69 years 56.8 25.0 121.0 42.3 18.6 91.0 
 
70+ years 8.9 3.9 19.0 4.2 1.9 8.8 
Accidental injury (excluding transport 
accidents) 
15-49 years 1,290.1 418.4 3,592.8 4,768.2 1,635.4 12,682.4 
50-69 years 425.7 136.0 1,231.3 1,385.0 448.8 3,942.1 
70+ years 350.2 112.5 994.6 529.4 169.5 1,476.3 
Self-harm 15-49 years 54.7 19.5 134.1 52.4 20.4 119.7 
 
50-69 years 15.7 5.7 39.1 16.5 6.1 40.5 
 
70+ years 3.9 1.4 9.9 3.2 1.2 7.9 
Total opioid attributable ill-health 15-49 years 1,597.1 556.0 4,216.9 5,131.5 1,812.3 13,386.4 
 
50-69 years 623.0 237.0 1,591.6 1,713.5 666.2 4,467.5 
 
70+ years 422.9 150.2 1,120.1 642.7 260.1 1,633.0 
 
All aged 15+ 2,643.0 943.2 6,928.6 7,487.7 2,738.5 19,486.9 
Source: YLD data, [Institute for Health Metrics and Evaluation (2019), Global Burden of Disease 2017, GBD Compare Tool, 
https://vizhub.healthdata.org/gbd-compare/, data extracted 9 April 2019. Share of harm attributable to opioid calculated from 
relative risks set out in Table 2.1. 
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Converting these YLD estimates to monetary values gives an estimate of the intangible cost of opioid 
attributable illness of $2.9 billion using the Abelson (2008) values of a statistical life year (low bound: $1.1 
billion; high bound $7.6 billion) (Table 11.6).  
 
Alternatively, if the value of a statistical life year implied by PBS decision criteria is used, the cost of opioid 
attributable ill-health is $471 million (low bound: $171 million, high bound $1.2 billion) (Community Affairs 
References Committee, 2015; Harris et al., 2008). Using the value of a statistical life year from the US 
Department of Transport (2015) gives an estimated cost of $8.6 billion (low bound $3.1 billion; high 
bound: $22.4 billion). 
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Table 11.6: Value of quality of life lost to opioid attributable ill-health and injury, 2015/16 
Condition Value of a Statistical Life Year  
from Abelson 2008 
Value of a statistical life year derived  
from PBS criteria 
Value of a statistical Life Year  




















Acute hepatitis B 4,103,281 1,036,980 10,698,720 665,302 168,135 1,734,680 12,157,534 3,072,447 31,699,039 
Acute hepatitis C 1,354,391 502,879 3,004,135 219,600 81,536 487,088 4,012,900 1,489,970 8,900,897 
HIV/AIDS and its complications 8,038,393 3,546,285 16,037,657 1,303,337 574,991 2,600,330 23,816,804 10,507,220 47,517,676 
Cirrhosis and other chronic liver diseases 
due to hepatitis B 12,072,820 3,149,492 30,504,793 1,957,475 510,656 4,946,017 35,770,333 9,331,571 90,382,082 
Cirrhosis and other chronic liver diseases 
due to hepatitis C 191,264,701 111,947,681 296,478,178 31,011,471 18,151,087 48,070,681 566,694,618 331,687,697 878,429,665 
Liver cancer due to hepatitis B 790,623 457,153 1,012,547 128,191 74,122 164,173 2,342,523 1,354,491 3,000,056 
Liver cancer due to hepatitis C 24,572,885 32,440,892 18,517,871 3,984,224 5,259,934 3,002,469 72,806,543 96,118,515 54,866,255 
Total illness secondary to  injecting drug 
use 242,197,094 153,081,361 376,253,901 39,269,599 24,820,462 61,005,439 717,601,255 453,561,912 1,114,795,668 
Complications of low birthweight & pre-term 
birth 111,907,959 49,499,934 238,356,457 18,144,647 8,025,871 38,646,882 331,570,007 146,662,430 706,221,902 
Accidental injury (excluding transport 
accidents) 2,506,916,813 836,888,231 6,854,174,779 406,469,035 135,692,237 1,111,329,180 7,427,697,087 2,479,600,537 20,308,106,664 
Self-harm 41,947,127 15,555,109 100,658,956 6,801,266 2,522,090 16,320,744 124,284,361 46,087,944 298,240,544 
Total intangible costs of opioid 
attributable ill-health 2,902,968,994 1,055,024,636 7,569,444,093 470,684,547 171,060,660 1,227,302,245 8,601,152,710 3,125,912,823 22,427,364,778 
Source: YLD data, [Institute for Health Metrics and Evaluation (2019), Global Burden of Disease 2017, GBD Compare Tool, https://vizhub.healthdata.org/gbd-compare/, data extracted 9 April 
2019. The proportion of harms attributed to opioids is the same as for the mortality and hospital separation calculations: see Table 2.1 for a summary of the relative risks. 
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11.7 Conclusions 
This chapter assembles costs from a diverse range of areas and has at times made speculative assumptions 
in attributing costs to extra-medical opioid use (Table 11.4). While in each case there is a clear argument that 
there will be costs, the quantum is different to determine. For example, ascribing childhood maltreatment, 
harms and deaths to a specific type of drug use is likely to be associated with a high level of uncertainty even 
though, by definition, there are links between maltreatment and harms (Radford et al., 2011). Using 
substantiated child protection cases is likely to identify the most severe instances of harm, but not all cases 
of harm or even all the cases of severe harm will be included in child protection data. 
 
The intangible costs of ill-health were not included in the last national estimate of drug-related costs (Collins 
and Lapsley, 2008) and, at $2.9 billion represents a significant source of substance attributable costs, despite 
the fact that the DALY lost from a number of sources of opioid attributable ill-health could not be quantified. 
Therefore, improved availability of data may well increase the estimate of intangible costs in future analyses. 
In reviewing the literature, few studies include intangible costs either for the opioid consumer or for others 
impacted by people who use opioids.  
 
11.8 Limitations 
The costs due to premature mortality are reported in Chapter 3, but deaths resulting from childhood neglect 
associated with parental drug use may not be detected using our search strategy, as whilst deaths resulting 
from interpersonal violence and road crashes include those aged <15 years, other accidental injuries do not. 
Similarly, cases of childhood neglect or harm requiring hospital care should be addressed in Chapter 4, but 
again whilst separations for interpersonal violence and road crashes cover all ages other forms of accidental 
injury only include those aged 15 and older. While the data from child protection and child death reviews 
highlight these potential gaps, with the data that are publicly available, we have not been able to the estimate 
the number of additional deaths or hospital episodes that should be added to those sections of the report. 
 
The issue of poly-substance use in child maltreatment, as with other sections of this report, also complicated 
the allocation of cases to a specific drug. Indeed, there is the additional difficulty in that the drug use is likely 
to be by a parent or guardian rather that the person incurring the harm. It is also more difficult to assert that 
extra-medical opioid use by a parent or guardian caused the harm and not some other characteristic of the 
person. Given the multifactorial nature of child neglect and harm (Field, 2016) even when case file based 
studies identify substance use, it is not a definitive assertion of causality between substance use and the 
maltreatment. 
 
Both NSP and MSIC have track records of reducing the harms and associated costs of drug use, but we 
were only able to report the gross cost of these programs, rather than the net outcomes. There are also many 
community and other organisations working in the harm reduction field either directly relating to drug use or 
associated conditions (e.g. AIDS Councils and Hepatitis Australia). All these organisations would incur costs 
arising from people who use extra-medial opioids. We were unable to determine an appropriate method for 
allocating a proportion of their budgets against these costs. 
 
In estimating the cost of school prevention programs and state-based prevention programs, we had to 
extrapolate from a single state (respectively Victoria and Western Australia) to national costs: these states 
may not be representative of the spending across jurisdictions. Clearly this is not ideal. Furthermore, although 
prevention activities were included in our previous report on the costs of methamphetamine use (Whetton et 
al., 2016), the expert advisory panel on tobacco recommended that, by convention, prevention activities are 
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not included in assessing the costs of smoking in Australia (Whetton et al., 2019). Therefore, in this respect, 
the figure reported here is not directly comparable to the costs of tobacco use. 
 
As shown by the wide range of estimated costs ($0.2 billion to $22.4 billion) this aspect of the analysis is at 
a formative stage. There are also disagreements in the literature around the preferred approach to valuing 
DALY and changes in the accepted practice could increase or decrease the estimates. Finally, a number of 
conditions with potentially significant impacts on quality of life, such as brain injuries, could not be quantified 
from the available data. 
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CHAPTER 12: CONCLUSIONS 
Robert J. Tait, Steve Whetton & Steve Allsop 
 
12.1 Findings 
The changes seen in the types of opioids used, and the increased prevalence of use since the start of the 
21st century have been accompanied by an increasing, age-standardised, rate of deaths (Australian Institute 
of Health and Welfare, 2018d). However, at 4.7 deaths per 100,000 this still remains below the peak in 1999 
when the rate was 6.5 deaths per 100,000, at a time when heroin and plant-based opioids where the most 
frequently implicated opioids (Australian Institute of Health and Welfare, 2018d). Currently, pharmaceutical 
opioids, both synthetic and plant derived, represent three out of five deaths (Chrzanowska et al., 2019). 
These changes, together with the interval since the last evaluation by Moore (2007) are important contexts 
to the production of this report. 
 
In the current study, the tangible cost of extra-opioid use was $5.63 billion with a further $10.13 billion in 
intangible costs with an overall total of $15.76 billion. The last comprehensive assessment of the social costs 
of opioids in Australia was conducted for 2004 (Moore, 2007) and included costs from: premature mortality; 
years lost due to disability; crime; and, road accidents. The total estimated cost was $4.75 billion, which after 
adjusting for CPI, equates to $6.08 billion in 2015/16 values (Australian Bureau of Statistics, 2016c). Leaving 
aside the intangible costs, the current estimate of tangible costs was $5.63 billion: 7.4 percent less than the 
previous estimate. The current estimate included a greater range of cost domains, including those of hospital 
separations, out-of-hospital care, primary care, medications and the contribution of informal carers. The 
previous estimate included welfare and labour market costs in the upper estimate: we have included 
workplace absenteeism; injuries and disruption due to premature mortality; and, work related traffic accidents 
(although these were included in the general estimate of traffic accident costs). The difference was mainly 
associated with the cost of crime, which at $1.71 billion in 2004, was nearly double our estimate, with the 
inclusion of property loss in the Moore estimates accounting for most of the difference.  
 
There were an estimated 2,203 deaths attributable to opioids in the 12-months of 2015/16. While drug toxicity 
was the leading cause of death, BBV also extracted a considerable toll, representing about 40 percent of 
deaths. The mean age at death was 43 years for drug-induced deaths such as overdoses. Although this is a 
higher age than that for people who use methamphetamine (39 years (Whetton et al., 2016)), the number of 
cases was far greater than the 170 attributed to methamphetamine in 2013/14. There was a correspondingly 
greater cost of premature death at $12.61 billion compared with $781.8 45 million for methamphetamine. By 
comparison the cost of premature mortality (tangible and intangible) from tobacco was $93.88 billion in 
2015/16 (Whetton et al., 2019). 
 
The extra-medical use of opioids has effects that are experienced across the health system. We estimated 
that there were more than 32,000 hospital separations, but the largest costs were for out-of-hospital care. 
We estimated that the cost of pharmaceuticals for opioid attributable ill-health exceeded $311 million, not 
including OST, with primary care costing a further $234 million. In estimating the cost of tobacco-related ill-
health, the value of informal carers was the greatest single item, accounting for 30 percent of health costs 
(Whetton et al., 2019). With respect to extra-medical opioids, informal care represented less than 8 percent 
of other healthcare costs. However, from the data that were available, we were unable to assign costs to 
some of the major chronic problems arising from opioid use, especially those that can arise through IDU e.g. 
                                                     
45 CPI adjusted to December 2015 $795.0 million (Reserve Bank of Australia, 2019) 
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infection with BBV and their sequelae. Conversely, living with a person who is dependent on extra-medical 
opioids, is likely to have significant impacts on the quality of life of co-residents, which may include addressing 
acute health needs: in relation to tobacco use no cost was assigned to being a co-resident other than via 
hospital separations due to second-hand smoking. 
 
The costs associated with extra-medical opioid use in terms of crime and the criminal justice system were 
substantial at $936.1 million. This cost domain was second only to premature mortality in terms of tangible 
costs. In comparison, the 2013/14 equivalent cost relating to criminal justice due to methamphetamine was 
$3.24 billion 46 (Whetton et al., 2016), which was the largest tangible cost. This difference reflects the 
significantly higher AF for methamphetamine in DUMA data (16.2% of total crime in 2013/1447 compared with 
3.4% for heroin in 2015/16), as well as real terms increases in justice system costs, the exclusion of opioids 
other than heroin from the DUMA survey, and the greater prevalence of methamphetamine use compared to 
heroin (Whetton et al., 2016)). 
 
There were also some domains where we estimated the cost but did not include these in the overall total. 
There was $14.9 billion arising from the pain and suffering for those people who were dependent on extra-
medical opioids and $1.4 billion spent on drug purchases. In addition to these ‘internalities’ for those 
dependent on opioid drugs, we estimated that their partners and children incurred $11.98 billion in lost quality 
of life from living with a person dependent on extra-medical opioids. We adopted a conservative approach 
and excluded this latter estimate from the total cost because it may result in ‘double counting’ some intangible 
costs, for example being the victim of a crime. 
 
A recent review from the USA noted that social cost studies often under-estimate the economic costs of 
opioids by omitting the ‘value of a statistical life’ from their calculations (Council of Economic Advisers, 2017). 
After adjusting all costs to 2015 values, the Council of Economic Advisers’ total of USD 504.0 billion was 
more than six times greater than the next highest estimate for the USA (2017). The Council of Economic 
Advisors noted the importance of including the full cost of fatalities, given that the total of non-fatal costs (e.g. 
general health care, substance use treatment, criminal justice, reduced workforce productivity) was USD 72.3 
billion, which amounted to just 13 percent of the total costs of opioid use in the USA (Council of Economic 
Advisers, 2017). In the current analysis the tangible and intangible cost of premature mortality was 80.1 
percent of the total. 
 
12.2 Limitations 
There will always be a margin of error in attributing events to opioid use and assigning costs from 
administrative data not designed for the task. However, we did identify some major cost areas where we 
were unable to find or develop a rationale for apportioning costs. For example, we did not allocate any costs 
attributable to Federal criminal matters, neither did we allocate any portion of the budgets for border 
protection, drug interdiction or coronial investigations. Similarly, there were a range of other health costs such 
as dental care and out-of-hospital physiotherapy / rehabilitation services where this also occurred. In Section 
11.2 we speculate that some of the cases that undergo child death reviews could be attributed to opioids, but 
we were unable to definitively identify any cases to add to our estimate derived from the NCIS. 
 
                                                     
46 CPI adjusted to December 2015 $3.35 billion (Reserve Bank of Australia, 2019). 
47 The proportion of crime attributed to methamphetamine from the DUMA data has increased still further, reaching 27.0% in 
2015/16 and so the disparity in costs would likely be even greater were the methamphetamine estimates updated (AIC DUMA 
collection 2015/16 [computer file]). 
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This report drew on methods used in two earlier reports on the social costs of methamphetamine (Whetton 
et al., 2016) and the social costs of tobacco (Whetton et al., 2019). However, some differences are apparent 
because of data availability, improved methods, and differences in the types of costs conventionally included. 
The largest cost areas that were added in the cost of tobacco study were those of the intangible costs of the 
lost quality of life arising from ill-health, and the contribution of informal carers, neither of which were included 
in the methamphetamine report. The differences in the methods that were used are summarised in Table 
12.1 and show if methods were the same/similar (), different (x) or if the domain was not relevant to a 
specific substance (n/a). Further, there were some unique costs for specific substances: for example, damage 
from clandestine laboratories (methamphetamine) and fires from discarded cigarettes (tobacco) that are not 
noted in the table. Finally, it should be noted that the costs for the methamphetamine report were for the 
financial year 2013/14. 
 
In Chapter 3, we identified 894 deaths relating to BBV and their sequelae. In Chapter 4, more than $44 million 
was attributed to hospital separations with these conditions and in Chapter 5 a further $311 million was 
allocated in PBS pharmacotherapies, primarily for HCV. However, in Chapter 11 we note what appears to be 
a dramatic change in the HCV antibody prevalence following the introduction of universal access to direct 
acting antiviral therapy (Heard et al., 2018). Similarly, the introduction of pre-exposure prophylaxis (PrEP) is 
likely to change rates of HIV infection (Grulich et al., 2018) which have remained at or below 2.1 percent 
since 1995 (Heard et al., 2019; Iversen and Maher, 2015). Therefore, care will be needed if this cost 
estimation is updated in the future, to re-assess premature deaths, hospital separations and medication costs 
for these conditions. 
 
In estimating the costs related to methamphetamine, crime and the criminal justice system was the largest 
single cost domain, representing 65 percent of the total (Whetton et al., 2016). In this instance crime and the 
criminal justice system accounted for 5.9 percent of the costs. The primary difference in the drivers of cost 
was the proportion of police detainees attributing their offending to the substance in question (and having 
used that substance in the last 30 days). In the combined 2015 and 2016 data, 21.8 percent of those in the 
survey whose most serious offence was a violent crime attributed their offending to methamphetamines (data 
not in results). In contrast, 2.1 percent attributed their offending to heroin. Similar proportions were reported 
in 2018 for violent crime, where the attribution for methamphetamine was 21 percent and for heroin, 2 percent 
(Voce and Sullivan, 2018). Therefore, if we were to update the costs, it is likely that crime would account for 
an even larger share of the methamphetamine attributable costs. 
 
However, in both analyses, the limitation of using AF derived from DUMA were apparent. Firstly, because 
these only consider the most serious offence category, and more importantly, the extent to which it is 
appropriate to generalise from these AF based on those detained by police to different stages of the justice 
system. In addition, no reliable data were available with which to calculate the relevant AF for juvenile 
offenders, who account for 13 percent of offenders (Australian Bureau of Statistics, 2017g, Table 18). While 
the omission of costs for juveniles will underestimate the costs in this domain, the direction of the effect of 
generalising the AF from police detainees to more distal aspects of the system is unknown.  
 
In the current analysis we improved the method of estimating deaths arising from IDU compared to the 
analysis used for methamphetamine (Whetton et al., 2016). BBV and their sequelea were eligible for inclusion 
but could not be identifed in the NCIS data. In the current analysis, we used indirect attribution for specific 
conditions (HBV and HCV, HIV, liver cirrhosis secondary to HBV and HCV, liver cancer secondary to HBV 
and HCV) with data from the GBD (2018). As with the methamphetamine report, we were still unable to 
quantify deaths from infective endocarditis. 
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Table 12.1 Comparison of methods between recent social cost reports 
Domain Opioids Tobacco Methamphetamine Comments on difference 
Tangible costs 
     
Mortality  x  
National Mortality Data (indirect 
attribution) v National Coronial 
Information System data (direct 
attribution) 
Mortality (injecting drug use)  n/a x Improved method – see Section 12.2 for details. 
Avoided health care cost     
Hospital separations     
Primary care   x Unique methamphetamine data set 
ED / Outpatients   x Unique methamphetamine data set 
Ambulance   x Unique methamphetamine data set 
Community mental health  n/a   
Cessation medications   n/a (None approved for methamphetamine) 
PBS medications   x Method developed post methamphetamine report 
Informal carers   x Method developed post methamphetamine report 
Crime ? n/a ? Minor differences in offender categories 
Workplace absenteeism    Minor differences in reference wage rates 
Workplace presenteeism x  x Unable to estimate presenteeism for illicit drugs 
Workplace injuries    Minor differences in reference wage rates 
Road traffic accidents  x  Unable to estimate RTA for tobacco 
Child maltreatment  n/a   
Prevention  x  Excluded from tobacco for reasons of convention 
Drug purchase x  x 
Illicit drug purchase costs too 
speculative to include in the 
totals, however spending was 
estimated and reported in 
Chapter 11 
Intangible Costs     
Premature mortality   ? 
Central estimate cost for 1 year 
(high bound values same 
methods used) 
Ill-health  x  More data available on tobacco ill health 
Harms from living with a dependent person  n/a   
Sources: Methamphetamine (Whetton et al., 2016): Tobacco (Whetton et al., 2019). 
n/a = not applicable: x = different method: ? = some / minor differences:  comparable methods. 
 
12.3 Future directions 
A major difficulty in assessing harms from illicit drug use compared with licit drugs such as tobacco or alcohol, 
is determining the size of the population at risk. In this case we used the GBD compare tool to identify the 
population, but this does not differentiate dependence on heroin from dependence on other (pharmaceutical) 
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opioids. From national survey data, the prevalence of heroin use is much lower than the use of other opioids 
(see Table 2.1). In contrast, heroin represents 59 percent of the identified treatment episodes for opioids 
(Australian Institute of Health and Welfare, 2017c) with the implication that for those using opioids there are 
greater harms or costs and hence demand for treatment arising from the use of heroin. Therefore, an analysis 
that includes an assumption that all types of extra-medical opioid dependence are equivalent may be 
inaccurate. Further work is warranted to determine the ratio of heroin to other forms of opioid dependence 
and their respective levels of harm.  
 
We excluded the costs arising to resident partners and children from living with a person with extra-medical 
opioid dependence from our main analysis because of their potential overlap with other costs that were 
included. Nevertheless, the cost estimates in this area, although tentative, may be considerable (see Chapter 
11). We were unable to find any research specifically on the intangible harms experienced by partners and 
children so instead used estimates of improvements when an individual receives treatment for a substance 
use disorder (Mortimer and Segal, 2006). In addition, some have argued that there is a tendency for couples 
to have similar drug use patterns either through assortative mating or direct influence (Kendler et al., 2018). 
This means that some resident children are likely to have both parents affected by substance use disorders, 
thus potentially increasing the risk and nature of the harms that they experience. 
 
While noting the impact of new medications for BBV, further reductions in the harms and especially overdose 
deaths from opioid use may follow the rescheduling of naloxone in Australia (Lenton et al., 2016). Given the 
costs associated with premature mortality, even reversing a single overdose would have substantial cost 
savings. The release of an intranasal spray, which should be easier to use than injectable formulations 
(Paola, 2019), may also increase the number of people willing to carry and administer naloxone. It is too early 
to determine if this will have a noticeable effect of the number of opioid deaths in Australia, but in the USA 
there were 26,463 overdose reversals performed by laypersons between 1996 and 2014 (Wheeler et al., 
2015). Finally, the importance of opioid agonist treatment (e.g. methadone, buprenorphine) in reducing 
mortality and improving multiple other health and social outcomes must be emphasised, with modelling 
suggesting that it could reduce deaths over 20 years by between 7.7 percent and 25.9 percent (depending 
in the relevant prevalence of HIV) (Degenhardt et al., 2019). Therefore, there is significant potential that the 
number of opioid related deaths and costs can be reduced. Nevertheless, while each of these individual 
programs provide benefits, a comprehensive ‘overdose’ prevention strategy is required to coordinate 




The overall costs for pharmaceutical opioid misuse and illicit opioid use was $15.76 billion: two-thirds of this 
cost was attributed to intangibles. Premature deaths, health problems and crime were the leading sources of 
tangible costs  We have also commented on domains where there are insufficient data to allow us to include 
figures in the main estimate and there were some gaps in data suggesting our estimate of costs is 
conservative. Even so, we have identified significant impacts for consumers, their families, friends and work 
colleagues and the broader Australian community. While the number of deaths was the main driver of costs, 
crime, poor health and accidents also have significant imposts across the community. 
 
These differences in costs may indicate different focuses are appropriate for public policy, for example, in 
the case of opioids, policies that act to reduce the number of deaths such as those from acute toxicity would 
target the greatest area of cost. 
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APPENDICES 
Appendix 2.1: Detailed method - Basis for inclusion of social costs 
It is generally accepted that social cost/cost of illness studies of substance use should exclude any net private 
costs borne by the user themselves. This is because the standard assumption underpinning much economic 
analysis is that consumption decisions are made through a rational assessment of their benefits and costs, 
and any private costs incurred would be expected to have an equal or greater private benefit offsetting them. 
For example, it is reasonable to assume that when deciding to buy tickets to a sports game or concert that a 
consumer has not only considered the purchase price but has also factored in their expectation of the time 
and cost of travelling to and from the venue, any expected annoyance from queuing or congestion etc. (Cost 
benefit studies will include all of the purely private costs, but they will also attempt to quantify the increase in 
utility arising from the use of the substance).  
 
Whilst there is a consensus around this approach for “normal” goods and services, there is considerable 
debate on how such studies should treat those costs incurred by users with a drug dependence. This situation 
does not necessary meet the criteria of a rational, fully informed, consumer which is the basis for excluding 
these costs from a social cost study; and therefore such costs cannot necessarily be considered as a purely 
private cost (or at least cannot be considered as a cost that can be assumed to have an at least equal benefit 
offsetting it). The text by Cawley and Ruhm (Cawley and Ruhm, 2011) informed this section. 
 
Some economists maintain that, even for those drugs that have the potential to cause dependence, harms 
borne by the substance user themselves should be excluded in assessing public policy approaches to the 
substance in question. The rationale for this approach is the view that these costs would have been fully 
internalised by the users in their consumption decisions. This contention rests on two key assumptions: 
1) That users would have anticipated the possibility of a dependence developing and have 
internalised any potential costs associated with the potential for developing a drug dependence 
when they were making their initial consumption decisions, and that for those individuals the 
expected benefits of the consumptions must have outweighed the expected value of the 
potential costs, including any potential costs associated with dependence, e.g. they will have 
fully internalised the costs; and,  
2) That dependent users are best characterised as normal consumers who, as a result of the 
dependence derive much higher utility from their use of the substance. This is because they 
gain utility not just from their current consumption of the substance on which they are dependent, 
but also from the “stock” of previous consumption. In effect, dependence is treated as a 
hysteretic process where each unit of consumption increases the value of future consumption. 
 
This approach to considering costs to users of drugs of dependence is what is known as the rational addiction 
hypothesis, which was first set out in Becker and Murphy (1988), and is supported by a considerable body of 
empirical work (c.f. (Becker et al., 2008; Chaloupka, 1991)).  
 
Some conclusions from the ‘rational addiction’ hypothesis are broadly accepted, for example the conclusion 
that a dependent user will still respond to price signals, both in the present but also anticipated future price 
changes. However, there are two key implications of the hypothesis which have attracted considerable 
criticism, namely the contentions that: 
• dependent users’ current consumption is optimal for them given current and anticipated future 
costs; and,  
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• that dependent consumers will be more responsive to permanent increases in price than non-
dependent users (due to the importance of past “stocks” of consumption on current utility).  
 
More formally the hypothesis postulates that the consumer maximises lifetime utility (U) at time t=0 subject 
to an expected budget constraint in a way that can be characterised by the following utility function: 





σ =  a constant rate of time preference;  
t =  the period of time, from t=0 (the present) to t=T (expected years of life remaining);  
C(t) =  the consumption of the addictive good at time t;  
Y(t) =  the consumption of all other goods at time t; and, 
S(t) =  the current “stock” of past consumption of the addictive good at time t. 
 
The stock of past consumption evolves over time according to: 
?̇?𝑉(𝑡𝑡) = 𝐶𝐶(𝑡𝑡) − 𝛿𝛿𝑉𝑉(𝑡𝑡) − ℎ[𝐷𝐷(𝑡𝑡)] 
Where: 
C(t) =  the consumption of the addictive good at time t; 
δ =  the depreciation rate in the addictive stock; and, 
D(t) = expenditure on the endogenous depreciation (appreciation) of the stock of the addictive good (Becker 
and Murphy, 1988).  
 
The key implication of the hypothesis for cost of illness studies is that even if users can become dependent 
on the substance in question, any costs borne by the user should still be excluded from the social 
cost calculation as they would have been offset by private benefits. 
 
The ‘rational addiction’ model has been very influential in economic analysis of addiction since it was first 
proposed, and historically social cost studies of drugs of dependence have excluded most or all of the costs 
borne by the addict themselves (Makate et al., 2019). 
 
However, the core assumptions that underpin the ‘rational addiction’ models treatment of drugs of 
dependence – that drug users have perfect foresight in making a fully rational and informed decision to 
commence and continue drug use – have been increasingly called into question based on the findings of 
empirical work with drug users (U.S. National Cancer Institute and World Health Organization, 2016). 
 
There is an increasing body of research that contends that the weight of the evidence from behavioural 
studies does not support critical underpinning assumptions of the ‘rational addiction’ hypothesis. This has led 
researchers to argue that current consumption levels for the drug of dependence are not necessarily optimal. 
The evidence presented to refute the assumption that current consumption is a rational optimisation of the 
costs and benefits of the study are data suggesting that consumers generally: 
• Underestimate the probability that their individual consumption patterns will lead to dependence 
(Gruber and Köszegi, 2001; Kenkel, 1991);  
• Hold incomplete information on the potential health impacts of consuming the drug in question, 
and in particular underestimate the potential impacts on themselves (Gruber and Köszegi, 2001; 
Kenkel, 1991; Khwaja et al., 2007; Smith et al., 2008; US Department of Health and Human 
Services, 1994); 
165  Appendices: Appendix 2.1 
 
• Have different preferences for their preferred drug over their lifetime, such as holding positive 
views about drug use when young but later wishing that they had not started (this is more 
formally known as time inconsistent preferences (Angeletos et al., 2001; Gruber and Köszegi, 
2001; Laibson, 2001)); and,  
• Engage in optimisation behaviours that can be characterised by ‘bounded rationality’, that is 
using ‘rules of thumb’ to make decisions or optimising using an incomplete information sets 
(Akerlof, 1991; Suranovic et al., 1999).  
 
If any of the four departures from rational, fully informed consumers listed above do hold with respect to a 
potentially addictive (and potentially harmful) substance, then it can no longer be asserted that current 
consumption levels of the addictive good will maximise the lifetime utility of use to the dependent user.48 
Thus, at least some of the costs arising from dependence can justify public policy responses to reduce 
consumption to its optimal level for the user once all costs are fully taken into account (U.S. National Cancer 
Institute and World Health Organization, 2016). This could involve, but is not limited to, decreasing availability, 
increasing price, or providing information to users and potential users.  
 
Following this rationale, whilst costs to a dependent user are not strictly social costs, in that they are borne 
by the users themselves, but have not been included (or have only been partially included) in consumption 
decisions, and therefore cannot necessarily be assumed to have delivered an equal or greater benefit to the 
consumer to offset their costs. Such costs are often referred to as ‘internalities’; costs to the user that were 
not factored into their consumption decision. Internality theory postulates that government policies should 
include both internal and external costs, such that changes in taxation levels can be justified even when there 
are no external costs as such interventions ensure that consumers are taking these costs into account in 
their decision making (U.S. National Cancer Institute and World Health Organization, 2016). The question 
then arises as to how, if at all, these costs should be included in a social cost study.  
 
There is no consensus in the literature on how internalities should be incorporated into economic analyses 
such as social cost studies. 
 
Many social cost studies continue to exclude costs borne by the substance user themselves either because 
the authors consider the ‘rational addiction’ hypothesis to still be a useful heuristic for considering individual 
behaviours, or due to the difficulty in identifying what net costs borne by the user should be included given 
that even for drugs of dependence consumers are likely to derive some utility from their consumption. 
 
Another approach that is often taken is to include those cost borne by the consumers themselves that are 
most closely related to dependent use (potentially including their expenditure induced by dependence) but to 
disregard costs incurred by non-dependent users as the four departures from a rational utility maximising 
consumer are greatest in the presence of drug dependence. In some cases an attempt is made to identify 
the level of consumption (and therefore harm) that these consumers would face if they were not dependent 
(see, for example, the Productivity Commission’s inquiry into the social costs of gambling in Australia 
(Productivity Commission, 1991)). In other cases, a subset of all costs borne by dependent users are treated 
as internalities. For example Collins and Lapsley (2008) included the intangible costs of premature mortality 
of all substance users, and the expenditure by dependent users on the drug of dependence. 
 
                                                     
48 The rational addiction hypothesis still has considerable ‘positive’ value (that is in predicting behavioural responses to policy 
changes), for example it correctly predicts that increasing prices such as by restricting supply, will be effective at reducing 
drug consumption despite the dependence forming nature of the drug. 
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The final approach that can be taken is to treat all costs borne by dependent consumers as social costs, on 
the basis that empirical research with people who use drugs suggests that the assumptions underpinning 
rational utility maximisation are met amongst dependent consumers (see above), and as the evidence 
suggests that continued use those who are dependent is driven by the dependence rather than by utility 
maximisation amongst consumers (US Department of Health and Human Services, 2010, p.9). If consumers 
are not aware of these costs, or have not consistently taken them into account in their consumption decisions, 
then there is no reason to assume that the harms associated with drug consumption will have been offset by 
a utility gain to drug consumers. Costs borne by non-dependent persons as a result of their own substance 
use is still treated as a private cost and excluded from the analysis.  
 
This latter approach has been adopted in the current study, and all costs borne by those with drug 
dependence will be included in the social cost calculation. 
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Appendix 4.1: Relationship between conditions and ICD codes 
Table A4.1 Relationship between conditions and ICD-10-AM codes 
Condition ICD-10-AM Diagnosis/external causes Source 
Directly opioid-related   
Mental and behavioural disorders due to use of opioids    F11* 
(Australian Institute of Health and 
Welfare, 2018) 
Poisoning by opium T40.0 
Poisoning by heroin  T40.1  
Poisoning by other opioids (incl. Codeine, Morphine) T40.2  
Poisoning by methadone  T40.3  
Poisoning by other synthetic narcotics (incl. Pethidine) T40.4  
Poisoning by other and unspecified narcotics  T40.6  
Related conditions    
Injecting-related skin and vascular infections  (Janjua et al., 2018) 
Skin and soft tissue infections including vascular infections   
Cutaneous abscess, furuncle and carbuncle L02*  
Cellulitis L03*  
Phlebitis or thrombophlebitis I80*  
Ulcer of lower limb, not elsewhere classified L97*  
Other specified disorders of skin and subcutaneous tissue L98.8  
Panniculitis, unspecified M79.3  
Gas gangrene A48.0  
Intracranial and intraspinal abscess and granuloma G06*  
Sequelae of inflammatory diseases of central nervous 
system G09 
 
Abscess of intestine K63.0  
Acute peritonitis K65.0  
Abscess of liver K75.0  
Panniculitis affecting regions of neck and back, cervical 
region M54.02 
 
Necrotising fasciitis M72.6*  
Acute tubulo-interstitial nephritis N10  
Gangrene, not elsewhere classified R02  
Bacteremia or Sepsis A40*, A41*, I26.9, I40.0, R57.2, R65.1, R65.9  
Osteomyelitis M86*, M89.9  
Brain injury   
Episodic and paroxysmal disorders G40-G47   
Toxic encephalopathy G92  
Anoxic brain damage, not elsewhere classified G93.1   
Cerebral Oedema G93.6   
Disorder of brain, unspecified G93.9   
Hydrocephalus in other diseases classified elsewhere G94.2   
Somnolence, stupor, coma R40  
Asphyxia R09.0  
Respiratory arrest R09.2  
HIV  (World Health Organization, 2014) 
Human immunodeficiency virus disease resulting in 
infectious and parasitic diseases B20* 
 
Human immunodeficiency virus disease resulting in 
malignant neoplasms B21* 
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Condition ICD-10-AM Diagnosis/external causes Source 
Human immunodeficiency virus disease resulting in other 
specified diseases B22* 
 
Human immunodeficiency virus disease resulting in other 
conditions B23* 
 
Unspecified human immunodeficiency virus [HIV] disease B24*  
HBV  (Australian Consortium for Classification Development, 2014) 
Acute hepatitis B  B16*  
Acute delta-(super)infection of hepatitis B carrier B17.0  
Chronic viral hepatitis B with delta-agent B18.0  
Chronic viral hepatitis B without delta-agent B18.1  
HCV  (Australian Consortium for Classification Development, 2014) 
Acute hepatitis C B17.1  
Chronic viral hepatitis C B18.2  
Liver cancer (Malignant neoplasm of liver and intrahepatic 
bile ducts) C22* 
(Australian Consortium for 
Classification Development, 2014) 
Cirrhosis  (Australian Consortium for Classification Development, 2014)  
Alcoholic fibrosis and sclerosis of liver K70.2 (Powell et al., 2019) 
Alcoholic cirrhosis of liver K70.3  
Alcoholic hepatic failure K70.4 (Powell et al., 2019) 
Chronic hepatic failure K72.1 (Powell et al., 2019) 
Fibrosis and cirrhosis of liver  K74.0 (Powell et al., 2019) 
Primary biliary cirrhosis K74.3  
Secondary biliary cirrhosis K74.4  
Biliary cirrhosis, unspecified K74.5  
Other and unspecified cirrhosis of liver K74.6  
Oesophageal varices I85.0 & .9 (Powell et al., 2019) 
Gastric varices I86.4 (Powell et al., 2019) 
Oesophageal varices without bleeding in diseases classified 
elsewhere I98.2 (Powell et al., 2019) 
Oesophageal varices with bleeding in diseases classified 
elsewhere I98.3 (Powell et al., 2019) 
Maternal exposure - Low birthweight P07.0, P07.1 (Australian Consortium for Classification Development, 2014) 
Infective Endocarditis (Acute and subacute infective 
endocarditis) I33.0 
(Australian Consortium for 
Classification Development, 2014) 
Neonatal withdrawal symptoms from maternal use of drugs 
of addiction (NAS) P96.1 
(Australian Consortium for 
Classification Development, 2014) 
Accidental injuries   (Australian Consortium for Classification Development, 2014) 
 Road crash injuries 
V12-V14 (.3 -.9),  
V19.4-V19.6, V19.9,  
V20-V28 (.3 -.9),  
V29-V79 (.4 -.9),  
V80.3-V80.5,  
V81.1, V82.1, V82.9,  
V83-V86 (.0 -.3),  
V87.0-V87.9,  
V89.2, V89.3, V89.9  
V02-V04 (.1, .9), V06.1, 
V09.2, V09.3 
(Chihuri and Li, 2019) 
Other transport accidents V01–V99 (excl. road crash injuries)  
Falls W00–W19  
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Condition ICD-10-AM Diagnosis/external causes Source 
Exposure to mechanical forces W20–W64  
Accidental drowning and submersion W65–W74  
Other accidental threats to breathing W75–W84  
Exposure to electricity, radiation, extreme 
temperature/pressure W85–W99  
Exposure to smoke, fire, flames, hot substances X00–X19  
Accidental exposure to other and unspecified factors X58–X59  
Sequelae of other accidents Y85*, Y86  
Intentional self-harm X60-84 (Australian Consortium for Classification Development, 2014) 
Sequelae of intentional self-harm Y87.0  
Interpersonal violence injury (Assault) X85–Y09 (Australian Institute of Health and Welfare, 2012) 
Sequelae of assault Y87.1  
 *All ICD-10-AM codes that start with this letter-digit combination. 
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Appendix 4.2: Alternative estimate for infective endocarditis 
As noted in section 4.4.2, the cost for infective endocarditis could alternatively be estimated using the 
population attributable fraction (PAF = 0.14) developed by English et al. (1995) for injecting drug use, 
multiplied by the proportion of people who inject opioids. It is unclear whether this approach would under or 
over-estimate the cost given the passage of time since the original estimate and scale-up of interventions 
(e.g., needle-syringe programs) to reduce injecting risk behaviour.  
 
Table A4.2: Alternative estimate for infective endocarditis (IE) 
    Number of separations Attributable separations    
 
























cost Total cost 
Male 0.14 59.60% 0.08344 1378 2235 114 186 300 5.104208 $5,194 $7,953,377.27 
Female 0.14 61.30% 0.08582 609 1018 52 87 139 5.333526 $5,194 $3,850,624.10 
Persons        439   $11,804,001.37 
 
171  Appendix 5.1 
 
Appendix 5.1: PBS item codes 
Table A5.1: PBS Items used for calculating pharmaceutical costs 
Condition PBS item codes 
HIV / AIDS 
10272P, 10284G, 10285H, 10297Y, 10305J, 10307L, 10314W, 10327M, 10345L, 10347N, 
10357D, 10903W, 11099E, 11104K, 11113X, 11114Y, 11146P, 11149T, 11246X, 11276L, 
11296M, 11306C, 10266H, 10273Q, 10275T, 10276W, 10286J, 10298B, 10299C, 10300D, 
10303G, 10304H, 10307L, 10319D, 10321F, 10326L, 10335Y, 10336B, 10337C, 10349Q, 
10360G, 10361H, 10366N, 11103J, 11107N, 11114Y, 11248B, 
Hepatitis C 
10623D, 10624E, 10625F, 10628J, 10629K, 10630L, 10631M, 10635R, 10637W, 10638X, 
10641C, 10642D, 10643E, 10644F, 10645G, 10646H, 10647J, 10648K, 10651N, 10653Q, 
10654R, 10657X, 10659B, 10660C, 10661D, 10663F, 10665H, 10666J, 10667K, 10668L, 
10669M, 10670N, 10671P, 10672Q, 10673R, 10675W, 10676X, 10678B, 10679C, 10747P, 
10749R, 10750T, 10751W, 10752X, 10753Y, 10754B, 10761J, 10765N, 10766P, 10768R, 
10769T, 10771X, 10772Y, 10773B, 10914K, 10923X, 10928E, 10929F, 10937P, 10938Q, 
10978T, 10979W, 10986F, 10991L, 11011M, 11021C, 11144M, 11145N, 11147Q, 11332K, 
11333L, 11337Q, 11344C, 11345D, 11346E, 11353M, 11354N, 11355P 
Hepatitis B 
10279B, 10290N, 10310P, 10311Q, 10315X, 10317B, 10320E, 10348P, 10353X, 10369R, 
11155D, 5759D, 5762G, 5945X, 5946Y, 5949D, 5998Q, 6210W, 6213B, 8180M, 8181N, 
8184R, 8553E, 6439X, 6449K, 9515T, 9516W 
Skin and Soft Tissue 
Infections  
10605E, 10609J, 10784N, 10788T, 1525G, 1526H, 1527J, 1884E, 1886G, 1887H, 1888J, 
1889K, 1891M, 1892N, 2269K, 2270L, 2824P, 2951H, 3103H, 3113W, 3114X, 3130R, 3131T, 
3138E, 3300Q, 3301R, 3302T, 3310F, 3323X, 3390K, 3391L, 3393N, 5006L, 5008N, 5009P, 
5011R, 5057E, 5083M, 5090X, 5091Y, 5095E, 5225B, 5257Q, 5258R, 8254K, 8319W, 8581P, 
8705E, 9149M, 9150N, 9714G 
Neonatal Abstinence 
Syndrome  1850J, 2122Q, 2123R, 2124T, 2138M, 5237P, 5238Q, 5239R 
Opioid Agonist Therapy 
10746N, 10755C, 10756D, 10770W, 10948F, 10949G, 10953L, 10957Q, 10959T, 10964C, 
10970J, 1606M, 1609Q, 5399E, 5400F, 6171T, 6172W, 6307Y, 6308B, 6309C, 8865N, 
8866P, 8867Q, 9749D, 9750E 
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Appendix 6.1: Safe Work Australia’s incident approach methodology 
Safe Work Australia’s incidence approach assessed the number of people entering the compensation system 
during 2012/13 as a result of a work-related incident and the costs (both current and expected future costs) 
associated with those cases. In order to estimate total costs, the expected future lifetime cost of each new 
cases was used to represent the cost of cases in the reference year that were already in the compensation 
system (Safe Work Australia, 2015).  
 
Appendix 6.2: Safe Work Australia’s cost estimation methodology  
The cost estimation methodology utilised by Safe Work Australia (2015) was based on the concept of the 
‘human cost’ of occupational injury with only costs associated with actual injuries including: 
• Production costs - costs incurred in the short term until production is returned to pre-incident 
levels;  
• Human capital costs - long run costs, such as loss of potential output, occurring after a 
restoration of pre-incident production levels;  
• Medical costs - costs incurred by workers and the community though medical treatment of 
workers injured in work-related incidents;  
• Administrative costs - costs incurred in administering compensation schemes, investigating 
incidents and legal costs; 
• Transfer costs - deadweight losses associated with the administration of taxation and welfare 
payments; and; 
• Other costs - costs not classified in other areas, such as the cost of carers and aids and 
modifications (Safe Work Australia, 2015). 
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Appendix 6.3: Recalculated workplace absenteeism costs with different daily wage 
estimate 
The Social Costs of Methamphetamine in Australia (Whetton et al., 2016) used a similar methodology to that 
reported here (see Section 6.2.2). The main difference between the two costing projects was the year and 
type of daily wage value used from the ABS average weekly earnings report. The ABS provides average 
weekly earnings that are seasonally adjusted and trend estimates (see explanatory notes in 
https://www.abs.gov.au/ausstats/abs@.nsf/mf/6302.0 for more information). The methamphetamine costing 
project used November 2013 weekly wage trend data for person’s total earnings (Australian Bureau of 
Statistics, 2014). The daily wage calculated was $267.70 (including 20% employer on-costs). Workplace 
absenteeism costs attributed to the use of extra-medical opioids were determined using seasonally adjusted 
full-time adult total weekly earnings for November 2015 (Australian Bureau of Statistics, 2016). The daily 
wage calculated was $373.66 (including 20% employer on-costs). The following three tables recalculate the 
cost of extra-medical use of opioids using the daily wage of $274.94. This daily wage was calculated from 
person’s total weekly earnings for November 2015 (trend data) with 20% employer on-costs added 
(Australian Bureau of Statistics, 2016).  
 
It is also important to note that the NDSHS collection years were different compared with the present report 
which used 2016 data whilst the methamphetamine report used 2013 data. 
 
Table A6.3.1: Recalculation of Table 6.5. Adjusted excess workplace absenteeism due to illness/injury 
among opioid users and other drug users compared to non-drug users (2016 NDSHS data a) and 
associated costs (2015 ABS data b) c 
  Annual Illness or Injury Absence 






Excess Days Absent  
(95% CI) e 
Cost $  
(95% CI) f 
No drug use 8,536,278 7.556 (6.909 – 8.203)    
Extra-medical opioid 
use at least weekly 
80,106 19.692 (12.619 – 26.765) 
12.136 (5.710 
– 18.562) 






use less often than 
weekly 
302,521 4.247 (0.909 – 7.584) 
-3.309 (-6.000 
– -0.619) 0 (0 – 0) 
g 0 (0 – 0) g 
Other drug use 1,449,475 11.074 (9.547 – 12.600) 
3.518 (2.638 – 
4.397) 
5,098,715 (3,824,159 




a Australian Institute of Health and Welfare, 2017. National Drug Strategy Household Survey (NDSHS) 2016, Drug Statistics Series. 
Canberra, Government of Australia. 
b Australian Bureau of Statistics (ABS), 2016. Average Weekly Earnings, Australia, Nov 2015. Cat. no. 6302.0. Canberra, ABS. 
c Calculations based on estimated absenteeism means adjusted for age, gender, marital status, socio-economic status, and 
occupation. 
d Mean days absent due to a) illness/injury for extra-medical use of opioids at least weekly, b) extra-medical use of opioids less 
often than weekly, c) other drug use, minus mean days absent for no drug use. 
e Difference in mean absence multiplied by estimated population. 
e Excess absence multiplied by $274.94 (2015 average daily wage for person total earnings (trend data) plus 20% employer on-
costs). 
g To simplify interpretation of results, negative difference values (including 95% confidence intervals) were rounded to 0. 
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Table A 6.3.2: Recalculation of Table 6.6. Adjusted excess workplace absenteeism due to illicit drug use by 
drug use type (2016 NDSHS data a) and associated costs (2015 ABS data b) c 
  Annual Absence Due to Drug Use 
Drug use status Estimated Population 
Mean Days Absent 
(95% CI) 
Excess Days Absent  
(95% CI) d 
Cost $  
(95% CI) e 
Extra-medical opioid use at 
least weekly 80,106 0.402 (-0.640 – 1.445) 32,240 (0 – 115,786) 
f 8,864,116 (0 – 31,834,259) f 
Extra-medical opioid use 
less often than weekly 302,521 0.262 (-0.248 – 0.772) 88,902 (0 – 233,452) 
f 24,442,840 (0 – 64,185,188) f 
Other drug use 1,449,475 0.208 (-0.015 – 0.430) 301,024 (0 – 623,604) 
f 82,763,558 (0 – 171,453,592) f 
a Australian Institute of Health and Welfare, 2017. National Drug Strategy Household Survey (NDSHS) 2016, Drug Statistics Series. 
Canberra, Government of Australia. 
b Australian Bureau of Statistics (ABS), 2016. Average Weekly Earnings, Australia, Nov 2015. Cat. no. 6302.0. Canberra, ABS. 
c Calculations based on estimated absenteeism means adjusted for age, gender, marital status, socio-economic status, and 
occupation. 
d Days in excess of non-drug users. Mean days absent multiplied by estimated population. 
e Excess absence multiplied by $274.94 (2015 average daily wage for person total earnings (trend data) plus 20% employer on-
costs). 
f To simplify interpretation of results, negative difference values (including 95% confidence intervals) were rounded to 0. 
 
Table A6.3.3: Recalculation of Table 6.8. Summary: Workplace costs due to extra-medical opioid use 
Cost area Central estimate $ Low bound $ High bound $ 
Occupational injury a 319,145,000 a 142,770,000 b 495,520,000 c 
Absenteeism  102,660,461 c 22,750,653 182,570,270 
Total   421,805,461 165,520,653 678,090,270 
a Cost to employer ($61,765,000) plus cost to community ($257,380,000). Employee costs are an internal cost and thus not 
included in the total cost estimate for occupational injury (see Table 6.3). 
b Cost to employer ($27,630,000) plus cost to community ($115,140,000). Employee costs are an internal cost and thus not 
included in the total cost estimate for occupational injury (see Table 6.3). 
c The mid point of the low and high bound estimates. 
 
Note: the figures in Recalculated Table 6.8 account for poly-drug use. That is, illness/injury-related 
absenteeism (Recalculated Table 6.5) and drug-related absenteeism (Recalculated Table 6.6) costs 
attributed to extra-medical opioid use were divided by 1.464 (see main report Section 6.3.2 and Table 6.7 for 
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